Patent Publication Number: US-2006014166-A1

Title: Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis

Description:
CROSS-REFERENCE TO RELATED APPLICATION(S)  
      THIS APPLICATION IS RELATED TO NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS OF ENDOMETRIOSIS, AND CLAIMS PRIORITY TO THE BELOW U.S. PROVISIONAL APPLICATIONS WHICH ARE INCORPORATED BY REFERENCE HEREIN: 
      APPLICATION No. 60/628,145 FILED Nov. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN PANCREATIC CANCER II     APPLICATION No. 60/628,178 FILED Nov. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN BRAIN CANCER II     APPLICATION No. 60/621,004 FILED Oct. 22, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN SKIN AND EPITHELIAL CANCER II     APPLICATION No. 60/628,230 FILED Nov. 17, 2004—DIFFERENTIAL EXPRESSION OF MARKERS IN ENDOMETRIOSIS     APPLICATION No. 60/539,129 FILED Jan. 27, 2004—METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES     APPLICATION No. 60/539,128 FILED Jan. 27, 2004—EVOLUTIONARY CONSERVED SPLICED SEQUENCES AND METHODS AND SYSTEMS FOR IDENTIFYING THEREOF   

    
    
     FIELD OF THE INVENTION  
      The present invention is related to novel nucleotide and protein sequences that are diagnostic markers for endometriosis, and assays and methods of use thereof.  
     BACKGROUND OF THE INVENTION  
      Endometriosis represents one of the most common admitting diagnoses in women of reproductive age. It is defined as the presence of endometrial tissue outside of the uterus and is typically present in the pelvis such as on the ovaries and pelvic peritoneum. It may also involve the bowel, ureter or bladder. Endometriosis is a common gynecologic disorder that presents with chronic pelvic pain or infertility. The histologic diagnosis requires the presence of endometrial glands and stroma from a tissue sample. (Clin Chim Acta. 2004 February; 340(1-2):41-56). Endometriosis diagnosis is problematic. Studies in the USA, UK and Australia have demonstrated that the delay in the diagnosis of endometriosis is universal. For example, a study by the Australian Endometriosis Society in 1990 found a delay of approximately 4.4 years from consultation to diagnosis. Younger women are more likely to experience a delay in diagnosis. Those between 15-19 years of age experience an average delay to diagnosis of 8.3 years (Aust Fam Physician. 2001 July; 30(7):649-53).  
      The gold standard for the diagnosis of endometriosis is a surgical intervention, a laparoscopy. The severity of disease is variable and patients are usually categorized according to the American Fertility Society classification of disease into four groups that represent mild to severe disease, stages I to IV. There is a poor correlation between the severity of disease and the patient&#39;s symptoms. Furthermore, the disease can be found in asymptomatic patients. This heterogeneity in clinical presentation has contributed to the difficulties in identifying a marker. Since some women are asymptomatic, clinical trials require a control group of women that require a surgical procedure to exclude the presence of endometriosis. Considerable effort has been invested in searching for non-invasive methods of diagnosis (Clin Chim Acta. 2004 February; 340(1-2):41-56).  
      Serum CA-125, a 200,000 Da glycoprotein, concentration has been associated with the presence of many gynecologic disorders including endometriosis (Int J Biol Markers. 1998 October-December; 13(4):231-7). The CA-125 antigen is expressed in many normal tissues such as the endometrium, endocervix and peritoneum. In some women, CA-125 levels increase during menstruation. Mean CA-125 levels are higher during menses in patients with and without endometriosis and it is therefore recommended that CA-125 levels not be drawn during a menstrual period (Am J Obstet Gynecol. 1987 December; 157(6):1426-8). Many studies tried to assess the role of serum CA-125 measurement in the detection of endometriosis. The main confounding variable in determining the sensitivity and specificity of serum CA-125 is the stage of the disease. Typically, most patients with advanced endometriosis (and few patients with early stage disease) will have elevated serum CA-125 levels (similar to what occurs in ovarian cancer). A recent meta-analysis performed to assess the diagnostic performance of serum CA-125 in detecting endometriosis (Fertil Steril. 1998 December; 70(6):1101-8) Showed sensitivity ranged from 4% to 100% and the specificity ranged from 38% to 100% for the diagnosis of any stage of disease. The ROC curve showed a poor diagnostic performance. At a specificity of 90%, a sensitivity of 28% was reported. If the sensitivity was increased to 50%, the specificity dropped to 72%. For advanced disease, the sensitivity ranged from 0% to 100% and the specificity ranged from 44% to 95%. For a specificity of approximately 90%, the sensitivity was 47%. If the sensitivity was increased to 60%, the specificity dropped to 81% (Fertil Steril. 1998 December; 70(6):1101-8). According to the authors of this study, a negative result would delay the diagnosis in 70% of patients with endometriosis. The routine use of serum CA-125 cannot be advocated as a diagnostic tool to exclude the diagnosis of endometriosis in patients with chronic pelvic pain or infertility. CA-125 may be more useful in evaluating recurrent disease or the success of a surgical treatment. Many investigators have measured levels of CA-125 in the peritoneal fluid of patients with and without endometriosis (Gynecol Obstet Invest. 1990; 30(2):105-8). Although peritoneal fluid levels of CA-125 are almost 10 times higher than serum levels, no differences were found between women with and without Endometriosis (Fertil Steril. 1991 November; 56(5):863-9). CA-125 levels have also been measured in other body fluids such as menstrual discharge and uterine fluid but were not found to be useful in clinical practice.  
      CA 19-9 is a high-molecular-weight glycoprotein elevated in patients with malignant and benign ovarian tumors including ovarian chocolate cysts. Serum CA19-9 levels in women with endometriosis fell significantly after treatment for endometriosis when compared with the basal levels before treatment (Eur J Gynaecol Oncol. 1998; 19(5):498-500). There are a limited number of reports on the significance of serum CA19-9 levels in the diagnosis of endometriosis but the overall conclusion is that the clinical utility of the CA19-9 measurement is not superior to that of the CA-125. For example, in one study (Fertil Steril. 2002 October; 78(4):733-9) when comparing the sensitivities of the CA19-9 and CA-125 tests for the diagnosis of endometriosis, the authors found that the sensitivity of the CA19-9 test was significantly lower than that of the CA-125 test (34% and 49%, respectively).  
      Soluble forms of the intercellular-adhesion molecule-1 (sICAM-1) are secreted from the endometrium and endometriotic implants. Moreover, endometrium from women with endometriosis secretes a higher amount of this molecule than tissue from women without the disease. Consequently, a strong correlation exists between levels of sICAM-1 shed by the endometrium and the number of endometriotic implants in the pelvis (Obstet Gynecol. 2000 January; 95(1):115-8). It has been hypothesized that sICAM-1 may be useful in the diagnosis of endometriosis. A few studies reported a significant increase in serum concentration of sICAM-1 in patients with endometriosis (for example, Am J Reprod Immunol. 2000 March; 43(3):160-6) but overall it was shown that serum levels of sICAM-1 were only slightly but not significantly higher in women with endometriosis than in women without the disease unless the disease is of high stage (deep peritoneal) (Fertil Steril. 2002 May; 77(5):1028-31). The sensitivity and specificity of sICAM-1 in detecting deep peritoneal endometriosis were 19% and 97%, respectively. It has been shown that in women with deep infiltrating Endometriosis measurement of CA-125 and sICAM-1 together may improve diagnosis.  
      Serum placental protein 14 (PP-14)—currently known as glycodelin-A was found to be significantly higher in endometriosis patients than in healthy controls (Am J Obstet Gynecol. 1989 October; 161(4):866-71). Levels were significantly lowered by conservative surgery as well as by treatment with danazol and medroxy progesterone acetate. The ability of serum PP-14 levels to diagnose of endometriosis is limited because of a low sensitivity (59%). Typically, the peritoneal fluid concentrations of PP-14 are low. The levels are elevated in the luteal phase of endometriosis patients. It is controversial whether this is of any diagnostic importance or not.  
      Tumor necrosis factors (TNF) play an essential role in the inflammatory process. TNF is believed to involve in many physiological and pathological reproductive processes. The main TNF is TNF-a. In the human endometrium, TNF-a is a factor in the normal physiology of endometrial proliferation and shedding. TNF-a is expressed mostly in epithelial cells, particularly in the secretory phase. Stromal cells stain for TNF-a mostly in the proliferative phase of the menstrual cycle. Therefore it is believed it is probably influenced by hormones. TNF-a concentrations in peritoneal fluid are elevated in patients with endometriosis, but it is controversial whether they are correlated with disease stage or not (ertil Steril. 1988 October; 50(4):573-9). It has been suggested that measurement of TNF-a peritoneal fluid can be used as a foundation for non-surgical diagnosis of endometriosis but that hasn&#39;t been comprehensively checked (Hum Reprod. 2002 February; 17(2):426-31).  
      IL-6 is a regulator of inflammation and immunity and modulates secretion of other cytokines, promotes T-cell activation and B-cell differentiation and inhibits growth of various human cell lines. IL-6 is produced by different cells including endometrial epithelial stromal cells. The role of IL-6 in the pathogenesis of endometriosis has been extensively studied. IL-6 response is different in peritoneal macrophages, endometrial stromal cells and peripheral macrophages in patients with endometriosis (Fertil Steril. 1996 June; 65(6):1125-9). It has been shown that IL-6 was significantly elevated in the sera of endometriosis patients but not in their peritoneal fluid as compared with patients with unexplained infertility and tubal ligation/reanastomosis (Hum Reprod. 2002 February; 17(2):426-31). That finding was contradicted by other works but it is thought the different results might be attributed to the antibody specificity of the assay.  
      There has been some work on the proliferation and neovascularization of the endometriotic implants, and particularly on the role of Vascular endothelial growth factor (VEGF). The basic physiological function of VEGF is to induce angiogenesis, which allows the endometrium to repair itself following menstruation. It also modulates the characteristics of the newly formed vessels by controlling the microvascular permeability and permitting the formation of a fibrin matrix for endothelial cell migration and proliferation (Science 1985; 227:1059-61). This modulation may be responsible for local endometrial edema, which helps prepare the endometrium for embryo implantation. In endometriosis patients, VEGF is localized in the epithelium of endometriotic implants (J Clin Endocrinol Metab 1996; 81:3112-8), particularly in hemorrhagic red implants (Hum Reprod 1998; 13:1686-90). Moreover, the concentration of VEGF is increased in the peritoneal fluid of endometriosis patients. The exact cellular sources of VEGF in peritoneal fluid have not yet been precisely defined. Although evidence suggests that endometriotic lesions themselves produce this factor, activated peritoneal macrophages also can synthesize and secrete VEGF (Hum Reprod 1996; 11:220-3). Antiangiogenic drugs are potential therapeutic agents in endometriosis.  
      There are many more cytokines which were considered for the purpose of Endometriosis diagnosis, among them RANTES (Regulated on Activation, Normal T-Cell Expressed and Secreted) where in vitro secretion of RANTES by endometrioma-derived stromal cell cultures is significantly greater than in eutopic endometrium (Am J Obstet Gynecol 1993; 169:1545-9), IL-1 where research has shown that the administration of exogenous IL-1 receptor antagonist blocks successful implantation in mice (Endocrinology 1994; 134:521-8), IL-4, IL-5, IL-8, IL-10, IL-12, IL-13, interferon-gamma; MCP-1, MCSF and TGF. Most often, they have not been extensively investigated as a diagnostic tool. One group studies a panel of serum and peritoneal fluid such markers for the prediction of endometriosis (Hum Reprod. 2002 February; 17(2):426-31). Serum and peritoneal fluid from 130 women were obtained while they underwent laparoscopy for pain, infertility, tubal ligation or sterilization reversal. They measured the concentrations of 6 cytokines (IL-1, IL-6, IL-8, IL-12, IL-13 and TNF-a) in serum and peritoneal fluid and levels of reactive oxygen species (ROS) in peritoneal fluid. Only serum IL-6 and peritoneal fluid TNF-a could discriminate between patients with and without endometriosis with a high degree of sensitivity and specificity. The peritoneal fluid TNF-a had a very good 99% area under the curve but in that study all peritoneal fluid samples that were contaminated by blood (a common procedure artifact) were excluded from study. Therefore this result has only a partial practical value.  
      A few Endometrial tissue biochemical markers were investigated in the context of endometriosis. Aromatase P450 is a catalyst of the conversion of androstenedione and testosterone to estrone and estradiol, respectively. It is expressed in both eutopic and ectopic endometrium of endometriosis patients but not in eutopic endometrium of healthy controls (Biol Reprod 1997; 57:514-9). Although endometrial aromatase P450 expression does not correlate with the disease stage, a recent study demonstrated that detection of aromatase P450 transcripts in the endometrium of endometriosis patients may be a potential qualitative marker of endometriosis Fertil Steril 2002; 78:825-9). The potential use of such marker as a clinically useful diagnostic tool of pelvic disease is limited by the observation that large numbers of women with endometriosis do not express aromatase P450 in their eutopic endometrium. Cytokeratins 8, 18, 19, vimentin and human leukocyte class I antigens were shown to be immunoreactive in endometriosis cell lines (Hum Reprod Update 1997; 3:117-23). More genes have shown to be aberrantly regulated in the endometrium of women with endometriosis including avBeta3 integrin, beta1-integrin, E-cadherin, 17b-hydroxysteroid dehydrogenase type-1, Monocyte chemotactic protein-1, interleukin-1 receptor type II, cyclooxygenase-2, Endoglin, C3 complement, Heat shock protein 27, Xanthine oxidase, Superoxidase dismutase, Endometrial bleeding-assoicated factor and HOX gene. No studies have evaluated the use of these molecular markers as a potential diagnostic/screening tool in endometriosis. The reasons for that are that the level of expression may vary considerably among individuals and biopsy samples, the abnormal expression pattern may be confined to a certain phase in the cycle and that immunostaining is subjective and observer dependant method (Obstet Gynecol Clin North Am. 2003 March; 30(1):95-114, viii-ix).  
     SUMMARY OF THE INVENTION  
      The background art does not teach or suggest markers for endometriosis that are sufficiently sensitive and/or accurate, alone or in combination.  
      The present invention overcomes these deficiencies of the background art by providing novel markers for endometriosis that are both sensitive and accurate. These markers are overexpressed in endometriosis specifically, as opposed to normal tissues. The measurement of these markers, alone or in combination, in patient (biological) Samples provides information that the diagnostician can correlate with a probable diagnosis of endometriosis. The markers of the present invention, alone or in combination, show a high degree of differential detection between normal and endometriosis states.  
      According to preferred embodiments of the present invention, examples of suitable biological samples which may optionally be used with preferred embodiments of the present invention include but are not limited to blood, serum, plasma, blood cells, urine, sputum, saliva, stool, spinal fluid or CSF, lymph fluid, the external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, milk, neuronal tissue, breast tissue, any human organ or tissue, including any tumor or normal tissue, any sample obtained by lavage (for example of the bronchial system or of the uterus), and also samples of in vivo cell culture constituents. In a preferred embodiment, the biological sample comprises uterine tissue, preferably endometrial tissue found anywhere in the pelvic or abdominal cavity and/or a serum sample and/or a urine sample and/or any other tissue or liquid sample. The sample can optionally be diluted with a suitable eluant before contacting the sample to an antibody and/or performing any other diagnostic assay.  
      Information given in the text with regard to cellular localization was determined according to four different software programs: (i) tmhmm (from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dtu.dk/services/TMHMM/TMHMM2.0b.guide.php) or (ii) tmpred (from EMBnet, maintained by the ISREC Bionformatics group and the LICR Information Technology Office, Ludwig Institute for Cancer Research, Swiss Institute of Bioinformatics, http://www.ch.embnet.org/software/TMPRED_form.html) for transmembrane region prediction; (iii) Signalp_hmm or (iv) Signalp_nn (both from Center for Biological Sequence Analysis, Technical University of Denmark DTU, http://www.cbs.dtu.dk/services/SignalP/background/prediction.php) for signal peptide prediction. The terms “signalphmm” and “signalp_nn” refer to two modes of operation for the program SignalP: hmm refers to Hidden Markov Model, while nn refers to neural networks. Localization was also determined through manual inspection of known protein localization and/or gene structure, and the use of heuristics by the individual inventor. In some cases for the manual inspection of cellular localization prediction inventors used the ProLoc computational platform [Einat Hazkani-Covo, Erez Levanon, Galit Rotman, Dan Graur and Amrit Novik; (2004) “Evolution of multicellularity in metazoa: comparative analysis of the subcellular localization of proteins in  Saccharomyces, Drosophila  and  Caenorhabditis .” Cell Biology International 2004; 28(3):171-8.], which predicts protein localization based on various parameters including, protein domains (e.g., prediction of trans-membranous regions and localization thereof within the protein), pI, protein length, amino acid composition, homology to pre-annotated proteins, recognition of sequence patterns which direct the protein to a certain organelle (such as, nuclear localization signal, NLS, mitochondria localization signal), signal peptide and anchor modeling and using unique domains from Pfam that are specific to a single compartment.  
      Information is given in the text with regard to SNPs (single nucleotide polymorphisms). A description of the abbreviations is as follows. “T-&gt;C”, for example, means that the SNP results in a change at the position given in the table from T to C. Similarly, “M-&gt;Q”, for example, means that the SNP has caused a change in the corresponding amino acid sequence, from methionine (M) to glutamine (Q). If, in place of a letter at the right hand side for the nucleotide sequence SNP, there is a space, it indicates that a frameshift has occurred. A frameshift may also be indicated with a hyphen (−). A stop codon is indicated with an asterisk at the right hand side (*). As part of the description of an SNP, a comment may be found in parentheses after the above description of the SNP itself. This comment may include an FTId, which is an identifier to a SwissProt entry that was created with the indicated SNP. An FTId is a unique and stable feature identifier, which allows construction of links directly from position-specific annotation in the feature table to specialized protein-related databases. The FTId is always the last component of a feature in the description field, as follows: FTId=XXX_number, in which XXX is the 3-letter code for the specific feature key, separated by an underscore from a 6-digit number. In the table of the amino acid mutations of the wild type proteins of the selected splice variants of the invention, the header of the first column is “SNP position(s) on amino acid sequence”, representing a position of a known mutation on amino acid sequence. SNPs may optionally be used as diagnostic markers according to the present invention, alone or in combination with one or more other SNPs and/or any other diagnostic marker. Preferred embodiments of the present invention comprise such SNPs, including but not limited to novel SNPs on the known (WT or wild type) protein sequences given below, as well as novel nucleic acid and/or amino acid sequences formed through such SNPs, and/or any SNP on a variant amino acid and/or nucleic acid sequence described herein.  
      Information given in the text with regard to the Homology to the known proteins was determined by Smith-Waterman version 5.1.2 using special (non default) parameters as follows: 
      model=sw.model     GAPEXT=0     GAPOP=100.     MATRIX=blosum 100    

      It should be noted that the terms “segment”, “seg” and “node” are used interchangeably in reference to nucleic acid sequences of the present invention; they refer to portions of nucleic acid sequences that were shown to have one or more properties as described below. They are also the building blocks that were used to construct complete nucleic acid sequences as described in greater detail below. Optionally and preferably, they are examples of oligonucleotides which are embodiments of the present invention, for example as amplicons, hybridization units and/or from which primers and/or complementary oligonucleotides may optionally be derived, and/or for any other use.  
      As used herein the phrase “endometriosis” refers to any type of endometriosis and/or disease of the endometrium and/or of endometrial tissue.  
      The term “marker” in the context of the present invention refers to a nucleic acid fragment, a peptide, or a polypeptide, which is differentially present in a sample taken from subjects (patients) Having endometriosis as compared to a comparable sample taken from subjects who do not have endometriosis.  
      The phrase “differentially present” refers to differences in the quantity of a marker present in a sample taken from patients having endometriosis as compared to a comparable sample taken from patients who do not have endometriosis. For example, a nucleic acid fragment may optionally be differentially present between the two samples if the amount of the nucleic acid fragment in one sample is significantly different from the amount of the nucleic acid fragment in the other sample, for example as measured by hybridization and/or NAT-based assays. A polypeptide is differentially present between the two samples if the amount of the polypeptide in one sample is significantly different from the amount of the polypeptide in the other sample. It should be noted that if the marker is detectable in one sample and not detectable in the other, then such a marker can be considered to be differentially present.  
      As used herein the phrase “diagnostic” means identifying the presence or nature of a pathologic condition. Diagnostic methods differ in their sensitivity and specificity. The “sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of “true positives”). Diseased individuals not detected by the assay are “false negatives.” Subjects who are not diseased and who test negative in the assay are termed “true negatives.” The “specificity” of a diagnostic assay is 1 minus the false positive rate, where the “false positive” rate is defined as the proportion of those without the disease who test positive. While a particular diagnostic method may not provide a definitive diagnosis of a condition, it suffices if the method provides a positive indication that aids in diagnosis.  
      As used herein the phrase “diagnosing” refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression, forecasting an outcome of a disease and/or prospects of recovery. The term “detecting” may also optionally encompass any of the above.  
      Diagnosis of a disease according to the present invention can be effected by determining a level of a polynucleotide or a polypeptide of the present invention in a biological sample obtained from the subject, wherein the level determined can be correlated with predisposition to, or presence or absence of the disease. It should be noted that a “biological sample obtained from the subject” may also optionally comprise a sample that has not been physically removed from the subject, as described in greater detail below.  
      As used herein, the term “level” refers to expression levels of RNA and/or protein or to DNA copy number of a marker of the present invention.  
      Typically the level of the marker in a biological sample obtained from the subject is different (i.e., increased or decreased) from the level of the same variant in a similar sample obtained from a healthy individual (examples of biological samples are described herein).  
      Numerous well known tissue or fluid collection methods can be utilized to collect the biological sample from the subject in order to determine the level of DNA, RNA and/or polypeptide of the variant of interest in the subject.  
      Examples include, but are not limited to, fine needle biopsy, needle biopsy, core needle biopsy and surgical biopsy (e.g., brain biopsy), and lavage. Regardless of the procedure employed, once a biopsy/sample is obtained the level of the variant can be determined and a diagnosis can thus be made.  
      Determining the level of the same variant in normal tissues of the same origin is preferably effected along-side to detect an elevated expression and/or amplification and/or a decreased expression, of the variant as opposed to the normal tissues.  
      A “test amount” of a marker refers to an amount of a marker in a subject&#39;s sample that is consistent with a diagnosis of endometriosis. A test amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals).  
      A “control amount” of a marker can be any amount or a range of amounts to be compared against a test amount of a marker. For example, a control amount of a marker can be the amount of a marker in a patient with endometriosis or a person without endometriosis. A control amount can be either in absolute amount (e.g., microgram/ml) or a relative amount (e.g., relative intensity of signals).  
      “Detect” refers to identifying the presence, absence or amount of the object to be detected.  
      A “label” includes any moiety or item detectable by spectroscopic, photo chemical, biochemical, immunochemical, or chemical means. For example, useful labels include  32 P,  35 S, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin-streptavadin, dioxigenin, haptens and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules with a sequence complementary to a target. The label often generates a measurable signal, such as a radioactive, chromogenic, or fluorescent signal, that can be used to quantify the amount of bound label in a sample. The label can be incorporated in or attached to a primer or probe either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., incorporation of radioactive nucleotides, or biotinylated nucleotides that are recognized by streptavadin. The label may be directly or indirectly detectable. Indirect detection can involve the binding of a second label to the first label, directly or indirectly. For example, the label can be the ligand of a binding partner, such as biotin, which is a binding partner for streptavadin, or a nucleotide sequence, which is the binding partner for a complementary sequence, to which it can specifically hybridize. The binding partner may itself be directly detectable, for example, an antibody may be itself labeled with a fluorescent molecule. The binding partner also may be indirectly detectable, for example, a nucleic acid having a complementary nucleotide sequence can be a part of a branched DNA molecule that is in turn detectable through hybridization with other labeled nucleic acid molecules (see, e.g., P. D. Fahrlander and A. Klausner, Bio/Technology 6:1165 (1988)). Quantitation of the signal is achieved by, e.g., scintillation counting, densitometry, or flow cytometry.  
      Exemplary detectable labels, optionally and preferably for use with immunoassays, include but are not limited to magnetic beads, fluorescent dyes, radiolabels, enzymes (e.g., horse radish peroxide, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic beads. Alternatively, the marker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is used to detect bound marker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the marker are incubated simultaneously with the mixture.  
      “Immunoassay” is an assay that uses an antibody to specifically bind an antigen. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.  
      The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide (or other epitope), refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times greater than the background (non-specific signal) and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to seminal basic protein from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with seminal basic protein and not with other proteins, except for polymorphic variants and alleles of seminal basic protein. This selection may be achieved by subtracting out antibodies that cross-react with seminal basic protein molecules from other species. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow &amp; Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.  
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            S71513_T2 (SEQ ID NO: 1)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            S71513_node_0 (SEQ ID NO: 2)           S71513_node_5 (SEQ ID NO: 3)           S71513_node_6 (SEQ ID NO: 4)           S71513_node_8 (SEQ ID NO: 5)           S71513_node_1 (SEQ ID NO: 6)           S71513_node_4 (SEQ ID NO: 7)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            S71513_P2 (SEQ ID NO: 9)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            HUMELAM1A_T1 (SEQ ID NO: 10)           HUMELAM1A_T5 (SEQ ID NO: 11)           HUMELAM1A_T6 (SEQ ID NO: 12)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HUMELAM1A_node_5 (SEQ ID NO: 13)           HUMELAM1A_node_8 (SEQ ID NO: 14)           HUMELAM1A_node_10 (SEQ ID NO: 15)           HUMELAM1A_node_11 (SEQ ID NO: 16)           HUMELAM1A_node_13 (SEQ ID NO: 17)           HUMELAM1A_node_15 (SEQ ID NO: 18)           HUMELAM1A_node_18 (SEQ ID NO: 19)           HUMELAM1A_node_19 (SEQ ID NO: 20)           HUMELAM1A_node_20 (SEQ ID NO: 21)           HUMELAM1A_node_22 (SEQ ID NO: 22)           HUMELAM1A_node_33 (SEQ ID NO: 23)           HUMELAM1A_node_0 (SEQ ID NO: 24)           HUMELAM1A_node_2 (SEQ ID NO: 25)           HUMELAM1A_node_7 (SEQ ID NO: 26)           HUMELAM1A_node_24 (SEQ ID NO: 27)           HUMELAM1A_node_26 (SEQ ID NO: 28)           HUMELAM1A_node_29 (SEQ ID NO: 29)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            HUMELAM1A_P2 (SEQ ID NO: 31)           HUMELAM1A_P2 (SEQ ID NO: 32)           HUMELAM1A_P2 (SEQ ID NO: 33)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            HUMHPA1B_PEA_1_T1 (SEQ ID NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID NO: 46)                      
 
      and/or a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HUMHPA1B_PEA_1_node_20 (SEQ ID           NO: 47)           HUMHPA1B_PEA_1_node_25 (SEQ ID           NO: 48)           HUMHPA1B_PEA_1_node_28 (SEQ ID           NO: 49)           HUMHPA1B_PEA_1_node_35 (SEQ ID           NO: 50)           HUMHPA1B_PEA_1_node_88 (SEQ ID           NO: 51)           HUMHPA1B_PEA_1_node_0 (SEQ ID           NO: 52)           HUMHPA1B_PEA_1_node_1 (SEQ ID           NO: 53)           HUMHPA1B_PEA_1_node_3 (SEQ ID           NO: 54)           HUMHPA1B_PEA_1_node_4 (SEQ ID           NO: 55)           HUMHPA1B_PEA_1_node_5 (SEQ ID           NO: 56)           HUMHPA1B_PEA_1_node_6 (SEQ ID           NO: 57)           HUMHPA1B_PEA_1_node_7 (SEQ ID           NO: 58)           HUMHPA1B_PEA_1_node_10 (SEQ ID           NO: 59)           HUMHPA1B_PEA_1_node_11 (SEQ ID           NO: 60)           HUMHPA1B_PEA_1_node_12 (SEQ ID           NO: 61)           HUMHPA1B_PEA_1_node_13 (SEQ ID           NO: 62)           HUMHPA1B_PEA_1_node_14 (SEQ ID           NO: 63)           HUMHPA1B_PEA_1_node_15 (SEQ ID           NO: 64)           HUMHPA1B_PEA_1_node_16 (SEQ ID           NO: 65)           HUMHPA1B_PEA_1_node_17 (SEQ ID           NO: 66)           HUMHPA1B_PEA_1_node_18 (SEQ ID           NO: 67)           HUMHPA1B_PEA_1_node_19 (SEQ ID           NO: 68)           HUMHPA1B_PEA_1_node_21 (SEQ ID           NO: 69)           HUMHPA1B_PEA_1_node_22 (SEQ ID           NO: 70)           HUMHPA1B_PEA_1_node_23 (SEQ ID           NO: 71)           HUMHPA1B_PEA_1_node_24 (SEQ ID           NO: 72)           HUMHPA1B_PEA_1_node_27 (SEQ ID           NO: 73)           HUMHPA1B_PEA_1_node_29 (SEQ ID           NO: 74)           HUMHPA1B_PEA_1_node_30 (SEQ ID           NO: 75)           HUMHPA1B_PEA_1_node_31 (SEQ ID           NO: 76)           HUMHPA1B_PEA_1_node_32 (SEQ ID           NO: 77)           HUMHPA1B_PEA_1_node_33 (SEQ ID           NO: 78)           HUMHPA1B_PEA_1_node_34 (SEQ ID           NO: 79)           HUMHPA1B_PEA_1_node_36 (SEQ ID           NO: 80)           HUMHPA1B_PEA_1_node_37 (SEQ ID           NO: 81)           HUMHPA1B_PEA_1_node_38 (SEQ ID           NO: 82)           HUMHPA1B_PEA_1_node_39 (SEQ ID           NO: 83)           HUMHPA1B_PEA_1_node_40 (SEQ ID           NO: 84)           HUMHPA1B_PEA_1_node_41 (SEQ ID           NO: 85)           HUMHPA1B_PEA_1_node_42 (SEQ ID           NO: 86)           HUMHPA1B_PEA_1_node_43 (SEQ ID           NO: 87)           HUMHPA1B_PEA_1_node_44 (SEQ ID           NO: 88)           HUMHPA1B_PEA_1_node_45 (SEQ ID           NO: 89)           HUMHPA1B_PEA_1_node_46 (SEQ ID           NO: 90)           HUMHPA1B_PEA_1_node_47 (SEQ ID           NO: 91)           HUMHPA1B_PEA_1_node_48 (SEQ ID           NO: 92)           HUMHPA1B_PEA_1_node_49 (SEQ ID           NO: 93)           HUMHPA1B_PEA_1_node_50 (SEQ ID           NO: 94)           HUMHPA1B_PEA_1_node_51 (SEQ ID           NO: 95)           HUMHPA1B_PEA_1_node_52 (SEQ ID           NO: 96)           HUMHPA1B_PEA_1_node_53 (SEQ ID           NO: 97)           HUMHPA1B_PEA_1_node_54 (SEQ ID           NO: 98)           HUMHPA1B_PEA_1_node_55 (SEQ ID           NO: 99)           HUMHPA1B_PEA_1_node_56 (SEQ ID           NO: 100)           HUMHPA1B_PEA_1_node_57 (SEQ ID           NO: 101)           HUMHPA1B_PEA_1_node_58 (SEQ ID           NO: 102)           HUMHPA1B_PEA_1_node_59 (SEQ ID           NO: 103)           HUMHPA1B_PEA_1_node_60 (SEQ ID           NO: 104)           HUMHPA1B_PEA_1_node_61 (SEQ ID           NO: 105)           HUMHPA1B_PEA_1_node_62 (SEQ ID           NO: 106)           HUMHPA1B_PEA_1_node_63 (SEQ ID           NO: 107)           HUMHPA1B_PEA_1_node_64 (SEQ ID           NO: 108)           HUMHPA1B_PEA_1_node_65 (SEQ ID           NO: 109)           HUMHPA1B_PEA_1_node_66 (SEQ ID           NO: 110)           HUMHPA1B_PEA_1_node_67 (SEQ ID           NO: 111)           HUMHPA1B_PEA_1_node_69 (SEQ ID           NO: 112)           HUMHPA1B_PEA_1_node_70 (SEQ ID           NO: 113)           HUMHPA1B_PEA_1_node_71 (SEQ ID           NO: 114)           HUMHPA1B_PEA_1_node_72 (SEQ ID           NO: 115)           HUMHPA1B_PEA_1_node_73 (SEQ ID           NO: 116)           HUMHPA1B_PEA_1_node_74 (SEQ ID           NO: 117)           HUMHPA1B_PEA_1_node_75 (SEQ ID           NO: 118)           HUMHPA1B_PEA_1_node_76 (SEQ ID           NO: 119)           HUMHPA1B_PEA_1_node_77 (SEQ ID           NO: 120)           HUMHPA1B_PEA_1_node_78 (SEQ ID           NO: 121)           HUMHPA1B_PEA_1_node_79 (SEQ ID           NO: 122)           UMHPA1B_PEA_1_node_80 (SEQ ID           NO: 123)           HUMHPA1B_PEA_1_node_81 (SEQ ID           NO: 124)           HUMHPA1B_PEA_1_node_82 (SEQ ID           NO: 125)           HUMHPA1B_PEA_1_node_83 (SEQ ID           NO: 126)           HUMHPA1B_PEA_1_node_84 (SEQ ID           NO: 127)           HUMHPA1B_PEA_1_node_85 (SEQ ID           NO: 128)           HUMHPA1B_PEA_1_node_86 (SEQ ID           NO: 129)           HUMHPA1B_PEA_1_node_87 (SEQ ID           NO: 130)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            HUMHPA1B_PEA_1_P61 (SEQ ID NO: 133)           HUMHPA1B_PEA_1_P62 (SEQ ID NO: 134)           HUMHPA1B_PEA_1_P64 (SEQ ID NO: 135)           HUMHPA1B_PEA_1_P65 (SEQ ID NO: 136)           HUMHPA1B_PEA_1_P68 (SEQ ID NO: 137)           HUMHPA1B_PEA_1_P72 (SEQ ID NO: 138)           HUMHPA1B_PEA_1_P75 (SEQ ID NO: 139)           HUMHPA1B_PEA_1_P76 (SEQ ID NO: 140)           HUMHPA1B_PEA_1_P81 (SEQ ID NO: 141)           HUMHPA1B_PEA_1_P83 (SEQ ID NO: 142)           HUMHPA1B_PEA_1_P106 (SEQ ID           NO: 143)           HUMHPA1B_PEA_1_P107 (SEQ ID           NO: 144)           HUMHPA1B_PEA_1_P115 (SEQ ID           NO: 145)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            HSHGFR_T1 (SEQ ID NO: 146)           HSHGFR_T6 (SEQ ID NO: 147)           HSHGFR_T8 (SEQ ID NO: 148)           HSHGFR_T13 (SEQ ID NO: 149)           HSHGFR_T14 (SEQ ID NO: 150)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HSHGFR_node_2 (SEQ ID NO: 151)           HSHGFR_node_2 (SEQ ID NO: 152)           HSHGFR_node_6 (SEQ ID NO: 153)           HSHGFR_node_11 (SEQ ID NO: 154)           HSHGFR_node_15 (SEQ ID NO: 155)           HSHGFR_node_16 (SEQ ID NO: 156)           HSHGFR_node_18 (SEQ ID NO: 157)           HSHGFR_node_22 (SEQ ID NO: 158)           HSHGFR_node_24 (SEQ ID NO: 159)           HSHGFR_node_8 (SEQ ID NO: 160)           HSHGFR_node_10 (SEQ ID NO: 161)           HSHGFR_node_14 (SEQ ID NO: 162)           HSHGFR_node_20 (SEQ ID NO: 163)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            HSHGFR_P6 (SEQ ID NO: 165)           HSHGFR_P11 (SEQ ID NO: 166)           HSHGFR_P12 (SEQ ID NO: 167)           HSHGFR_P13 (SEQ ID NO: 168)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            S56892_PEA_1_T3 (SEQ ID NO: 169)           S56892_PEA_1_T9 (SEQ ID NO: 170)           S56892_PEA_1_T10 (SEQ ID NO: 171)           S56892_PEA_1_T13 (SEQ ID NO: 172)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            S56892_PEA_1_node_0 (SEQ ID NO: 173)           S56892_PEA_1_node_5 (SEQ ID NO: 174)           S56892_PEA_1_node_10 (SEQ ID NO: 175)           S56892_PEA_1_node_18 (SEQ ID NO: 176)           S56892_PEA_1_node_21 (SEQ ID NO: 177)           S56892_PEA_1_node_3 (SEQ ID NO: 178)           S56892_PEA_1_node_4 (SEQ ID NO: 179)           S56892_PEA_1_node_6 (SEQ ID NO: 180)           S56892_PEA_1_node_7 (SEQ ID NO: 181)           S56892_PEA_1_node_8 (SEQ ID NO: 182)           S56892_PEA_1_node_9 (SEQ ID NO: 183)           S56892_PEA_1_node_12 (SEQ ID NO: 184)           S56892_PEA_1_node_13 (SEQ ID NO: 185)           S56892_PEA_1_node_14 (SEQ ID NO: 186)           S56892_PEA_1_node_16 (SEQ ID NO: 187)           S56892_PEA_1_node_17 (SEQ ID NO: 188)           S56892_PEA_1_node_19 (SEQ ID NO: 189)           S56892_PEA_1_node_20 (SEQ ID NO: 190)           S56892_PEA_1_node_22 (SEQ ID NO: 191)           S56892_PEA_1_node_23 (SEQ ID NO: 192)                      
 
      According to preferred embodiments, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            S56892_PEA_1_P2 (SEQ ID NO: 194)           S56892_PEA_1_P8 (SEQ ID NO: 195)           S56892_PEA_1_P9 (SEQ ID NO: 196)           S56892_PEA_1_P11 (SEQ ID NO: 197)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            HSIGFACI_PEA_1_T9 (SEQ ID NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID NO: 199)           HSIGFACI_PEA_1_T12 (SEQ ID NO: 200)           HSIGFACI_PEA_1_T15 (SEQ ID NO: 201)           HSIGFACI_PEA_1_T16 (SEQ ID NO: 202)           HSIGFACI_PEA_1_T17 (SEQ ID NO: 203)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HSIGFACI_PEA_1_node_0 (SEQ ID NO: 204)           HSIGFACI_PEA_1_node_2 (SEQ ID NO: 205)           HSIGFACI_PEA_1_node_6 (SEQ ID NO: 206)           HSIGFACI_PEA_1_node_9 (SEQ ID NO: 207)           HSIGFACI_PEA_1_node_11 (SEQ ID           NO: 208)           HSIGFACI_PEA_1_node_14 (SEQ ID           NO: 209)           HSIGFACI_PEA_1_node_19 (SEQ ID           NO: 210)           HSIGFACI_PEA_1_node_20 (SEQ ID           NO: 211)           HSIGFACI_PEA_1_node_21 (SEQ ID           NO: 212)           HSIGFACI_PEA_1_node_24 (SEQ ID           NO: 213)           HSIGFACI_PEA_1_node_25 (SEQ ID           NO: 214)           HSIGFACI_PEA_1_node_26 (SEQ ID           NO: 215)           HSIGFACI_PEA_1_node_27 (SEQ ID           NO: 216)           HSIGFACI_PEA_1_node_13 (SEQ ID           NO: 217)           HSIGFACI_PEA_1_node_22 (SEQ ID           NO: 218)           HSIGFACI_PEA_1_node_23 (SEQ ID           NO: 219)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            HSIGFACI_PEA_1_P5 (SEQ ID NO: 225)           HSIGFACI_PEA_1_P2 (SEQ ID NO: 226)           HSIGFACI_PEA_1_P6 (SEQ ID NO: 227)           HSIGFACI_PEA_1_P1 (SEQ ID NO: 228)           HSIGFACI_PEA_1_P7 (SEQ ID NO: 229)           HSIGFACI_PEA_1_P8 (SEQ ID NO: 230)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                  HSSTROMR_PEA_1_T3 (SEQ ID NO: 231)                  
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HSSTROMR_PEA_1_node_0 (SEQ ID           NO: 232)           HSSTROMR_PEA_1_node_5 (SEQ ID           NO: 233)           HSSTROMR_PEA_1_node_7 (SEQ ID           NO: 234)           HSSTROMR_PEA_1_node_9 (SEQ ID           NO: 235)           HSSTROMR_PEA_1_node_13 (SEQ ID           NO: 236)           HSSTROMR_PEA_1_node_16 (SEQ ID           NO: 237)           HSSTROMR_PEA_1_node_18 (SEQ ID           NO: 238)           HSSTROMR_PEA_1_node_20 (SEQ ID           NO: 239)           HSSTROMR_PEA_1_node_28 (SEQ ID           NO: 240)           HSSTROMR_PEA_1_node_14 (SEQ ID           NO: 241)           HSSTROMR_PEA_1_node_22 (SEQ ID           NO: 242)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            HSSTROMR_PEA_1_P4 (SEQ ID NO: 244)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            HUM4COLA_PEA_1_T1 (SEQ ID NO: 245)           HUM4COLA_PEA_1_T5 (SEQ ID NO: 246)           HUM4COLA_PEA_1_T6 (SEQ ID NO: 247)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HUM4COLA_PEA_1_node_0 (SEQ ID           NO: 248)           HUM4COLA_PEA_1_node_0 (SEQ ID           NO: 249)           HUM4COLA_PEA_1_node_4 (SEQ ID           NO: 250)           HUM4COLA_PEA_1_node_7 (SEQ ID           NO: 251)           HUM4COLA_PEA_1_node_11 (SEQ ID           NO: 252)           HUM4COLA_PEA_1_node_19 (SEQ ID           NO: 253)           HUM4COLA_PEA_1_node_40 (SEQ ID           NO: 254)           HUM4COLA_PEA_1_node_41 (SEQ ID           NO: 255)           HUM4COLA_PEA_1_node_8 (SEQ ID           NO: 256)           HUM4COLA_PEA_1_node_9 (SEQ ID           NO: 257)           HUM4COLA_PEA_1_node_10 (SEQ ID           NO: 258)           HUM4COLA_PEA_1_node_12 (SEQ ID           NO: 259)           HUM4COLA_PEA_1_node_13 (SEQ ID           NO: 260)           HUM4COLA_PEA_1_node_16 (SEQ ID           NO: 261)           HUM4COLA_PEA_1_node_17 (SEQ ID           NO: 262)           HUM4COLA_PEA_1_node_22 (SEQ ID           NO: 263)           HUM4COLA_PEA_1_node_23 (SEQ ID           NO: 264)           HUM4COLA_PEA_1_node_24 (SEQ ID           NO: 265)           HUM4COLA_PEA_1_node_25 (SEQ ID           NO: 266)           HUM4COLA_PEA_1_node_26 (SEQ ID           NO: 267)           HUM4COLA_PEA_1_node_27 (SEQ ID           NO: 268)           HUM4COLA_PEA_1_node_29 (SEQ ID           NO: 269)           HUM4COLA_PEA_1_node_30 (SEQ ID           NO: 270)           HUM4COLA_PEA_1_node_32 (SEQ ID           NO: 271)           HUM4COLA_PEA_1_node_33 (SEQ ID           NO: 272)           HUM4COLA_PEA_1_node_36 (SEQ ID           NO: 273)           HUM4COLA_PEA_1_node_37 (SEQ ID           NO: 274)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            HUM4COLA_PEA_1_P7 (SEQ ID NO: 276)           HUM4COLA_PEA_1_P14 (SEQ ID NO: 277)           HUM4COLA_PEA_1_P15 (SEQ ID NO: 278)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            HUMICAMA1A_PEA_1_T2 (SEQ ID           NO: 279)           HUMICAMA1A_PEA_1_T4 (SEQ ID           NO: 280)           HUMICAMA1A_PEA_1_T5 (SEQ ID           NO: 281)           HUMICAMA1A_PEA_1_T8 (SEQ ID           NO: 282)           HUMICAMA1A_PEA_1_T12 (SEQ ID           NO: 283)           HUMICAMA1A_PEA_1_T16 (SEQ ID           NO: 284)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HUMICAMA1A_PEA_1_node_0 (SEQ ID           NO: 285)           HUMICAMA1A_PEA_1_node_3 (SEQ ID           NO: 286)           HUMICAMA1A_PEA_1_node_12 (SEQ ID           NO: 287)           HUMICAMA1A_PEA_1_node_13 (SEQ ID           NO: 288)           HUMICAMA1A_PEA_1_node_14 (SEQ ID           NO: 289)           HUMICAMA1A_PEA_1_node_20 (SEQ ID           NO: 290)           HUMICAMA1A_PEA_1_node_21 (SEQ ID           NO: 291)           HUMICAMA1A_PEA_1_node_24 (SEQ ID           NO: 292)           HUMICAMA1A_PEA_1_node_25 (SEQ ID           NO: 293)           HUMICAMA1A_PEA_1_node_27 (SEQ ID           NO: 294)           HUMICAMA1A_PEA_1_node_29 (SEQ ID           NO: 295)           HUMICAMA1A_PEA_1_node_2 (SEQ ID           NO: 296)           HUMICAMA1A_PEA_1_node_4 (SEQ ID           NO: 297)           HUMICAMA1A_PEA_1_node_15 (SEQ ID           NO: 298)           HUMICAMA1A_PEA_1_node_16 (SEQ ID           NO: 299)           HUMICAMA1A_PEA_1_node_17 (SEQ ID           NO: 300)           HUMICAMA1A_PEA_1_node_18 (SEQ ID           NO: 301)           HUMICAMA1A_PEA_1_node_19 (SEQ ID           NO: 302)           HUMICAMA1A_PEA_1_node_22 (SEQ ID           NO: 303)           HUMICAMA1A_PEA_1_node_23 (SEQ ID           NO: 304)           HUMICAMA1A_PEA_1_node_26 (SEQ ID           NO: 305)           HUMICAMA1A_PEA_1_node_28 (SEQ ID           NO: 306)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Protein Name                                            HUMICAMA1A_PEA_1_P2 (SEQ ID           NO: 309)           HUMICAMA1A_PEA_1_P5 (SEQ ID           NO: 310)           HUMICAMA1A_PEA_1_P8 (SEQ ID           NO: 311)           HUMICAMA1A_PEA_1_P15 (SEQ ID           NO: 312)                      
 
      According to preferred embodiments of the present invention, there is provided a nucleic acid sequence comprising a sequence from the table below; and/or  
                               Transcript Name                                            HUMLYSYL_PEA_1_T2 (SEQ ID NO: 313)           HUMLYSYL_PEA_1_T4 (SEQ ID NO: 314)           HUMLYSYL_PEA_1_T5 (SEQ ID NO: 315)           HUMLYSYL_PEA_1_T6 (SEQ ID NO: 316)           HUMLYSYL_PEA_1_T8 (SEQ ID NO: 317)           HUMLYSYL_PEA_1_T9 (SEQ ID NO: 318)           HUMLYSYL_PEA_1_T19 (SEQ ID NO: 319)           HUMLYSYL_PEA_1_T20 (SEQ ID NO: 320)           HUMLYSYL_PEA_1_T22 (SEQ ID NO: 321)           HUMLYSYL_PEA_1_T24 (SEQ ID NO: 322)                      
 
      a nucleic acid sequence comprising a sequence from the table below:  
                               Segment Name                                            HUMLYSYL_PEA_1_node_6 (SEQ ID           NO: 323)           HUMLYSYL_PEA_1_node_14 (SEQ ID           NO: 324)           HUMLYSYL_PEA_1_node_19 (SEQ ID           NO: 325)           HUMLYSYL_PEA_1_node_38 (SEQ ID           NO: 326)           HUMLYSYL_PEA_1_node_55 (SEQ ID           NO: 327)           HUMLYSYL_PEA_1_node_59 (SEQ ID           NO: 328)           HUMLYSYL_PEA_1_node_61 (SEQ ID           NO: 329)           HUMLYSYL_PEA_1_node_62 (SEQ ID           NO: 330)           HUMLYSYL_PEA_1_node_65 (SEQ ID           NO: 331)           HUMLYSYL_PEA_1_node_71 (SEQ ID           NO: 332)           HUMLYSYL_PEA_1_node_72 (SEQ ID           NO: 333)           HUMLYSYL_PEA_1_node_3 (SEQ ID           NO: 334)           HUMLYSYL_PEA_1_node_4 (SEQ ID           NO: 335)           HUMLYSYL_PEA_1_node_8 (SEQ ID           NO: 336)           HUMLYSYL_PEA_1_node_10 (SEQ ID           NO: 337)           HUMLYSYL_PEA_1_node_11 (SEQ ID           NO: 338)           HUMLYSYL_PEA_1_node_12 (SEQ ID           NO: 339)           HUMLYSYL_PEA_1_node_16 (SEQ ID           NO: 340)           HUMLYSYL_PEA_1_node_20 (SEQ ID           NO: 341)           HUMLYSYL_PEA_1_node_23 (SEQ ID           NO: 342)           HUMLYSYL_PEA_1_node_25 (SEQ ID           NO: 343)           HUMLYSYL_PEA_1_node_28 (SEQ ID           NO: 344)           HUMLYSYL_PEA_1_node_30 (SEQ ID           NO: 345)           HUMLYSYL_PEA_1_node_31 (SEQ ID           NO: 346)           HUMLYSYL_PEA_1_node_33 (SEQ ID           NO: 347)           HUMLYSYL_PEA_1_node_34 (SEQ ID           NO: 348)           HUMLYSYL_PEA_1_node_36 (SEQ ID           NO: 349)           HUMLYSYL_PEA_1_node_40 (SEQ ID           NO: 350)           HUMLYSYL_PEA_1_node_41 (SEQ ID           NO: 351)           HUMLYSYL_PEA_1_node_42 (SEQ ID           NO: 352)           HUMLYSYL_PEA_1_node_44 (SEQ ID           NO: 353)           HUMLYSYL_PEA_1_node_45 (SEQ ID           NO: 354)           HUMLYSYL_PEA_1_node_46 (SEQ ID           NO: 355)           HUMLYSYL_PEA_1_node_48 (SEQ ID           NO: 356)           HUMLYSYL_PEA_1_node_49 (SEQ ID           NO: 357)           HUMLYSYL_PEA_1_node_52 (SEQ ID           NO: 358)           HUMLYSYL_PEA_1_node_53 (SEQ ID           NO: 359)           HUMLYSYL_PEA_1_node_56 (SEQ ID           NO: 360)           HUMLYSYL_PEA_1_node_63 (SEQ ID           NO: 361)           HUMLYSYL_PEA_1_node_64 (SEQ ID           NO: 362)           HUMLYSYL_PEA_1_node_66 (SEQ ID           NO: 363)           HUMLYSYL_PEA_1_node_67 (SEQ ID           NO: 364)           HUMLYSYL_PEA_1_node_68 (SEQ ID           NO: 365)           HUMLYSYL_PEA_1_node_70 (SEQ ID           NO: 366)                      
 
      According to preferred embodiments of the present invention, there is provided an amino acid sequence comprising a sequence from the table below:  
                               Pretein Name                                            HUMLYSYL_PEA_1_P2 (SEQ ID NO: 369)           HUMLYSYL_PEA_1_P4 (SEQ ID NO: 370)           HUMLYSYL_PEA_1_P5 (SEQ ID NO: 371)           HUMLYSYL_PEA_1_P6 (SEQ ID NO: 372)           HUMLYSYL_PEA_1_P7 (SEQ ID NO: 373)           HUMLYSYL_PEA_1_P13 (SEQ ID NO: 374)           HUMLYSYL_PEA_1_P14 (SEQ ID NO: 375)           HUMLYSYL_PEA_1_P16 (SEQ ID NO: 376)           HUMLYSYL_PEA_1_P18 (SEQ ID NO: 377)           HUMLYSYL_PEA_1_P24 (SEQ ID NO: 378)                      
 
      According to preferred embodiments of the present invention, preferably any of the above nucleic acid and/or amino acid sequences further comprises any sequence having at least about 70%, preferably at least about 80%, more preferably at least about 90%, most preferably at least about 95% homology thereto.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQ corresponding to amino acids 1-490 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-490 of HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSQERAAQDALWMGQAGRMCSCS (SEQ ID NO:474) corresponding to amino acids 491-513 of HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSQERAAQDALWMGQAGRMCSCS (SEQ ID NO:474) in HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPE corresponding to amino acids 1-25 of PLO1_HUMAN_V1 (SEQ ID NO:3681, which also corresponds to amino acids 1-25 of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence APCCQEGLRAGGSGSLHLGRDFTVLAGARGSPSPSVSSIPRFWIPGS (SEQ ID NO:504) corresponding to amino acids 26-72 of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), and a third amino acid sequence being at least 90% homologous to DNLLVLTVATKETEGFRRFKRSAQFFNYKIQALGLGEDWNVEKGTSAGGGQKVRLLK KALEKHADKEDLVILFADSYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETK YPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITLD HRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYLGNYIPR FWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQRLLRLHYPQKHMR LFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARNMGADLCRQDRSCT YYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWGALSADGYYARSED YVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDV FMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHMNQIGFE REWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSLMPHHDASTFTINIAL NRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEGLPTTRGTRYIAVSFVD P corresponding to amino acids 26-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 73-774 of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for APCCQEGLRAGGSGSLHLGRDFTVLAGARGSPSPSVSSIPRFWIPGS (SEQ ID NO:504), corresponding to HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIG corresponding to amino acids 1-281 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-281 of HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371), and a second amino acid sequence being at least 90% homologous to RLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARN MGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWG ALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQS SDLFHHSKLDP DMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIH QNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGY ENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPS LMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEG LPTTRGTRYIAVSFVDP corresponding to amino acids 307-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 282-702 of HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P5 (SE ID NO:371), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise GR, having a structure as follows: a sequence starting from any of amino acid numbers 281−x to 281; and ending at any of amino acid numbers 282+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKI corresponding to amino acids 1-55 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-55 of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence QPVLRGVSL (SEQ ID NO:505) corresponding to amino acids 56-64 of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), and a third amino acid sequence being at least 90% homologous to QALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRE LLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEW EGQDSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARN LAYDTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVL VGVFIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVK LVGPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIA PLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALR GELQS SDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLW EVFSNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQW SLGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFD LAFVVRYKPDEQPSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIAAPRKGW TLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP corresponding to amino acids 56-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 65-736 of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for QPVLRGVSL (SEQ ID NO:505), corresponding to HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGAL corresponding to amino acids 1-214 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-214 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSPWGQGHLPGACYELTASVLTSELSVMPSFPA (SEQ ID NO:506) corresponding to amino acids 215-247 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), a third amino acid sequence being at least 90% homologous to VV corresponding to amino acids 217-218 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 248-249 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), and a fourth amino acid sequence being at least 90% homologous to LQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQR LLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARN MGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWG ALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQS SDLFHHSKLDP DMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIH QNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGY ENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPS LMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEG LPTTRGTRYIAVSFVDP corresponding to amino acids 248-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 250-729 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), wherein said first amino acid sequence, second amino acid sequence, third amino acid sequence and fourth amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for VSPWGQGHLPGACYELTASVLTSELSVMPSFPA (SEQ ID NO:506), corresponding to HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373).  
      According to preferred embodiments of the present invention, there is provided a bridge portion of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise LV, having a structure as follows (numbering according to HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373)): a sequence starting from any of amino acid numbers 214−x to 214; and ending at any of amino acid numbers 215+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise VL, having a structure as follows: a sequence starting from any of amino acid numbers 249−x to 249; and ending at any of amino acid numbers 250+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVF SNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLG NNK corresponding to amino acids 1-585 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-585 of HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GCPESGTSASMAGHESKP (SEQ ID NO:475) corresponding to amino acids 586-603 of HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GCPESGTSASMAGHESKP (SEQ ID NO:475) in HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVF SNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLG NNK corresponding to amino acids 1-585 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-585 of HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TATPENLLGDRRGICAQLDLLLACGEGSDRSTHHTGSPCPGCL (SEQ ID NO:476) corresponding to amino acids 586-628 of HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TATPENLLGDRRGICAQLDLLLACGEGSDRSTHHTGSPCPGCL (SEQ ID NO:476) in HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVF SNPEDWKEKYIHQNYTKALAGKLVET corresponding to amino acids 1-550 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-550 of HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRAMDTLLDQPCLLQGAGHRRETACPGEWGTAGWEL (SEQ ID NO:477) corresponding to amino acids 551-586 of HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRAMDTLLDQPCLLQGAGHRRETACPGEWGTAGWEL (SEQ ID NO:477) in HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKR corresponding to amino acids 1-193 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-193 of HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSRLHS (SEQ ID NO:478) corresponding to amino acids 194-199 of HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSRLHS (SEQ ID NO:478) in HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIE TPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELA PLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRR DHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVV CSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILG NQSQETLQTVTIYS corresponding to amino acids 1-309 of ICA1_HUMAN (SEQ ID NO:307), which also corresponds to amino acids 1-309 of HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KKGQGRSGASWGCDLNPGRGSLCAYSRLSGAQRDSDEARGLRRDRGDSEV (SEQ ID NO:479) corresponding to amino acids 310-359 of HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KKGQGRSGASWGCDLNPGRGSLCAYSRLSGAQRDSDEARGLRRDRGDSEV (SEQ ID NO:479) in HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIE TPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELA PLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRR DHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSRVLEVDTQGTVVC SLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGN QSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQL LLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVL corresponding to amino acids 1-393 of ICA1_HUMAN (SEQ ID NO:307), which also corresponds to amino acids 1-393 of HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence CEWGCWSMAPIPQGPISLKVP (SEQ ID NO:480) corresponding to amino acids 394-414 of HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence CEWGCWSMAPIPQGPISLKVP (SEQ ID NO:480) in HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPG corresponding to amino acids 1-23 of ICA1_HUMAN_V1 (SEQ ID NO:308), which also corresponds to amino acids 1-23 of HUMICAMA1A_PEA_L_P8 (SEQ ID NO:311), and a second amino acid sequence being at least 90% homologous to TPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEV TTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLE VDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQ RLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVP AQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPG NWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQ GEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTP MKPNTQATPP corresponding to amino acids 112-532 of ICA1_HUMAN_V1 (SEQ ID NO:308), which also corresponds to amino acids 24-444 of HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise GT, having a structure as follows: a sequence starting from any of amino acid numbers 23−x to 23; and ending at any of amino acid numbers 24+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIE TPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELA PLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRR DHHGANFSCRTELDLRPQGLELFENTSAPYQLQTF corresponding to amino acids 1-212 of ICA1_HUMAN (SEQ ID NO:307), which also corresponds to amino acids 1-212 of HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GED corresponding to amino acids 213-215 of HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUM4COLA_PEA — 1_P7 (SEQ ID NO:276), comprising a first amino acid sequence being at least 90% homologous to MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVA EMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKW HHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEH GDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHF PFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFP FIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVF PFTFLGKE corresponding to amino acids 1-357 of MM09_HUMAN (SEQ ID NO:275), which also corresponds to amino acids 1-357 of HUM4COLA_PEA — 1_P7 (SEQ ID NO:276), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SSP (SEQ ID NO:481) corresponding to amino acids 358-360 of HUM4COLA_PEA — 1_P7 (SEQ ID NO:276), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUM4COLA-PEA — 1_P7 (SEQ ID NO:276), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SSP (SEQ ID NO:481) in HUM4COLA_PEA — 1_P7 (SEQ ID NO:276).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUM4COLA_PEA — 1_P14 (SEQ ID NO:277), comprising a first amino acid sequence being at least 90% homologous to MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVA EMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKW HHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEH GDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHF PFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSE corresponding to amino acids 1-274 of MM09_HUMAN (SEQ ID NO:275), which also corresponds to amino acids 1-274 of HUM4COLA_PEA — 1_P14 (SEQ ID NO:277), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SE corresponding to amino acids 275-276 of HUM4COLA_PEA — 1_P14 (SEQ ID NO:277), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), comprising a first amino acid sequence being at least 90% homologous to MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVA EMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKW HHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEH GDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGV corresponding to amino acids 1-216 of MM09_HUMAN (SEQ ID NO:275), which also corresponds to amino acids 1-216 of HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GEILSPPGP (SEQ ID NO:482) corresponding to amino acids 217-225 of HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GEILSPPGP (SEQ ID NO:482) in HUM4COLA_PEA — 1_P15 (SEQ ID NO:278).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), comprising a first amino acid sequence being at least 90% homologous to MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLV corresponding to amino acids 1-34 of MM03_HUMAN (SEQ ID NO:243), which also corresponds to amino acids 1-34 of HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), and a second amino acid sequence being at least 90% homologous to QKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLP KDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHA YAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHS LTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLR GEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIR GNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFP KQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC corresponding to amino acids 68-477 of MM03_HUMAN (SEQ ID NO:243), which also corresponds to amino acids 35-444 of HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise VQ, having a structure as follows: a sequence starting from any of amino acid numbers 34−x to 34; and ending at any of amino acid numbers 35+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPTVK (SEQ ID NO:483) corresponding to amino acids 1-7 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), a second amino acid sequence being at least 90% homologous to MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSS SRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK corresponding to amino acids 1-111 of Q9NP10 (SEQ ID NO:222), which also corresponds to amino acids 8-118 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) corresponding to amino acids 119-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPTVK (SEQ ID NO:483) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTS SATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKYQP PSTNKNTKSQRRKGSTFEERK corresponding to amino acids 3-139 of Q13429 (SEQ ID NO:224), which also corresponds to amino acids 6-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKYQP PSTNKNTKSQRRKG corresponding to amino acids 22-151 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 6-135 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence STFEERK corresponding to amino acids 136-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence STFEERK in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 90% homologous to MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNK PTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQ K corresponding to amino acids 1-118 of Q14620 (SEQ ID NO:221), which also corresponds to amino acids 1-118 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) corresponding to amino acids 119-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK corresponding to amino acids 22-134 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 6-118 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) corresponding to amino acids 119-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), and a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKEVH LKNASRGSAGNKNYRM (SEQ ID NO:487) corresponding to amino acids 22-153 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 6-137 of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELV DALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKS ARSVRAQRHTDMPKTQK corresponding to amino acids 1-134 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 1-134 of HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGK KGK (SEQ ID NO:486) corresponding to amino acids 135-195 of HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGK KGK (SEQ ID NO:486) in HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELV DALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKS ARSVRAQRHTDMPKTQK corresponding to amino acids 1-134 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 1-134 of HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence EVHLKNASRGSAGNKNYRM (SEQ ID NO:487) corresponding to amino acids 135-153 of HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence EVHLKNASRGSAGNKNYRM (SEQ ID NO:487) in HSIGFACI_PEA — 1_P1 (SEQ ID NO:228).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELV DALQFVCGDRGFYF corresponding to amino acids 1-73 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 1-73 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 74-108 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P7 (SEQ ID NO:229).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTS SATAGPETLCGAELV DALQFVCGDRGFYF corresponding to amino acids 1-73 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 1-73 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 74-108 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P7 (SEQ ID NO:229).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPTVK (SEQ ID NO:483) corresponding to amino acids 1-7 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 1-50 of Q9NP10 (SEQ ID NO:222), which also corresponds to amino acids 8-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPTVK (SEQ ID NO:483) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 3-54 of Q13429 (SEQ ID NO:224), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 90% homologous to MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 1-57 of Q14620 (SEQ ID NO:221), which also corresponds to amino acids 1-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 22-73 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 22-73 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 3-54 of Q13429 (SEQ ID NO:224), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 90% homologous to MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 1-57 of Q14620 (SEQ ID NO:221), which also corresponds to amino acids 1-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 22-73 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 22-73 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for S56892_PEA — 1_P2 (SEQ ID NO:194), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MNSFSTSKCRKSLALELPAAVEPCVREGCVAQGGLAGGQQQRQAPSCAVSSPLRSLPS GTG (SEQ ID NO:491) corresponding to amino acids 1-61 of S56892_PEA — 1_P2 (SEQ ID NO:194), and a second amino acid sequence being at least 90% homologous to AFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALR KETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLE YLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQW LQDMTTHLILRSFKEFLQSSLRALRQM corresponding to amino acids 8-212 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 62-266 of S56892_PEA — 1_P2 (SEQ ID NO:194), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a head of S56892_PEA — 1_P2 (SEQ ID NO:194), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MNSFSTSKCRKSLALELPAAVEPCVREGCVAQGGLAGGQQQRQAPSCAVSSPLRSLPS GTG (SEQ ID NO:491) of S56892_PEA — 1_P2 (SEQ ID NO:194).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for S56892_PEA — 1_P8 (SEQ ID NO:195), comprising a first amino acid sequence being at least 90% homologous to MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYIL DGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLL EFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKK corresponding to amino acids 1-157 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 1-157 of S56892_PEA — 1_P8 (SEQ ID NO:195), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGVSSFPQLGVGEDRLKDSVLDNSGMQCHFQKRRLHVNKRV (SEQ ID NO:492) corresponding to amino acids 158-198 of S56892-PEA — 1_P8 (SEQ ID NO:195), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of S56892_PEA — 1_P8 (SEQ ID NO:195), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VGVSSFPQLGVGEDRLKDSVLDNSGMQCHFQKRRLHVNKRV (SEQ ID NO:492) in S56892_PEA — 1_P8 (SEQ ID NO:195).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for S56892_PEA — 1_P9 (SEQ ID NO:196), comprising a first amino acid sequence being at least 90% homologous to MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYIL DGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNE corresponding to amino acids 1-108 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 1-108 of S56892_PEA — 1_P9 (SEQ ID NO:196), and a second amino acid sequence being at least 90% homologous to AKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM corresponding to amino acids 158-212 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 109-163 of S56892_PEA — 1_P9 (SEQ ID NO:196), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of S56892_PEA — 1_P9 (SEQ ID NO:196), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EA, having a structure as follows: a sequence starting from any of amino acid numbers 108−x to 108; and ending at any of amino acid numbers 109+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for S56892_PEA — 1_P11 (SEQ ID NO:197), comprising a first amino acid sequence being at least 90% homologous to MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYIL DGISALRKETCNKSN corresponding to amino acids 1-76 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 1-76 of S56892_PEA — 1_P11 (SEQ ID NO:197), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence IWLKKMDASNLDSMRRLAW (SEQ ID NO:493) corresponding to amino acids 77-95 of S56892_PEA — 1_P11 (SEQ ID NO:197), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of S56892_PEA — 1_P11 (SEQ ID NO:197), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence IWLKKMDASNLDSMRRLAW (SEQ ID NO:493) in S56892_PEA — 1_P11 (SEQ ID NO:197).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSHGFR_P6 (SEQ ID NO:165), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCR NPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWD HQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCA corresponding to amino acids 1-289 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 1-289 of HSHGFR_P6 (SEQ ID NO:165), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence E corresponding to amino acids 290-290 of HSHGFR_P6 (SEQ ID NO:165), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSHGFR_P11 (SEQ ID NO:166), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEH corresponding to amino acids 1-160 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 1-160 of HSHGFR_P11 (SEQ ID NO:166), a second amino acid sequence being at least 90% homologous to SYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSE corresponding to amino acids 166-208 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 161-203 of HSHGFR_P11 (SEQ ID NO:166), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GK corresponding to amino acids 204-205 of HSHGFR_P11 (SEQ ID NO:166), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HSHGFR_P11 (SEQ ID NO:166), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise HS, having a structure as follows: a sequence starting from any of amino acid numbers 160−x to 160; and ending at any of amino acid numbers 161+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSHGFR_P12 (SEQ ID NO:167), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEH corresponding to amino acids 1-160 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 1-160 of HSHGFR_P12 (SEQ ID NO:167), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence R corresponding to amino acids 161-161 of HSHGFR_P12 (SEQ ID NO:167), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HSHGFR_P13 (SEQ ID NO:168), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCR NPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWD HQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIK corresponding to amino acids 1-286 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 1-286 of HSHGFR_P13 (SEQ ID NO:168), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NMRDITWALN (SEQ ID NO:494) corresponding to amino acids 287-296 of HSHGFR_P13 (SEQ ID NO:168), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HSHGFR_P13 (SEQ ID NO:168), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NMRDITWALN (SEQ ID NO:494) in HSHGFR_P13 (SEQ ID NO:168).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDI corresponding to amino acids 1-28 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-28 of HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), and a second amino acid sequence being at least 90% homologous to ADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPE CEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTA KNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLIKLKQKVSVNE RVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPVADQDQCIRHYEGST VPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAVHDLEEDTWYATGIL SFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 88-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 29-347 of HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IA, having a structure as follows: a sequence starting from any of amino acid numbers 28−x to 28; and ending at any of amino acid numbers 29+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDG corresponding to amino acids 1-64 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-64 of HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) corresponding to amino acids 65-83 of HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) in HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWfNKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNY YKLRTEGDG corresponding to amino acids 1-123 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-123 of HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) corresponding to amino acids 124-142 of HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMEPA1B_PEA — 1_P64 (SEQ ID NO:135), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) in HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNY YKLRTEGDGVYTLNNEKQWINKAVGDKLPECEA corresponding to amino acids 1-147 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-147 of HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GGC corresponding to amino acids 148-150 of HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDK corresponding to amino acids 1-71 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-71 of HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137), and a second amino acid sequence being at least 90% homologous to KQWINKAVGDKLPECEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTT GATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVD IGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPV ADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAV HDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 131-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 72-347 of HUMHPA1B_PEA — 1P68 (SEQ ID NO:137), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1P68 (SEQ ID NO:137), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KK, having a structure as follows: a sequence starting from any of amino acid numbers 71−x to 71; and ending at any of amino acid numbers 72+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGD corresponding to amino acids 1-63 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-63 of HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ESGKPSAADPGWTPGCQRQLSLAG (SEQ ID NO:497) corresponding to amino acids 64-87 of HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ESGKPSAADPGWTPGCQRQLSLAG (SEQ ID NO:497) in HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNY YKLRTEGDGVYTLNNEKQWINKAVGDKLPECEA corresponding to amino acids 1-147 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-147 of HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), and a second amino acid sequence being at least 90% homologous to GATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVD IGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPV ADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAV HDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 188-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 148-366 of HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AG, having a structure as follows: a sequence starting from any of amino acid numbers 147−x to 147; and ending at any of amino acid numbers 148+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQ corresponding to amino acids 1-51 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-51 of HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), a second amino acid sequence bridging amino acid sequence comprising of L, and a third amino acid sequence being at least 90% homologous to QRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTAKNLFLNHSENATAKDI APTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLIKLKQKVSVNERVMPICLPSKDYAEVG RVGYVSGWGRNANFKFTDHLKYVMLPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPIL NEHTFCAGMSKYQEDTCYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVK VTSIQDWVQKTIAEN corresponding to amino acids 160-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 53-299 of HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least three amino acids comprise QLQ having a structure as follows (numbering according to HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140)): a sequence starting from any of amino acid numbers 51−x to 51; and ending at any of amino acid numbers 53+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEA corresponding to amino acids 1-88 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-88 of HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), and a second amino acid sequence being at least 90% homologous to GATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVD IGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPV ADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAV HDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 188-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 89-307 of HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AG, having a structure as follows: a sequence starting from any of amino acid numbers 88−x to 88; and ending at any of amino acid numbers 89+((n−2)−x), in which x varies from 0 to n−2.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMBPA1B_PEA — 1_P83 (SEQ ID NO:142), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIAD corresponding to amino acids 1-30 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-30 of HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GFPP (SEQ ID NO:498) corresponding to amino acids 31-34 of HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GFPP (SEQ ID NO:498) in HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNN corresponding to amino acids 1-70 of HPT_HUMAN_V1 (SEQ ID NO:132), which also corresponds to amino acids 1-70 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), a bridging amino acid E corresponding to amino acid 71 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), a bridging amino acid E corresponding to amino acid 71 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), a second amino acid sequence being at least 90% homologous to KQWINKAVGDKLPECEA corresponding to amino acids 72-88 of HPT_HUMAN_V1 (SEQ ID NO:132), which also corresponds to amino acids 72-88 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AHTE (SEQ ID NO:499) corresponding to amino acids 89-92 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), wherein said first amino acid sequence, bridging amino acid, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence AHTE (SEQ ID NO:499) in HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDI corresponding to amino acids 1-28 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-28 of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), a second amino acid sequence being at least 90% homologous to ADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPE CEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTT corresponding to amino acids 88-187 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 29-128 of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPLPFTTWRRTPGMRLGS (SEQ ID NO:500) corresponding to amino acids 129-146 of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IA, having a structure as follows: a sequence starting from any of amino acid numbers 28-x to 28; and ending at any of amino acid numbers 29+((n−2)−x), in which x varies from 0 to n-2.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPLPFTTWRRTPGMRLGS (SEQ ID NO:500) in HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEA corresponding to amino acids 1-88 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-88 of HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GGC corresponding to amino acids 89-91 of HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMELAM1A_P2 (SEQ ID NO:31), comprising a first amino acid sequence being at least 90% homologous to MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYL NSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIK REKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKC EQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPI PACNVVECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNW DNEKPTCKAVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECT TQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKR LQCGPTGEWDNEKPTCE corresponding to amino acids 1-426 of LEM2_HUMAN (SEQ ID NO:30), which also corresponds to amino acids 1-426 of HUMELAM1A_P2 (SEQ ID NO:31), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GTVFVFILF (SEQ ID NO:501) corresponding to amino acids 427-435 of HUMELAM1A_P2 (SEQ ID NO:31, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMELAM1A_P2 (SEQ ID NO:31, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GTVFVFILF (SEQ ID NO:501) in HUMELAM1A_P2 (SEQ ID NO:31).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for S71513_P2 (SEQ ID NO:9), comprising a first amino acid sequence being at least 90% homologous to MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCP KEAV corresponding to amino acids 1-64 of SY02_HUMAN, which also corresponds to amino acids 1-64 of S71513_P2 (SEQ ID NO:9), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence M corresponding to amino acids 65-65 of S71513_P2 (SEQ ID NO:9, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMELAM1A_P2 (SEQ ID NO:32), comprising a first amino acid sequence being at least 90% homologous to MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYL NSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIK REKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKC EQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPI PACN corresponding to amino acids 1-238 of LEM2_HUMAN (SEQ ID NO:30), which also corresponds to amino acids 1-238 of HUMELAM1A_P2 (SEQ ID NO:32, and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GKSL (SEQ ID NO:502) corresponding to amino acids 239-242 of HUMELAM1A_P2 (SEQ ID NO:32), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMELAM1A_P2 (SEQ ID NO:32, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GKSL (SEQ ID NO:502) in HUMELAM1A_P2 (SEQ ID NO:32).  
      According to preferred embodiments of the present invention, there is provided an isolated chimeric polypeptide encoding for HUMELAM1A_P2 (SEQ ID NO:33), comprising a first amino acid sequence being at least 90% homologous to MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYL NSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIK REKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKC EQ corresponding to amino acids 1-176 of LEM2_HUMAN (SEQ ID NO:30, which also corresponds to amino acids 1-176 of HUMELAM1A_P2 (SEQ ID NO:33), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SKSGSCLFLHLRW (SEQ ID NO:503) corresponding to amino acids 177-189 of HUMELAM1A_P2 (SEQ ID NO:33), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      According to preferred embodiments of the present invention, there is provided an isolated polypeptide encoding for a tail of HUMELAM1A_P2 (SEQ ID NO:33), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SKSGSCLFLHLRW (SEQ ID NO:503) in HUMELAM1A_P2 (SEQ ID NO:33).  
      According to preferred embodiments of the present invention, there is provided an antibody capable of specifically binding to an epitope of an amino acid sequence as described herein. Optionally and preferably, the amino acid sequence corresponds to a bridge, edge portion, tail, head or insertion as in any of the above described embodiments. For example, the amino acid sequence may optionally correspond to a bridge including amino acids 64 and 65 of SEQ ID NO: 9, of at least about 10 amino acids (amino acids 55-65 of SEQ ID NO:9), preferably at least about 20 amino acids (amino acids 45-65 of SEQ ID NO:9), more preferably at least about 30 amino acids (amino acids 35-65 of SEQ ID NO:9) and most preferably at least about 40 amino acids (amino acids 25-65 of SEQ ID NO:9) in length. More preferably, the antibody is capable of differentiating between a splice variant having the epitope and a corresponding known protein.  
      According to preferred embodiments of the present invention, there is provided kit for detecting endometriosis, comprising a kit detecting overexpression of a splice variant according to the above described embodiments. Optionally, the kit comprises a NAT-based technology. Also optionally, the kit further comprises at least one primer pair capable of selectively hybridizing to a nucleic acid sequence according to any of the above described embodiments. Preferably, the kit further comprises at least one oligonucleotide capable of selectively hybridizing to a nucleic acid sequence according to any of the above described embodiments. More preferably, the kit comprises an antibody as described herein. Most preferably, the kit further comprises at least one reagent for performing an ELISA or a Western blot.  
      According to preferred embodiments of the present invention, there is provided a method for detecting endometriosis, comprising detecting overexpression and/or underexpression of a splice variant according to any of the above described embodiments. Optionally, detecting overexpression is performed with a NAT-based technology. Alternatively, detecting overexpression is performed with an immunoassay. Preferably, the immunoassay comprises an antibody according to any of the above described embodiments.  
      According to preferred embodiments of the present invention, there is provided a biomarker capable of detecting endometriosis, comprising any of the above nucleic acid sequences or a fragment thereof, or any of the above amino acid sequences or a fragment thereof.  
      According to preferred embodiments of the present invention, there is provided method for screening for endometriosis, comprising detecting endometriosis cells with a biomarker or an antibody or a method or assay according to any of the above described embodiments or as described herein.  
      According to preferred embodiments of the present invention, there is provided a method for diagnosing endometriosis, comprising detecting endometriosis cells with a biomarker or an antibody or a method or assay according to any of the above described embodiments or as described herein.  
      According to preferred embodiments of the present invention, there is provided a method for monitoring disease progression and/or treatment efficacy and/or relapse of endometriosis, comprising detecting endometriosis cells with a biomarker or an antibody or a method or assay according to any of the above described embodiments or as described herein.  
      According to preferred embodiments of the present invention, there is provided a method of selecting a therapy for endometriosis, comprising detecting endometriosis cells with a biomarker or an antibody or a method or assay according to any of the above described embodiments or as described herein, and selecting a therapy according to the detection.  
      Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale &amp; Marham, The Harper Collins Dictionary of Biology (1991). All of these are hereby incorporated by reference as if fully set forth herein. As used herein, the following terms have the meanings ascribed to them unless specified otherwise. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS  
      In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:  
       FIG. 1  shows a comparison of the human and mouse CHL2 variant I and CHL proteins.  
       FIG. 2  shows a schematic representation of the human and mouse CHL2 and CHL genes (sequence identification numbers as for  FIG. 1 ).  
       FIG. 3  shows alternative splicing of the hCHL2 gene.  
    
    
     DESCRIPTION OF PREFERRED EMBODIMENTS  
      The present invention is of novel markers for endometriosis that are both sensitive and accurate.  
      These markers are differentially expressed, and preferably in endometriosis specifically, as opposed to normal tissues. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of endometriosis. The markers of the present invention, alone or in combination, show a high degree of differential detection between normal and endometriosis states. The markers of the present invention, alone or in combination, can be used for prognosis, prediction, screening, early diagnosis, staging, therapy selection and treatment monitoring of endometriosis. For example, optionally and preferably, these markers may be used for staging endometriosis and/or monitoring the progression of the disease. Also, one or more of the markers may optionally be used in combination with one or more other endometriosis markers (other than those described herein).  
      Biomolecular sequences (amino acid and/or nucleic acid sequences) uncovered using the methodology of the present invention and described herein can be efficiently utilized as tissue or pathological markers and/or as drugs or drug targets for treating or preventing a disease.  
      These markers are specifically released to the bloodstream under conditions of endometriosis, and/or are otherwise expressed at a much higher level and/or specifically expressed in endometrial tissue or cells. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of endometriosis.  
      The present invention therefore also relates to diagnostic assays for endometriosis, and methods of use of such markers for detection of endometriosis, optionally and preferably in a sample taken from a subject (patient), which is more preferably some type of blood sample.  
      In another embodiment, the present invention relates to bridges, tails, heads and/or insertions, and/or analogs, homologs and derivatives of such peptides. Such bridges, tails, heads and/or insertions are described in greater detail below with regard to the Examples.  
      As used herein a “tail” refers to a peptide sequence at the end of an amino acid sequence that is unique to a splice variant according to the present invention. Therefore, a splice variant having such a tail may optionally be considered as a chimera, in that at least a first portion of the splice variant is typically highly homologous (often 100% identical) to a portion of the corresponding known protein, while at least a second portion of the variant comprises the tail.  
      As used herein a “head” refers to a peptide sequence at the beginning of an amino acid sequence that is unique to a splice variant according to the present invention. Therefore, a splice variant having such a head may optionally be considered as a chimera, in that at least a first portion of the splice variant comprises the head, while at least a second portion is typically highly homologous (often 100% identical) to a portion of the corresponding known protein.  
      As used herein “an edge portion” refers to a connection between two portions of a splice variant according to the present invention that were not joined in the wild type or known protein. An edge may optionally arise due to a join between the above “known protein” portion of a variant and the tail, for example, and/or may occur if an internal portion of the wild type sequence is no longer present, such that two portions of the sequence are now contiguous in the splice variant that were not contiguous in the known protein. A “bridge” may optionally be an edge portion as described above, but may also include a join between a head and a “known protein” portion of a variant, or a join between a tail and a “known protein” portion of a variant, or a join between a unique insertion and a “known protein” portion of a variant. Optionally and preferably, a bridge between a tail or a head or a unique insertion, and a “known protein” portion of a variant, comprises at least about 10 amino acids, more preferably at least about 20 amino acids, most preferably at least about 30 amino acids, and even more preferably at least about 40 amino acids, in which at least one amino acid is from the tail/head/insertion and at least one amino acid is from the “known protein” portion of a variant. Also optionally, the bridge may comprise any number of amino acids from about 10 to about 40 amino acids (for example, 10, 11, 12, 13.37, 38, 39, 40 amino acids in length, or any number in between).  
      It should be noted that a bridge cannot be extended beyond the length of the sequence in either direction, and it should be assumed that every bridge description is to be read in such manner that the bridge length does not extend beyond the sequence itself.  
      Furthermore, bridges are described with regard to a sliding window in certain contexts below. For example, certain descriptions of the bridges feature the following format: a bridge between two edges (in which a portion of the known protein is not present in the variant) may optionally be described as follows: a bridge portion of CONTIG-NAME_P1 (representing the name of the protein), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise XX (2 amino acids in the center of the bridge, one from each end of the edge), having a structure as follows (numbering according to the sequence of CONTIG-NAME_P1): a sequence starting from any of amino acid numbers 49−x to 49 (for example); and ending at any of amino acid numbers 50+((n−2)−x) (for example), in which x varies from 0 to n−2. In this example, it should also be read as including bridges in which n is any number of amino acids between 10-50 amino acids in length. Furthermore, the bridge polypeptide cannot extend beyond the sequence, so it should be read such that 49−x (for example) is not less than 1, nor 50+((n−2)−x) (for example) greater than the total sequence length.  
      In another embodiment, this invention provides antibodies specifically recognizing the splice variants and polypeptide fragments thereof of this invention. Preferably such antibodies differentially recognize splice variants of the present invention but do not recognize a corresponding known protein (such known proteins are discussed with regard to their splice variants in the Examples below).  
      In another embodiment, this invention provides an isolated nucleic acid molecule encoding for a splice variant according to the present invention, having a nucleotide sequence as set forth in any one of the sequences listed herein, or a sequence complementary thereto. In another embodiment, this invention provides an isolated nucleic acid molecule, having a nucleotide sequence as set forth in any one of the sequences listed herein, or a sequence complementary thereto. In another embodiment, this invention provides an oligonucleotide of at least about 12 nucleotides, specifically hybridizable with the nucleic acid molecules of this invention. In another embodiment, this invention provides vectors, cells, liposomes and compositions comprising the isolated nucleic acids of this invention.  
      In another embodiment, this invention provides a method for detecting a splice variant according to the present invention in a biological sample, comprising: contacting a biological sample with an antibody specifically recognizing a splice variant according to the present invention under conditions whereby the antibody specifically interacts with the splice variant in the biological sample but do not recognize known corresponding proteins (wherein the known protein is discussed with regard to its splice variant(s) in the Examples below), and detecting said interaction; wherein the presence of an interaction correlates with the presence of a splice variant in the biological sample.  
      In another embodiment, this invention provides a method for detecting a splice variant nucleic acid sequences in a biological sample, comprising: hybridizing the isolated nucleic acid molecules or oligonucleotide fragments of at least about a minimum length to a nucleic acid material of a biological sample and detecting a hybridization complex; wherein the presence of a hybridization complex correlates with the presence of a splice variant nucleic acid sequence in the biological sample.  
      According to the present invention, the splice variants described herein are non-limiting examples of markers for diagnosing endometriosis. Each splice variant marker of the present invention can be used alone or in combination, for various uses, including but not limited to, prognosis, prediction, screening, early diagnosis, determination of progression, therapy selection and treatment monitoring of endometriosis.  
      According to optional but preferred embodiments of the present invention, any marker according to the present invention may optionally be used alone or combination. Such a combination may optionally comprise a plurality of markers described herein, optionally including any subcombination of markers, and/or a combination featuring at least one other marker, for example a known marker. Furthermore, such a combination may optionally and preferably be used as described above with regard to determining a ratio between a quantitative or semi-quantitative measurement of any marker described herein to any other marker described herein, and/or any other known marker, and/or any other marker. With regard to such a ratio between any marker described herein (or a combination thereof) and a known marker, more preferably the known marker comprises the “known protein” as described in greater detail below with regard to each cluster or gene.  
      According to other preferred embodiments of the present invention, a splice variant protein or a fragment thereof, or a splice variant nucleic acid sequence or a fragment thereof, may be featured as a biomarker for detecting endometriosis, such that a biomarker may optionally comprise any of the above.  
      According to still other preferred embodiments, the present invention optionally and preferably encompasses any amino acid sequence or fragment thereof encoded by a nucleic acid sequence corresponding to a splice variant protein as described herein. Any oligopeptide or peptide relating to such an amino acid sequence or fragment thereof may optionally also (additionally or alternatively) be used as a biomarker, including but not limited to the unique amino acid sequences of these proteins that are depicted as tails, heads, insertions, edges or bridges. The present invention also optionally encompasses antibodies capable of recognizing, and/or being elicited by, such oligopeptides or peptides.  
      The present invention also optionally and preferably encompasses any nucleic acid sequence or fragment thereof, or amino acid sequence or fragment thereof, corresponding to a splice variant of the present invention as described above, optionally for any application.  
      Non-limiting examples of methods or assays are described below.  
      The present invention also relates to kits based upon such diagnostic methods or assays.  
      Nucleic Acid Sequences and Oligonucleotides  
      Various embodiments of the present invention encompass nucleic acid sequences described hereinabove; fragments thereof, sequences hybridizable therewith, sequences homologous thereto, sequences encoding similar polypeptides with different codon usage, altered sequences characterized by mutations, such as deletion, insertion or substitution of one or more nucleotides, either naturally occurring or artificially induced, either randomly or in a targeted fashion.  
      The present invention encompasses nucleic acid sequences described herein; fragments thereof, sequences hybridizable therewith, sequences homologous thereto [e.g., at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95% or more say 100% identical to the nucleic acid sequences set forth below], sequences encoding similar polypeptides with different codon usage, altered sequences characterized by mutations, such as deletion, insertion or substitution of one or more nucleotides, either naturally occurring or man induced, either randomly or in a targeted fashion. The present invention also encompasses homologous nucleic acid sequences (i.e., which form a part of a polynucleotide sequence of the present invention) which include sequence regions unique to the polynucleotides of the present invention.  
      In cases where the polynucleotide sequences of the present invention encode previously unidentified polypeptides, the present invention also encompasses novel polypeptides or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.  
      A “nucleic acid fragment” or an “oligonucleotide” or a “polynucleotide” are used herein interchangeably to refer to a polymer of nucleic acids. A polynucleotide sequence of the present invention refers to a single or double stranded nucleic acid sequences which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).  
      As used herein the phrase “complementary polynucleotide sequence” refers to a sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence can be subsequently amplified in vivo or in vitro using a DNA dependent DNA polymerase.  
      As used herein the phrase “genomic polynucleotide sequence” refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.  
      As used herein the phrase “composite polynucleotide sequence” refers to a sequence, which is composed of genomic and cDNA sequences. A composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some intronic sequences interposing therebetween. The intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements.  
      Preferred embodiments of the present invention encompass oligonucleotide probes.  
      An example of an oligonucleotide probe which can be utilized by the present invention is a single stranded polynucleotide which includes a sequence complementary to the unique sequence region of any variant according to the present invention, including but not limited to a nucleotide sequence coding for an amino sequence of a bridge, tail, head and/or insertion according to the present invention, and/or the equivalent portions of any nucleotide sequence given herein (including but not limited to a nucleotide sequence of a node, segment or amplicon described herein).  
      Alternatively, an oligonucleotide probe of the present invention can be designed to hybridize with a nucleic acid sequence encompassed by any of the above nucleic acid sequences, particularly the portions specified above, including but not limited to a nucleotide sequence coding for an amino sequence of a bridge, tail, head and/or insertion according to the present invention, and/or the equivalent portions of any nucleotide sequence given herein (including but not limited to a nucleotide sequence of a node, segment or amplicon described herein).  
      Oligonucleotides designed according to the teachings of the present invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for executing solid-phase synthesis are commercially available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the capabilities of one skilled in the art and can be accomplished via established methodologies as detailed in, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Md. (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley &amp; Sons, New York (1988) and “Oligonucleotide Synthesis” Gait, M. J., ed. (1984) utilizing solid phase chemistry, e.g. cyanoethyl phosphoramidite followed by deprotection, desalting and purification by for example, an automated trityl-on method or HPLC.  
      Oligonucleotides used according to this aspect of the present invention are those having a length selected from a range of about 10 to about 200 bases preferably about 15 to about 150 bases, more preferably about 20 to about 100 bases, most preferably about 20 to about 50 bases. Preferably, the oligonucleotide of the present invention features at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 or at least 40, bases specifically hybridizable with the biomarkers of the present invention.  
      The oligonucleotides of the present invention may comprise heterocylic nucleosides consisting of purines and the pyrimidines bases, bonded in a 3′ to 5′ phosphodiester linkage.  
      Preferably used oligonucleotides are those modified at one or more of the backbone, internucleoside linkages or bases, as is broadly described hereinunder.  
      Specific examples of preferred oligonucleotides useful according to this aspect of the present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone, as disclosed in U.S. Pat. Nos. 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466, 677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.  
      Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms can also be used.  
      Alternatively, modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH 2  component parts, as disclosed in U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.  
      Other oligonucleotides which can be used according to the present invention, are those modified in both sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for complementation with the appropriate polynucleotide target. An example for such an oligonucleotide mimetic, includes peptide nucleic acid (PNA). United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Other backbone modifications, which can be used in the present invention are disclosed in U.S. Pat. No. 6,303,374.  
      Oligonucleotides of the present invention may also include base modifications or substitutions. As used herein, “unmodified” or “natural” bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include but are not limited to other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further bases particularly useful for increasing the binding affinity of the oligomeric compounds of the invention include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.  
      Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety, as disclosed in U.S. Pat. No. 6,303,374.  
      It is not necessary for all positions in a given oligonucleotide molecule to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.  
      It will be appreciated that oligonucleotides of the present invention may include further modifications for more efficient use as diagnostic agents and/or to increase bioavailability, therapeutic efficacy and reduce cytotoxicity.  
      To enable cellular expression of the polynucleotides of the present invention, a nucleic acid construct according to the present invention may be used, which includes at least a coding region of one of the above nucleic acid sequences, and further includes at least one cis acting regulatory element. As used herein, the phrase “cis acting regulatory element” refers to a polynucleotide sequence, preferably a promoter, which binds a trans acting regulator and regulates the transcription of a coding sequence located downstream thereto.  
      Any suitable promoter sequence can be used by the nucleic acid construct of the present invention.  
      Preferably, the promoter utilized by the nucleic acid construct of the present invention is active in the specific cell population transformed. Examples of cell type-specific and/or tissue-specific promoters include promoters such as albumin that is liver specific, lymphoid specific promoters [Calame et al., (1988) Adv. Immunol. 43:235-275]; in particular promoters of T-cell receptors [Winoto et al., (1989) EMBO J. 8:729-733] and immunoglobulins; [Baneiji et al. (1983) Cell 33729-740], neuron-specific promoters such as the neurofilament promoter [Byrne et al. (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477], pancreas-specific promoters [Edlunch et al. (1985) Science 230:912-916] or mammary gland-specific promoters such as the milk whey promoter (U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). The nucleic acid construct of the present invention can further include an enhancer, which can be adjacent or distant to the promoter sequence and can function in up regulating the transcription therefrom.  
      The nucleic acid construct of the present invention preferably further includes an appropriate selectable marker and/or an origin of replication. Preferably, the nucleic acid construct utilized is a shuttle vector, which can propagate both in  E. coli  (wherein the construct comprises an appropriate selectable marker and origin of replication) and be compatible for propagation in cells, or integration in a gene and a tissue of choice. The construct according to the present invention can be, for example, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a virus or an artificial chromosome.  
      Examples of suitable constructs include, but are not limited to, pcDNA3, pcDNA3.1 (+/−), pGL3, PzeoSV2 (+/−), pDisplay, pEF/myc/cyto, pCMV/myc/cyto each of which is commercially available from Invitrogen Co. (www.invitrogen.com). Examples of retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif., including Retro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the trasgene is transcribed from CMV promoter. Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5′LTR promoter.  
      Currently preferred in vivo nucleic acid transfer techniques include transfection with viral or non-viral constructs, such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV) and lipid-based systems. Useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol [Tonkinson et al., Cancer Investigation, 14(1): 54-65 (1996)]. The most preferred constructs for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral construct such as a retroviral construct includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used, unless it is already present in the viral construct. In addition, such a construct typically includes a signal sequence for secretion of the peptide from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence or the signal sequence of the polypeptide variants of the present invention. Optionally, the construct may also include a signal that directs polyadenylation, as well as one or more restriction sites and a translation termination sequence. By way of example, such constructs will typically include a 5′ LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3′ LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.  
      Hybridization Assays  
      Detection of a nucleic acid of interest in a biological sample may optionally be effected by hybridization-based assays using an oligonucleotide probe (non-limiting examples of probes according to the present invention were previously described).  
      Traditional hybridization assays include PCR, RT-PCR, Real-time PCR, RNase protection, in-situ hybridization, primer extension, Southern blots (DNA detection), dot or slot blots (DNA, RNA), and Northern blots (RNA detection) (NAT type assays are described in greater detail below). More recently, PNAs have been described (Nielsen et al. 1999, Current Opin. Biotechnol. 10:71-75). Other detection methods include kits containing probes on a dipstick setup and the like.  
      Hybridization based assays which allow the detection of a variant of interest (i.e., DNA or RNA) in a biological sample rely on the use of oligonucleotides which can be 10, 15, 20, or 30 to 100 nucleotides long preferably from 10 to 50, more preferably from 40 to 50 nucleotides long.  
      Thus, the isolated polynucleotides (oligonucleotides) of the present invention are preferably hybridizable with any of the herein described nucleic acid sequences under moderate to stringent hybridization conditions.  
      Moderate to stringent hybridization conditions are characterized by a hybridization solution such as containing 10% dextrane sulfate, 1 M NaCl, 1% SDS and 5×10 6  cpm  32 P labeled probe, at 65° C., with a final wash solution of 0.2×SSC and 0.1% SDS and final wash at 65° C. and whereas moderate hybridization is effected using a hybridization solution containing 10% dextrane sulfate, 1 M NaCl, 1% SDS and 5×10 6  cpm  32 P labeled probe, at 65° C., with a final wash solution of 1×SSC and 0.1% SDS and final wash at 50° C.  
      More generally, hybridization of short nucleic acids (below 200 bp in length, e.g. 17-40 bp in length) can be effected using the following exemplary hybridization protocols which can be modified according to the desired stringency; (i) Hybridization solution of 6×SSC and 1% SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 0.1% nonfat dried milk, hybridization temperature of 1-1.5° C. below the T m , final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS at 1-1.5° C. below the T m ; (ii) Hybridization solution of 6×SSC and 0.1% SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 0.1% nonfat dried milk, hybridization temperature of 2-2.5° C. below the T m , final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS at 1-1.5° C. below the T m , final wash solution of 6×SSC, and final wash at 22° C.; (iii) Hybridization solution of 6×SSC and 1% SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 0.1% nonfat dried milk, hybridization temperature.  
      The detection of hybrid duplexes can be carried out by a number of methods. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Such labels refer to radioactive, fluorescent, biological or enzymatic tags or labels of standard use in the art. A label can be conjugated to either the oligonucleotide probes or the nucleic acids derived from the biological sample.  
      Probes can be labeled according to numerous well known methods. Non-limiting examples of radioactive labels include 3H, 14C, 32P, and 35S. Non-limiting examples of detectable markers include ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. Other detectable markers for use with probes, which can enable an increase in sensitivity of the method of the invention, include biotin and radio-nucleotides. It will become evident to the person of ordinary skill that the choice of a particular label dictates the manner in which it is bound to the probe.  
      For example, oligonucleotides of the present invention can be labeled subsequent to synthesis, by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent. Alternatively, when fluorescently-labeled oligonucleotide probes are used, fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, Fluor X (Amersham) and others [e.g., Kricka et al. (1992), Academic Press San Diego, Calif.] can be attached to the oligonucleotides.  
      Those skilled in the art will appreciate that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the oligonucleotide primers and probes.  
      It will be appreciated that a variety of controls may be usefully employed to improve accuracy of hybridization assays. For instance, samples may be hybridized to an irrelevant probe and treated with RNAse A prior to hybridization, to assess false hybridization.  
      Although the present invention is not specifically dependent on the use of a label for the detection of a particular nucleic acid sequence, such a label might be beneficial, by increasing the sensitivity of the detection. Furthermore, it enables automation. Probes can be labeled according to numerous well known methods.  
      As commonly known, radioactive nucleotides can be incorporated into probes of the invention by several methods. Non-limiting examples of radioactive labels include  3 H,  14 C,  32 P, and  35 S.  
      Those skilled in the art will appreciate that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the oligonucleotide primers and probes.  
      It will be appreciated that a variety of controls may be usefully employed to improve accuracy of hybridization assays.  
      Probes of the invention can be utilized with naturally occurring sugar-phosphate backbones as well as modified backbones including phosphorothioates, dithionates, alkyl phosphonates and a-nucleotides and the like. Probes of the invention can be constructed of either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and preferably of DNA.  
      NAT Assays  
      Detection of a nucleic acid of interest in a biological sample may also optionally be effected by NAT-based assays, which involve nucleic acid amplification technology, such as PCR for example (or variations thereof such as real-time PCR for example).  
      As used herein, a “primer” defines an oligonucleotide which is capable of annealing to (hybridizing with) a target sequence, thereby creating a double stranded region which can serve as an initiation point for DNA synthesis under suitable conditions.  
      Amplification of a selected, or target, nucleic acid sequence may be carried out by a number of suitable methods. See generally Kwoh et al., 1990, Am. Biotechnol. Lab. 8:14 Numerous amplification techniques have been described and can be readily adapted to suit particular needs of a person of ordinary skill. Non-limiting examples of amplification techniques include polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-based amplification, the q3 replicase system and NASBA (Kwoh et al., 1989, Proc. NatI. Acad. Sci. USA 86, 1173-1177; Lizardi et al., 1988, BioTechnology 6:1197-1202; Malek et al., 1994, Methods Mol. Biol., 28:253-260; and Sambrook et al., 1989, supra).  
      The terminology “amplification pair” (or “primer pair”) refers herein to a pair of oligonucleotides (oligos) of the present invention, which are selected to be used together in amplifying a selected nucleic acid sequence by one of a number of types of amplification processes, preferably a polymerase chain reaction. Other types of amplification processes include ligase chain reaction, strand displacement amplification, or nucleic acid sequence-based amplification, as explained in greater detail below. As commonly known in the art, the oligos are designed to bind to a complementary sequence under selected conditions.  
      In one particular embodiment, amplification of a nucleic acid sample from a patient is amplified under conditions which favor the amplification of the most abundant differentially expressed nucleic acid. In one preferred embodiment, RT-PCR is carried out on an mRNA sample from a patient under conditions which favor the amplification of the most abundant mRNA. In another preferred embodiment, the amplification of the differentially expressed nucleic acids is carried out simultaneously. It will be realized by a person skilled in the art that such methods could be adapted for the detection of differentially expressed proteins instead of differentially expressed nucleic acid sequences.  
      The nucleic acid (i.e. DNA or RNA) for practicing the present invention may be obtained according to well known methods.  
      Oligonucleotide primers of the present invention may be of any suitable length, depending on the particular assay format and the particular needs and targeted genomes employed. Optionally, the oligonucleotide primers are at least 12 nucleotides in length, preferably between 15 and 24 molecules, and they may be adapted to be especially suited to a chosen nucleic acid amplification system. As commonly known in the art, the oligonucleotide primers can be designed by taking into consideration the melting point of hybridization thereof with its targeted sequence (Sambrook et al., 1989, Molecular Cloning—A Laboratory Manual, 2nd Edition, CSH Laboratories; Ausubel et al., 1989, in Current Protocols in Molecular Biology, John Wiley &amp; Sons Inc., N.Y.).  
      It will be appreciated that antisense oligonucleotides may be employed to quantify expression of a splice isoform of interest. Such detection is effected at the pre-mRNA level. Essentially the ability to quantitate transcription from a splice site of interest can be effected based on splice site accessibility. Oligonucleotides may compete with splicing factors for the splice site sequences. Thus, low activity of the antisense oligonucleotide is indicative of splicing activity.  
      The polymerase chain reaction and other nucleic acid amplification reactions are well known in the art (various non-limiting examples of these reactions are described in greater detail below). The pair of oligonucleotides according to this aspect of the present invention are preferably selected to have compatible melting temperatures (Tm), e.g., melting temperatures which differ by less than that 7° C., preferably less than 5° C., more preferably less than 4° C., most preferably less than 3° C., ideally between 3° C. and 0° C.  
      Polymerase Chain Reaction (PCR): The polymerase chain reaction (PCR), as described in U.S. Pat. Nos. 4,683,195 and 4,683,202 to Mullis and Mullis et al., is a method of increasing the concentration of a segment of target sequence in a mixture of genomic DNA without cloning or purification. This technology provides one approach to the problems of low target sequence concentration. PCR can be used to directly increase the concentration of the target to an easily detectable level. This process for amplifying the target sequence involves the introduction of a molar excess of two oligonucleotide primers which are complementary to their respective strands of the double-stranded target sequence to the DNA mixture containing the desired target sequence. The mixture is denatured and then allowed to hybridize. Following hybridization, the primers are extended with polymerase so as to form complementary strands. The steps of denaturation, hybridization (annealing), and polymerase extension (elongation) can be repeated as often as needed, in order to obtain relatively high concentrations of a segment of the desired target sequence.  
      The length of the segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and, therefore, this length is a controllable parameter. Because the desired segments of the target sequence become the dominant sequences (in terms of concentration) in the mixture, they are said to be “PCR-amplified.” 
      Ligase Chain Reaction (LCR or LAR): The ligase chain reaction [LCR; sometimes referred to as “Ligase Amplification Reaction” (LAR)] has developed into a well-recognized alternative method of amplifying nucleic acids. In LCR, four oligonucleotides, two adjacent oligonucleotides which uniquely hybridize to one strand of target DNA, and a complementary set of adjacent oligonucleotides, which hybridize to the opposite strand are mixed and DNA ligase is added to the mixture. Provided that there is complete complementarity at the junction, ligase will covalently link each set of hybridized molecules. Importantly, in LCR, two probes are ligated together only when they base-pair with sequences in the target sample, without gaps or mismatches. Repeated cycles of denaturation, and ligation amplify a short segment of DNA. LCR has also been used in combination with PCR to achieve enhanced detection of single-base changes: see for example Segev, PCT Publication No. W09001069 A1 (1990). However, because the four oligonucleotides used in this assay can pair to form two short ligatable fragments, there is the potential for the generation of target-independent background signal. The use of LCR for mutant screening is limited to the examination of specific nucleic acid positions.  
      Self-Sustained Synthetic Reaction (3SR/NASBA): The self-sustained sequence replication reaction (3SR) is a transcription-based in vitro amplification system that can exponentially amplify RNA sequences at a uniform temperature. The amplified RNA can then be utilized for mutation detection. In this method, an oligonucleotide primer is used to add a phage RNA polymerase promoter to the 5′ end of the sequence of interest. In a cocktail of enzymes and substrates that includes a second primer, reverse transcriptase, RNase H, RNA polymerase and ribo- and deoxyribonucleoside triphosphates, the target sequence undergoes repeated rounds of transcription, cDNA synthesis and second-strand synthesis to amplify the area of interest. The use of 3SR to detect mutations is kinetically limited to screening small segments of DNA (e.g., 200-300 base pairs).  
      Q-Beta (Qβ) Replicase: In this method, a probe which recognizes the sequence of interest is attached to the replicatable RNA template for Qβ replicase. A previously identified major problem with false positives resulting from the replication of unhybridized probes has been addressed through use of a sequence-specific ligation step. However, available thermostable DNA ligases are not effective on this RNA substrate, so the ligation must be performed by T4 DNA ligase at low temperatures (37 degrees C.). This prevents the use of high temperature as a means of achieving specificity as in the LCR, the ligation event can be used to detect a mutation at the junction site, but not elsewhere.  
      A successful diagnostic method must be very specific. A straight-forward method of controlling the specificity of nucleic acid hybridization is by controlling the temperature of the reaction. While the 3SR/NASBA, and Qβ systems are all able to generate a large quantity of signal, one or more of the enzymes involved in each cannot be used at high temperature (i.e., &gt;55 degrees C.). Therefore the reaction temperatures cannot be raised to prevent non-specific hybridization of the probes. If probes are shortened in order to make them melt more easily at low temperatures, the likelihood of having more than one perfect match in a complex genome increases. For these reasons, PCR and LCR currently dominate the research field in detection technologies.  
      The basis of the amplification procedure in the PCR and LCR is the fact that the products of one cycle become usable templates in all subsequent cycles, consequently doubling the population with each cycle. The final yield of any such doubling system can be expressed as: (1+X) n =y, where “X” is the mean efficiency (percent copied in each cycle), “n” is the number of cycles, and “y” is the overall efficiency, or yield of the reaction. If every copy of a target DNA is utilized as a template in every cycle of a polymerase chain reaction, then the mean efficiency is 100%. If 20 cycles of PCR are performed, then the yield will be 2 20 , or 1,048,576 copies of the starting material. If the reaction conditions reduce the mean efficiency to 85%, then the yield in those 20 cycles will be only 1.85 20 , or 220,513 copies of the starting material. In other words, a PCR running at 85% efficiency will yield only 21% as much final product, compared to a reaction running at 100% efficiency. A reaction that is reduced to 50% mean efficiency will yield less than 1% of the possible product.  
      In practice, routine polymerase chain reactions rarely achieve the theoretical maximum yield, and PCRs are usually run for more than 20 cycles to compensate for the lower yield. At 50% mean efficiency, it would take 34 cycles to achieve the million-fold amplification theoretically possible in 20, and at lower efficiencies, the number of cycles required becomes prohibitive. In addition, any background products that amplify with a better mean efficiency than the intended target will become the dominant products.  
      Also, many variables can influence the mean efficiency of PCR, including target DNA length and secondary structure, primer length and design, primer and dNTP concentrations, and buffer composition, to name but a few. Contamination of the reaction with exogenous DNA (e.g., DNA spilled onto lab surfaces) or cross-contamination is also a major consideration. Reaction conditions must be carefully optimized for each different primer pair and target sequence, and the process can take days, even for an experienced investigator. The laboriousness of this process, including numerous technical considerations and other factors, presents a significant drawback to using PCR in the clinical setting. Indeed, PCR has yet to penetrate the clinical market in a significant way. The same concerns arise with LCR, as LCR must also be optimized to use different oligonucleotide sequences for each target sequence. In addition, both methods require expensive equipment, capable of precise temperature cycling.  
      Many applications of nucleic acid detection technologies, such as in studies of allelic variation, involve not only detection of a specific sequence in a complex background, but also the discrimination between sequences with few, or single, nucleotide differences. One method of the detection of allele-specific variants by PCR is based upon the fact that it is difficult for Taq polymerase to synthesize a DNA strand when there is a mismatch between the template strand and the 3′ end of the primer. An allele-specific variant may be detected by the use of a primer that is perfectly matched with only one of the possible alleles; the mismatch to the other allele acts to prevent the extension of the primer, thereby preventing the amplification of that sequence. This method has a substantial limitation in that the base composition of the mismatch influences the ability to prevent extension across the mismatch, and certain mismatches do not prevent extension or have only a minimal effect.  
      A similar 3′-mismatch strategy is used with greater effect to prevent ligation in the LCR. Any mismatch effectively blocks the action of the thermostable ligase, but LCR still has the drawback of target-independent background ligation products initiating the amplification. Moreover, the combination of PCR with subsequent LCR to identify the nucleotides at individual positions is also a clearly cumbersome proposition for the clinical laboratory.  
      The direct detection method according to various preferred embodiments of the present invention may be, for example a cycling probe reaction (CPR) or a branched DNA analysis.  
      When a sufficient amount of a nucleic acid to be detected is available, there are advantages to detecting that sequence directly, instead of making more copies of that target, (e.g., as in PCR and LCR). Most notably, a method that does not amplify the signal exponentially is more amenable to quantitative analysis. Even if the signal is enhanced by attaching multiple dyes to a single oligonucleotide, the correlation between the final signal intensity and amount of target is direct. Such a system has an additional advantage that the products of the reaction will not themselves promote further reaction, so contamination of lab surfaces by the products is not as much of a concern. Recently devised techniques have sought to eliminate the use of radioactivity and/or improve the sensitivity in automatable formats. Two examples are the “Cycling Probe Reaction” (CPR), and “Branched DNA” (bDNA).  
      Cycling probe reaction (CPR): The cycling probe reaction (CPR), uses a long chimeric oligonucleotide in which a central portion is made of RNA while the two termini are made of DNA. Hybridization of the probe to a target DNA and exposure to a thermostable RNase H causes the RNA portion to be digested. This destabilizes the remaining DNA portions of the duplex, releasing the remainder of the probe from the target DNA and allowing another probe molecule to repeat the process. The signal, in the form of cleaved probe molecules, accumulates at a linear rate. While the repeating process increases the signal, the RNA portion of the oligonucleotide is vulnerable to RNases that may carried through sample preparation.  
      Branched DNA: Branched DNA (bDNA), involves oligonucleotides with branched structures that allow each individual oligonucleotide to carry 35 to 40 labels (e.g., alkaline phosphatase enzymes). While this enhances the signal from a hybridization event, signal from non-specific binding is similarly increased.  
      The detection of at least one sequence change according to various preferred embodiments of the present invention may be accomplished by, for example restriction fragment length polymorphism (RFLP analysis), allele specific oligonucleotide (ASO) analysis, Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE), Single-Strand Conformation Polymorphism (SSCP) analysis or Dideoxy fingerprinting (ddF).  
      The demand for tests which allow the detection of specific nucleic acid sequences and sequence changes is growing rapidly in clinical diagnostics. As nucleic acid sequence data for genes from humans and pathogenic organisms accumulates, the demand for fast, cost-effective, and easy-to-use tests for as yet mutations within specific sequences is rapidly increasing.  
      A handful of methods have been devised to scan nucleic acid segments for mutations. One option is to determine the entire gene sequence of each test sample (e.g., a bacterial isolate). For sequences under approximately 600 nucleotides, this may be accomplished using amplified material (e.g., PCR reaction products). This avoids the time and expense associated with cloning the segment of interest. However, specialized equipment and highly trained personnel are required, and the method is too labor-intense and expensive to be practical and effective in the clinical setting.  
      In view of the difficulties associated with sequencing, a given segment of nucleic acid may be characterized on several other levels. At the lowest resolution, the size of the molecule can be determined by electrophoresis by comparison to a known standard run on the same gel. A more detailed picture of the molecule may be achieved by cleavage with combinations of restriction enzymes prior to electrophoresis, to allow construction of an ordered map. The presence of specific sequences within the fragment can be detected by hybridization of a labeled probe, or the precise nucleotide sequence can be determined by partial chemical degradation or by primer extension in the presence of chain-terminating nucleotide analogs.  
      Restriction fragment length polymorphism (RFLP): For detection of single-base differences between like sequences, the requirements of the analysis are often at the highest level of resolution. For cases in which the position of the nucleotide in question is known in advance, several methods have been developed for examining single base changes without direct sequencing. For example, if a mutation of interest happens to fall within a restriction recognition sequence, a change in the pattern of digestion can be used as a diagnostic tool (e.g., restriction fragment length polymorphism [RFLP] analysis).  
      Single point mutations have been also detected by the creation or destruction of RFLPs. Mutations are detected and localized by the presence and size of the RNA fragments generated by cleavage at the mismatches. Single nucleotide mismatches in DNA heteroduplexes are also recognized and cleaved by some chemicals, providing an alternative strategy to detect single base substitutions, generically named the “Mismatch Chemical Cleavage” (MCC). However, this method requires the use of osmium tetroxide and piperidine, two highly noxious chemicals which are not suited for use in a clinical laboratory.  
      RFLP analysis suffers from low sensitivity and requires a large amount of sample. When RFLP analysis is used for the detection of point mutations, it is, by its nature, limited to the detection of only those single base changes which fall within a restriction sequence of a known restriction endonuclease. Moreover, the majority of the available enzymes have 4 to 6 base-pair recognition sequences, and cleave too frequently for many large-scale DNA manipulations. Thus, it is applicable only in a small fraction of cases, as most mutations do not fall within such sites.  
      A handful of rare-cutting restriction enzymes with 8 base-pair specificities have been isolated and these are widely used in genetic mapping, but these enzymes are few in number, are limited to the recognition of G+C-rich sequences, and cleave at sites that tend to be highly clustered. Recently, endonucleases encoded by group I introns have been discovered that might have greater than 12 base-pair specificity, but again, these are few in number.  
      Allele specific oligonucleotide (ASO): If the change is not in a recognition sequence, then allele-specific oligonucleotides (ASOs), can be designed to hybridize in proximity to the mutated nucleotide, such that a primer extension or ligation event can bused as the indicator of a match or a mis-match. Hybridization with radioactively labeled allelic specific oligonucleotides (ASO) also has been applied to the detection of specific point mutations. The method is based on the differences in the melting temperature of short DNA fragments differing by a single nucleotide. Stringent hybridization and washing conditions can differentiate between mutant and wild-type alleles. The ASO approach applied to PCR products also has been extensively utilized by various researchers to detect and characterize point mutations in ras genes and gsp/gip oncogenes. Because of the presence of various nucleotide changes in multiple positions, the ASO method requires the use of many oligonucleotides to cover all possible oncogenic mutations.  
      With either of the techniques described above (i.e., RFLP and ASO), the precise location of the suspected mutation must be known in advance of the test. That is to say, they are inapplicable when one needs to detect the presence of a mutation within a gene or sequence of interest.  
      Denaturing/Temperature Gradient Gel Electrophoresis (DGGE/TGGE): Two other methods rely on detecting changes in electrophoretic mobility in response to minor sequence changes. One of these methods, termed “Denaturing Gradient Gel Electrophoresis” (DGGE) is based on the observation that slightly different sequences will display different patterns of local melting when electrophoretically resolved on a gradient gel. In this manner, variants can be distinguished, as differences in melting properties of homoduplexes versus heteroduplexes differing in a single nucleotide can detect the presence of mutations in the target sequences because of the corresponding changes in their electrophoretic mobilities. The fragments to be analyzed, usually PCR products, are “clamped” at one end by a long stretch of G-C base pairs (30-80) to allow complete denaturation of the sequence of interest without complete dissociation of the strands. The attachment of a GC “clamp” to the DNA fragments increases the fraction of mutations that can be recognized by DGGE. Attaching a GC clamp to one primer is critical to ensure that the amplified sequence has a low dissociation temperature. Modifications of the technique have been developed, using temperature gradients, and the method can be also applied to RNA:RNA duplexes.  
      Limitations on the utility of DGGE include the requirement that the denaturing conditions must be optimized for each type of DNA to be tested. Furthermore, the method requires specialized equipment to prepare the gels and maintain the needed high temperatures during electrophoresis. The expense associated with the synthesis of the clamping tail on one oligonucleotide for each sequence to be tested is also a major consideration. In addition, long running times are required for DGGE. The long running time of DGGE was shortened in a modification of DGGE called constant denaturant gel electrophoresis (CDGE). CDGE requires that gels be performed under different denaturant conditions in order to reach high efficiency for the detection of mutations.  
      A technique analogous to DGGE, termed temperature gradient gel electrophoresis (TGGE), uses a thermal gradient rather than a chemical denaturant gradient. TGGE requires the use of specialized equipment which can generate a temperature gradient perpendicularly oriented relative to the electrical field. TGGE can detect mutations in relatively small fragments of DNA therefore scanning of large gene segments requires the use of multiple PCR products prior to running the gel.  
      Single-Strand Conformation Polymorphism (SSCP): Another common method, called “Single-Strand Conformation Polymorphism” (SSCP) was developed by Hayashi, Sekya and colleagues and is based on the observation that single strands of nucleic acid can take on characteristic conformations in non-denaturing conditions, and these conformations influence electrophoretic mobility. The complementary strands assume sufficiently different structures that one strand may be resolved from the other. Changes in sequences within the fragment will also change the conformation, consequently altering the mobility and allowing this to be used as an assay for sequence variations.  
      The SSCP process involves denaturing a DNA segment (e.g., a PCR product) that is labeled on both strands, followed by slow electrophoretic separation on a non-denaturing polyacrylamide gel, so that intra-molecular interactions can form and not be disturbed during the run. This technique is extremely sensitive to variations in gel composition and temperature. A serious limitation of this method is the relative difficulty encountered in comparing data generated in different laboratories, under apparently similar conditions.  
      Dideoxy fingerprinting (ddF): The dideoxy fingerprinting (ddF) is another technique developed to scan genes for the presence of mutations. The ddF technique combines components of Sanger dideoxy sequencing with SSCP. A dideoxy sequencing reaction is performed using one dideoxy terminator and then the reaction products are electrophoresed on nondenaturing polyacrylamide gels to detect alterations in mobility of the termination segments as in SSCP analysis. While ddF is an improvement over SSCP in terms of increased sensitivity, ddF requires the use of expensive dideoxynucleotides and this technique is still limited to the analysis of fragments of the size suitable for SSCP (i.e., fragments of 200-300 bases for optimal detection of mutations).  
      In addition to the above limitations, all of these methods are limited as to the size of the nucleic acid fragment that can be analyzed. For the direct sequencing approach, sequences of greater than 600 base pairs require cloning, with the consequent delays and expense of either deletion sub-cloning or primer walking, in order to cover the entire fragment. SSCP and DGGE have even more severe size limitations. Because of reduced sensitivity to sequence changes, these methods are not considered suitable for larger fragments. Although SSCP is reportedly able to detect 90% of single-base substitutions within a 200 base-pair fragment, the detection drops to less than 50% for 400 base pair fragments. Similarly, the sensitivity of DGGE decreases as the length of the fragment reaches 500 base-pairs. The ddF technique, as a combination of direct sequencing and SSCP, is also limited by the relatively small size of the DNA that can be screened.  
      According to a presently preferred embodiment of the present invention the step of searching for any of the nucleic acid sequences described here, in tumor cells or in cells derived from a cancer patient is effected by any suitable technique, including, but not limited to, nucleic acid sequencing, polymerase chain reaction, ligase chain reaction, self-sustained synthetic reaction, Qβ-Replicase, cycling probe reaction, branched DNA, restriction fragment length polymorphism analysis, mismatch chemical cleavage, heteroduplex analysis, allele-specific oligonucleotides, denaturing gradient gel electrophoresis, constant denaturant gel electrophoresis, temperature gradient gel electrophoresis and dideoxy fingerprinting.  
      Detection may also optionally be performed with a chip or other such device. The nucleic acid sample which includes the candidate region to be analyzed is preferably isolated, amplified and labeled with a reporter group. This reporter group can be a fluorescent group such as phycoerythrin. The labeled nucleic acid is then incubated with the probes immobilized on the chip using a fluidics station describe the fabrication of fluidics devices and particularly microcapillary devices, in silicon and glass substrates.  
      Once the reaction is completed, the chip is inserted into a scanner and patterns of hybridization are detected. The hybridization data is collected, as a signal emitted from the reporter groups already incorporated into the nucleic acid, which is now bound to the probes attached to the chip. Since the sequence and position of each probe immobilized on the chip is known, the identity of the nucleic acid hybridized to a given probe can be determined.  
      It will be appreciated that when utilized along with automated equipment, the above described detection methods can be used to screen multiple samples for a disease and/or pathological condition both rapidly and easily.  
      Amino Acid Sequences and Peptides  
      The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides can be modified, e.g., by the addition of carbohydrate residues to form glycoproteins. The terms “polypeptide,” “peptide” and “protein” include glycoproteins, as well as non-glycoproteins.  
      Polypeptide products can be biochemically synthesized such as by employing standard solid phase techniques. Such methods include but are not limited to exclusive solid phase synthesis, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.  
      Solid phase polypeptide synthesis procedures are well known in the art and further described by John Morrow Stewart and Janis Dillaha Young, Solid Phase Peptide Syntheses (2nd Ed., Pierce Chemical Company, 1984).  
      Synthetic polypeptides can optionally be purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y.], after which their composition can be confirmed via amino acid sequencing.  
      In cases where large amounts of a polypeptide are desired, it can be generated using recombinant techniques such as described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach &amp; Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.  
      The present invention also encompasses polypeptides encoded by the polynucleotide sequences of the present invention, as well as polypeptides according to the amino acid sequences described herein. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95% or more say 100% homologous to the amino acid sequences set forth below, as can be determined using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters, optionally and preferably including the following: filtering on (this option filters repetitive or low-complexity sequences from the query using the Seg (protein) program), scoring matrix is BLOSUM62 for proteins, word size is 3, E value is 10, gap costs are 11, 1 (initialization and extension), and number of alignments shown is 50. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or artificially induced, either randomly or in a targeted fashion. Similarly, homology (identity) for nucleic acid sequences is given herein as determined by BlastN software of the National Center of Biotechnology Information (NCBI) using default parameters, which preferably include using the DUST filter program, and also preferably include having an E value of 10, filtering low complexity sequences and a word size of 11.  
      It will be appreciated that peptides identified according the present invention may be degradation products, synthetic peptides or recombinant peptides as well as peptidomimetics, typically, synthetic peptides and peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells. Such modifications include, but are not limited to N terminus modification, C terminus modification, peptide bond modification, including, but not limited to, CH2-NH, CH2-S, CH2-S═O, O═C—NH, CH2-O, CH2-CH2, S═C—NH, CH═CH or CF═CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified. Further details in this respect are provided hereinunder.  
      Peptide bonds (—CO—NH—) within the peptide may be substituted, for example, by N-methylated bonds (—N(CH3)-CO—), ester bonds (—C(R)H—C—O—O—C(R)—N—), ketomethylen bonds (—CO—CH2-), α-aza bonds (—NH—N(R)—CO—), wherein R is any alkyl, e.g., methyl, carba bonds (—CH2-NH—), hydroxyethylene bonds (—CH(OH)—CH2-), thioamide bonds (—CS—NH—), olefinic double bonds (—CH═CH—), retro amide bonds (—NH—CO—), peptide derivatives (—N(R)—CH2-CO—), wherein R is the “normal” side chain, naturally presented on the carbon atom.  
      These modifications can occur at any of the bonds along the peptide chain and even at several (2-3) at the same time.  
      Natural aromatic amino acids, Trp, Tyr and Phe, may be substituted for synthetic non-natural acid such as Phenylglycine, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.  
      In addition to the above, the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. fatty acids, complex carbohydrates etc).  
      As used herein in the specification and in the claims section below the term “amino acid” or “amino acids” is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term “amino acid” includes both D- and L-amino acids.  
      Table 1 Non-Conventional or Modified Amino Acids which can be Used with the Present Invention.  
                           TABLE 1                       Non-conventional amino acid   Code   Non-conventional amino acid   Code                  α-aminobutyric acid   Abu   L-N-methylalanine   Nmala       α-amino-α-methylbutyrate   Mgabu   L-N-methylarginine   Nmarg       aminocyclopropane-   Cpro   L-N-methylasparagine   Nmasn       Carboxylate       L-N-methylaspartic acid   Nmasp       aminoisobutyric acid   Aib   L-N-methylcysteine   Nmcys       aminonorbornyl-   Norb   L-N-methylglutamine   Nmgin       Carboxylate       L-N-methylglutamic acid   Nmglu       Cyclohexylalanine   Chexa   L-N-methylhistidine   Nmhis       Cyclopentylalanine   Cpen   L-N-methylisolleucine   Nmile       D-alanine   Dal   L-N-methylleucine   Nmleu       D-arginine   Darg   L-N-methyllysine   Nmlys       D-aspartic acid   Dasp   L-N-methylmethionine   Nmmet       D-cysteine   Dcys   L-N-methylnorleucine   Nmnle       D-glutamine   Dgln   L-N-methylnorvaline   Nmnva       D-glutamic acid   Dglu   L-N-methylornithine   Nmorn       D-histidine   Dhis   L-N-methylphenylalanine   Nmphe       D-isoleucine   Dile   L-N-methylproline   Nmpro       D-leucine   Dleu   L-N-methylserine   Nmser       D-lysine   Dlys   L-N-methylthreonine   Nmthr       D-methionine   Dmet   L-N-methyltryptophan   Nmtrp       D-ornithine   Dorn   L-N-methyltyrosine   Nmtyr       D-phenylalanine   Dphe   L-N-methylvaline   Nmval       D-proline   Dpro   L-N-methylethylglycine   Nmetg       D-serine   Dser   L-N-methyl-t-butylglycine   Nmtbug       D-threonine   Dthr   L-norleucine   Nle       D-tryptophan   Dtrp   L-norvaline   Nva       D-tyrosine   Dtyr   α-methyl-aminoisobutyrate   Maib       D-valine   Dval   α-methyl-γ-aminobutyrate   Mgabu       D-α-methylalanine   Dmala   α-methylcyclohexylalanine   Mchexa       D-α-methylarginine   Dmarg   α-methylcyclopentylalanine   Mcpen       D-α-methylasparagine   Dmasn   α-methyl-α-napthylalanine   Manap       D-α-methylaspartate   Dmasp   α-methylpenicillamine   Mpen       D-α-methylcysteine   Dmcys   N-(4-aminobutyl)glycine   Nglu       D-α-methylglutamine   Dmgln   N-(2-aminoethyl)glycine   Naeg       D-α-methylhistidine   Dmhis   N-(3-aminopropyl)glycine   Norn       D-α-methylisoleucine   Dmile   N-amino-α-methylbutyrate   Nmaabu       D-α-methylleucine   Dmleu   α-napthylalanine   Anap       D-α-methyllysine   Dmlys   N-benzylglycine   Nphe       D-α-methylmethionine   Dmmet   N-(2-carbamylethyl)glycine   Ngln       D-α-methylornithine   Dmorn   N-(carbamylmethyl)glycine   Nasn       D-α-methylphenylalanine   Dmphe   N-(2-carboxyethyl)glycine   Nglu       D-α-methylproline   Dmpro   N-(carboxymethyl)glycine   Nasp       D-α-methylserine   Dmser   N-cyclobutylglycine   Ncbut       D-α-methylthreonine   Dmthr   N-cycloheptylglycine   Nchep       D-α-methyltryptophan   Dmtrp   N-cyclohexylglycine   Nchex       D-α-methyltyrosine   Dmty   N-cyclodecylglycine   Ncdec       D-α-methylvaline   Dmval   N-cyclododeclglycine   Ncdod       D-α-methylalnine   Dnmala   N-cyclooctylglycine   Ncoct       D-α-methylarginine   Dnmarg   N-cyclopropylglycine   Ncpro       D-α-methylasparagine   Dnmasn   N-cycloundecylglycine   Ncund       D-α-methylasparatate   Dnmasp   N-(2,2-diphenylethyl)glycine   Nbhm       D-α-methylcysteine   Dnmcys   N-(3,3-   Nbhe               diphenylpropyl)glycine       D-N-methylleucine   Dnmleu   N-(3-indolylyethyl) glycine   Nhtrp       D-N-methyllysine   Dnmlys   N-methyl-γ-aminobutyrate   Nmgabu       N-methylcyclohexylalanine   Nmchexa   D-N-methylmethionine   Dnmmet       D-N-methylornithine   Dnmorn   N-methylcyclopentylalanine   Nmcpen       N-methylglycine   Nala   D-N-methylphenylalanine   Dnmphe       N-methylaminoisobutyrate   Nmaib   D-N-methylproline   Dnmpro       N-(1-methylpropyl)glycine   Nile   D-N-methylserine   Dnmser       N-(2-methylpropyl)glycine   Nile   D-N-methylserine   Dnmser       N-(2-methylpropyl)glycine   Nleu   D-N-methylthreonine   Dnmthr       D-N-methyltryptophan   Dnmtrp   N-(1-methylethyl)glycine   Nva       D-N-methyltyrosine   Dnmtyr   N-methyla-napthylalanine   Nmanap       D-N-methylvaline   Dnmval   N-methylpenicillamine   Nmpen       γ-aminobutyric acid   Gabu   N-(p-hydroxyphenyl)glycine   Nhtyr       L-t-butylglycine   Tbug   N-(thiomethyl)glycine   Ncys       L-ethylglycine   Etg   penicillamine   Pen       L-homophenylalanine   Hphe   L-α-methylalanine   Mala       L-α-methylarginine   Marg   L-α-methylasparagine   Masn       L-α-methylaspartate   Masp   L-α-methyl-t-butylglycine   Mtbug       L-α-methylcysteine   Mcys   L-methylethylglycine   Metg       L-α-methylglutamine   Mgln   L-α-methylglutamate   Mglu       L-α-methylhistidine   Mhis   L-α-methylhomo   Mhphe               phenylalanine       L-α-methylisoleucine   Mile   N-(2-methylthioethyl)glycine   Nmet       D-N-methylglutamine   Dnmgln   N-(3-   Narg               guanidinopropyl)glycine       D-N-methylglutamate   Dnmglu   N-(1-hydroxyethyl)glycine   Nthr       D-N-methylhistidine   Dnmhis   N-(hydroxyethyl)glycine   Nser       D-N-methylisoleucine   Dnmile   N-(imidazolylethyl)glycine   Nhis       D-N-methylleucine   Dnmleu   N-(3-indolylyethyl)glycine   Nhtrp       D-N-methyllysine   Dnmlys   N-methyl-γ-aminobutyrate   Nmgabu       N-   Nmchexa   D-N-methylmethionine   Dnmmet       methylcyclohexylalanine       D-N-methylornithine   Dnmorn   N-methylcyclopentylalanine   Nmcpen       N-methylglycine   Nala   D-N-methylphenylalanine   Dnmphe       N-methylaminoisobutyrate   Nmaib   D-N-methylproline   Dnmpro       N-(1-methylpropyl)glycine   Nile   D-N-methylserine   Dnmser       N-(2-methylpropyl)glycine   Nleu   D-N-methylthreonine   Dnmthr       D-N-methyltryptophan   Dnmtrp   N-(1-methylethyl)glycine   Nval       D-N-methyltyrosine   Dnmtyr   N-methyla-napthylalanine   Nmanap       D-N-methylvaline   Dnmval   N-methylpenicillamine   Nmpen       γ-aminobutyric acid   Gabu   N-(p-hydroxyphenyl)glycine   Nhtyr       L-t-butylglycine   Tbug   N-(thiomethyl)glycine   Ncys       L-ethylglycine   Etg   penicillamine   Pen       L-homophenylalanine   Hphe   L-α-methylalanine   Mala       L-α-methylarginine   Marg   L-α-methylasparagine   Masn       L-α-methylaspartate   Masp   L-α-methyl-t-butylglycine   Mtbug       L-α-methylcysteine   Mcys   L-methylethylglycine   Metg       L-α-methylglutamine   Mgln   L-α-methylglutamate   Mglu       L-α-methylhistidine   Mhis   L-α-   Mhphe               methylhomophenylalanine       L-α-methylisoleucine   Mile   N-(2-methylthioethyl)glycine   Nmet       L-α-methylleucine   Mleu   L-α-methyllysine   Mlys       L-α-methylmethionine   Mmet   L-α-methylnorleucine   Mnle       L-α-methylnorvaline   Mnva   L-α-methylornithine   Morn       L-α-methylphenylalanine   Mphe   L-α-methylproline   Mpro       L-α-methylserine   mser   L-α-methylthreonine   Mthr       L-α-methylvaline   Mtrp   L-α-methyltyrosine   Mtyr       L-α-methylleucine   Mval   L-N-methylhomophenylalanine   Nmhphe           Nnbhm       N-(N-(2,2-diphenylethyl)       N-(N-(3,3-diphenylpropyl)       carbamylmethyl-glycine   Nnbhm   carbamylmethyl(1)glycine   Nnbhe       1-carboxy-1-(2,2-diphenyl   Nmbc       ethylamino)cyclopropane                  
 
      Since the peptides of the present invention are preferably utilized in diagnostics which require the peptides to be in soluble form, the peptides of the present invention preferably include one or more non-natural or natural polar amino acids, including but not limited to serine and threonine which are capable of increasing peptide solubility due to their hydroxyl-containing side chain.  
      The peptides of the present invention are preferably utilized in a linear form, although it will be appreciated that in cases where cyclicization does not severely interfere with peptide characteristics, cyclic forms of the peptide can also be utilized.  
      The peptides of present invention can be biochemically synthesized such as by using standard solid phase techniques. These methods include exclusive solid phase synthesis well known in the art, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.  
      Synthetic peptides can be purified by preparative high performance liquid chromatography and the composition of which can be confirmed via amino acid sequencing.  
      In cases where large amounts of the peptides of the present invention are desired, the peptides of the present invention can be generated using recombinant techniques such as described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach &amp; Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463 and also as described above.  
      Antibodies  
      “Antibody” refers to a polypeptide ligand that is preferably substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically binds and recognizes an epitope (e.g., an antigen). The recognized immunoglobulin genes include the kappa and lambda light chain constant region genes, the alpha, gamma, delta, epsilon and mu heavy chain constant region genes, and the myriad-immunoglobulin variable region genes. Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. This includes, e.g., Fab′ and F(ab)′ 2  fragments. The term “antibody,” as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies. It also includes polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, or single chain antibodies. “Fc” portion of an antibody refers to that portion of an immunoglobulin heavy chain that comprises one or more heavy chain constant region domains, CH1, CH2 and CH3, but does not include the heavy chain variable region.  
      The functional fragments of antibodies, such as Fab, F(ab′)2, and Fv that are capable of binding to macrophages, are described as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab′, the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab′ fragments are obtained per antibody molecule; (3) (Fab′) 2 , the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab′)2 is a dimer of two Fab′ fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody (“SCA”), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.  
      Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).  
      Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in  E. coli  or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′)2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab′ monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab′ fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.  
      Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar et al. [Proc. Nat&#39;l Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as  E. coli . The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird et al., Science 242:423-426 (1988); Pack et al., Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.  
      Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides (“minimal recognition units”) can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)].  
      Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) Such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].  
      Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.  
      Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boemer et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10: 779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).  
      Preferably, the antibody of this aspect of the present invention specifically binds at least one epitope of the polypeptide variants of the present invention. As used herein, the term “epitope” refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.  
      Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.  
      Optionally, a unique epitope may be created in a variant due to a change in one or more post-translational modifications, including but not limited to glycosylation and/or phosphorylation, as described below. Such a change may also cause a new epitope to be created, for example through removal of glycosylation at a particular site.  
      An epitope according to the present invention may also optionally comprise part or all of a unique sequence portion of a variant according to the present invention in combination with at least one other portion of the variant which is not contiguous to the unique sequence portion in the linear polypeptide itself, yet which are able to form an epitope in combination. One or more unique sequence portions may optionally combine with one or more other non-contiguous portions of the variant (including a portion which may have high homology to a portion of the known protein) to form an epitope.  
      Immunoassays  
      In another embodiment of the present invention, an immunoassay can be used to qualitatively or quantitatively detect and analyze markers in a sample. This method comprises: providing an antibody that specifically binds to a marker; contacting a sample with the antibody; and detecting the presence of a complex of the antibody bound to the marker in the sample.  
      To prepare an antibody that specifically binds to a marker, purified protein markers can be used. Antibodies that specifically bind to a protein marker can be prepared using any suitable methods known in the art.  
      After the antibody is provided, a marker can be detected and/or quantified using any of a number of well recognized immunological binding assays. Useful assays include, for example, an enzyme immune assay (EIA) Such as enzyme-linked immunosorbent assay (ELISA), a radioimmune assay (RIA), a Western blot assay, or a slot blot assay see, e.g., U.S. Pat. Nos. 4,366,241; 4,376,110; 4,517,288; and 4,837,168). Generally, a sample obtained from a subject can be contacted with the antibody that specifically binds the marker.  
      Optionally, the antibody can be fixed to a solid support to facilitate washing and subsequent isolation of the complex, prior to contacting the antibody with a sample. Examples of solid supports include but are not limited to glass or plastic in the form of, e.g., a microtiter plate, a stick, a bead, or a microbead. Antibodies can also be attached to a solid support.  
      After incubating the sample with antibodies, the mixture is washed and the antibody-marker complex formed can be detected. This can be accomplished by incubating the washed mixture with a detection reagent. Alternatively, the marker in the sample can be detected using an indirect assay, wherein, for example, a second, labeled antibody is used to detect bound marker-specific antibody, and/or in a competition or inhibition assay wherein, for example, a monoclonal antibody which binds to a distinct epitope of the marker are incubated simultaneously with the mixture.  
      Throughout the assays, incubation and/or washing steps may be required after each combination of reagents. Incubation steps can vary from about 5 seconds to several hours, preferably from about 5 minutes to about 24 hours. However, the incubation time will depend upon the assay format, marker, volume of solution, concentrations and the like. Usually the assays will be carried out at ambient temperature, although they can be conducted over a range of temperatures, such as 10° C. to 40° C.  
      The immunoassay can be used to determine a test amount of a marker in a sample from a subject. First, a test amount of a marker in a sample can be detected using the immunoassay methods described above. If a marker is present in the sample, it will form an antibody-marker complex with an antibody that specifically binds the marker under suitable incubation conditions described above. The amount of an antibody-marker complex can optionally be determined by comparing to a standard. As noted above, the test amount of marker need not be measured in absolute units, as long as the unit of measurement can be compared to a control amount and/or signal.  
      Preferably used are antibodies which specifically interact with the polypeptides of the present invention and not with wild type proteins or other isoforms thereof, for example. Such antibodies are directed, for example, to the unique sequence portions of the polypeptide variants of the present invention, including but not limited to bridges, heads, tails and insertions described in greater detail below. Preferred embodiments of antibodies according to the present invention are described in greater detail with regard to the section entitled “Antibodies”.  
      Radio-immunoassay (RIA): In one version, this method involves precipitation of the desired substrate and in the methods detailed hereinbelow, with a specific antibody and radiolabelled antibody binding protein (e.g., protein A labeled with I 125 ) immobilized on a precipitable carrier such as agarose beads. The number of counts in the precipitated pellet is proportional to the amount of substrate.  
      In an alternate version of the RIA, a labeled substrate and an unlabelled antibody binding protein are employed. A sample containing an unknown amount of substrate is added in varying amounts. The decrease in precipitated counts from the labeled substrate is proportional to the amount of substrate in the added sample.  
      Enzyme linked immunosorbent assay (ELISA): This method involves fixation of a sample (e.g., fixed cells or a proteinaceous solution) containing a protein substrate to a surface such as a well of a microtiter plate. A substrate specific antibody coupled to an enzyme is applied and allowed to bind to the substrate. Presence of the antibody is then detected and quantitated by a colorimetric reaction employing the enzyme coupled to the antibody. Enzymes commonly employed in this method include horseradish peroxidase and alkaline phosphatase. If well calibrated and within the linear range of response, the amount of substrate present in the sample is proportional to the amount of color produced. A substrate standard is generally employed to improve quantitative accuracy.  
      Western blot: This method involves separation of a substrate from other protein by means of an acrylamide gel followed by transfer of the substrate to a membrane (e.g., nylon or PVDF). Presence of the substrate is then detected by antibodies specific to the substrate, which are in turn detected by antibody binding reagents. Antibody binding reagents may be, for example, protein A, or other antibodies. Antibody binding reagents may be radiolabelled or enzyme linked as described hereinabove. Detection may be by autoradiography, colorimetric reaction or chemiluminescence. This method allows both quantitation of an amount of substrate and determination of its identity by a relative position on the membrane which is indicative of a migration distance in the acrylamide gel during electrophoresis.  
      Immunohistochemical analysis: This method involves detection of a substrate in situ in fixed cells by substrate specific antibodies. The substrate specific antibodies may be enzyme linked or linked to fluorophores. Detection is by microscopy and subjective evaluation. If enzyme linked antibodies are employed, a colorimetric reaction may be required.  
      Fluorescence activated cell sorting (FACS): This method involves detection of a substrate in situ in cells by substrate specific antibodies. The substrate specific antibodies are linked to fluorophores. Detection is by means of a cell sorting machine which reads the wavelength of light emitted from each cell as it passes through a light beam. This method may employ two or more antibodies simultaneously.  
      Radio-Imaging Methods  
      These methods include but are not limited to, positron emission tomography (PET) single photon emission computed tomography (SPECT). Both of these techniques are non-invasive, and can be used to detect and/or measure a wide variety of tissue events and/or functions, such as detecting cancerous cells for example. Unlike PET, SPECT can optionally be used with two labels simultaneously. SPECT has some other advantages as well, for example with regard to cost and the types of labels that can be used. For example, U.S. Pat. No. 6,696,686 describes the use of SPECT for detection of breast cancer, and is hereby incorporated by reference as if fully set forth herein.  
      Display Libraries  
      According to still another aspect of the present invention there is provided a display library comprising a plurality of display vehicles (such as phages, viruses or bacteria) each displaying at least 6, at least 7, at least 8, at least 9, at least 10, 10-15, 12-17, 15-20, 15-30 or 20-50 consecutive amino acids derived from the polypeptide sequences of the present invention.  
      Methods of constructing such display libraries are well known in the art. Such methods are described in, for example, Young A C, et al., “The three-dimensional structures of a polysaccharide binding antibody to  Cryptococcus neoformans  and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes” J Mol Biol 1997 Dec. 12; 274(4):622-34; Giebel L B et al. “Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities” Biochemistry 1995 Nov. 28; 34(47): 15430-5; Davies E L et al., “Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes” J Immunol Methods 1995 Oct. 12; 186(1):125-35; Jones C R T al. “Current trends in molecular recognition and bioseparation” J Chromatogr A 1995 Jul. 14; 707(1):3-22; Deng S J et al. “Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries” Proc Natl Acad Sci USA 1995 May 23; 92(11):4992-6; and Deng S J et al. “Selection of antibody single-chain variable fragments with improved carbohydrate binding by phage display” J Biol Chem 1994 Apr. 1; 269(13):9533-8, which are incorporated herein by reference.  
      The following sections relate to Candidate Marker Examples. It should be noted that Table numbering is restarted within each example relating to each cluster (each such section begins with “Description for Cluster” followed by the name of the cluster).  
      Candidate Marker Examples Section  
      This Section relates to Examples of sequences and markers according to the present invention.  
      Description of the methodology undertaken to uncover the biomolecular sequences of the present invention  
      Human ESTs and cDNAs were obtained from GenBank versions 136 (Jun. 15, 2003 ftp.ncbi.nih.gov/genbank/release.notes/bgb136.release.notes); NCBI genome assembly of April 2003; RefSeq sequences from June 2003; Genbank version 139 (December 2003); Human Genome from NCBI (Build 34) (from October 2003); and RefSeq sequences from December 2003. With regard to GenBank sequences, the human EST sequences from the EST (GBEST) Section and the human mRNA sequences from the primate (GBPR1) Section were used; also the human nucleotide RefSeq mRNA sequences were used (see for example www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html and for a reference to the EST section, see www.ncbi.nlm.nih.gov/dbEST/; a general reference to dbEST, the EST database in GenBank, may be found in Boguski et al, Nat Genet. 1993 August; 4(4):332-3; all of which are hereby incorporated by reference as if fully set forth herein).  
      Novel splice variants were predicted using the LEADS clustering and assembly system as described in Sorek, R., Ast, G. &amp; Graur, D. Alu-containing exons are alternatively spliced. Genome Res 12, 1060-7 (2002); U.S. Pat. No. 6,625,545; and U.S. patent application Ser. No. 10/426,002, published as U.S. 20040101876 on May 27, 2004; all of which are hereby incorporated by reference as if fully set forth herein. Briefly, the software cleans the expressed sequences from repeats, vectors and immunoglobulins. It then aligns the expressed sequences to the genome taking alternatively splicing into account and clusters overlapping expressed sequences into “clusters” that represent genes or partial genes.  
      These were annotated using the GeneCarta (Compugen, Tel-Aviv, Israel) platform. The GeneCarta platform includes a rich pool of annotations, sequence information (particularly of spliced sequences), chromosomal information, alignments, and additional information such as SNPs, gene ontology terms, expression profiles, functional analyses, detailed domain structures, known and predicted proteins and detailed homology reports.  
     Description for Cluster S71513  
      Cluster S71513 features 1 transcript(s) and 6 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       S71513_T2   1                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 S71513_node_0 
                 2 
               
               
                   
                 S71513_node_5 
                 3 
               
               
                   
                 S71513_node_6 
                 4 
               
               
                   
                 S71513_node_8 
                 5 
               
               
                   
                 S71513_node_1 
                 6 
               
               
                   
                 S71513_node_4 
                 7 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                 Protein Name 
                 Sequence ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 S71513_P2 
                 9 
                 S71513_T2 (SEQ ID NO: 1) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Small inducible cytokine A2 precursor (SEQ ID NO:8) (SwissProt accession identifier SY02_HUMAN; known also according to the synonyms CCL2; Monocyte chemotactic protein 1; MCP-1; Monocyte chemoattractant protein-1; Monocyte chemotactic and activating factor; MCAF; Monocyte secretory protein JE; HCl 1), referred to herein as the previously known protein.  
      Protein Small inducible cytokine A2 precursor (SEQ ID NO:8) is known or believed to have the following function(s): chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. Binds to CCR2 and CCR4. The sequence for protein Small inducible cytokine A2 precursor (SEQ ID NO:8) is given at the end of the application, as “Small inducible cytokine A2 precursor amino acid sequence” (SEQ ID NO:8). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on           amino acid sequence   Comment               76   A -&gt; T./FTId = VAR_001632.       24   Missing: Loss of activity.       25-32   Missing: Loss of activity.       24-85   MISSING: 90% REDUCTION IN ACTIVITY.       24-91   MISSING: 83% REDUCTION IN ACTIVITY.       26   D-&gt;A: 90% REDUCTION IN ACTIVITY.       29   N-&gt;A: 50% REDUCTION IN ACTIVITY.       47   R-&gt;F: 95% REDUCTION IN ACTIVITY.       50   S-&gt;Q: 40% REDUCTION IN ACTIVITY.       51   Y-&gt;D: LOSS OF ACTIVITY.       53   R-&gt;L: LOSS OF ACTIVITY.       91   D-&gt;L: 90% REDUCTION IN ACTIVITY.                  
 
      Protein Small inducible cytokine A2 precursor (SEQ ID NO:8) localization is believed to be Secreted.  
      Rong et al reported that MCP-1 causes (or at least is associated with) an inflammatory action of peritoneal fluid of women with endometriosis (Fertil Steril. 2002 October; 78(4):843-8). Therefore, variants according to the present invention are believed to be useful as diagnostic markers for endometriosis.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: protein amino acid phosphorylation; calcium ion homeostasis; anti-apoptosis; chemotaxis; inflammatory response; humoral defense mechanism; cell adhesion; G-protein signaling, coupled to cyclic nucleotide second messenger; JAK-STAT cascade; cell-cell signaling; response to pathogenic bacteria; viral genome replication, which are annotation(s) related to Biological Process; protein kinase; ligand; chemokine, which are annotation(s) related to Molecular Function; and extracellular space; membrane, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      As noted above, cluster S71513 features 1 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Small inducible cytokine A2 precursor (SEQ ID NO:8). A description of each variant protein according to the present invention is now provided.  
      Variant protein S71513_P2 (SEQ ID NO:9) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) S71513_T2 (SEQ ID NO:1). An alignment is given to the known protein (Small inducible cytokine A2 precursor (SEQ ID NO:8)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between S71513_P2 (SEQ ID NO:9) and SY02_HUMAN (SEQ ID NO:8):  
      1. An isolated chimeric polypeptide encoding for S71513_P2 (SEQ ID NO:9), comprising a first amino acid sequence being at least 90% homologous to MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCP KEAV corresponding to amino acids 1-64 of SY02_HUMAN (SEQ ID NO:8), which also corresponds to amino acids 1-64 of S71513_P2 (SEQ ID NO:9), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence M corresponding to amino acids 65-65 of S71513_P2 (SEQ ID NO:9, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein S71513_P2 (SEQ ID NO:9) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S71513_P2 (SEQ ID NO:9) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 5                          Amino acid mutations                         SNP position(s) on amino acid   Alternative           sequence   amino acid(s)   Previously known SNP?               15   A -&gt;   No       15   A -&gt; G   No       22   L -&gt; P   No                  
 
      The glycosylation sites of variant protein S71513_P2 (SEQ ID NO:9), as compared to the known protein Small inducible cytokine A2 precursor (SEQ ID NO:8), are described in Table 6 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 6                          Glycosylation site(s)                         Position(s) on known amino   Present in           acid sequence   variant protein?   Position in variant protein?               37   yes   37                  
 
      The phosphorylation sites of variant protein S71513_P2 (SEQ ID NO:9), as compared to the known protein Small inducible cytokine A2 precursor (SEQ ID NO:8), are described in Table 7 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 7                          Phosphorylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?               24   yes   24                  
 
      Variant protein S71513_P2 (SEQ ID NO:9) is encoded by the following transcript(s): S71513_T2 (SEQ ID NO:1), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S71513_T2 (SEQ ID NO:1) is shown in bold; this coding portion starts at position 341 and ends at position 535. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S71513_P2 (SEQ ID NO:9) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 8                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 219   G -&gt; T   Yes       222   C -&gt; T   Yes       383   G -&gt;   No       384   C -&gt;   No       384   C -&gt; G   No       403   G -&gt; T   No       405   T -&gt; C   No       439   C -&gt; T   No       445   T -&gt; C   Yes       559   C -&gt; T   Yes       963   A -&gt; G   No       1045   A -&gt; G   No       1045   A -&gt; T   No       1087   C -&gt; T   Yes       1090   T -&gt;   No       1090   T -&gt; G   No       1110   T -&gt;   No       1127   A -&gt;   No       1203   T -&gt;   No       1203   T -&gt; G   No       1247   C -&gt; T   Yes       1360   -&gt; G   No       1360   -&gt; T   No       1388   T -&gt;   No                  
 
      As noted above, cluster S71513 features 6 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster S71513_node — 0 (SEQ ID NO:2) according to the present invention is supported by 292 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S71513_T2 (SEQ ID NO:1). Table 9 below describes the starting and ending position of this segment on each transcript.  
               TABLE 9                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               S71513_T2 (SEQ ID NO: 1)   1   387                  
 
      Segment cluster S71513_node_(SEQ ID NO:3) according to the present invention is supported by 39 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S71513-T2 (SEQ ID NO:1). Table 10 below describes the starting and ending position of this segment on each transcript.  
               TABLE 10                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               S71513_T2 (SEQ ID NO: 1)   535   916                  
 
      Segment cluster S71513_node — 6 (SEQ ID NO:4) according to the present invention is supported by 326 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S71513-T2 (SEQ ID NO:1). Table 11 below describes the starting and ending position of this segment on each transcript.  
               TABLE 11                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               S71513_T2 (SEQ ID NO: 1)   917   1272                  
 
      Segment cluster S71513_node — 8 (SEQ ID NO:5) according to the present invention is supported by 165 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S71513_T2 (SEQ ID NO:1). Table 12 below describes the starting and ending position of this segment on each transcript.  
               TABLE 12                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               S71513_T2 (SEQ ID NO: 1)   1273   1404                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster S71513_node — 1 (SEQ ID NO:6) according to the present invention is supported by 296 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S71513_T2 (SEQ ID NO:1). Table 13 below describes the starting and ending position of this segment on each transcript.  
               TABLE 13                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               S71513_T2 (SEQ ID NO: 1)   388   416                  
 
      Segment cluster S71513_node — 4 (SEQ ID NO:7) according to the present invention is supported by 319 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S71513 T2 (SEQ ID NO:1). Table 14 below describes the starting and ending position of this segment on each transcript.  
               TABLE 14                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               S71513_T2 (SEQ ID NO: 1)   417   534                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: SY02_HUMAN (SEQ ID NO: 8)                   Sequence documentation:               Alignment of: S71513_P2 (SEQ ID NO: 9) × SY02_HUMAN (SEQ ID NO: 8) ..               Alignment segment 1/1:                                             Quality:   619.00   Escore:   0                       Matching length:   65   Total length:   65               Matching Percent Similarity:   100.00   Matching Percent Identity:   98.46               Total Percent Similarity:   100.00   Total Percent Identity:   98.46               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLAS   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLAS   50                            .       51   YRRITSSKCPKEAVM   65           ||||||||||||||:       51   YRRITSSKCPKEAVI   65          
 
     Description for Cluster HUMELAM1A  
      Cluster HUMELAM1A features 3 transcript(s) and 17 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   SEQ ID No.                       HUMELAM1A_T1   10           HUMELAM1A_T5   11           HUMELAM1A_T6   12                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 SEQ ID No. 
               
               
                   
                   
               
               
                   
                 HUMELAM1A_node_5 
                 13 
               
               
                   
                 HUMELAM1A_node_8 
                 14 
               
               
                   
                 HUMELAM1A_node_10 
                 15 
               
               
                   
                 HUMELAM1A_node_11 
                 16 
               
               
                   
                 HUMELAM1A_node_13 
                 17 
               
               
                   
                 HUMELAM1A_node_15 
                 18 
               
               
                   
                 HUMELAM1A_node_18 
                 19 
               
               
                   
                 HUMELAM1A_node_19 
                 20 
               
               
                   
                 HUMELAM1A_node_20 
                 21 
               
               
                   
                 HUMELAM1A_node_22 
                 22 
               
               
                   
                 HUMELAM1A_node_33 
                 23 
               
               
                   
                 HUMELAM1A_node_0 
                 24 
               
               
                   
                 HUMELAM1A_node_2 
                 25 
               
               
                   
                 HUMELAM1A_node_7 
                 26 
               
               
                   
                 HUMELAM1A_node_24 
                 27 
               
               
                   
                 HUMELAM1A_node_26 
                 28 
               
               
                   
                 HUMELAM1A_node_29 
                 29 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                 Protein Name 
                 SEQ ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HUMELAM1A_P2 
                 31 
                 HUMELAM1A_T1 (SEQ ID 
               
               
                   
                   
                 NO: 10) 
               
               
                 HUMELAM1A_P4 
                 32 
                 HUMELAM1A_T5 (SEQ ID 
               
               
                   
                   
                 NO: 11) 
               
               
                 HUMELAM1A_P5 
                 33 
                 HUMELAM1A_T6 (SEQ ID 
               
               
                   
                   
                 NO: 12) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein E-selectin precursor (SEQ ID NO:30) (SwissProt accession identifier LEM2_HUMAN (SEQ ID NO:30; known also according to the synonyms Endothelial leukocyte adhesion molecule 1; ELAM-1; Leukocyte-endothelial cell adhesion molecule 2; LECAM2; CD62E antigen), referred to herein as the previously known protein.  
      Protein E-selectin precursor (SEQ ID NO:30) is known or believed to have the following function(s): expressed on cytokine induced endothelial cells and mediates their binding to leukocytes. The ligand recognized by ELAM-1 is sialyl-lewis X (alpha(1-&gt;3)fucosylated derivatives of polylactosamine that are found at the nonreducing termini of glycolipids). The sequence for protein E-selectin precursor is given at the end of the application, as “E-selectin precursor amino acid sequence” (SEQ ID NO:30). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on           amino acid sequence   Comment                             21   A -&gt; S. /FTId = VAR_014300.       31   M -&gt; I. /FTId = VAR_014301.       130   C -&gt; W (in dbSNP: 5360). /FTId = VAR_011790.       149   S -&gt; R (polymorphism associated with coronary           artery disease; dbSNP: 5361). /FTId =           VAR_004191.       257   Q -&gt; P. /FTId = VAR_014302.       295   E -&gt; K (in dbSNP: 5364). /FTId = VAR_011791.       421   E -&gt; Q (in dbSNP: 5366). /FTId = VAR_011792.       468   H -&gt; Y (in dbSNP: 5368). /FTId = VAR_011793.       550   P -&gt; S. /FTId = VAR_014303.       575   L -&gt; F (in dbSNP: 5355). /FTId = VAR_011794.                  
 
      Protein E-selectin precursor (SEQ ID NO:30) localization is believed to be Type I membrane protein.  
      Yang et al reported that E-selectin may be involved in, or related to, endometrisosis (Best Pract Res Clin Obstet Gynaecol. 2004 April; 18(2):305-18). Therefore, variants according to the present invention are believed to be useful as diagnostic markers for endometriosis.  
      The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Ischaemia, cerebral. It has been investigated for clinicat/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: E selectin agonist; Immunostimulant. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Anti-inflammatory; Neuroprotective.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: inflammatory response; cell adhesion; heterophilic cell adhesion, which are annotation(s) related to Biological Process; protein binding; sugar binding, which are annotation(s) related to Molecular Function; and plasma membrane; integral membrane protein, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      As noted above, cluster HUMELAM1A features 3 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein E-selectin precursor (SEQ ID NO:30). A description of each variant protein according to the present invention is now provided.  
      Variant protein HUMELAM1A_P2 (SEQ ID NO:31) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMELAM1A_T1 (SEQ ID NO:10). An alignment is given to the known protein (E-selectin precursor (SEQ ID NO:30) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMELAM1A_P2 (SEQ ID NO:31) and LEM2_HUMAN (SEQ ID NO:30):  
      1. An isolated chimeric polypeptide encoding for HUMELAM1A_P2 (SEQ ID NO:31), comprising a first amino acid sequence being at least 90% homologous to MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYL NSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIK REKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETNNYTCKCDPGFSGLKC EQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPI PACNVVECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNW DNEKPTCKAVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECT TQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKR LQCGPTGEWDNEKPTCE corresponding to amino acids 1-426 of LEM2_HUMAN (SEQ ID NO:30), which also corresponds to amino acids 1-426 of HUMELAM1A_P2 (SEQ ID NO:31), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GTVFVFILF (SEQ ID NO:501) corresponding to amino acids 427-435 of HUMELAM1A_P2 (SEQ ID NO:31), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMELAM1A_P2 (SEQ ID NO:31), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GTVFVFILF (SEQ ID NO:501) in HUMELAM1A_P2 (SEQ ID NO:31).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMELAM1A_P2 (SEQ ID NO:31) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMELAM1A_P2 (SEQ ID NO:31) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 5                          Amino acid mutations                         SNP position(s) on               amino acid       sequence   Alternative amino acid(s)   Previously known SNP?                                 21   A -&gt; S   Yes       31   M -&gt; I   Yes       130   C -&gt; W   Yes       149   S -&gt; R   Yes       257   Q -&gt; P   Yes       295   E -&gt; K   Yes       421   E -&gt; Q   Yes                  
 
      The glycosylation sites of variant protein HUMELAM1A_P2 (SEQ ID NO:31), as compared to the known protein E-selectin precursor (SEQ ID NO:30), are described in Table 6 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 6                          Glycosylation site(s)                         Position(s) on known amino   Present   Position in variant       acid sequence   in variant protein?   protein?                                 199   yes   199       203   yes   203       312   yes   312       145   yes   145       332   yes   332       503   no       265   yes   265       160   yes   160       25   yes   25       527   no       179   yes   179                  
 
      Variant protein HUMELAM1A_P2 (SEQ ID NO:31) is encoded by the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMELAM1A_T1 (SEQ ID NO:10) is shown in bold; this coding portion starts at position 164 and ends at position 1468. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMELAM1A_P2 (SEQ ID NO:31) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 43   A -&gt; G   Yes       65   A -&gt; G   Yes       145   G -&gt; T   Yes       224   G -&gt; T   Yes       256   G -&gt; T   Yes       436   A -&gt; G   Yes       439   A -&gt; G   Yes       553   C -&gt; G   Yes       608   A -&gt; C   Yes       904   T -&gt; C   Yes       933   A -&gt; C   Yes       1036   T -&gt; C   Yes       1046   G -&gt; A   Yes       1423   C -&gt; T   Yes       1424   G -&gt; C   Yes       1475   A -&gt; G   Yes       1524   T -&gt; A   Yes       1565   T -&gt; C   Yes       1695   T -&gt; C   Yes       1941   C -&gt; T   Yes       1982   T -&gt; C   Yes       2016   C -&gt; T   Yes       2093   T -&gt; C   Yes       2114   T -&gt; C   Yes       2332   T -&gt; A   Yes       2486   A -&gt; G   Yes       3079   T -&gt; C   Yes       3116   T -&gt; G   Yes       3270   A -&gt; G   Yes       3660   A -&gt; G   Yes       3671   C -&gt; G   Yes                  
 
      Variant protein HUMELAM1A_P2 (SEQ ID NO:32) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMELAM1A_T5 (SEQ ID NO:11. An alignment is given to the known protein (E-selectin precursor (SEQ ID NO:30)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMELAM1A_P2 (SEQ ID NO:32) and LEM2_HUMAN (SEQ ID NO:30):  
      1. An isolated chimeric polypeptide encoding for HUMELAM1A_P2 (SEQ ID NO:32), comprising a first amino acid sequence being at least 90% homologous to MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYL NSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIK REKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKC EQIVNCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPI PACN corresponding to amino acids 1-238 of LEM2_HUMAN (SEQ ID NO:30, which also corresponds to amino acids 1-238 of HUMELAM1A_P2 (SEQ ID NO:32), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GKSL (SEQ ID NO:502) corresponding to amino acids 239-242 of HUMELAM1A_P2 (SEQ ID NO:32, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMELAM1A_P2 (SEQ ID NO:32), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GKSL (SEQ ID NO:502) in HUMELAM1A_P2 (SEQ ID NO:32.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMELAM1A_P2 (SEQ ID NO:32) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 8, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMELAM1A_P2 (SEQ ID NO:32) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 8                          Amino acid mutations                         SNP position(s) on amino acid   Alternative           sequence   amino acid(s)   Previously known SNP?                                 21   A -&gt; S   Yes       31   M -&gt; I   Yes       130   C -&gt; W   Yes       149   S -&gt; R   Yes                  
 
      The glycosylation sites of variant protein HUMELAM1A_P2 (SEQ ID NO:32), as compared to the known protein E-selectin precursor (SEQ ID NO:30, are described in Table 9 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 9                          Glycosylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?                                 199   yes   199       203   yes   203       312   no       145   yes   145       332   no       503   no       265   no       160   yes   160       25   yes   25       527   no       179   yes   179                  
 
      Variant protein HUMELAM1A_P2 (SEQ ID NO:32) is encoded by the following transcript(s): HUMELAM1A_T5 (SEQ ID NO:11), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMELAM1A_T5 (SEQ ID NO:11) is shown in bold; this coding portion starts at position 164 and ends at position 889. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMELAM1A_P2 (SEQ ID NO:32) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 43   A -&gt; G   Yes       65   A -&gt; G   Yes       145   G -&gt; T   Yes       224   G -&gt; T   Yes       256   G -&gt; T   Yes       436   A -&gt; G   Yes       439   A -&gt; G   Yes       553   C -&gt; G   Yes       608   A -&gt; C   Yes                  
 
      Variant protein HUMELAM1A_P2 (SEQ ID NO:33) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMELAM1A_T6 (SEQ ID NO:12). An alignment is given to the known protein (E-selectin precursor (SEQ ID NO:30) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMELAM1A_P2 (SEQ ID NO:33) and LEM2_HUMAN (SEQ ID NO:30):  
      1. An isolated chimeric polypeptide encoding for HUMELAM1A_P2 (SEQ ID NO:33), comprising a first amino acid sequence being at least 90% homologous to MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYL NSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIK REKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINbYTCKCDPGFSGLKC EQ corresponding to amino acids 1-176 of LEM2_HUMAN (SEQ ID NO:30), which also corresponds to amino acids 1-176 of HUMELAM1A_P2 (SEQ ID NO:33), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SKSGSCLFLHLRW (SEQ ID NO:503) corresponding to amino acids 177-189 of HUMELAM1A_P2 (SEQ ID NO:33), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMELAM1A_P2 (SEQ ID NO:33), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SKSGSCLFLHLRW (SEQ ID NO:503) in HUMELAM1A_P2 (SEQ ID NO:33).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMELAM1A_P2 (SEQ ID NO:33) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMELAM1A_P2 (SEQ ID NO:33) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 11                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 21   A -&gt; S   Yes       31   M -&gt; I   Yes       130   C -&gt; W   Yes       149   S -&gt; R   Yes       182   C -&gt; R   Yes                  
 
      The glycosylation sites of variant protein HUMELAM1A_P2 (SEQ ID NO:33), as compared to the known protein E-selectin precursor (SEQ ID NO:30), are described in Table 12 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 12                          Glycosylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?                                 199   no           203   no       312   no       145   yes   145       332   no       503   no       265   no       160   yes   160       25   yes   25       527   no       179   no                  
 
      Variant protein HUMELAM1A_P2 (SEQ ID NO:33) is encoded by the following ript(s): HUMELAM1A_T6 (SEQ ID NO:12), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMELAM1A_T6 (SEQ ID NO: 12) is shown in bold; this coding portion starts at position 164 and ends at position 730. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMELAM1A_P2 (SEQ ID NO:33) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 13                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 43   A -&gt; G   Yes       65   A -&gt; G   Yes       145   G -&gt; T   Yes       224   G -&gt; T   Yes       256   G -&gt; T   Yes       436   A -&gt; G   Yes       439   A -&gt; G   Yes       553   C -&gt; G   Yes       608   A -&gt; C   Yes       707   T -&gt; C   Yes       815   C -&gt; T   Yes       912   T -&gt; A   Yes                  
 
      As noted above, cluster HUMELAM1A features 17 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HUMELAM1A_node — 5 (SEQ ID NO:13) according to the present invention is supported by 16 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10), HUMELAM1A_T5 (SEQ ID NO:11) and HUMELAM1A_T6 (SEQ ID NO:12). Table 14 below describes the starting and ending position of this segment on each transcript.  
               TABLE 14                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMELAM1A_T1 (SEQ ID NO: 10)   201   584       HUMELAM1A_T5 (SEQ ID NO: 11)   201   584       HUMELAM1A_T6 (SEQ ID NO: 12)   201   584                  
 
      Segment cluster HUMELAM1A_node — 8 (SEQ ID NO:14) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T6 (SEQ ID NO:12). Table 15 below describes the starting and ending position of this segment on each transcript.  
               TABLE 15                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMELAM1A_T6 (SEQ ID NO: 12)   693   1061                  
 
      Segment cluster HUMELAM1A_node — 10 (SEQ ID NO:15) according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10) and HUMELAM1A_T5 (SEQ ID NO:11). Table 16 below describes the starting and ending position of this segment on each transcript.  
               TABLE 16                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   693   878       HUMELAM1A_T5 (SEQ ID NO: 11)   693   878                  
 
      Segment cluster HUMELAM1A_node — 11 (SEQ ID NO:16) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T5 (SEQ ID NO:11). Table 17 below describes the starting and ending position of this segment on each transcript.  
               TABLE 17                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T5 (SEQ ID NO: 11)   879   1150                  
 
      Segment cluster HUMELAM1A_node — 13 (SEQ ID NO:17) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 18 below describes the starting and ending position of this segment on each transcript.  
               TABLE 18                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   879   1064                  
 
      Segment cluster HUMELAM1A_node — 15 (SEQ ID NO:18) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 19 below describes the starting and ending position of this segment on each transcript.  
               TABLE 19                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   1065   1253                  
 
      Segment cluster HUMELAM1A_node — 18 (SEQ ID NO:19) according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEE ID NO:10). Table 20 below describes the starting and ending position of this segment on each transcript.  
               TABLE 20                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   1254   1442                  
 
      Segment cluster HUMELAM1A_node — 19 (SEQ ID NO:20) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 21 below describes the starting and ending position of this segment on each transcript.  
               TABLE 21                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   1443   1572                  
 
      Segment cluster HUMELAM1A_node — 20 (SEQ ID NO:21) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 22 below describes the starting and ending position of this segment on each transcript.  
               TABLE 22                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   1573   1761                  
 
      Segment cluster HUMELAM1A_node — 22 (SEQ ID NO:22) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 23 below describes the starting and ending position of this segment on each transcript.  
               TABLE 23                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   1762   1938                  
 
      Segment cluster HUMELAM1A_node — 33 (SEQ ID NO:23) according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 24 below describes the starting and ending position of this segment on each transcript.  
               TABLE 24                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   2142   4016                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HUMELAM1A_node — 0 (SEQ ID NO:24) according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10), HUMELAM1A_T5 (SEQ ID NO:11 and HUMELAM1A_T6 (SEQ ID NO:12). Table 25 below describes the starting and ending position of this segment on each transcript.  
               TABLE 25                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMELAM1A_T1 (SEQ ID NO: 10)   1   115       HUMELAM1A_T5 (SEQ ID NO: 11)   1   115       HUMELAM1A_T6 (SEQ ID NO: 12)   1   115                  
 
      Segment cluster HUMELAM1A_node — 2 (SEQ ID NO:25) according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10), HUMELAM1A_T5 (SEQ ID NO:11) and HUMELAM1A_T6 (SEQ ID NO:12). Table 26 below describes the starting and ending position of this segment on each transcript.  
               TABLE 26                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMELAM1A_T1 (SEQ ID NO: 10)   116   200       HUMELAM1A_T5 (SEQ ID NO: 11)   116   200       HUMELAM1A_T6 (SEQ ID NO: 12)   116   200                  
 
      Segment cluster HUMELAM1A_node — 7 (SEQ ID NO:26) according to the present invention is supported by 13 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10), HUMELAM1A_T5 (SEQ ID NO:1) and HUMELAM1A_T6 (SEQ ID NO:12). Table 27 below describes the starting and ending position of this segment on each transcript.  
               TABLE 27                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMELAM1A_T1 (SEQ ID NO: 10)   585   692       HUMELAM1A_T5 (SEQ ID NO: 11)   585   692       HUMELAM1A_T6 (SEQ ID NO: 12)   585   692                  
 
      Segment cluster HUMELAM1A_node — 24 (SEQ ID NO:27) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:11). Table 28 below describes the starting and ending position of this segment on each transcript.  
               TABLE 28                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMELAM1A_T1 (SEQ ID NO: 10)   1939   2046                  
 
      Segment cluster HUMELAM1A_node — 26 (SEQ ID NO:28) according to the present invention can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 29 below describes the starting and ending position of this segment on each transcript.  
               TABLE 29                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMELAM1A_T1 (SEQ ID NO: 10)   2047   2068                  
 
      Segment cluster HUMELAM1A_node — 29 (SEQ ID NO:29) according to the present invention is supported by 8 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMELAM1A_T1 (SEQ ID NO:10). Table 30 below describes the starting and ending position of this segment on each transcript.  
               TABLE 30                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMELAM1A_T1 (SEQ ID NO: 10)   2069   2141                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: LEM2_HUMAN (SEQ ID NO: 30)                   Sequence documentation:               Alignment of: HUMELAM1A_P2 (SEQ ID NO: 31) × LEM2_HUMAN (SEQ ID NO: 30) ..               Alignment segment 1/1:                                             Quality:   4376.00   Escore:   0                       Matching length:   426   Total length:   426               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAI   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAI   50                            .         .         .         .         .       51   QNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   QNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPG   100                            .         .         .         .         .       101   EPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSG   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   EPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSG   150                            .         .         .         .         .       151   HGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNF   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   HGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNF   200                            .         .         .         .         .       201   SYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVVECDAVTNPAN   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   SYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVVECDAVTNPAN   250                            .         .         .         .         .       251   GFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCK   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   GFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCK   300                            .         .         .         .         .       301   AVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECT   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   AVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECT   350                            .         .         .         .         .       351   TQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQ   400           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   TQGQWTQQIPVCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQ   400                            .         .       401   GFVLKGSKRLQGGPTGEWDNEKPTCE   426           ||||||||||||||||||||||||||       401   GFVLKGSKRLQCGPTGEWDNEKPTCE   426                             Sequence name: LEM2_HUMAN (SEQ ID NO: 30)                   Sequence documentation:               Alignment of: HUMELAM1A_P2 (SEQ ID NO: 32) × LEM2_HUMAN (SEQ ID NO: 30) ..               Alignment segment 1/1:                                             Quality:   2426.00   Escore:   0                       Matching length:   238   Total length:   238               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAI   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MIASQFLSALTLVLLIKESGAWSYNTSTEANTYDEASAYCQQRYTHLVAI   50                            .         .         .         .         .       51   QNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   QNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPG   100                            .         .         .         .         .       101   EPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSG   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   EPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSG   150                            .         .         .         .         .       151   HGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNF   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   HGECVETINNYTCKCDPGFSGLKCEQIVNCTALESPEHGSLVCSHPLGNF   200                            .         .         .       201   SYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACN   238           ||||||||||||||||||||||||||||||||||||||       201   SYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACN   238                             Sequence name: LEM2_HUMAN                   Sequence documentation:               Alignment of: HUMELAM1A_P2 (SEQ ID NO: 33) × LEM2_HUMAN (SEQ ID NO: 30) ..               Alignment segment 1/1:                                             Quality:   1786.00   Escore:   0                       Matching length:   176   Total length:   176               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAI   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAI   50                            .         .         .         .         .       51   QNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   QNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPG   100                            .         .         .         .         .       101   EPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSG   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   EPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSG   150                            .         .       151   HGECVETINNYTCKCDPGFSGLKCEQ   176           ||||||||||||||||||||||||||       151   HGECVETINNYTCKCDPGFSGLKCEQ   176          
 
     Description for Cluster HUMHPA1B  
      Cluster HUMHPA1B features 13 transcript(s) and 84 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       HUMHPA1B_PEA_1_T1   34           HUMHPA1B_PEA_1_T4   35           HUMHPA1B_PEA_1_T6   36           HUMHPA1B_PEA_1_T7   37           HUMHPA1B_PEA_1_T12   38           HUMHPA1B_PEA_1_T16   39           HUMHPA1B_PEA_1_T19   40           HUMHPA1B_PEA_1_T20   41           HUMHPA1B_PEA_1_T27   42           HUMHPA1B_PEA_1_T29   43           HUMHPA1B_PEA_1_T55   44           HUMHPA1B_PEA_1_T56   45           HUMHPA1B_PEA_1_T59   46                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
            
           
           
               
               
               
            
               
                   
                 HUMHPA1B_PEA_1_node_20 
                 47 
               
               
                   
                 HUMHPA1B_PEA_1_node_25 
                 48 
               
               
                   
                 HUMHPA1B_PEA_1_node_28 
                 49 
               
               
                   
                 HUMHPA1B_PEA_1_node_35 
                 50 
               
               
                   
                 HUMHPA1B_PEA_1_node_88 
                 51 
               
               
                   
                 HUMHPA1B_PEA_1_node_0 
                 52 
               
               
                   
                 HUMHPA1B_PEA_1_node_1 
                 53 
               
               
                   
                 HUMHPA1B_PEA_1_node_3 
                 54 
               
               
                   
                 HUMHPA1B_PEA_1_node_4 
                 55 
               
               
                   
                 HUMHPA1B_PEA_1_node_5 
                 56 
               
               
                   
                 HUMHPA1B_PEA_1_node_6 
                 57 
               
               
                   
                 HUMHPA1B_PEA_1_node_7 
                 58 
               
               
                   
                 HUMHPA1B_PEA_1_node_10 
                 59 
               
               
                   
                 HUMHPA1B_PEA_1_node_11 
                 60 
               
               
                   
                 HUMHPA1B_PEA_1_node_12 
                 61 
               
               
                   
                 HUMHPA1B_PEA_1_node_13 
                 62 
               
               
                   
                 HUMHPA1B_PEA_1_node_14 
                 63 
               
               
                   
                 HUMHPA1B_PEA_1_node_15 
                 64 
               
               
                   
                 HUMHPA1B_PEA_1_node_16 
                 65 
               
               
                   
                 HUMHPA1B_PEA_1_node_17 
                 66 
               
               
                   
                 HUMHPA1B_PEA_1_node_18 
                 67 
               
               
                   
                 HUMHPA1B_PEA_1_node_19 
                 68 
               
               
                   
                 HUMHPA1B_PEA_1_node_21 
                 69 
               
               
                   
                 HUMHPA1B_PEA_1_node_22 
                 70 
               
               
                   
                 HUMHPA1B_PEA_1_node_23 
                 71 
               
               
                   
                 HUMHPA1B_PEA_1_node_24 
                 72 
               
               
                   
                 HUMHPA1B_PEA_1_node_27 
                 73 
               
               
                   
                 HUMHPA1B_PEA_1_node_29 
                 74 
               
               
                   
                 HUMHPA1B_PEA_1_node_30 
                 75 
               
               
                   
                 HUMHPA1B_PEA_1_node_31 
                 76 
               
               
                   
                 HUMHPA1B_PEA_1_node_32 
                 77 
               
               
                   
                 HUMHPA1B_PEA_1_node_33 
                 78 
               
               
                   
                 HUMHPA1B_PEA_1_node_34 
                 79 
               
               
                   
                 HUMHPA1B_PEA_1_node_36 
                 80 
               
               
                   
                 HUMHPA1B_PEA_1_node_37 
                 81 
               
               
                   
                 HUMHPA1B_PEA_1_node_38 
                 82 
               
               
                   
                 HUMHPA1B_PEA_1_node_39 
                 83 
               
               
                   
                 HUMHPA1B_PEA_1_node_40 
                 84 
               
               
                   
                 HUMHPA1B_PEA_1_node_41 
                 85 
               
               
                   
                 HUMHPA1B_PEA_1_node_42 
                 86 
               
               
                   
                 HUMHPA1B_PEA_1_node_43 
                 87 
               
               
                   
                 HUMHPA1B_PEA_1_node_44 
                 88 
               
               
                   
                 HUMHPA1B_PEA_1_node_45 
                 89 
               
               
                   
                 HUMHPA1B_PEA_1_node_46 
                 90 
               
               
                   
                 HUMHPA1B_PEA_1_node_47 
                 91 
               
               
                   
                 HUMHPA1B_PEA_1_node_48 
                 92 
               
               
                   
                 HUMHPA1B_PEA_1_node_49 
                 93 
               
               
                   
                 HUMHPA1B_PEA_1_node_50 
                 94 
               
               
                   
                 HUMHPA1B_PEA_1_node_51 
                 95 
               
               
                   
                 HUMHPA1B_PEA_1_node_52 
                 96 
               
               
                   
                 HUMHPA1B_PEA_1_node_53 
                 97 
               
               
                   
                 HUMHPA1B_PEA_1_node_54 
                 98 
               
               
                   
                 HUMHPA1B_PEA_1_node_55 
                 99 
               
               
                   
                 HUMHPA1B_PEA_1_node_56 
                 100 
               
               
                   
                 HUMHPA1B_PEA_1_node_57 
                 101 
               
               
                   
                 HUMHPA1B_PEA_1_node_58 
                 102 
               
               
                   
                 HUMHPA1B_PEA_1_node_59 
                 103 
               
               
                   
                 HUMHPA1B_PEA_1_node_60 
                 104 
               
               
                   
                 HUMHPA1B_PEA_1_node_61 
                 105 
               
               
                   
                 HUMHPA1B_PEA_1_node_62 
                 106 
               
               
                   
                 HUMHPA1B_PEA_1_node_63 
                 107 
               
               
                   
                 HUMHPA1B_PEA_1_node_64 
                 108 
               
               
                   
                 HUMHPA1B_PEA_1_node_65 
                 109 
               
               
                   
                 HUMHPA1B_PEA_1_node_66 
                 110 
               
               
                   
                 HUMHPA1B_PEA_1_node_67 
                 111 
               
               
                   
                 HUMHPA1B_PEA_1_node_69 
                 112 
               
               
                   
                 HUMHPA1B_PEA_1_node_70 
                 113 
               
               
                   
                 HUMHPA1B_PEA_1_node_71 
                 114 
               
               
                   
                 HUMHPA1B_PEA_1_node_72 
                 115 
               
               
                   
                 HUMHPA1B_PEA_1_node_73 
                 116 
               
               
                   
                 HUMHPA1B_PEA_1_node_74 
                 117 
               
               
                   
                 HUMHPA1B_PEA_1_node_75 
                 118 
               
               
                   
                 HUMHPA1B_PEA_1_node_76 
                 119 
               
               
                   
                 HUMHPA1B_PEA_1_node_77 
                 120 
               
               
                   
                 HUMHPA1B_PEA_1_node_78 
                 121 
               
               
                   
                 HUMHPA1B_PEA_1_node_79 
                 122 
               
               
                   
                 HUMHPA1B_PEA_1_node_80 
                 123 
               
               
                   
                 HUMHPA1B_PEA_1_node_81 
                 124 
               
               
                   
                 HUMHPA1B_PEA_1_node_82 
                 125 
               
               
                   
                 HUMHPA1B_PEA_1_node_83 
                 126 
               
               
                   
                 HUMHPA1B_PEA_1_node_84 
                 127 
               
               
                   
                 HUMHPA1B_PEA_1_node_85 
                 128 
               
               
                   
                 HUMHPA1B_PEA_1_node_86 
                 129 
               
               
                   
                 HUMHPA1B_PEA_1_node_87 
                 130 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                   
                 Sequence 
                   
               
               
                 Protein Name 
                 ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HUMHPA1B_PEA_1_P61 
                 133 
                 HUMHPA1B_PEA_1_T1 
               
               
                   
                   
                 (SEQ ID NO: 34) 
               
               
                 HUMHPA1B_PEA_1_P62 
                 134 
                 HUMHPA1B_PEA_1_T4 
               
               
                   
                   
                 (SEQ ID NO: 35) 
               
               
                 HUMHPA1B_PEA_1_P64 
                 135 
                 HUMHPA1B_PEA_1_T6 
               
               
                   
                   
                 (SEQ ID NO: 36) 
               
               
                 HUMHPA1B_PEA_1_P65 
                 136 
                 HUMHPA1B_PEA_1_T7 
               
               
                   
                   
                 (SEQ ID NO: 37) 
               
               
                 HUMHPA1B_PEA_1_P68 
                 137 
                 HUMHPA1B_PEA_1_T12 
               
               
                   
                   
                 (SEQ ID NO: 38) 
               
               
                 HUMHPA1B_PEA_1_P72 
                 138 
                 HUMHPA1B_PEA_1_T16 
               
               
                   
                   
                 (SEQ ID NO: 39) 
               
               
                 HUMHPA1B_PEA_1_P75 
                 139 
                 HUMHPA1B_PEA_1_T19 
               
               
                   
                   
                 (SEQ ID NO: 40) 
               
               
                 HUMHPA1B_PEA_1_P76 
                 140 
                 HUMHPA1B_PEA_1_T20 
               
               
                   
                   
                 (SEQ ID NO: 41) 
               
               
                 HUMHPA1B_PEA_1_P81 
                 141 
                 HUMHPA1B_PEA_1_T27 
               
               
                   
                   
                 (SEQ ID NO: 42) 
               
               
                 HUMHPA1B_PEA_1_P83 
                 142 
                 HUMHPA1B_PEA_1_T29 
               
               
                   
                   
                 (SEQ ID NO: 43) 
               
               
                 HUMHPA1B_PEA_1_P106 
                 143 
                 HUMHPA1B_PEA_1_T55 
               
               
                   
                   
                 (SEQ ID NO: 44) 
               
               
                 HUMHPA1B_PEA_1_P107 
                 144 
                 HUMHPA1B_PEA_1_T56 
               
               
                   
                   
                 (SEQ ID NO: 45) 
               
               
                 HUMHPA1B_PEA_1_P115 
                 145 
                 HUMHPA1B_PEA_1_T59 
               
               
                   
                   
                 (SEQ ID NO: 46) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Haptoglobin precursor (SEQ ID NO:131) (SwissProt accession identifier HPT_HUMAN), referred to herein as the previously known protein.  
      Protein Haptoglobin precursor (SEQ ID NO:131) is known or believed to have the following function(s): haptoglobin combines with free plasma hemoglobin, preventing loss of iron through the kidneys and protecting the kidneys from damage by hemoglobin, while making the hemoglobin accessible to degradative enzymes. The sequence for protein Haptoglobin precursor is given at the end of the application, as “Haptoglobin precursor amino acid sequence” (SEQ ID NO:131). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on           amino acid sequence   Comment               29-87   Missing (in allele HP*1F and allele HP*1S).           /FTId = VAR_017112.       193   N -&gt; D (in allele HP*1F). /FTId = VAR_005294.       194   E -&gt; K (in allele HP*1F). /FTId = VAR_017113.       397   D -&gt; H (in dbSNP: 12646). /FTId = VAR_017114.        70   D -&gt; N        90   D -&gt; E                  
 
      Protein Haptoglobin precursor (SEQ ID NO:131) localization is believed to be Secreted.  
      Endometriotic lesions synthesize and secrete a unique form of haptoglobin (endometriosis protein-I) that is up-regulated by IL-6 (Sharpe-Timms et al, Fertil Steril. 2002 October; 78(4):810-9). Variants of this cluster are suitable as diagnostic markers for endometriosis.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: defense response, which are annotation(s) related to Biological Process.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      As noted above, cluster HUMHPA1B features 13 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Haptoglobin precursor (SEQ ID NO:131). A description of each variant protein according to the present invention is now provided.  
      Variant protein HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDI corresponding to amino acids 1-28 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-28 of HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), and a second amino acid sequence being at least 90% homologous to ADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPE CEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTA KNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLIKLKQKVSVNE RVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPVADQDQCIRHYEGST VPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAVHDLEEDTWYATGIL SFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 88-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 29-347 of HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IA, having a structure as follows: a sequence starting from any of amino acid numbers 28−x to 28; and ending at any of amino acid numbers 29+((n−2)−x), in which x varies from 0 to n−2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       71   E -&gt; G   No       71   E -&gt; K   No       108   L -&gt; V   No       136   Q -&gt;   No       162   L -&gt; V   No       176   K -&gt;   No       184   S -&gt; P   Yes       194   K -&gt;   No       242   L -&gt; P   No       260   P -&gt; L   No       296   A -&gt;   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 8 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 8                          Glycosylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?               207   yes   148       241   yes   182       184   yes   125       211   yes   152                  
 
      Variant protein HUMHPA1B_PEA — 1_P61 (SEQ ID NO:133) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34) is shown in bold; this coding portion starts at position 68 and ends at position 1108. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA11B_PEA — 1_P61 (SEQ ID NO:133) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 9                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       262   G -&gt; A   Yes       278   G -&gt; A   No       279   A -&gt; G   No       304   -&gt; G   No       337   -&gt; G   No       389   C -&gt; G   No       454   T -&gt; C   Yes       454   T -&gt; G   Yes       474   A -&gt;   No       547   T -&gt; C   No       550   -&gt; G   No       551   T -&gt; G   No       589   T -&gt; C   No       595   G -&gt;   No       617   T -&gt; C   Yes       622   G -&gt; A   No       647   A -&gt;   No       694   T -&gt; A   No       792   T -&gt; C   No       826   T -&gt; C   No       846   C -&gt; T   No       886   -&gt; C   No       913   T -&gt; C   No       929   -&gt; C   No       955   G -&gt;   No       955   G -&gt; C   No       978   -&gt; C   No       993   -&gt; C   No       1074   -&gt; C   No       1141   A -&gt; C   No       1142   A -&gt; G   No       1235   -&gt; G   No       1235   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDG corresponding to amino acids 1-64 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-64 of HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) corresponding to amino acids 65-83 of HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) in HUMHPA1B_PEA — 1_P62(SEQ ID NO:134).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Amino acid mutations                         SNP position(s) on amino   Alternative           acid sequence   amino acid(s)   Previously known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 11 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 11                          Glycosylation site(s)                             Position(s) on known amino               acid sequence   Present in variant protein?                       207   no           241   no           184   no           211   no                      
 
      Variant protein HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35) is shown in hold; this coding portion starts at position 68 and ends at position 316. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P62 (SEQ ID NO:134) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 12                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       512   G -&gt; C   No       781   T -&gt; C   Yes       798   G -&gt; C   Yes       879   A -&gt; G   Yes       1063   T -&gt;   No       1124   A -&gt; G   Yes       1173   A -&gt; G   No       1199   G -&gt; A   Yes       1215   G -&gt; A   No       1216   A -&gt; G   No       1241   -&gt; G   No       1274   -&gt; G   No       1326   C -&gt; G   No       1391   T -&gt; C   Yes       1391   T -&gt; G   Yes       1411   A -&gt;   No       1484   T -&gt; C   No       1487   -&gt; G   No       1488   T -&gt; G   No       1526   T -&gt; C   No       1532   G -&gt;   No       1554   T -&gt; C   Yes       1559   G -&gt; A   No       1584   A -&gt;   No       1631   T -&gt; A   No       1729   T -&gt; C   No       1763   T -&gt; C   No       1783   C -&gt; T   No       1823   -&gt; C   No       1850   T -&gt; C   No       1866   -&gt; C   No       1892   G -&gt;   No       1892   G -&gt; C   No       1915   -&gt; C   No       1930   -&gt; C   No       2011   -&gt; C   No       2078   A -&gt; C   No       2079   A -&gt; G   No       2172   -&gt; G   No       2172   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWfNKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNY YKLRTEGDG corresponding to amino acids 1-123 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-123 of HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) corresponding to amino acids 124-142 of HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KMWTTVSMPYIQPPSLTFP (SEQ ID NO:495) in HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 13                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       79   V -&gt;   No       116   K -&gt; E   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 14 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 14                          Glycosylation site(s)                             Position(s) on known amino               acid sequence   Present in variant protein?                       207   no           241   no           184   no           211   no                      
 
      Variant protein HUMHPA1B_PEA — 1_P64 (SEQ ID NO:135) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36) is shown in bold; this coding portion starts at position 68 and ends at position 493. The transcript also has the following SNPs as listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA_L_P64 (SEQ ID NO:135) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 15                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       303   T -&gt;   No       364   A -&gt; G   Yes       413   A -&gt; G   No       570   C -&gt; G   No       689   G -&gt; C   No       1060   A -&gt; T   Yes       1103   C -&gt; T   Yes       1109   G -&gt; A   Yes       1118   T -&gt; C   Yes       1180   C -&gt; T   Yes       1197   G -&gt; A   Yes       1213   G -&gt; A   No       1214   A -&gt; G   No       1239   -&gt; G   No       1272   -&gt; G   No       1324   C -&gt; G   No       1389   T -&gt; C   Yes       1389   T -&gt; G   Yes       1409   A -&gt;   No       1482   T -&gt; C   No       1485   -&gt; G   No       1486   T -&gt; G   No       1524   T -&gt; C   No       1530   G -&gt;   No       1552   T -&gt; C   Yes       1557   G -&gt; A   No       1582   A -&gt;   No       1629   T -&gt; A   No       1727   T -&gt; C   No       1761   T -&gt; C   No       1781   C -&gt; T   No       1821   -&gt; C   No       1848   T -&gt; C   No       1864   -&gt; C   No       1890   G -&gt;   No       1890   G -&gt; C   No       1913   -&gt; C   No       1928   -&gt; C   No       2009   -&gt; C   No       2076   A -&gt; C   No       2077   A -&gt; G   No       2170   -&gt; G   No       2170   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136) according to the present ion has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNY YKLRTEGDGVYTLNNEKQWINKAVGDKLPECEA corresponding to amino acids 1-147 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-147 of HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GGC corresponding to amino acids 148-150 of HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 16, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 16                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       79   V -&gt;   No       116   K -&gt; E   No       130   E -&gt; G   No       130   E -&gt; K   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 17 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 17                          Glycosylation site(s)                             Position(s) on known amino               acid sequence   Present in variant protein?                       207   no           241   no           184   no           211   no                      
 
      Variant protein HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37) is shown in bold; this coding portion starts at position 68 and ends at position 517. The transcript also has the following SNPs as listed in Table 18 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P65 (SEQ ID NO:136) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 18                          Nucleic acid SNPs                         SNP position on               nucleotide sequence   Alternative nucleic acid   Previously known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       303   T -&gt;   No       364   A -&gt; G   Yes       413   A -&gt; G   No       439   G -&gt; A   Yes       455   G -&gt; A   No       456   A -&gt; G   No       481   -&gt; G   No       556   C -&gt; A   Yes       730   T -&gt; C   Yes       751   T -&gt; C   Yes       945   A -&gt; C   Yes       956   G -&gt; A   Yes       1312   G -&gt; A   Yes       1332   T -&gt; C   Yes       1437   -&gt; G   No       1489   C -&gt; G   No       1554   T -&gt; C   Yes       1554   T -&gt; G   Yes       1574   A -&gt;   No       1647   T -&gt; C   No       1650   -&gt; G   No       1651   T -&gt; G   No       1689   T -&gt; C   No       1695   G -&gt;   No       1717   T -&gt; C   Yes       1722   G -&gt; A   No       1747   A -&gt;   No       1794   T -&gt; A   No       1892   T -&gt; C   No       1926   T -&gt; C   No       1946   C -&gt; T   No       1986   -&gt; C   No       2013   T -&gt; C   No       2029   -&gt; C   No       2055   G -&gt;   No       2055   G -&gt; C   No       2078   -&gt; C   No       2093   -&gt; C   No       2174   -&gt; C   No       2241   A -&gt; C   No       2242   A -&gt; G   No       2335   -&gt; G   No       2335   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38). An alignment is given to the known (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more ents to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDK corresponding to amino acids 1-71 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-71 of HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137), and a second amino acid sequence being at least 90% homologous to KQWINKAVGDKLPECEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTT GATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVD IGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPV ADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAV HDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 131-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 72-347 of HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KK, having a structure as follows: a sequence starting from any of amino acid numbers 71−x to 71; and ending at any of amino acid numbers 72+((n−2)−x), in which x varies from 0 to n-2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 19, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 19                          Amino acid mutations                         SNP position(s) on               amino acid sequence   Alternative amino acid(s)   Previously known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       79   V -&gt;   No       108   L -&gt; V   No       136   Q -&gt;   No       162   L -&gt; V   No       176   K -&gt;   No       184   S -&gt; P   Yes       194   K -&gt;   No       242   L -&gt; P   No       260   P -&gt; L   No       296   A -&gt;   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 20 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 20                          Glycosylation site(s)                         Position(s) on               known amino       acid sequence   Present in variant protein?   Position in variant protein?               207   yes   148       241   yes   182       184   yes   125       211   yes   152                  
 
      Variant protein HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38, for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T12 SEQ ID NO:38) is shown in bold; this coding portion starts at position 68 and ends at position 1108. The transcript also has the following SNPs as listed in Table 21 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P68 (SEQ ID NO:137) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 21                          Nucleic acid SNPs                         SNP position on               nucleotide sequence   Alternative nucleic acid   Previously known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       303   T -&gt;   No       337   -&gt; G   No       389   C -&gt; G   No       454   T -&gt; C   Yes       454   T -&gt; G   Yes       474   A -&gt;   No       547   T -&gt; C   No       550   -&gt; G   No       551   T -&gt; G   No       589   T -&gt; C   No       595   G -&gt;   No       617   T -&gt; C   Yes       622   G -&gt; A   No       647   A -&gt;   No       694   T -&gt; A   No       792   T -&gt; C   No       826   T -&gt; C   No       846   C -&gt; T   No       886   -&gt; C   No       913   T -&gt; C   No       929   -&gt; C   No       955   G -&gt;   No       955   G -&gt; C   No       978   -&gt; C   No       993   -&gt; C   No       1074   -&gt; C   No       1141   A -&gt; C   No       1142   A -&gt; G   No       1235   -&gt; G   No       1235   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGD corresponding to amino acids 1-63 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-63 of HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence ESGKPSAADPGWTPGCQRQLSLAG (SEQ ID NO:497) corresponding to amino acids 64-87 of HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence ESGKPSAADPGWTPGCQRQLSLAG (SEQ ID NO:497) in HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 22, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 22                          Amino acid mutations                         SNP position(s) on               amino acid sequence   Alternative amino acid(s)   Previously known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       77   P -&gt; R   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 23 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 23                          Glycosylation site(s)                             Position(s) on known amino               acid sequence   Present in variant protein?                       207   no           241   no           184   no           211   no                      
 
      Variant protein HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39) is shown in bold; this coding portion starts at position 68 and ends at position 328. The transcript also has the following SNPs as listed in Table 24 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P72 (SEQ ID NO:138) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 24                          Nucleic acid SNPs                         SNP position on               nucleotide sequence   Alternative nucleic acid   Previously known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       297   C -&gt; G   No       362   T -&gt; C   Yes       362   T -&gt; G   Yes       382   A -&gt;   No       455   T -&gt; C   No       458   -&gt; G   No       459   T -&gt; G   No       497   T -&gt; C   No       503   G -&gt;   No       525   T -&gt; C   Yes       530   G -&gt; A   No       555   A -&gt;   No       602   T -&gt; A   No       700   T -&gt; C   No       734   T -&gt; C   No       754   C -&gt; T   No       794   -&gt; C   No       821   T -&gt; C   No       837   -&gt; C   No       863   G -&gt;   No       863   G -&gt; C   No       886   -&gt; C   No       901   -&gt; C   No       982   -&gt; C   No       1049   A -&gt; C   No       1050   A -&gt; G   No       1143   -&gt; G   No       1143   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAHGYVEHSVRYQCKNY YKLRTEGDGVYTLNNEKQWINKAVGDKLPECEA corresponding to amino acids 1-147 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-147 of HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), and a second amino acid sequence being at least 90% homologous to GATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVD IGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPV ADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAV HDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 188-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 148-366 of HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AG, having a structure as follows: a sequence starting from any of amino acid numbers 147−x to 147; and ending at any of amino acid numbers 148+((n−2)−x), in which x varies from 0 to n−2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMHPA1_B_PEA — 1_P75 (SEQ ID NO:139) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 25, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 25                          Amino acid mutations                         SNP position(s) on               amino acid sequence   Alternative amino acid(s)   Previously known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       79   V -&gt;   No       116   K -&gt; E   No       130   E -&gt; G   No       130   E -&gt; K   No       155   Q -&gt;   No       181   L -&gt; V   No       195   K -&gt;   No       203   S -&gt; P   Yes       213   K -&gt;   No       261   L -&gt; P   No       279   P -&gt; L   No       315   A -&gt;   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139), compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 26 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 26                          Glycosylation site(s)                         Position(s) on               known amino       acid sequence   Present in variant protein?   Position in variant protein?               207   yes   167       241   yes   201       184   no       211   yes   171                  
 
      Variant protein HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40) is shown in bold; this coding portion starts at position 68 and ends at position 1165. The transcript also has the following SNPs as listed in Table 27 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P75 (SEQ ID NO:139) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 27                          Nucleic acid SNPs                         SNP position               nucleotide sequence   Alternative nucleic acid   Previously known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       303   T -&gt;   No       364   A -&gt; G   Yes       413   A -&gt; G   No       439   G -&gt; A   Yes       455   G -&gt; A   No       456   A -&gt; G   No       481   -&gt; G   No       511   T -&gt; C   Yes       511   T -&gt; G   Yes       531   A -&gt;   No       604   T -&gt; C   No       607   -&gt; G   No       608   T -&gt; G   No       646   T -&gt; C   No       652   G -&gt;   No       674   T -&gt; C   Yes       679   G -&gt; A   No       704   A -&gt;   No       751   T -&gt; A   No       849   T -&gt; C   No       883   T -&gt; C   No       903   C -&gt; T   No       943   -&gt; C   No       970   T -&gt; C   No       986   -&gt; C   No       1012   G -&gt;   No       1012   G -&gt; C   No       1035   -&gt; C   No       1050   -&gt; C   No       1131   -&gt; C   No       1198   A -&gt; C   No       1199   A -&gt; G   No       1292   -&gt; G   No       1292   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P76 (SEQ ID NO:40), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQ corresponding to amino acids 1-51 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-51 of HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), a second amino acid sequence bridging amino acid sequence comprising of L, and a third amino acid sequence being at least 90% homologous to QRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTTAKNLFLNHSENATAKDI APTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLIKLKQKVSVNERVMPICLPSKDYAEVG RVGYVSGWGRNANFKFTDHLKYVMLPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPIL NEHTFCAGMSKYQEDTCYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVK VTSIQDWVQKTIAEN corresponding to amino acids 160-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 53-299 of HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise QLQ having a structure as follows (numbering according to HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140)): a sequence starting from any of amino acid numbers 51−x to 51; and ending at any of amino acid numbers 53+((n−2)−x), in which x varies from 0 to n−2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 28, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 28                          Amino acid mutations                         SNP position(s)               on amino acid   Alternative   Previously       sequence   amino acid(s)   known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       60   L -&gt; V   No       88   Q -&gt;   No       114   L -&gt; V   No       128   K -&gt;   No       136   S -&gt; P   Yes       146   K -&gt;   No       194   L -&gt; P   No       212   P -&gt; L   No       248   A -&gt;   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 29 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 29                          Glycosylation site(s)                         Position(s) on known amino   Present in   Position in       acid sequence   variant protein?   variant protein?                                 207   yes   100       241   yes   134       184   yes   77       211   yes   104                  
 
      Variant protein HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41) is shown in bold; this coding portion starts at position 68 and ends at position 964. The transcript also has the following SNPs as listed in Table 30 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P76 (SEQ ID NO:140) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 30                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       245   C -&gt; G   No       310   T -&gt; C   Yes       310   T -&gt; G   Yes       330   A -&gt;   No       403   T -&gt; C   No       406   -&gt; G   No       407   T -&gt; G   No       445   T -&gt; C   No       451   G -&gt;   No       473   T -&gt; C   Yes       478   G -&gt; A   No       503   A -&gt;   No       550   T -&gt; A   No       648   T -&gt; C   No       682   T -&gt; C   No       702   C -&gt; T   No       742   -&gt; C   No       769   T -&gt; C   No       785   -&gt; C   No       811   G -&gt;   No       811   G -&gt; C   No       834   -&gt; C   No       849   -&gt; C   No       930   -&gt; C   No       997   A -&gt; C   No       998   A -&gt; G   No       1091   -&gt; G   No       1091   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T27 (SEQ ID NO 42). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEA corresponding to amino acids 1-88 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-88 of HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), and a second amino acid sequence being at least 90% homologous to GATLINEQWLLTTAKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVD IGLIKLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVMLPV ADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDTCYGDAGSAFAV HDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQKTIAEN corresponding to amino acids 188-406 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 89-307 of HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise AG, having a structure as follows: a sequence starting from any of amino acid numbers 88−x to 88; and ending at any of amino acid numbers 89+((n−2)−x), in which x varies from 0 to n−2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 31, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 31                          Amino acid mutations                                 SNP position(s) on amino acid   Alternative   Previously           sequence   amino acid(s)   known SNP?                                             8   I -&gt;   No           38   E -&gt; D   No           79   V -&gt;   No           96   Q -&gt;   No           122   L -&gt; V   No           136   K -&gt;   No           144   S -&gt; P   Yes           154   K -&gt;   No           202   L -&gt; P   No           220   P -&gt; L   No           256   A -&gt;   No                      
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 32 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 32                          Glycosylation site(s)                         Position(s) on known amino   Present in   Position in       acid sequence   variant protein?   variant protein?               207   yes   108       241   yes   142       184   no       211   yes   112                  
 
      Variant protein HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) is shown in bold; this coding portion starts at position 68 and ends at position 988. The transcript also has the following SNPs as listed in Table 33 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P81 (SEQ ID NO:141) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 33                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       303   T -&gt;   No       334   T -&gt; C   Yes       334   T -&gt; G   Yes       354   A -&gt;   No       427   T -&gt; C   No       430   -&gt; G   No       431   T -&gt; G   No       469   T -&gt; C   No       475   G -&gt;   No       497   T -&gt; C   Yes       502   G -&gt; A   No       527   A -&gt;   No       574   T -&gt; A   No       672   T -&gt; C   No       706   T -&gt; C   No       726   C -&gt; T   No       766   -&gt; C   No       793   T -&gt; C   No       809   -&gt; C   No       835   G -&gt;   No       835   G -&gt; C   No       858   -&gt; C   No       873   -&gt; C   No       954   -&gt; C   No       1021   A -&gt; C   No       1022   A -&gt; G   No       1115   -&gt; G   No       1115   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142) and HPT_HUMAN (SEQ ID NO:131):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIAD corresponding to amino acids 1-30 of HPT_HUMAN (SEQ ID NO:131), which also corresponds to amino acids 1-30 of HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GFPP (SEQ ID NO:498) corresponding to amino acids 31-34 of HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GFPP (SEQ ID NO:498) in HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 34, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 34                          Amino acid mutations                         SNP position(s) on amino acid   Alternative   Previously       sequence   amino acid(s)   known SNP?               8   I -&gt;   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 35 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 35                          Glycosylation site(s)                     Position(s) on known amino   Present in       acid sequence   variant protein?               207   no       241   no       184   no       211   no                  
 
      Variant protein HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) is shown in bold; this coding portion starts at position 68 and ends at position 169. The transcript also has the following SNPs as listed in Table 36 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P83 (SEQ ID NO:142) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 36                          Nucleic acid SNPs                         SNP position on   Alternative   Previously       nucleotide sequence   nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       185   T -&gt; C   Yes       185   T -&gt; G   Yes       205   A -&gt;   No       278   T -&gt; C   No       281   -&gt; G   No       282   T -&gt; G   No       320   T -&gt; C   No       326   G -&gt;   No       348   T -&gt; C   Yes       353   G -&gt; A   No       378   A -&gt;   No       425   T -&gt; A   No       523   T -&gt; C   No       557   T -&gt; C   No       577   C -&gt; T   No       617   -&gt; C   No       644   T -&gt; C   No       660   -&gt; C   No       686   G -&gt;   No       686   G -&gt; C   No       709   -&gt; C   No       724   -&gt; C   No       805   -&gt; C   No       872   A -&gt; C   No       873   A -&gt; G   No       966   -&gt; G   No       966   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44. An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143) and HPT_HUMAN_V1 (SEQ ID NO:132) (SEQ ID NO:132):  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNN corresponding to amino acids 1-70 of HPT_HUMAN_V1 (SEQ ID NO:132), which also corresponds to amino acids 1-70 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), a bridging amino acid E corresponding to amino acid 71 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), a bridging amino acid E corresponding to amino acid 71 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), a second amino acid sequence being at least 90% homologous to KQWINKAVGDKLPECEA corresponding to amino acids 72-88 of HPT_HUMAN_V1 (SEQ ID NO:132), which also corresponds to amino acids 72-88 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence AHTE (SEQ ID NO:499) corresponding to amino acids 89-92 of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), wherein said first amino acid sequence, bridging amino acid, bridging amino acid, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence AHTE (SEQ ID NO:499) in HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143).  
      It should be noted that the known protein sequence (HPT_HUMAN) Has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for HPT_HUMAN_V1 (SEQ ID NO:132) (SEQ ID NO:132). These changes were previously known to occur and are listed in the table below.  
               TABLE 37                          Changes to HPT_HUMAN_V1 (SEQ ID NO: 132)                     SNP position(s) on           amino acid sequence   Type of change               71   conflict                  
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 38, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 38                          Amino acid mutations                         SNP position(s) on   Alternative   Previously       amino acid sequence   amino acid(s)   known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       71   E -&gt; G   No       71   E -&gt; K   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) is shown in bold; this coding portion starts at position 68 and ends at position 343. The transcript also has the following SNPs as listed in Table 39 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P106 (SEQ ID NO:143) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 39                          Nucleic acid SNPs                         SNP position on   Alternative   Previously       nucleotide sequence   nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       262   G -&gt; A   Yes       278   G -&gt; A   No       279   A -&gt; G   No       304   -&gt; G   No       335   -&gt; C   No       362   T -&gt; C   No       378   -&gt; C   No       404   G -&gt;   No       404   G -&gt; C   No       427   -&gt; C   No       442   -&gt; C   No       523   -&gt; C   No       590   A -&gt; C   No       591   A -&gt; G   No       684   -&gt; G   No       684   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144)) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present application to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144)) and HPT_HUMAN:  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144)), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDI corresponding to amino acids 1-28 of HPT_HUMAN, which also corresponds to amino acids 1-28 of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144)), a second amino acid sequence being at least 90% homologous to ADDGCPKPPEIAHGYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPE CEAVCGKPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTT corresponding to amino acids 88-187 of HPT_HUMAN, which also corresponds to amino acids 29-128 of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144)), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VPLPFTTWRRTPGMRLGS (SEQ ID NO:500) corresponding to amino acids 129-146 of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise IA, having a structure as follows: a sequence starting from any of amino acid numbers 28−x to 28; and ending at any of amino acid numbers 29+((n−2)−x), in which x varies from 0 to n−2.  
      3. An isolated polypeptide encoding for a tail of HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VPLPFTTWRRTPGMRLGS (SEQ ID NO:500) in HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144)  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144)) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 40, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P — 107 (SEQ ID NO:144)) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 40                          Amino acid mutations                         SNP position(s) on   Alternative   Previously       amino acid sequence   amino acid(s)   known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       71   E -&gt; G   No       71   E -&gt; K   No       108   L -&gt; V   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P — 107 (SEQ ID NO:144), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 41 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 41                          Glycosylation site(s)                         Position(s) on known   Present in   Position in       amino acid sequence   variant protein?   variant protein?               207   no           241   no       184   yes   125       211   no                  
 
      Variant protein HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) is shown in bold; this coding portion starts at position 68 and ends at position 505. The transcript also has the following SNPs as listed in Table 42 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P107 (SEQ ID NO:144) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 42                          Nucleic acid SNPs                         SNP position on   Alternative   Previously       nucleotide sequence   nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       262   G -&gt; A   Yes       278   G -&gt; A   No       279   A -&gt; G   No       304   -&gt; G   No       337   -&gt; G   No       389   C -&gt; G   No       470   -&gt; C   No       485   -&gt; C   No       566   -&gt; C   No       633   A -&gt; C   No       634   A -&gt; G   No       727   -&gt; G   No       727   -&gt; T   No                  
 
      Variant protein HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). An alignment is given to the known protein (Haptoglobin precursor (SEQ ID NO:131)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145) and HPT_HUMAN:  
      1. An isolated chimeric polypeptide encoding for HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145), comprising a first amino acid sequence being at least 90% homologous to MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRYQCKNYYK LRTEGDGVYTLNDKKQWINKAVGDKLPECEA corresponding to amino acids 1-88 of HPT_HUMAN, which also corresponds to amino acids 1-88 of HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GGC corresponding to amino acids 89-91 of HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because of manual inspection of known protein localization and/or gene structure.  
      Variant protein HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 43, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 43                          Amino acid mutations                         SNP position(s) on   Alternative   Previously       amino acid sequence   amino acid(s)   known SNP?                                 8   I -&gt;   No       38   E -&gt; D   No       79   V -&gt;   No                  
 
      The glycosylation sites of variant protein HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145), as compared to the known protein Haptoglobin precursor (SEQ ID NO:131), are described in Table 44 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 44                          Glycosylation site(s)                             Position(s) on known   Present in           amino acid sequence   variant protein?                       207   no           241   no           184   no           211   no                      
 
      Variant protein HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145) is encoded by the following transcript(s): HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46) is shown in bold; this coding portion starts at position 68 and ends at position 340. The transcript also has the following SNPs as listed in Table 45 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMHPA1B_PEA — 1_P115 (SEQ ID NO:145) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 45                          Nucleic acid SNPs                         SNP position on   Alternative   Previously       nucleotide sequence   nucleic acid   known SNP?                                 40   T -&gt; G   No       77   C -&gt; T   No       90   T -&gt;   No       181   G -&gt; T   No       303   T -&gt;   No       510   G -&gt; A   Yes       560   C -&gt; T   Yes       581   C -&gt; T   Yes       615   A -&gt; G   Yes                  
 
      As noted above, cluster HUMHPA1B features 84 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HUMHPA1B_PEA — _node — 20 (SEQ ID NO:47) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35). Table 46 below describes the starting and ending position of this segment on each transcript.  
               TABLE 46                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMHPA1B_PEA_1_T4 (SEQ ID   258   1017       NO: 35)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 25 (SEQ ID NO:48) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 47 below describes the starting and ending position of this segment on each transcript.  
               TABLE 47                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMHPA1B_PEA_1_T59   333   920       (SEQ ID NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 28 (SEQ ID NO:49) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36). Table 48 below describes the starting and ending position of this segment on each transcript.  
               TABLE 48                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMHPA1B_PEA_1_T6 (SEQ ID   435   1192       NO: 36)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 35 (SEQ ID NO:50) according to the present invention is supported by 9 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37). Table 49 below describes the starting and ending position of this segment on each transcript.  
               TABLE 49                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMHPA1B_PEA_1_T7 (SEQ ID   524   1432       NO: 37)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 88 (SEQ ID NO:51) according to the present invention is supported by 95 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43, HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 50 below describes the starting and ending position of this segment on each transcript.  
               TABLE 50                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   1155   1276       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   2092   2213       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   2090   2211       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   2255   2376       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   1155   1276       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   1063   1184       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   1212   1333       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   1011   1132       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   1035   1156       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   886   1007       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   604   725       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   647   768       NO: 45)                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HUMHPA1B_PEA — 1_node — 0 (SEQ ID NO:52) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35, HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 51 below describes the starting and ending position of this segment on each transcript.  
               TABLE 51                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   1   63       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1   63       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1   63       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1   63       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   1   63       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   1   63       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   1   63       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   1   63       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   1   63       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   1   63       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   1   63       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   1   63       NO: 45)       HUMHPA1B_PEA_1_T59 (SEQ ID   1   63       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 1 (SEQ ID NO:53) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43, HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 52 below describes the starting and ending position of this segment on each transcript.  
               TABLE 52                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   64   72       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   64   72       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   64   72       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   64   72       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   64   72       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   64   72       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   64   72       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   64   72       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   64   72       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   64   72       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   64   72       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   64   72       NO: 45)       HUMHPA1B_PEA_1_T59 (SEQ ID   64   72       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 3 (SEQ ID NO:54) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA I_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — _T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA I_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 53 below describes the starting and ending position of this segment on each transcript.  
               TABLE 53                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   73   97       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   73   97       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   73   97       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   73   97       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   73   97       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   73   97       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   73   97       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   73   97       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   73   97       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   73   97       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   73   97       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   73   97       NO: 45)       HUMHPA1B_PEA_1_T59 (SEQ ID   73   97       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 4 (SEQ ID NO:55) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35, HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA —1 _T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 54 below describes the starting and ending position of this segment on each transcript.  
               TABLE 54                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   98   112       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   98   112       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   98   112       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   98   112       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   98   112       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   98   112       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   98   112       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   98   112       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   98   112       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   98   112       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   98   112       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   98   112       NO: 45)       HUMHPA1B_PEA_1_T59 (SEQ ID   98   112       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 5 (SEQ ID NO:56) according to the present invention is supported by 90 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43, HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 55 below describes the starting and ending position of this segment on each transcript.  
               TABLE 55                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   113   144       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   113   144       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   113   144       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   113   144       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   113   144       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   113   144       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   113   144       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   113   144       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   113   144       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   113   144       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   113   144       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   113   144       NO: 45)       HUMHPA1B_PEA_1_T59 (SEQ ID   113   144       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 6 (SEQ ID NO:57) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45 and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 56 below describes the starting and ending position of this segment on each transcript.  
               TABLE 56                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   145   150       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   145   150       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   145   150       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   145   150       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   145   150       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   145   150       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   145   150       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   145   150       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   145   150       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   145   150       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   145   150       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   145   150       NO: 45)       HUMHPA1B_PEA_1_T59 (SEQ ID   145   150       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 7 (SEQ ID NO:58) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 57 below describes the starting and ending position of this segment on each transcript.  
               TABLE 57                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   151   155       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   151   155       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   151   155       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   151   155       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   151   155       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   151   155       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   151   155       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   151   155       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   151   155       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   151   155       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   151   155       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   151   155       NO: 45)       HUMHPA1B_PEA_1_T59 (SEQ ID   151   155       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 10 (SEQ ID NO:59) according to the present invention is supported by 95 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46. Table 58 below describes the starting and ending position of this segment on each transcript.  
               TABLE 58                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   156   188           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   156   188           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   156   188           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   156   188           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   156   188           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   156   188           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   156   188           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   156   188           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   156   188           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   156   188           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   156   188           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   156   188           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 1 (SEQ ID NO:60) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44, HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 59 below describes the starting and ending position of this segment on each transcript.  
               TABLE 59                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   189   192           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   189   192           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   189   192           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   189   192           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   189   192           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   189   192           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   189   192           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   189   192           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   189   192           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   189   192           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   189   192           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   189   192           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 12 (SEQ ID NO:61) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41, HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46. Table 60 below describes the starting and ending position of this segment on each transcript.  
               TABLE 60                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   193   196           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   193   196           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   193   196           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   193   196           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   193   196           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   193   196           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   193   196           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   193   196           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   193   196           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   193   196           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   193   196           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   193   196           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 13 (SEQ ID NO:62) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 61 below describes the starting and ending position of this segment on each transcript.  
               TABLE 61                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   197   217           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   197   217           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   197   217           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   197   217           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   197   217           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   197   217           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   197   217           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   197   217           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   197   217           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   197   217           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   197   217           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   197   217           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA-1_node — 14 (SEQ ID NO:63) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44, HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 62 below describes the starting and ending position of this segment on each transcript.  
               TABLE 62                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   218   221           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   218   221           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   218   221           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   218   221           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   218   221           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   218   221           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   218   221           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   218   221           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   218   221           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   218   221           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   218   221           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   218   221           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1 node — 15 (SEQ ID NO:64) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 63 below describes the starting and ending position of this segment on each transcript.  
               TABLE 63                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   222   231           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   222   231           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   222   231           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   222   231           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   222   231           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   222   231           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   222   231           NO: 40)           HUMHPA1B_PEA_1_T27 (SEQ ID   222   231           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   222   231           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   222   231           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   222   231           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 16 (SEQ ID NO:65) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA —1 _T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 64 below describes the starting and ending position of this segment on each transcript.  
               TABLE 64                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   232   238           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   232   238           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   232   238           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   232   238           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   232   238           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   232   238           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   232   238           NO: 40)           HUMHPA1B_PEA_1_T27 (SEQ ID   232   238           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   232   238           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   232   238           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   232   238           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 17 (SEQ ID NO:66) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 65 below describes the starting and ending position of this segment on each transcript.  
               TABLE 65                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   239   243           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   239   243           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   239   243           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   239   243           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   239   243           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   239   243           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   239   243           NO: 40)           HUMHPA1B_PEA_1_T27 (SEQ ID   239   243           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   239   243           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   239   243           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   239   243           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA-1_node — 18 (SEQ ID NO:67) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35, HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42, HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 66 below describes the starting and ending position of this segment on each transcript.  
               TABLE 66                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   244   247           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   244   247           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   244   247           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   244   247           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   244   247           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   244   247           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   244   247           NO: 40)           HUMHPA1B_PEA_1_T27 (SEQ ID   244   247           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   244   247           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   244   247           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   244   247           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 19 (SEQ ID NO:68) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44), HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 67 below describes the starting and ending position of this segment on each transcript.  
               TABLE 67                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HUMHPA1B_PEA_1_T1 (SEQ ID   248   257           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   248   257           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   248   257           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   248   257           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   248   257           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   248   257           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   248   257           NO: 40)           HUMHPA1B_PEA_1_T27 (SEQ ID   248   257           NO: 42)           HUMHPA1B_PEA_1_T55 (SEQ ID   248   257           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   248   257           NO: 45)           HUMHPA1B_PEA_1_T59 (SEQ ID   248   257           NO: 46)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 21 (SEQ ID NO:69) according to the present invention is supported by 66 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 68 below describes the starting and ending position of this segment on each transcript.  
               TABLE 68                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T4 (SEQ ID   1018   1043       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   258   283       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   258   283       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   258   283       NO: 38)       HUMHPA1B_PEA_1_T19 (SEQ ID   258   283       NO: 40)       HUMHPA1B_PEA_1_T27 (SEQ ID   258   283       NO: 42)       HUMHPA1B_PEA_1_T59 (SEQ ID   258   283       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 22 (SEQ ID NO:70) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — _T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 69 below describes the starting and ending position of this segment on each transcript.  
               TABLE 69                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T4 (SEQ ID   1044   1059       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   284   299       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   284   299       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   284   299       NO: 38)       HUMHPA1B_PEA_1_T19 (SEQ ID   284   299       NO: 40)       HUMHPA1B_PEA_1_T27 (SEQ ID   284   299       NO: 42)       HUMHPA1B_PEA_1_T59 (SEQ ID   284   299       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 23 (SEQ ID NO:71) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 70 below describes the starting and ending position of this segment on each transcript.  
               TABLE 70                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T4 (SEQ ID   1060   1077       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   300   317       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   300   317       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   300   317       NO: 38)       HUMHPA1B_PEA_1_T19 (SEQ ID   300   317       NO: 40)       HUMHPA1B_PEA_1_T27 (SEQ ID   300   317       NO: 42)       HUMHPA1B_PEA_1_T59 (SEQ ID   300   317       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 24 (SEQ ID NO:72) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T59 (SEQ ID NO:46). Table 71 below describes the starting and ending position of this segment on each transcript.  
               TABLE 71                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T4 (SEQ ID   1078   1092       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   318   332       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   318   332       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   318   332       NO: 38)       HUMHPA1B_PEA_1_T19 (SEQ ID   318   332       NO: 40)       HUMHPA1B_PEA_1_T27 (SEQ ID   318   332       NO: 42)       HUMHPA1B_PEA_1_T59 (SEQ ID   318   332       NO: 46)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 27 (SEQ ID NO:73) according to the present invention is supported by 62 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37) and HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40). Table 72 below describes the starting and ending position of this segment on each transcript.  
               TABLE 72                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T4 (SEQ ID   1093   1194       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   333   434       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   333   434       NO: 37)       HUMHPA1B_PEA_1_T19 (SEQ ID   333   434       NO: 40)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 29 (SEQ ID NO:74) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 73 below describes the starting and ending position of this segment on each transcript.  
               TABLE 73                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   258   277       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1195   1214       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1193   1212       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   435   454       NO: 37)       HUMHPA1B_PEA_1_T19 (SEQ ID   435   454       NO: 40)       HUMHPA1B_PEA_1_T55 (SEQ ID   258   277       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   258   277       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 30 (SEQ ID NO:75) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 74 below describes the starting and ending position of this segment on each transcript.  
               TABLE 74                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   278   283       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1215   1220       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1213   1218       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   455   460       NO: 37)       HUMHPA1B_PEA_1_T19 (SEQ ID   455   460       NO: 40)       HUMHPA1B_PEA_1_T55 (SEQ ID   278   283       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   278   283       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 31 (SEQ ID NO:76) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 75 below describes the starting and ending position of this segment on each transcript.  
               TABLE 75                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   284   289       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1221   1226       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1219   1224       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   461   466       NO: 37)       HUMHPA1B_PEA_1_T19 (SEQ ID   461   466       NO: 40)       HUMHPA1B_PEA_1_T55 (SEQ ID   284   289       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   284   289       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 32 (SEQ ID NO:77) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 76 below describes the starting and ending position of this segment on each transcript.  
               TABLE 76                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   290   299       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1227   1236       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1225   1234       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   467   476       NO: 37)       HUMHPA1B_PEA_1_T19 (SEQ ID   467   476       NO: 40)       HUMHPA1B_PEA_1_T55 (SEQ ID   290   299       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   290   299       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 33 (SEQ ID NO:78) according to the present invention is supported by 88 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 77 below describes the starting and ending position of this segment on each transcript.  
               TABLE 77                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   300   332       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1237   1269       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1235   1267       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   477   509       NO: 37)       HUMHPA1B_PEA_1_T19 (SEQ ID   477   509       NO: 40)       HUMHPA1B_PEA_1_T55 (SEQ ID   300   332       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   300   332       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 34 (SEQ ID NO:79) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37). Table 78 below describes the starting and ending position of this segment on each transcript.  
               TABLE 78                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMHPA1B_PEA_1_T7 (SEQ ID   510   523       NO: 37)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 36 (SEQ ID NO:80) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 79 below describes the starting and ending position of this segment on each transcript.  
               TABLE 79                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   333   343       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1270   1280       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1268   1278       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1433   1443       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   333   343       NO: 38)       HUMHPA1B_PEA_1_T56 (SEQ ID   333   343       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 37 (SEQ ID NO:81) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 80 below describes the starting and ending position of this segment on each transcript.  
               TABLE 80                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   344   349       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1281   1286       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1279   1284       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1444   1449       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   344   349       NO: 38)       HUMHPA1B_PEA_1_T56 (SEQ ID   344   349       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 38 (SEQ ID NO:82) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 81 below describes the starting and ending position of this segment on each transcript.  
               TABLE 81                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   350   361       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1287   1298       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1285   1296       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1450   1461       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   350   361       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   258   269       NO: 39)       HUMHPA1B_PEA_1_T56 (SEQ ID   350   361       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 39 (SEQ ID NO:83) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 82 below describes the starting and ending position of this segment on each transcript.  
               TABLE 82                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   362   365       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1299   1302       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1297   1300       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1462   1465       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   362   365       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   270   273       NO: 39)       HUMHPA1B_PEA_1_T56 (SEQ ID   362   365       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 40 (SEQ ID NO:84) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 83 below describes the starting and ending position of this segment on each transcript.  
               TABLE 83                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   366   370       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1303   1307       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1301   1305       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1466   1470       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   366   370       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   274   278       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   222   226       NO: 41)       HUMHPA1B_PEA_1_T56 (SEQ ID   366   370       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 41 (SEQ ID NO:85) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35, HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 84 below describes the starting and ending position of this segment on each transcript.  
               TABLE 84                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   371   376       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1308   1313       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1306   1311       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1471   1476       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   371   376       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   279   284       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   227   232       NO: 41)       HUMHPA1B_PEA_1_T56 (SEQ ID   371   376       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 42 (SEQ ID NO:86) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 85 below describes the starting and ending position of this segment on each transcript.  
               TABLE 85                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   377   388       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1314   1325       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1312   1323       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1477   1488       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   377   388       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   285   296       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   233   244       NO: 41)       HUMHPA1B_PEA_1_T56 (SEQ ID   377   388       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 43 (SEQ ID NO:87) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45. Table 86 below describes the starting and ending position of this segment on each transcript.  
               TABLE 86                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   389   411       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1326   1348       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1324   1346       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1489   1511       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   389   411       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   297   319       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   245   267       NO: 41)       HUMHPA1B_PEA_1_T56 (SEQ ID   389   411       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 44 (SEQ ID NO:88) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 87 below describes the starting and ending position of this segment on each transcript.  
               TABLE 87                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   412   424       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1349   1361       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1347   1359       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1512   1524       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   412   424       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   320   332       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   268   280       NO: 41)       HUMHPA1B_PEA_1_T56 (SEQ ID   412   424       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 45 (SEQ ID NO:89) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 88 below describes the starting and ending position of this segment on each transcript.  
               TABLE 88                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   425   436       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1362   1373       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1360   1371       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1525   1536       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   425   436       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   333   344       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   281   292       NO: 41)       HUMHPA1B_PEA_1_T29 (SEQ ID   156   167       NO: 43)       HUMHPA1B_PEA_1_T56 (SEQ ID   425   436       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 46 (SEQ ID NO:90) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 89 below describes the starting and ending position of this segment on each transcript.  
               TABLE 89                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   437   447       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1374   1384       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1372   1382       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1537   1547       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   437   447       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   345   355       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   293   303       NO: 41)       HUMHPA1B_PEA_1_T29 (SEQ ID   168   178       NO: 43)       HUMHPA1B_PEA_1_T56 (SEQ ID   437   447       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 47 (SEQ ID NO:91) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 90 below describes the starting and ending position of this segment on each transcript.  
               TABLE 90                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   448   452       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1385   1389       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1383   1387       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1548   1552       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   448   452       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   356   360       NO: 39)       HUMHPA1B_PEA_1_T20 (SEQ ID   304   308       NO: 41)       HUMHPA1B_PEA_1_T29 (SEQ ID   179   183       NO: 43)       HUMHPA1B_PEA_1_T56 (SEQ ID   448   452       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 48 (SEQ ID NO:92) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 91 below describes the starting and ending position of this segment on each transcript.  
               TABLE 91                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   453   473       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1390   1410       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1388   1408       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1553   1573       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   453   473       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   361   381       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   510   530       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   309   329       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   333   353       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   184   204       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 49 (SEQ ID NO:93) according to the present invention is supported by 105 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38, HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 92 below describes the starting and ending position of this segment on each transcript.  
               TABLE 92                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   474   511       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1411   1448       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1409   1446       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1574   1611       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   474   511       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   382   419       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   531   568       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   330   367       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   354   391       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   205   242       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 50 (SEQ ID NO:94) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 93 below describes the starting and ending position of this segment on each transcript.  
               TABLE 93                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   512   530       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1449   1467       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1447   1465       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1612   1630       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   512   530       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   420   438       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   569   587       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   368   386       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   392   410       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   243   261       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 51 (SEQ ID NO:95) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 94 below describes the starting and ending position of this segment on each transcript.  
               TABLE 94                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   531   549       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1468   1486       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1466   1484       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1631   1649       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   531   549       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   439   457       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   588   606       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   387   405       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   411   429       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   262   280       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 52 (SEQ ID NO:96) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 95 below describes the starting and ending position of this segment on each transcript.  
               TABLE 95                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   550   558       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1487   1495       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1485   1493       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1650   1658       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   550   558       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   458   466       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   607   615       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   406   414       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   430   438       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   281   289       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 53 (SEQ ID NO:97) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37, HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 96 below describes the starting and ending position of this segment on each transcript.  
               TABLE 96                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   559   567       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1496   1504       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1494   1502       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1659   1667       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   559   567       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   467   475       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   616   624       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   415   423       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   439   447       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   290   298       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 54 (SEQ ID NO:98) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35, HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41, HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 97 below describes the starting and ending position of this segment on each transcript.  
               TABLE 97                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   568   574       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1505   1511       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1503   1509       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1668   1674       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   568   574       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   476   482       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   625   631       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   424   430       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   448   454       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   299   305       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 55 (SEQ ID NO:99) according to the present invention is supported by 113 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40, HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 98 below describes the starting and ending position of this segment on each transcript.  
               TABLE 98                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   575   616           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1512   1553           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1510   1551           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1675   1716           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   575   616           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   483   524           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   632   673           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   431   472           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   455   496           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   306   347           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 56 (SEQ ID NO:100) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 99 below describes the starting and ending position of this segment on each transcript.  
               TABLE 99                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   617   622           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1554   1559           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1552   1557           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1717   1722           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   617   622           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   525   530           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   674   679           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   473   478           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   497   502           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   348   353           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 57 (SEQ ID NO:101) according to the present invention is supported by 110 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 100 below describes the starting and ending position of this segment on each transcript.  
               TABLE 100                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   623   649           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1560   1586           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1558   1584           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1723   1749           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   623   649           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   531   557           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   680   706           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   479   505           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   503   529           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   354   380           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 58 (SEQ ID NO:102) according to the present invention is supported by 108 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40, HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 101 below describes the starting and ending position of this segment on each transcript.  
               TABLE 101                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   650   684           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1587   1621           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1585   1619           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1750   1784           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   650   684           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   558   592           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   707   741           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   506   540           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   530   564           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   381   415           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1 node — 59 (SEQ ID NO:103) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 102 below describes the starting and ending position of this segment on each transcript.  
               TABLE 102                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   685   692           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1622   1629           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1620   1627           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1785   1792           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   685   692           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   593   600           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   742   749           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   541   548           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   565   572           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   416   423           NO: 43)                      
 
      Segment cluster HUMHPA1_B_PEA — 1_node — 60 (SEQ ID NO:104) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43. Table 103 below describes the starting and ending position of this segment on each transcript.  
               TABLE 103                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   693   700           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1630   1637           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1628   1635           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1793   1800           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   693   700           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   601   608           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   750   757           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   549   556           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   573   580           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   424   431           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 61 (SEQ ID NO:105) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43. Table 104 below describes the starting and ending position of this segment on each transcript.  
               TABLE 104                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   701   712           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1638   1649           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1636   1647           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1801   1812           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   701   712           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   609   620           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   758   769           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   557   568           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   581   592           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   432   443           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 62 (SEQ ID NO:106) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 105 below describes the starting and ending position of this segment on each transcript.  
               TABLE 105                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   713   723           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1650   1660           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1648   1658           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1813   1823           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   713   723           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   621   631           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   770   780           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   569   579           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   593   603           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   444   454           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 63 (SEQ ID NO:107) according to the present invention is supported by 112 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40, HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43 Table 106 below describes the starting and ending position of this segment on each transcript.  
               TABLE 106                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   724   767           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1661   1704           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1659   1702           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1824   1867           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   724   767           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   632   675           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   781   824           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   580   623           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   604   647           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   455   498           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 64 (SEQ ID NO:108) according to the present invention is supported by 115 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 107 below describes the starting and ending position of this segment on each transcript.  
               TABLE 107                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   768   815           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1705   1752           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1703   1750           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   1868   1915           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   768   815           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   676   723           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   825   872           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   624   671           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   648   695           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   499   546           NO: 43)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 65 (SEQ ID NO:109) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35, HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 108 below describes the starting and ending position of this segment on each transcript.  
               TABLE 108                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   816   837       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1753   1774       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1751   1772       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1916   1937       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   816   837       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   724   745       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   873   894       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   672   693       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   696   717       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   547   568       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 66 (SEQ ID NO:110) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 109 below describes the starting and ending position of this segment on each transcript.  
               TABLE 109                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   838   846       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1775   1783       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1773   1781       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1938   1946       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   838   846       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   746   754       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   895   903       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   694   702       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   718   726       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   569   577       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 67 (SEQ ID NO:111) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41, HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43). Table 110 below describes the starting and ending position of this segment on each transcript.  
               TABLE 110                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   847   856       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1784   1793       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1782   1791       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1947   1956       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   847   856       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   755   764       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   904   913       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   703   712       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   727   736       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   578   587       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 69 (SEQ ID NO:112) according to the present invention is supported by 107 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34, HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36, HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42) and HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43 Table 111 below describes the starting and ending position of this segment on each transcript.  
               TABLE 111                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   857   883       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1794   1820       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1792   1818       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1957   1983       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   857   883       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   765   791       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   914   940       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   713   739       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   737   763       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   588   614       NO: 43)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 70 (SEQ ID NO:113) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44). Table 112 below describes the starting and ending position of this segment on each transcript.  
               TABLE 112                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   884   890       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1821   1827       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1819   1825       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1984   1990       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   884   890       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   792   798       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   941   947       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   740   746       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   764   770       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   615   621       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   333   339       NO: 44)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 71 (SEQ ID NO:114) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41, HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44). Table 113 below describes the starting and ending position of this segment on each transcript.  
               TABLE 113                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   891   899       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1828   1836       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1826   1834       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   1991   1999       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   891   899       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   799   807       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   948   956       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   747   755       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   771   779       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   622   630       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   340   348       NO: 44)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 72 (SEQ ID NO:115) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44). Table 114 below describes the starting and ending position of this segment on each transcript.  
               TABLE 114                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   900   903       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1837   1840       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1835   1838       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   2000   2003       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   900   903       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   808   811       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   957   960       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   756   759       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   780   783       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   631   634       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   349   352       NO: 44)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 73 (SEQ ID NO:116) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44). Table 115 below describes the starting and ending position of this segment on each transcript.  
               TABLE 115                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   904   920       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1841   1857       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1839   1855       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   2004   2020       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   904   920       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   812   828       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   961   977       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   760   776       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   784   800       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   635   651       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   353   369       NO: 44)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 74 (SEQ ID NO:117) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44). Table 116 below describes the starting and ending position of this segment on each transcript.  
               TABLE 116                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   921   928       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1858   1865       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1856   1863       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   2021   2028       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   921   928       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   829   836       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   978   985       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   777   784       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   801   808       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   652   659       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   370   377       NO: 44)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 75 (SEQ ID NO:118) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T9 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44). Table 117 below describes the starting and ending position of this segment on each transcript.  
               TABLE 117                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   929   939       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   1866   1876       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   1864   1874       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   2029   2039       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   929   939       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   837   847       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   986   996       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   785   795       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   809   819       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   660   670       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   378   388       NO: 44)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 76 (SEQ ID NO:119) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39, HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43) and HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44). Table 118 below describes the starting and ending position of this segment on each transcript.  
               TABLE 118                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   940   960           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1877   1897           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1875   1895           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2040   2060           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   940   960           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   848   868           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   997   1017           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   796   816           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   820   840           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   671   691           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   389   409           NO: 44)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 77 (SEQ ID NO:120) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41, HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45. Table 119 below describes the starting and ending position of this segment on each transcript.  
               TABLE 119                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   961   979           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1898   1916           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1896   1914           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2061   2079           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   961   979           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   869   887           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1018   1036           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   817   835           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   841   859           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   692   710           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   410   428           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   453   471           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 78 (SEQ ID NO:121) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 120 below describes the starting and ending position of this segment on each transcript.  
               TABLE 120                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   980   988           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1917   1925           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1915   1923           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2080   2088           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   980   988           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   888   896           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1037   1045           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   836   844           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   860   868           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   711   719           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   429   437           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   472   480           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 79 (SEQ ID NO:122) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 121 below describes the starting and ending position of this segment on each transcript.  
               TABLE 121                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   989   993           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1926   1930           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1924   1928           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2089   2093           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   989   993           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   897   901           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1046   1050           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   845   849           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   869   873           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   720   724           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   438   442           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   481   485           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 80 (SEQ ID NO:123) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA I_T4 (SEQ ID NO:35, HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 122 below describes the starting and ending position of this segment on each transcript.  
               TABLE 122                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   994   1005           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1931   1942           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1929   1940           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2094   2105           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   994   1005           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   902   913           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1051   1062           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   850   861           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   874   885           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   725   736           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   443   454           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   486   497           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 81 (SEQ ID NO:124) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41, HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 123 below describes the starting and ending position of this segment on each transcript.  
               TABLE 123                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   1006   1017           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1943   1954           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1941   1952           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2106   2117           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   1006   1017           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   914   925           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1063   1074           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   862   873           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   886   897           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   737   748           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   455   466           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   498   509           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 82 (SEQ ID NO:125) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 124 below describes the starting and ending position of this segment on each transcript.  
               TABLE 124                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   1018   1029           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1955   1966           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1953   1964           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2118   2129           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   1018   1029           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   926   937           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1075   1086           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   874   885           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   898   909           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   749   760           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   467   478           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   510   521           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 83 (SEQ ID NO:126) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45. Table 125 below describes the starting and ending position of this segment on each transcript.  
               TABLE 125                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   1030   1040           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1967   1977           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1965   1975           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2130   2140           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   1030   1040           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   938   948           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1087   1097           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   886   896           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   910   920           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   761   771           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   479   489           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   522   532           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 84 (SEQ ID NO:127) according to the present invention is supported by 104 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41) HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 126 below describes the starting and ending position of this segment on each transcript.  
               TABLE 126                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   1041   1071           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   1978   2008           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   1976   2006           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2141   2171           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   1041   1071           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   949   979           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1098   1128           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   897   927           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   921   951           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   772   802           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   490   520           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   533   563           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 85 (SEQ ID NO:128) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43, HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 127 below describes the starting and ending position of this segment on each transcript.  
               TABLE 127                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HUMHPA1B_PEA_1_T1 (SEQ ID   1072   1078           NO: 34)           HUMHPA1B_PEA_1_T4 (SEQ ID   2009   2015           NO: 35)           HUMHPA1B_PEA_1_T6 (SEQ ID   2007   2013           NO: 36)           HUMHPA1B_PEA_1_T7 (SEQ ID   2172   2178           NO: 37)           HUMHPA1B_PEA_1_T12 (SEQ ID   1072   1078           NO: 38)           HUMHPA1B_PEA_1_T16 (SEQ ID   980   986           NO: 39)           HUMHPA1B_PEA_1_T19 (SEQ ID   1129   1135           NO: 40)           HUMHPA1B_PEA_1_T20 (SEQ ID   928   934           NO: 41)           HUMHPA1B_PEA_1_T27 (SEQ ID   952   958           NO: 42)           HUMHPA1B_PEA_1_T29 (SEQ ID   803   809           NO: 43)           HUMHPA1B_PEA_1_T55 (SEQ ID   521   527           NO: 44)           HUMHPA1B_PEA_1_T56 (SEQ ID   564   570           NO: 45)                      
 
      Segment cluster HUMHPA1B_PEA — 1_node — 86 (SEQ ID NO:129) according to the present invention can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38), HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45). Table 128 below describes the starting and ending position of this segment on each transcript.  
               TABLE 128                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   1079   1090       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   2016   2027       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   2014   2025       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   2179   2190       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   1079   1090       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   987   998       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   1136   1147       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   935   946       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   959   970       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   810   821       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   528   539       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   571   582       NO: 45)                  
 
      Segment cluster HUMHPA1B_PEA — 1_node — 87 (SEQ ID NO:130) according to the present invention is supported by 102 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMHPA1B_PEA — 1_T1 (SEQ ID NO:34), HUMHPA1B_PEA — 1_T4 (SEQ ID NO:35), HUMHPA1B_PEA — 1_T6 (SEQ ID NO:36), HUMHPA1B_PEA — 1_T7 (SEQ ID NO:37), HUMHPA1B_PEA — 1_T12 (SEQ ID NO:38, HUMHPA1B_PEA — 1_T16 (SEQ ID NO:39), HUMHPA1B_PEA — 1_T19 (SEQ ID NO:40), HUMHPA1B_PEA — 1_T20 (SEQ ID NO:41), HUMHPA1B_PEA — 1_T27 (SEQ ID NO:42), HUMHPA1B_PEA — 1_T29 (SEQ ID NO:43), HUMHPA1B_PEA — 1_T55 (SEQ ID NO:44) and HUMHPA1B_PEA — 1_T56 (SEQ ID NO:45 Table 129 below describes the starting and ending position of this segment on each transcript.  
               TABLE 129                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMHPA1B_PEA_1_T1 (SEQ ID   1091   1154       NO: 34)       HUMHPA1B_PEA_1_T4 (SEQ ID   2028   2091       NO: 35)       HUMHPA1B_PEA_1_T6 (SEQ ID   2026   2089       NO: 36)       HUMHPA1B_PEA_1_T7 (SEQ ID   2191   2254       NO: 37)       HUMHPA1B_PEA_1_T12 (SEQ ID   1091   1154       NO: 38)       HUMHPA1B_PEA_1_T16 (SEQ ID   999   1062       NO: 39)       HUMHPA1B_PEA_1_T19 (SEQ ID   1148   1211       NO: 40)       HUMHPA1B_PEA_1_T20 (SEQ ID   947   1010       NO: 41)       HUMHPA1B_PEA_1_T27 (SEQ ID   971   1034       NO: 42)       HUMHPA1B_PEA_1_T29 (SEQ ID   822   885       NO: 43)       HUMHPA1B_PEA_1_T55 (SEQ ID   540   603       NO: 44)       HUMHPA1B_PEA_1_T56 (SEQ ID   583   646       NO: 45)                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: HPT_HUMAN                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P61 (SEQ ID NO: 133) × HPT_HUMAN (SEQ ID NO: 131) ..                   Alignment segment 1/1:                                             Quality:   3336.00   Escore:   0                       Matching length:   347   Total length:   406               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   85.47   Total Percent Identity:   85.47               Gaps:   1                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDI......................   28           ||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .         .         .       29   .....................................ADDGCPKPPEIAH   41                                                |||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .         .         .         .       42   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   91           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   150                            .         .         .         .         .       92   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   141           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   200                            .         .         .         .         .       142   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   191           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   250                            .         .         .         .         .       192   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   241           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   300                            .         .         .         .         .       242   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   291           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   350                            .         .         .         .         .       292   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   341           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   400               342   KTIAEN   347           ||||||       401   KTIAEN   406                             Sequence name: HPT_HUMAN                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P62 (SEQ ID NO: 134) × HPT_HUMAN (SEQ ID NO: 131) ..               Alignment segment 1/1:                                             Quality:   630.00   Escore:   0                       Matching length:   64   Total length:   64               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .       51   QCKNYYKLRTEGDG   64           ||||||||||||||       51   QCKNYYKLRTEGDG   64                             Sequence name: HPT_HUMAN                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P64 (SEQ ID NO: 135) × HPT_HUMAN (SEQ ID NO: 131) ..               Alignment segment 1/1:                                             Quality:   1236.00   Escore:   0                       Matching length:   123   Total length:   123               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPEPPEIAHGYVEHSVRY   50                            .         .         .         .         .       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .       101   GYVEHSVRYQCKNYYKLRTEGDG   123           |||||||||||||||||||||||       101   GYVEHSVRYQCKNYYKLRTEGDG   123                             Sequence name: HPT_HUMAN (SEQ ID NO: 131)                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P65 (SEQ ID NO: 136) × HPT_HUMAN (SEQ ID NO: 131) ..               Alignment segment 1/1:                                             Quality:   1479.00   Escore:   0                       Matching length:   147   Total length:   147               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .         .         .       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .         .         .       101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEA   147           |||||||||||||||||||||||||||||||||||||||||||||||       101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEA   147                             Sequence name: HPT_HUMAN                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P68 (SEQ ID NO: 137) × HPT_HUMAN (SEQ ID NO: 131) ..               Alignment segment 1/1:                                             Quality:   3335.00   Escore:   0                       Matching length:   347   Total length:   406               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   85.47   Total Percent Identity:   85.47               Gaps:   1                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .         .         .       51   QCKNYYKLRTEGDGVYTLNDK.............................   71           |||||||||||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .         .         .         .       72   ..............................KQWINKAVGDKLPECEAVCG   91                                         ||||||||||||||||||||       101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   150                            .         .         .         .         .       92   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   141           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   200                            .         .         .         .         .       142   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   191           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   250                            .         .         .         .         .       192   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   241           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   300                            .         .         .         .         .       242   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   291           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   350                            .         .         .         .         .       292   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   341           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   400               342   KTIAEN   347           ||||||       401   KTIAEN   406                             Sequence name: HPT_HUMAN (SEQ ID NO: 131)                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P72 (SEQ ID NO: 138) × HPT_HUMAN (SEQ ID NO: 131)         ..               Alignment segment 1/1:                                             Quality:   621.00   Escore:   0                       Matching length:   63   Total length:   63               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .       51   QCKNYYKLRTEGD   63           |||||||||||||       51   QCKNYYKLRTEGD   63                             Sequence name: HPT_HUMAN                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P75 (SEQ ID NO: 139) × HPT_HUMAN (SEQ ID NO: 131)         ..               Alignment segment 1/1:                                             Quality:   3534.00   Escore:   0                       Matching length:   366   Total length:   406               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   90.15   Total Percent Identity:   90.15               Gaps:   1                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .         .         .       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .         .         .         .       101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEA...   147           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   150                            .         .         .         .         .       148   .....................................GATLINEQWLLTT   160                                                |||||||||||||       151   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   200                            .         .         .         .         .       161   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   210           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   AKNLFLNHSENATAKDIAPTLTLYVGRKQLVEIEKVVLHPNYSQVDIGLI   250                            .         .         .         .         .       211   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   260           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   300                            .         .         .         .         .       261   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   310           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   350                            .         .         .         .         .       311   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   360           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   400               361   KTIAEN   366           ||||||       401   KTIAEN   406                             Sequence name: HPT_HUMAN (SEQ ID NO: 131)                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P76 (SEQ ID NO: 140) × HPT_HUMAN (SEQ ID NO: 131)         ..               Alignment segment 1/1:                                             Quality:   2834.00   Escore:   0                       Matching length:   299   Total length:   406               Matching Percent Similarity:   100.00   Matching Percent Identity:   99.67               Total Percent Similarity:   73.65   Total Percent Identity:   73.40               Gaps:   1                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .         .         .       51   Q.................................................   51           |       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .         .         .         .       51   ..................................................   51               101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   150                            .         .         .         .         .       52   ........LQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   93                   :|||||||||||||||||||||||||||||||||||||||||       151   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   200                            .         .         .         .         .       94   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   143           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   250                            .         .         .         .         .       144   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   193           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   300                            .         .         .         .         .       194   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   243           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   350                            .         .         .         .         .       244   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   293           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   400               294   KTIAEN   299           ||||||       401   KTIAEN   406                             Sequence name: HPT_HUMAN                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P81 (SEQ ID NO: 141) × HPT HUMAN (SEQ ID NO: 131)         ..               Alignment segment 1/1:                                             Quality:   2927.00   Escore:   0                       Matching length:   307   Total length:   406               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   75.62   Total Percent Identity:   75.62               Gaps:   1                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .         .         .       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEA............   88           ||||||||||||||||||||||||||||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .         .         .         .       88   ..................................................   88               101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   150                            .         .         .         .         .       89   .....................................GATLINEQWLLTT   101                                                |||||||||||||       151   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTTGATLINEQWLLTT   200                            .         .         .         .         .       102   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   151           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   AKNLFLNHSENATAKDIAPTLTLYVGKKQLVEIEKVVLHPNYSQVDIGLI   250                            .         .         .         .         .       152   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   201           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   KLKQKVSVNERVMPICLPSKDYAEVGRVGYVSGWGRNANFKFTDHLKYVM   300                            .         .         .         .         .       202   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   251           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   LPVADQDQCIRHYEGSTVPEKKTPKSPVGVQPILNEHTFCAGMSKYQEDT   350                            .         .         .         .         .       252   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   301           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   CYGDAGSAFAVHDLEEDTWYATGILSFDKSCAVAEYGVYVKVTSIQDWVQ   400               302   KTIAEN   307           ||||||       401   KTIAEN   406                             Sequence name: HPT_HUMAN (SEQ ID NO: 131)                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P83 (SEQ ID NO: 142) × HPT_HUMAN (SEQ ID NO: 131)         ..               Alignment segment 1/1:                                             Quality:   276.00   Escore:   0                       Matching length:   30   Total length:   30               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIAD   30           ||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIAD   30                             Sequence name: HPT_HUMAN_V1 (SEQ ID NO: 132)                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P106 (SEQ ID NO: 143) × HPT_HUMAN_V1 (SEQ ID NO: 132) ..               Alignment segment 1/1:                                             Quality:   863.00   Escore:   0                       Matching length:   88   Total length:   88               Matching Percent Similarity:   100.00   Matching Percent Identity:   98.86               Total Percent Similarity:   100.00   Total Percent Identity:   98.86               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .       51   QCKNYYELRTEGDGVYTLNNEKQWINKAVGDKLPECEA   88           ||||||||||||||||||||||||||||||||||||||       51   QCKNYYKLRTEGDGVYTLNNKKQWINKAVGDKLPECEA   88                             Sequence name: HPT_HUMAN (SEQ ID NO: 131)                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P107 (SEQ ID NO: 144) × HPT_HUMAN (SEQ ID NO: 131)         ..               Alignment segment 1/1:                                             Quality:   1181.00   Escore:   0                       Matching length:   128   Total length:   187               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   68.45   Total Percent Identity:   68.45               Gaps:   1                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDI......................   28           ||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .         .         .       29   .....................................ADDGCPKPPEIAH   41                                                |||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEADDGCPKPPEIAH   100                            .         .         .         .         .       42   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   91           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   GYVEHSVRYQCKNYYKLRTEGDGVYTLNNEKQWINKAVGDKLPECEAVCG   150                            .         .         .       92   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTT   128           |||||||||||||||||||||||||||||||||||||       151   KPKNPANPVQRILGGHLDAKGSFPWQAKMVSHHNLTT   187                             Sequence name: HPT_HUMAN (SEQ ID NO: 131)                   Sequence documentation:               Alignment of: HUMHPA1B_PEA_1_P115 (SEQ ID NO: 145)) × HPT_HUMAN (SEQ ID NO: 131)         ..               Alignment segment 1/1:                                             Quality:   872.00   Escore:   0                       Matching length:   88   Total length:   88               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSALGAVIALLLWGQLFAVDSGNDVTDIADDGCPKPPEIAHGYVEHSVRY   50                            .         .         .       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEA   88           ||||||||||||||||||||||||||||||||||||||       51   QCKNYYKLRTEGDGVYTLNDKKQWINKAVGDKLPECEA   88          
 
     Description for Cluster HSHGFR  
      Cluster HSHGFR features 5 transcript(s) and 13 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       HSHGFR_T1   146           HSHGFR_T6   147           HSHGFR_T8   148           HSHGFR_T13   149           HSHGFR_T14   150                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 HSHGFR_node_2 
                 151 
               
               
                   
                 HSHGFR_node_3 
                 152 
               
               
                   
                 HSHGFR_node_6 
                 153 
               
               
                   
                 HSHGFR_node_11 
                 154 
               
               
                   
                 HSHGFR_node_15 
                 155 
               
               
                   
                 HSHGFR_node_16 
                 156 
               
               
                   
                 HSHGFR_node_18 
                 157 
               
               
                   
                 HSHGFR_node_22 
                 158 
               
               
                   
                 HSHGFR_node_24 
                 159 
               
               
                   
                 HSHGFR_node_8 
                 160 
               
               
                   
                 HSHGFR_node_10 
                 161 
               
               
                   
                 HSHGFR_node_14 
                 162 
               
               
                   
                 HSHGFR_node_20 
                 163 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                 Protein Name 
                 Sequence ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HSHGFR_P6 
                 165 
                 HSHGFR_T6 (SEQ ID 
               
               
                   
                   
                 NO: 147); HSHGFR_T8 (SEQ 
               
               
                   
                   
                 ID NO: 148) 
               
               
                 HSHGFR_P11 
                 166 
                 HSHGFR_T13 (SEQ ID 
               
               
                   
                   
                 NO: 149) 
               
               
                 HSHGFR_P12 
                 167 
                 HSHGFR_T14 (SEQ ID 
               
               
                   
                   
                 NO: 150) 
               
               
                 HSHGFR_P13 
                 168 
                 HSHGFR_T1 (SEQ ID 
               
               
                   
                   
                 NO: 146) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Hepatocyte growth factor precursor (SEQ ID NO:164) (SwissProt accession identifier HGF_HUMAN; known also according to the synonyms Scatter factor; SF; Hepatopoeitin A), referred to herein as the previously known protein.  
      Protein Hepatocyte growth factor precursor (SEQ ID NO:164) is known or believed to have the following function(s): HGF is a potent mitogen for mature parenchymal hepatocyte cells, seems to be an hepatotrophic factor, and acts as growth factor for a broad spectrum of tissues and cell types. It has no detectable protease activity. The sequence for protein Hepatocyte growth factor precursor is given at the end of the application, as “Hepatocyte growth factor precursor amino acid sequence” (SEQ ID NO:164). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on           amino acid sequence   Comment               153   S -&gt; I (in dbSNP: 17566). /FTId = VAR_014570.       32-33   QR -&gt; HK        78   K -&gt; N       162-166   Missing       180   P -&gt; T       293   M -&gt; V       300   L -&gt; M       317   V -&gt; A       336   E -&gt; K       387   H -&gt; N       416   D -&gt; N       505   I -&gt; V       509   V -&gt; I       558   D -&gt; E       561   C -&gt; R       592   D -&gt; N       595   S -&gt; N                  
 
      The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Cancer; Hepatic dysfunction; Buerger&#39;s syndrome. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Angiogenesis inhibitor; Hepatocyte growth factor modulator. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Hepatoprotective; Hormone; Radio/chemoprotective; Anticancer; Cardiovascular; Hypolipaemic/Antiatherosclerosis.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: proteolysis and peptidolysis; mitosis, which are annotation(s) related to Biological Process; and chymotrypsin; trypsin; growth factor, which are annotation(s) related to Molecular Function.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      It was found that concentrations of the known protein in the peritoneal fluid of patients with endometriosis were significantly higher than in those without endometriosis and correlated positively with revised American Society of Reproductive Medicine scores (Yoshida et al, J Clin Endocrinol Metab. 2004 February; 89(2):823-32). Variants of this cluster are suitable as diagnostic markers for endometriosis.  
      As noted above, cluster HSHGFR features 5 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Hepatocyte growth factor precursor (SEQ ID NO:164). A description of each variant protein according to the present invention is now provided.  
      Variant protein HSHGFR_P6 (SEQ ID NO:165) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSHGFR_T6 (SEQ ID NO:147) and HSHGFR_T8 (SEQ ID NO:148). An alignment is given to the known protein (Hepatocyte growth factor precursor (SEQ ID NO:164)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSHGFR_P6 (SEQ ID NO:165) and HGF_HUMAN (SEQ ID NO:164):  
      1. An isolated chimeric polypeptide encoding for HSHGFR_P6 (SEQ ID NO:165), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCR NPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWD HQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCA corresponding to amino acids 1-289 of HGF_HUMAN) (SEQ ID NO:164), which also corresponds to amino acids 1-289 of HSHGFR_P6 (SEQ ID NO:165), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence E corresponding to amino acids 290-290 of HSHGFR_P6 (SEQ ID NO:165), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSHGFR_P6 (SEQ ID NO:165) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P6 (SEQ ID NO:165) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 5                          Amino acid mutations                         SNP position(s) on amino acid   Alternative           sequence   amino acid(s)   Previously known SNP?                                 53   I -&gt; V   No       58   K -&gt; R   No       73   R -&gt; G   No       90   D -&gt; G   No       94   K -&gt; E   No       118   L -&gt; P   No       126   R -&gt; G   No       162   F -&gt; L   No       167   Y -&gt; C   No       210   E -&gt; G   No       232   C -&gt; R   No       236   D -&gt; G   No       244   K -&gt;   No       250   Y -&gt; H   No       258   N -&gt; D   No                  
 
      The glycosylation sites of variant protein HSHGFR_P6 (SEQ ID NO:165), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 6 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 6                          Glycosylation site(s)                     Position(s) on known amino           acid sequence   Present in variant protein?               653   no       476   no       566   no       402   no       294   no                  
 
      The phosphorylation sites of variant protein HSHGFR_P6 (SEQ ID NO:165), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 7 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 7                          Phosphorylation site(s)                         Position(s) on known amino   Present in           acid sequence   variant protein?   Position in variant protein?               32   yes   32                  
 
      Variant protein HSHGFR_P6 (SEQ ID NO:165) is encoded by the following transcript(s): HSHGFR_T6 (SEQ ID NO:147) and HSHGFR_T8 (SEQ ID NO:148), for which the sequence(s) is/are given at the end of the application.  
      The coding portion of transcript HSHGFR_T6 (SEQ ID NO:147) is shown in bold; this coding portion starts at position 229 and ends at position 1098. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P6 (SEQ ID NO:165) sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 8                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative           sequence   nucleic acid   Previously known SNP?                                 218   C -&gt;   No       219   C -&gt; T   No       256   C -&gt; T   No       385   A -&gt; G   No       401   A -&gt; G   No       445   A -&gt; G   No       497   A -&gt; G   No       508   A -&gt; G   No       552   G -&gt; A   No       561   A -&gt; G   No       581   T -&gt; C   No       604   A -&gt; G   No       712   T -&gt; C   No       728   A -&gt; G   No       760   C -&gt; A   No       780   A -&gt; G   No       825   A -&gt; G   No       857   A -&gt; G   No       922   T -&gt; C   No       935   A -&gt; G   No       958   A -&gt;   No       976   T -&gt; C   No       1000   A -&gt; G   No       1059   C -&gt; T   No                  
 
      The coding portion of transcript HSHGFR_T8 (SEQ ID NO:148) is shown in bold; this coding portion starts at position 229 and ends at position 1098. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P6 (SEQ ID NO:165) sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 9                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 218   C -&gt;   No       219   C -&gt; T   No       256   C -&gt; T   No       385   A -&gt; G   No       401   A -&gt; G   No       445   A -&gt; G   No       497   A -&gt; G   No       508   A -&gt; G   No       552   G -&gt; A   No       561   A -&gt; G   No       581   T -&gt; C   No       604   A -&gt; G   No       712   T -&gt; C   No       728   A -&gt; G   No       760   C -&gt; A   No       780   A -&gt; G   No       825   A -&gt; G   No       857   A -&gt; G   No       922   T -&gt; C   No       935   A -&gt; G   No       958   A -&gt;   No       976   T -&gt; C   No       1000   A -&gt; G   No       1059   C -&gt; T   No                  
 
      Variant protein HSHGFR_P11 (SEQ ID NO:166) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSHGFR_T13 (SEQ ID NO:149). An alignment is given to the known protein (Hepatocyte growth factor precursor (SEQ ID NO:164)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSHGFR_P11 (SEQ ID NO:166) and HGF_HUMAN (SEQ ID NO:164):  
      1. An isolated chimeric polypeptide encoding for HSHGFR_P11 (SEQ ID NO:166), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEH corresponding to amino acids 1-160 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 1-160 of HSHGFR_P11 (SEQ ID NO:166), a second amino acid sequence being at least 90% homologous to SYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSE corresponding to amino acids 166-208 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 161-203 of HSHGFR_P11 (SEQ ID NO:166), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GK corresponding to amino acids 204-205 of HSHGFR_P11 (SEQ ID NO:166), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HSHGFR_P11 (SEQ ID NO: 166), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise HS, having a structure as follows: a sequence starting from any of amino acid numbers 160−x to 160; and ending at any of amino acid numbers 161+((n−2)−x), in which x varies from 0 to n−2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSHGFR_P11 (SEQ ID NO:166) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P11 (SEQ ID NO:166) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 53   I -&gt; V   No       58   K -&gt; R   No       73   R -&gt; G   No       90   D -&gt; G   No       94   K -&gt; E   No       118   L -&gt; P   No       126   R -&gt; G   No       162   Y -&gt; C   No                  
 
      The glycosylation sites of variant protein HSHGFR_P11 (SEQ ID NO:166), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 11 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 11                          Glycosylation site(s)                             Position(s) on known amino               acid sequence   Present in variant protein?                       653   no           476   no           566   no           402   no           294   no                      
 
      The phosphorylation sites of variant protein HSHGFR_P11 (SEQ ID NO:166), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 12 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 12                          Phosphorylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?               32   yes   32                  
 
      Variant protein HSHGFR_P11 (SEQ ID NO:166) is encoded by the following transcript(s): HSHGFR_T13 (SEQ ID NO:149), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSHGFR_T13 (SEQ ID NO:149) is shown in bold; this coding portion starts at position 229 and ends at position 843. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P11 (SEQ ID NO:166) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 13                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?               218   C -&gt;   No       219   C -&gt; T   No       256   C -&gt; T   No       385   A -&gt; G   No       401   A -&gt; G   No       445   A -&gt; G   No       497   A -&gt; G   No       508   A -&gt; G   No       552   G -&gt; A   No       561   A -&gt; G   No       581   T -&gt; C   No       604   A -&gt; G   No       713   A -&gt; G   No       745   C -&gt; A   No       765   A -&gt; G   No       810   A -&gt; G   No       948   A -&gt; G   No                  
 
      Variant protein HSHGFR_P12 (SEQ ID NO:167) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSHGFR_T14 (SEQ ID NO:150). An alignment is given to the known protein (Hepatocyte growth factor precursor (SEQ ID NO:164)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSHGFR_P12 (SEQ ID NO:167) and HGF_HUMAN (SEQ ID NO: 164):  
      1. An isolated chimeric polypeptide encoding for HSHGFR_P12 (SEQ ID NO:167), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEH corresponding to amino acids 1-160 of HGF_HUMAN (SEQ ID NO:164) which also corresponds to amino acids 1-160 of HSHGFR_P12 (SEQ ID NO:167), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence R corresponding to amino acids 161-161 of HSHGFR_P12 (SEQ ID NO:167), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSHGFR_P12 (SEQ ID NO:167) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 14, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P12 (SEQ ID NO:167) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 14                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 53   I -&gt; V   No       58   K -&gt; R   No       73   R -&gt; G   No       90   D -&gt; G   No       94   K -&gt; E   No       118   L -&gt; P   No       126   R -&gt; G   No                  
 
      The glycosylation sites of variant protein HSHGFR_P12 (SEQ ID NO:167), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 15 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 15                          Glycosylation site(s)                             Position(s) on known amino               acid sequence   Present in variant protein?                       653   no           476   no           566   no           402   no           294   no                      
 
      The phosphorylation sites of variant protein HSHGFR_P12 (SEQ ID NO:167), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 16 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 16                          Phosphorylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?               32   yes   32                  
 
      Variant protein HSHGFR_P12 (SEQ ID NO:167) is encoded by the following transcript(s): HSHGFR_T14 (SEQ ID NO:150), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSHGFR_T14 (SEQ ID NO:150) is shown in bold; this coding portion starts at position 229 and ends at position 711. The transcript also has the following SNPs as listed in Table 17 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P12 (SEQ ID NO:167) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 17                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?               218   C -&gt;   No       219   C -&gt; T   No       256   C -&gt; T   No       385   A -&gt; G   No       401   A -&gt; G   No       445   A -&gt; G   No       497   A -&gt; G   No       508   A -&gt; G   No       552   G -&gt; A   No       561   A -&gt; G   No       581   T -&gt; C   No       604   A -&gt; G   No                  
 
      Variant protein HSHGFR_P13 (SEQ ID NO:168) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSHGFR_T1. An alignment is given to the known protein (Hepatocyte growth factor precursor (SEQ ID NO:164)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSHGFR_P13 (SEQ ID NO:168) and HGF_HUMAN (SEQ ID NO:164):  
      1. An isolated chimeric polypeptide encoding for HSHGFR_P13 (SEQ ID NO:168), comprising a first amino acid sequence being at least 90% homologous to MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKT KKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDL YENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCR NPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWD HQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIK corresponding to amino acids 1-286 of HGF_HUMAN (SEQ ID NO:164), which also corresponds to amino acids 1-286 of HSHGFR_P13 (SEQ ID NO:168), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence NMRDITWALN (SEQ ID NO:494) corresponding to amino acids 287-296 of HSHGFR_P13 (SEQ ID NO:168), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HSHGFR_P13 (SEQ ID NO:168), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence NMRDITWALN (SEQ ID NO:494) in HSHGFR_P13 (SEQ ID NO:168).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSHGFR_P13 (SEQ ID NO:168) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 18, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P13 (SEQ ID NO:168) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 18                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 53   I -&gt; V   No       58   K -&gt; R   No       73   R -&gt; G   No       90   D -&gt; G   No       94   K -&gt; E   No       118   L -&gt; P   No       126   R -&gt; G   No       162   F -&gt; L   No       167   Y -&gt; C   No       210   E -&gt; G   No       232   C -&gt; R   No       236   D -&gt; G   No       244   K -&gt;   No       250   Y -&gt; H   No       258   N -&gt; D   No                  
 
      The glycosylation sites of variant protein HSHGFR_P13 (SEQ ID NO:168), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 19 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 19                          Glycosylation site(s)                             Position(s) on known amino               acid sequence   Present in variant protein?                       653   no           476   no           566   no           402   no           294   no                      
 
      The phosphorylation sites of variant protein HSHGFR_P13 (SEQ ID NO:168), as compared to the known protein Hepatocyte growth factor precursor (SEQ ID NO:164), are described in Table 20 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the phosphorylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 20                          Phosphorylation site(s)                         Position(s) on known amino   Present in           acid sequence   variant protein?   Position in variant protein?               32   yes   32                  
 
      Variant protein HSHGFR_P13 (SEQ ID NO:168) is encoded by the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSHGFR_T1 (SEQ ID NO:146) is shown in bold; this coding portion starts at position 229 and ends at position 1115. The transcript also has the following SNPs as listed in Table 21 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSHGFR_P13 (SEQ ID NO:168) sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 21                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative           sequence   nucleic acid   Previously known SNP?                                 218   C -&gt;   No       219   C -&gt; T   No       256   C -&gt; T   No       385   A -&gt; G   No       401   A -&gt; G   No       445   A -&gt; G   No       497   A -&gt; G   No       508   A -&gt; G   No       552   G -&gt; A   No       561   A -&gt; G   No       581   T -&gt; C   No       604   A -&gt; G   No       712   T -&gt; C   No       728   A -&gt; G   No       760   C -&gt; A   No       780   A -&gt; G   No       825   A -&gt; G   No       857   A -&gt; G   No       922   T -&gt; C   No       935   A -&gt; G   No       958   A -&gt;   No       976   T -&gt; C   No       1000   A -&gt; G   No       1059   C -&gt; T   No       1094   A -&gt; C   No       1117   G -&gt; A   No       1203   C -&gt; T   No       1353   A -&gt; T   No                  
 
      As noted above, cluster HSHGFR features 13 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HSHGFR_node — 2 (SEQ ID NO:151) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147), HSHGFR_T8 (SEQ ID NO:148), HSHGFR_T13 (SEQ ID NO:149) and HSHGFR_T14 (SEQ ID NO:150). Table 22 below describes the starting and ending position of this segment on each transcript.  
               TABLE 22                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   1   171       HSHGFR_T6 (SEQ ID NO: 147)   1   171       HSHGFR_T8 (SEQ ID NO: 148)   1   171       HSHGFR_T13 (SEQ ID NO: 149)   1   171       HSHGFR_T14 (SEQ ID NO: 150)   1   171                  
 
      Segment cluster HSHGFR_node — 2 (SEQ ID NO:152) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147), HSHGFR_T8 (SEQ ID NO:148), HSHGFR_T13 (SEQ ID NO:149) and HSHGFR_T14 (SEQ ID NO:150). Table 23 below describes the starting and ending position of this segment on each transcript.  
               TABLE 23                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   172   316       HSHGFR_T6 (SEQ ID NO: 147)   172   316       HSHGFR_T8 (SEQ ID NO: 148)   172   316       HSHGFR_T13 (SEQ ID NO: 149)   172   316       HSHGFR_T14 (SEQ ID NO: 150)   172   316                  
 
      Segment cluster HSHGFR_node — 6 (SEQ ID NO:153) according to the present invention is supported by 31 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147), HSHGFR_T8 (SEQ ID NO:148), HSHGFR_T13 (SEQ ID NO:149) and HSHGFR_T14 (SEQ ID NO:150). Table 24 below describes the starting and ending position of this segment on each transcript.  
               TABLE 24                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   317   482       HSHGFR_T6 (SEQ ID NO: 147)   317   482       HSHGFR_T8 (SEQ ID NO: 148)   317   482       HSHGFR_T13 (SEQ ID NO: 149)   317   482       HSHGFR_T14 (SEQ ID NO: 150)   317   482                  
 
      Segment cluster HSHGFR_node — 11 (SEQ ID NO:154) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T14 (SEQ ID NO:150). Table 25 below describes the starting and ending position of this segment on each transcript.  
               TABLE 25                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T14 (SEQ ID NO: 150)   711   1221                  
 
      Segment cluster HSHGFR_node — 15 (SEQ ID NO:155) according to the present invention is supported by 24 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147), HSHGFR_T8 (SEQ ID NO:148) and HSHGFR_T13 (SEQ ID NO:149). Table 26 below describes the starting and ending position of this segment on each transcript.  
               TABLE 26                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   726   853       HSHGFR_T6 (SEQ ID NO: 147)   726   853       HSHGFR_T8 (SEQ ID NO: 148)   726   853       HSHGFR_T13 (SEQ ID NO: 149)   711   838                  
 
      Segment cluster HSHGFR_node — 16 (SEQ ID NO:156) according to the present invention is supported by 15 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T13 (SEQ ID NO:149). Table 27 below describes the starting and ending position of this segment on each transcript.  
               TABLE 27                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T13 (SEQ ID NO: 149)   839   2068                  
 
      Segment cluster HSHGFR_node — 18 (SEQ ID NO:157) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147) and HSHGFR_T8 (SEQ ID NO:148). Table 28 below describes the starting and ending position of this segment on each transcript.  
               TABLE 28                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   854   974       HSHGFR_T6 (SEQ ID NO: 147)   854   974       HSHGFR_T8 (SEQ ID NO: 148)   854   974                  
 
      Segment cluster HSHGFR_node — 22 (SEQ ID NO:158) according to the present invention is supported by 12 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146). Table 29 below describes the starting and ending position of this segment on each transcript.  
               TABLE 29                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   1094   1353                  
 
      Segment cluster HSHGFR_node — 24 (SEQ ID NO:159) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T6 (SEQ ID NO:147) and HSHGFR_T8 (SEQ ID NO:148). Table 30 below describes the starting and ending position of this segment on each transcript.  
               TABLE 30                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T6 (SEQ ID NO: 147)   1094   1286       HSHGFR_T8 (SEQ ID NO: 148)   1094   1367                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HSHGFR_node — 8 (SEQ ID NO:160) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147), HSHGFR_T8 (SEQ ID NO:148), HSHGFR_T13 (SEQ ID NO:149) and HSHGFR_T14 (SEQ ID NO:150). Table 31 below describes the starting and ending position of this segment on each transcript.  
               TABLE 31                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   483   595       HSHGFR_T6 (SEQ ID NO: 147)   483   595       HSHGFR_T8 (SEQ ID NO: 148)   483   595       HSHGFR_T13 (SEQ ID NO: 149)   483   595       HSHGFR_T14 (SEQ ID NO: 150)   483   595                  
 
      Segment cluster HSHGFR_node — 10 (SEQ ID NO:161) according to the present invention is supported by 26 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147), HSHGFR_T8 (SEQ ID NO:148), HSHGFR_T13 (SEQ ID NO:149) and HSHGFR_T14 (SEQ ID NO:150). Table 32 below describes the starting and ending position of this segment on each transcript.  
               TABLE 32                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   596   710       HSHGFR_T6 (SEQ ID NO: 147)   596   710       HSHGFR_T8 (SEQ ID NO: 148)   596   710       HSHGFR_T13 (SEQ ID NO: 149)   596   710       HSHGFR_T14 (SEQ ID NO: 150)   596   710                  
 
      Segment cluster HSHGFR_node — 14 (SEQ ID NO:162) according to the present invention can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147) and HSHGFR_T8 (SEQ ID NO:148). Table 33 below describes the starting and ending position of this segment on each transcript.  
               TABLE 33                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   711   725       HSHGFR_T6 (SEQ ID NO: 147)   711   725       HSHGFR_T8 (SEQ ID NO: 148)   711   725                  
 
      Segment cluster HSHGFR_node — 20 (SEQ ID NO:163) according to the present invention is supported by 25 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSHGFR_T1 (SEQ ID NO:146), HSHGFR_T6 (SEQ ID NO:147) and HSHGFR_T8 (SEQ ID NO:148). Table 34 below describes the starting and ending position of this segment on each transcript.  
               TABLE 34                          3Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSHGFR_T1 (SEQ ID NO: 146)   975   1093       HSHGFR_T6 (SEQ ID NO: 147)   975   1093       HSHGFR_T8 (SEQ ID NO: 148)   975   1093                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: HGF_HUMAN (SEQ ID NO: 164)                   Sequence documentation:               Alignment of: HSHGFR_P6 (SEQ ID NO: 165) × HGF_HUMAN (SEQ ID NO: 164) ..               Alignment segment 1/1:                                             Quality:   2989.00   Escore:   0                       Matching length:   290   Total length:   290               Matching Percent Similarity:   100.00   Matching Percent Identity:   99.66               Total Percent Similarity:   100.00   Total Percent Identity:   99.66               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50                            .         .         .         .         .       51   IKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFP   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   IKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFP   100                            .         .         .         .         .       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150                            .         .         .         .         .       151   PWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEV   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   PWSSMIPHEHSFLPSSYRGKOLQENYCRNPRGEEGGPWCFTSNPEVRYEV   200                            .         .         .         .         .       201   CDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERY   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   CDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERY   250                            .         .         .         .       251   PDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCAE   290           |||||||||||||||||||||||||||||||||||||||:       251   PDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCAD   290                             Sequence name: HGF_HUMAN (SEQ ID NO: 164)                   Sequence documentation:               Alignment of: HSHGFR_P11 (SEQ ID NO: 166) × HGF_HUMAN (SEQ ID NO: 164) ..               Alignment segment 1/1:                                             Quality:   1957.00   Escore:   0                       Matching length:   203   Total length:   208               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   97.60   Total Percent Identity:   97.60               Gaps:   1                             Alignment:                                                          .         .         .         .         .                   1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50                            .         .         .         .         .       51   IKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFP   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   IKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFP   100                            .         .         .         .         .       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150                            .         .         .         .         .       151   PWSSMIPHEH.....SYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEV   195           ||||||||||     |||||||||||||||||||||||||||||||||||       151   PWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEV   200               196   CDIPQCSE   203           ||||||||       201   CDIPQCSE   208                             Sequence name: HGF_HUMAN (SEQ ID NO: 164)                   Sequence documentation:               Alignment of: HSHGFR_P12 (SEQ ID NO: 167) × HGF_HUMAN (SEQ ID NO: 164) ..               Alignment segment 1/1:                                             Quality:   1600.00   Escore:   0                       Matching length:   160   Total length:   160               Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00               Total Percent Similarity:   100.00   Total Percent Identity:   100.00               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50                            .         .         .         .         .       51   IKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFP   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   IKIDPALKIKTKKVNTADQCANRCTRNEGLPFTCKAFVFDKARKQCLWFP   100                            .         .         .         .         .       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150                            .       151   PWSSMIPHEH   160           ||||||||||       151   PWSSMIPHEH   160                             Sequence name: HGF_HUMAN (SEQ ID NO: 164)                   Sequence documentation:               Alignment of: HSHGFR_P13 (SEQ ID NO: 168) × HGF_HUMAN (SEQ ID NO: 164) ..               Alignment segment 1/1:                                             Quality:   2960.00   Escore:   0                       Matching length:   292   Total length:   292               Matching Percent Similarity:   98.63   Matching Percent Identity:   98.63               Total Percent Similarity:   98.63   Total Percent Identity:   98.63               Gaps:   0                             Alignment:                                                          .         .         .         .         .                   1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MWVTKLLPALLLQHVLLHLLLLPIAIPYAEGQRKRRNTIHEFKKSAKTTL   50                            .         .         .         .         .       51   IKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFP   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   IKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFP   100                            .         .         .         .         .       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   FNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQ   150                            .         .         .         .         .       151   PWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEV   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   PWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEV   200                            .         .         .         .         .       201   CDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERY   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   CDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERY   250                            .         .         .         .       251   PDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKNMRDIT   292           ||||||||||||||||||||||||||||||||||||   | |       251   PDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNT   292          
 
     Description for Cluster S56892  
      Cluster S56892 features 4 transcript(s) and 20 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       S56892_PEA_1_T3   169           S56892_PEA_1_T9   170           S56892_PEA_1_T10   171           S56892_PEA_1_T13   172                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 S56892_PEA_1_node_0 
                 173 
               
               
                   
                 S56892_PEA_1_node_5 
                 174 
               
               
                   
                 S56892_PEA_1_node_10 
                 175 
               
               
                   
                 S56892_PEA_1_node_18 
                 176 
               
               
                   
                 S56892_PEA_1_node_21 
                 177 
               
               
                   
                 S56892_PEA_1_node_3 
                 178 
               
               
                   
                 S56892_PEA_1_node_4 
                 179 
               
               
                   
                 S56892_PEA_1_node_6 
                 180 
               
               
                   
                 S56892_PEA_1_node_7 
                 181 
               
               
                   
                 S56892_PEA_1_node_8 
                 182 
               
               
                   
                 S56892_PEA_1_node_9 
                 183 
               
               
                   
                 S56892_PEA_1_node_12 
                 184 
               
               
                   
                 S56892_PEA_1_node_13 
                 185 
               
               
                   
                 S56892_PEA_1_node_14 
                 186 
               
               
                   
                 S56892_PEA_1_node_16 
                 187 
               
               
                   
                 S56892_PEA_1_node_17 
                 188 
               
               
                   
                 S56892_PEA_1_node_19 
                 189 
               
               
                   
                 S56892_PEA_1_node_20 
                 190 
               
               
                   
                 S56892_PEA_1_node_22 
                 191 
               
               
                   
                 S56892_PEA_1_node_23 
                 192 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                   
                 Sequence ID 
                   
               
               
                 Protein Name 
                 No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 S56892_PEA_1_P2 
                 194 
                 S56892_PEA_1_T3 (SEQ ID 
               
               
                   
                   
                 NO: 169) 
               
               
                 S56892_PEA_1_P8 
                 195 
                 S56892_PEA_1_T9 (SEQ ID 
               
               
                   
                   
                 NO: 170) 
               
               
                 S56892_PEA_1_P9 
                 196 
                 S56892_PEA_1_T10 (SEQ 
               
               
                   
                   
                 ID NO: 171) 
               
               
                 S56892_PEA_1_P11 
                 197 
                 S56892_PEA_1_T13 (SEQ 
               
               
                   
                   
                 ID NO: 172) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Interleukin-6 precursor (SEQ ID NO:193) (SwissProt accession identifier IL6_HUMAN (SEQ ID NO:193); known also according to the synonyms IL-6; B-cell stimulatory factor 2; BSF-2; Interferon beta-2; Hybridoma growth factor; CTL differentiation factor; CDF), referred to herein as the previously known protein.  
      Protein Interleukin-6 precursor (SEQ ID NO:193) is known or believed to have the following function(s): IL-6 is a cytokine with a wide variety of biological functions: it plays an essential role in the final differentiation of B-cells into Ig-secreting cells, it induces myeloma and plasmacytoma growth, it induces nerve cells differentiation and in hepatocytes it induces acute phase reactants. The sequence for protein Interleukin-6 precursor is given at the end of the application, as “Interleukin-6 precursor amino acid sequence” (SEQ ID NO:193). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on amino           acid sequence   Comment                             32   P -&gt; S. /FTId = VAR_013075.       162   D -&gt; V. /FTId = VAR_013076.       173   A -&gt; V: ALMOST NO LOSS OF           ACTIVITY.       185   W -&gt; R: NO LOSS OF ACTIVITY.       204   S -&gt; P: 87% LOSS OF ACTIVITY.       210   R -&gt; K, E, Q, T, A, P: LOSS OF           ACTIVITY.       212   M -&gt; T, N, S, R: LOSS OF ACTIVITY.                  
 
      Protein Interleukin-6 precursor (SEQ ID NO:193) localization is believed to be Secreted.  
      Serum levels of IL-6 were significantly higher in women with endometriosis than in controls (P&lt;0.001), with highest levels seen in women with chocolate cysts (Wieser et al, J Soc Gynecol Investig. 2003 January; 10(1):32-6). Variants of this cluster are suitable as diagnostic markers for endometriosis.  
      The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Chemotherapy-induced injury; Cancer, sarcoma, Kaposi&#39;s; Cancer, myeloma; Chemotherapy-induced injury, bone marrow, thrombocytopenia; Thrombocytopenia; Infection, HIV/AIDS; Chemotherapy-induced injury, bone marrow, neutropenia; Cancer, breast; Cancer, colorectal; Cancer, leukaemia, acute myelogenous; Cancer, melanoma; Myelodysplastic syndrome; Hepatic dysfunction. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Interleukin 1 antagonist; Interleukin 2 agonist; Interleukin 6 modulator. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Antiarthritic, immunological; Radio/chemoprotective; Anticancer; Cytokine; Haematological; Anti-inflammatory; Antianaemic; Antiviral, interferon; Anabolic; Hepatoprotective.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: skeletal development; acute-phase response; humoral defense mechanism; cell surface receptor linked signal transduction; cell-cell signaling; developmental processes; cell proliferation; positive control of cell proliferation; negative control of cell proliferation, which are annotation(s) related to Biological Process; cytokine; interleukin-6 receptor ligand, which are annotation(s) related to Molecular Function; and extracellular space, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      As noted above, cluster S56892 features 4 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Interleukin-6 precursor (SEQ ID NO:193). A description of each variant protein according to the present invention is now provided.  
      Variant protein S56892_PEA — 1_P2 (SEQ ID NO:194) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) S56892_PEA — 1_T3 (SEQ ID NO:169). An alignment is given to the known protein (Interleukin-6 precursor (SEQ ID NO:193)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between S56892_PEA — 1_P2 (SEQ ID NO:194) and IL6_HUMAN (SEQ ID NO:193):  
      1. An isolated chimeric polypeptide encoding for S56892_PEA — 1_P2 (SEQ ID NO:194), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MNSFSTSKCRKSLALELPAAVEPCVREGCVAQGGLAGGQQQRQAPSCAVSSPLRSLPS GTG (SEQ ID NO:491) corresponding to amino acids 1-61 of S56892_PEA — 1_P2 (SEQ ID NO:194), and a second amino acid sequence being at least 90% homologous to AFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALR KETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLE YLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQW LQDMTTHLILRSFKEFLQSSLRALRQM corresponding to amino acids 8-212 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 62-266 of S56892_PEA — 1_P2 (SEQ ID NO:194), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of S56892_PEA — 1_P2 (SEQ ID NO:194), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MNSFSTSKCRKSLALELPAAVEPCVREGCVAQGGLAGGQQQRQAPSCAVSSPLRSLPS GTG (SEQ ID NO:491) of S56892_PEA — 1_P2 (SEQ ID NO:194).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: intracellularly. The protein localization is believed to be intracellularly because only one of the two trans-membrane region prediction programs (Tmpred: 1, Tmhmm: 0) Has predicted that this protein has a trans-membrane region. In addition both signal-peptide prediction programs predict that this protein is a non-secreted protein.  
      Variant protein S56892_PEA — 1_P2 (SEQ ID NO:194) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S56892_PEA — 1_P2 (SEQ ID NO:194) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 5                          Amino acid mutations                         SNP position(s)               on amino acid   Alternative   Previously       sequence   amino acid(s)   known SNP?               224   T -&gt;   No       231   T -&gt; A   No       251   S -&gt;   No                  
 
      The glycosylation sites of variant protein S56892_PEA — 1_P2 (SEQ ID NO:194), as compared to the known protein Interleukin-6 precursor (SEQ ID NO:193), are described in Table 6 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 6                          Glycosylation site(s)                         Position(s) on known amino   Present in   Position in       acid sequence   variant protein?   variant protein?               73   yes   127                  
 
      Variant protein S56892_PEA — 1_P2 (SEQ ID NO:194) is encoded by the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S56892_PEA — 1_T3 (SEQ ID NO:169) is shown in bold; this coding portion starts at position 458 and ends at position 1255. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S56892_PEA — 1_P2 (SEQ ID NO:194) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 407   A -&gt; T   No       408   G -&gt; T   No       706   A -&gt; G   No       1128   C -&gt;   No       1148   A -&gt; G   No       1209   G -&gt;   No       1222   C -&gt; T   No       1594   -&gt; A   No       1594   -&gt; T   No                  
 
      Variant protein S56892-PEA — 1_P8 (SEQ ID NO:195) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) S56892_PEA — 1_T9 (SEQ ID NO:170). An alignment is given to the known protein (Interleukin-6 precursor (SEQ ID NO:193)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between S56892_PEA — 1_P8 (SEQ ID NO:195) and IL6_HUMAN (SEQ ID NO:193):  
      1. An isolated chimeric polypeptide encoding for S56892_PEA — 1_P8 (SEQ ID NO:195), comprising a first amino acid sequence being at least 90% homologous to MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYIL DGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLL EFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKK corresponding to amino acids 1-157 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 1-157 of S56892_PEA — 1_P8 (SEQ ID NO:195), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VGVSSFPQLGVGEDRLKDSVLDNSGMQCHFQKRRLHVNKRV (SEQ ID NO:492) corresponding to amino acids 158-198 of S56892_PEA — 1_P8 (SEQ ID NO:195), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of S56892_PEA — 1_P8 (SEQ ID NO:195), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VGVSSFPQLGVGEDRLKDSVLDNSGMQCHFQKRRLHVNKRV (SEQ ID NO:492) in S56892_PEA — 1_P8 (SEQ ID NO:195).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      The glycosylation sites of variant protein S56892_PEA — 1_P8 (SEQ ID NO:195), as compared to the known protein Interleukin-6 precursor (SEQ ID NO:193), are described in Table 8 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 8                          Glycosylation site(s)                         Position(s) on known amino   Present in   Position in       acid sequence   variant protien?   variant protein?               73   yes   73                  
 
      Variant protein S56892_PEA — 1_P8 (SEQ ID NO:195) is encoded by the following transcript(s): S56892_PEA — 1_T9 (SEQ ID NO:170), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S56892_PEA — 1_T9 (SEQ ID NO:170) is shown in bold; this coding portion starts at position 458 and ends at position 1051. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S56892_PEA — 1_P8 (SEQ ID NO:195) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 9                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 407   A -&gt; T   No       408   G -&gt; T   No       544   A -&gt; G   No       1798   A -&gt; G   Yes       2257   G -&gt; A   Yes       2711   C -&gt;   No       2731   A -&gt; G   No       2792   G -&gt;   No       2805   C -&gt; T   No       3177   -&gt; A   No       3177   -&gt; T   No                  
 
      Variant protein S56892_PEA — 1_P9 (SEQ ID NO:196) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) S56892_PEA — 1_T10 (SEQ ID NO:171). An alignment is given to the known protein (Interleukin-6 precursor (SEQ ID NO:193)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between S56892_PEA — 1_P9 (SEQ ID NO:196) and IL6_HUMAN (SEQ ID NO:193):  
      1. An isolated chimeric polypeptide encoding for S56892_PEA — 1_P9 (SEQ ID NO:196), comprising a first amino acid sequence being at least 90% homologous to MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYIL DGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNE corresponding to amino acids 1-108 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 1-108 of S56892_PEA — 1_P9 (SEQ ID NO:196), and a second amino acid sequence being at least 90% homologous to AKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM corresponding to amino acids 158-212 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 109-163 of S56892_PEA — 1_P9 (SEQ ID NO:196), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of S56892_PEA — 1_P9 (SEQ ID NO:196), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EA, having a structure as follows: a sequence starting from any of amino acid numbers 108−x to 108; and ending at any of amino acid numbers 109+((n−2)−x), in which x varies from 0 to n−2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein S56892_PEA — 1_P9 (SEQ ID NO:196) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S56892_PEA — 1_P9 (SEQ ID NO:196) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Amino acid mutations                         SNP position(s) on amino acid   Alternative amino   Previously       sequence   acid(s)   known SNP?               121   T -&gt;   No       128   T -&gt; A   No       148   S -&gt;   No                  
 
      The glycosylation sites of variant protein S56892_PEA — 1_P9 (SEQ ID NO:196), as compared to the known protein Interleukin-6 precursor (SEQ ID NO:193), are described in Table 11 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 11                          Glycosylation site(s)                         Position(s) on known amino   Present in   Position in       acid sequence   variant protein?   variant protein?               73   yes   73                  
 
      Variant protein S56892_PEA — 1_P9 (SEQ ID NO:196) is encoded by the following transcript(s): S56892_PEA — 1_T10 (SEQ ID NO:171), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S56892_PEA — 1_T10 (SEQ ID NO:171) is shown in bold; this coding portion starts at position 113 and ends at position 601. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S56892_PEA — 1_P9 (SEQ ID NO:196) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 12                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 62   A -&gt; T   No       63   G -&gt; T   No       199   A -&gt; G   No       474   C -&gt;   No       494   A -&gt; G   No       555   G -&gt;   No       568   C -&gt; T   No       940   -&gt; A   No       940   -&gt; T   No                  
 
      Variant protein S56892_PEA — 1_P11 (SEQ ID NO:197) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) S56892_PEA — 1_T13 (SEQ ID NO:172). An alignment is given to the known protein (Interleukin-6 precursor (SEQ ID NO:193)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between S56892_PEA — 1_P11 (SEQ ID NO:197) and IL6_HUMAN (SEQ ID NO:193):  
      1. An isolated chimeric polypeptide encoding for S56892_PEA — 1_P11 (SEQ ID NO:197), comprising a first amino acid sequence being at least 90% homologous to MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYIL DGISALRKETCNKSN corresponding to amino acids 1-76 of IL6_HUMAN (SEQ ID NO:193), which also corresponds to amino acids 1-76 of S56892_PEA — 1_P11 (SEQ ID NO:197), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence IWLKKMDASNLDSMRRLAW (SEQ ID NO:493) corresponding to amino acids 77-95 of S56892_PEA — 1_P11 (SEQ ID NO:197), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of S56892_PEA — 1_P11 (SEQ ID NO:197), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence IWLKKMDASNLDSMRRLAW (SEQ ID NO:493) in S56892_PEA — 1_P11 (SEQ ID NO:197).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      The glycosylation sites of variant protein S56892_PEA — 1_P11 (SEQ ID NO:197), as compared to the known protein Interleukin-6 precursor (SEQ ID NO:193), are described in Table 13 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 13                          Glycosylation site(s)                         Position(s) on known amino   Present in   Position in       acid sequence   variant protein?   variant protein?               73   yes   73                  
 
      Variant protein S56892_PEA — 1_P11 (SEQ ID NO:197) is encoded by the following transcript(s): S56892_PEA — 1_T13 (SEQ ID NO:172), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript S56892_PEA — 1_T13 (SEQ ID NO:172) is shown in bold; this coding portion starts at position 458 and ends at position 742. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein S56892_PEA — 1_P11 (SEQ ID NO:197) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 14                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 407   A -&gt; T   No       408   G -&gt; T   No       544   A -&gt; G   No       914   C -&gt;   No       934   A -&gt; G   No       995   G -&gt;   No       1008   C -&gt; T   No       1380   -&gt; A   No       1380   -&gt; T   No                  
 
      As noted above, cluster S56892 features 20 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster S56892_PEA — 1_node — 0 (SEQ ID NO:173) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 15 below describes the starting and ending position of this segment on each transcript.  
               TABLE 15                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T3 (SEQ ID NO: 169)   1   373       S56892_PEA_1_T9 (SEQ ID NO: 170)   1   373       S56892_PEA_1_T13 (SEQ ID   1   373       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 5 (SEQ ID NO:174) according to the present invention is supported by 6 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169). Table 16 below describes the starting and ending position of this segment on each transcript.  
               TABLE 16                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T3 (SEQ ID NO: 169)   477   632                  
 
      Segment cluster S56892_PEA — 1_node — 10 (SEQ ID NO:175) according to the present invention is supported by 98 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 17 below describes the starting and ending position of this segment on each transcript.  
               TABLE 17                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T3 (SEQ ID NO: 169)   708   829       S56892_PEA_1_T9 (SEQ ID NO: 170)   546   667       S56892_PEA_1_T10 (SEQ ID   201   322       NO: 171)       S56892_PEA_1_T13 (SEQ ID   546   667       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 18 (SEQ ID NO:176) according to the present invention is supported by 22 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T9 (SEQ ID NO:170). Table 18 below describes the starting and ending position of this segment on each transcript.  
               TABLE 18                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T9 (SEQ ID NO: 170)   929   2673                  
 
      Segment cluster S56892_PEA — 1_node — 21 (SEQ ID NO:177) according to the present invention is supported by 111 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 19 below describes the starting and ending position of this segment on each transcript.  
               TABLE 19                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   1169   1625       S56892_PEA_1_T9 (SEQ ID NO: 170)   2752   3208       S56892_PEA_1_T10 (SEQ ID   515   971       NO: 171)       S56892_PEA_1_T13 (SEQ ID   955   1411       NO: 172)                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster S56892_PEA — 1_node — 3 (SEQ ID NO:178) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T10 (SEQ ID NO:171). Table 20 below describes the starting and ending position of this segment on each transcript.  
               TABLE 20                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               S56892_PEA_1_T10 (SEQ ID   1   28       NO: 171)                  
 
      Segment cluster S56892_PEA — 1_node — 4 (SEQ ID NO:179) according to the present invention is supported by 93 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 21 below describes the starting and ending position of this segment on each transcript.  
               TABLE 21                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   374   476       S56892_PEA_1_T9 (SEQ ID NO: 170)   374   476       S56892_PEA_1_T10 (SEQ ID   29   131       NO: 171)       S56892_PEA_1_T13 (SEQ ID   374   476       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 6 (SEQ ID NO:180) according to the present invention can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169). Table 22 below describes the starting and ending position of this segment on each transcript.  
               TABLE 22                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T3 (SEQ ID NO: 169)   633   638                  
 
      Segment cluster S56892_PEA — 1_node — 7 (SEQ ID NO:181) according to the present invention can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 23 below describes the starting and ending position of this segment on each transcript.  
               TABLE 23                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T3 (SEQ ID NO: 169)   639   657       S56892_PEA_1_T9 (SEQ ID NO: 170)   477   495       S56892_PEA_1_T10 (SEQ ID   132   150       NO: 171)       S56892_PEA_1_T13 (SEQ ID   477   495       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 8 (SEQ ID NO:182) according to the present invention is supported by 89 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 24 below describes the starting and ending position of this segment on each transcript.  
               TABLE 24                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T3 (SEQ ID NO: 169)   658   693       S56892_PEA_1_T9 (SEQ ID NO: 170)   496   531       S56892_PEA_1_T10 (SEQ ID   151   186       NO: 171)       S56892_PEA_1_T13 (SEQ ID   496   531       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 9 (SEQ ID NO:183) according to the present invention can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 25 below describes the starting and ending position of this segment on each transcript.  
               TABLE 25                          Segment location on transcripts                             Segment   Segment           starting   ending       Transcript name   position   position               S56892_PEA_1_T3 (SEQ ID NO: 169)   694   707       S56892_PEA_1_T9 (SEQ ID NO: 170)   532   545       S56892_PEA_1_T10 (SEQ ID   187   200       NO: 171)       S56892_PEA_1_T13 (SEQ ID   532   545       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 12 (SEQ ID NO:184) according to the present invention can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 26 below describes the starting and ending position of this segment on each transcript.  
               TABLE 26                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               S56892_PEA_1_T3 (SEQ ID NO: 169)   830   849       S56892_PEA_1_T9 (SEQ ID NO: 170)   668   687       S56892_PEA_1_T10 (SEQ ID   323   342       NO: 171)       S56892_PEA_1_T13 (SEQ ID   668   687       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 13 (SEQ ID NO:185) according to the present invention is supported by 70 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170) and S56892_PEA — 1_T10 (SEQ ID NO:171). Table 27 below describes the starting and ending position of this segment on each transcript.  
               TABLE 27                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               S56892_PEA_1_T3 (SEQ ID NO: 169)   850   901       S56892_PEA_1_T9 (SEQ ID NO: 170)   688   739       S56892_PEA_1_T10 (SEQ ID   343   394       NO: 171)                  
 
      Segment cluster S56892_PEA — 1_node — 14 (SEQ ID NO:186) according to the present invention is supported by 64 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 28 below describes the starting and ending position of this segment on each transcript.  
               TABLE 28                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               S56892_PEA_1_T3 (SEQ ID NO: 169)   902   943       S56892_PEA_1_T9 (SEQ ID NO: 170)   740   781       S56892_PEA_1_T10 (SEQ ID   395   436       NO: 171)       S56892_PEA_1_T13 (SEQ ID   688   729       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 16 (SEQ ID NO:187) according to the present invention is supported by 78 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 29 below describes the starting and ending position of this segment on each transcript.  
               TABLE 29                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   944   1051       S56892_PEA_1_T9 (SEQ ID NO: 170)   782   889       S56892_PEA_1_T13 (SEQ ID   730   837       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 17 (SEQ ID NO:188) according to the present invention is supported by 73 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 30 below describes the starting and ending position of this segment on each transcript.  
               TABLE 30                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   1052   1090       S56892_PEA_1_T9 (SEQ ID NO: 170)   890   928       S56892_PEA_1_T13 (SEQ ID   838   876       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 19 (SEQ ID NO:189) according to the present invention is supported by 78 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170) S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 31 below describes the starting and ending position of this segment on each transcript.  
               TABLE 31                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   1091   1124       S56892_PEA_1_T9 (SEQ ID NO: 170)   2674   2707       S56892_PEA_1_T10 (SEQ ID   437   470       NO: 171)       S56892_PEA_1_T13 (SEQ ID   877   910       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 20 (SEQ ID NO:190) according to the present invention is supported by 83 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 32 below describes the starting and ending position of this segment on each transcript.  
               TABLE 32                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   1125   1168       S56892_PEA_1_T9 (SEQ ID NO: 170)   2708   2751       S56892_PEA_1_T10 (SEQ ID   471   514       NO: 171)       S56892_PEA_1_T13 (SEQ ID   911   954       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 22 (SEQ ID NO:191) according to the present invention can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169), S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 33 below describes the starting and ending position of this segment on each transcript.  
               TABLE 33                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   1626   1638       S56892_PEA_1_T9 (SEQ ID NO: 170)   3209   3221       S56892_PEA_1_T10 (SEQ ID   972   984       NO: 171)       S56892_PEA_1_T13 (SEQ ID   1412   1424       NO: 172)                  
 
      Segment cluster S56892_PEA — 1_node — 23 (SEQ ID NO:192) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): S56892_PEA — 1_T3 (SEQ ID NO:169, S56892_PEA — 1_T9 (SEQ ID NO:170), S56892_PEA — 1_T10 (SEQ ID NO:171) and S56892_PEA — 1_T13 (SEQ ID NO:172). Table 34 below describes the starting and ending position of this segment on each transcript.  
               TABLE 34                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 S56892_PEA_1_T3 (SEQ ID NO: 169)   1639   1696       S56892_PEA_1_T9 (SEQ ID NO: 170)   3222   3279       S56892_PEA_1_T10 (SEQ ID   985   1042       NO: 171)       S56892_PEA_1_T13 (SEQ ID   1425   1482       NO: 172)                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: IL6_HUMAN (SEQ ID NO:193)                   Sequence documentation:       Alignment of: S56892_PEA_1_P2 (SEQ ID NO:194) ×       IL6_HUMAN (SEQ ID NO:193)   . .               Alignment segment 1/1:                                 Quality:   1997.00   Escore:   0           Matching length:   207   Total length:   207       Matching Percent   99.52   Matching Percent   99.52       Similarity:       Identity:       Total Percent   99.52   Total Percent   99.52       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               60   TGAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDK   109           | ||||||||||||||||||||||||||||||||||||||||||||||||       6   TSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDK   55                            .         .         .         .         .       110   QIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSG   159           ||||||||||||||||||||||||||||||||||||||||||||||||||       56   QIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSG   105                            .         .         .         .         .       160   FNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQ   209           ||||||||||||||||||||||||||||||||||||||||||||||||||       106   FNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQ   155                            .         .         .         .         .       210   KKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSS   259           ||||||||||||||||||||||||||||||||||||||||||||||||||       156   KKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSS   205               260   LRALRQM   266           |||||||       206   LRALRQM   212                             Sequence name: IL6_HUMAN (SEQ ID NO:193)                   Sequence documentation:       Alignment of: S56892_PEA_1_P8 (SEQ ID NO:195) ×       IL6_HUMAN (SEQ ID NO:193)   . .               Alignment segment 1/1:                                 Quality:   1526.00   Escore:   0           Matching length:   157   Total length:   157       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS   50                            .         .         .         .         .       51   ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG   100                            .         .         .         .         .       101   CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVL   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVL   150               151   IQFLQKK   157           |||||||       151   IQFLQKK   157                             Sequence name: IL6_HUMAN (SEQ ID NO:193)                   Sequence documentation:       Alignment of: S56892_PEA_1_P9 (SEQ ID NO:196) ×       IL6_HUMAN (SEQ ID NO:193)   . .               Alignment segment 1/1:                                 Quality:   1490.00   Escore:   0           Matching length:   163   Total length:   212       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   76.89   Total Percent   76.89       Similarity:       Identity:       Gaps:   1                             Alignment:                                              .         .         .         .         .               1   MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS   50                            .         .         .         .         .       51   ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG   100                            .         .         .         .         .       101   CFQSGFNE..........................................   108           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVL   150                            .         .         .         .         .       109   .......AKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKE   151           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   IQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKE   200                            .       152   FLQSSLRALRQM   163           ||||||||||||       201   FLQSSLRALRQM   212                             Sequence name: IL6_HUMAN (SEQ ID NO:193)                   Sequence documentation:       Alignment of: S56892_PEA_1_P11 (SEQ ID NO:197) ×       IL6_HUMAN (SEQ ID NO:193)   . .               Alignment segment 1/1:                                 Quality:   733.00   Escore:   0           Matching length:   77   Total length:   77       Matching Percent   100.00   Matching Percent   98.70       Similarity:       Identity:       Total Percent   100.00   Total Percent   98.70       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS   50                            .         .       51   ERIDKQIRYILDGISALRKETCNKSNI   77           ||||||||||||||||||||||||||||       51   ERIDKQIRYILDGISALRKETCNKSNM   77          
 
     Description for Cluster HSIGFACI  
      Cluster HSIGFACI features 6 transcript(s) and 16 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       HSIGFACI_PEA_1_T9   198           HSIGFACI_PEA_1_T10   199           HSIGFACI_PEA_1_T12   200           HSIGFACI_PEA_1_T15   201           HSIGFACI_PEA_1_T16   202           HSIGFACI_PEA_1_T17   203                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 HSIGFACI_PEA_1_node_0 
                 204 
               
               
                   
                 HSIGFACI_PEA_1_node_2 
                 205 
               
               
                   
                 HSIGFACI_PEA_1_node_6 
                 206 
               
               
                   
                 HSIGFACI_PEA_1_node_9 
                 207 
               
               
                   
                 HSIGFACI_PEA_1_node_11 
                 208 
               
               
                   
                 HSIGFACI_PEA_1_node_14 
                 209 
               
               
                   
                 HSIGFACI_PEA_1_node_19 
                 210 
               
               
                   
                 HSIGFACI_PEA_1_node_20 
                 211 
               
               
                   
                 HSIGFACI_PEA_1_node_21 
                 212 
               
               
                   
                 HSIGFACI_PEA_1_node_24 
                 213 
               
               
                   
                 HSIGFACI_PEA_1_node_25 
                 214 
               
               
                   
                 HSIGFACI_PEA_1_node_26 
                 215 
               
               
                   
                 HSIGFACI_PEA_1_node_27 
                 216 
               
               
                   
                 HSIGFACI_PEA_1_node_13 
                 217 
               
               
                   
                 HSIGFACI_PEA_1_node_22 
                 218 
               
               
                   
                 HSIGFACI_PEA_1_node_23 
                 219 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                   
                 Sequence 
                   
               
               
                 Protein Name 
                 ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HSIGFACI_PEA_1_P5 
                 225 
                 HSIGFACI_PEA_1_T9 (SEQ 
               
               
                   
                   
                 ID NO: 198) 
               
               
                 HSIGFACI_PEA_1_P2 
                 226 
                 HSIGFACI_PEA_1_T12 
               
               
                   
                   
                 (SEQ ID NO: 200) 
               
               
                 HSIGFACI_PEA_1_P6 
                 227 
                 HSIGFACI_PEA_1_T15 
               
               
                   
                   
                 (SEQ ID NO: 201) 
               
               
                 HSIGFACI_PEA_1_P1 
                 228 
                 HSIGFACI_PEA_1_T16 
               
               
                   
                   
                 (SEQ ID NO: 202) 
               
               
                 HSIGFACI_PEA_1_P7 
                 229 
                 HSIGFACI_PEA_1_T10 
               
               
                   
                   
                 (SEQ ID NO: 199) 
               
               
                 HSIGFACI_PEA_1_P8 
                 230 
                 HSIGFACI_PEA_1_T17 
               
               
                   
                   
                 (SEQ ID NO: 203) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Insulin-like growth factor IB precursor (SEQ ID NO:220) (SwissProt accession identifier IGFB_HUMAN; known also according to the synonyms IGF-IB; Somatomedin C), referred to herein as the previously known protein.  
      Protein Insulin-like growth factor IB precursor (SEQ ID NO:220) is known or believed to have the following function(s): insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. The sequence for protein Insulin-like growth factor IB precursor is given at the end of the application, as “Insulin-like growth factor IB precursor amino acid sequence” (SEQ ID NO:220). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on           amino acid sequence   Comment               187   A -&gt; D (in dbSNP: 6213). /FTId = VAR_013945.                  
 
      Protein Insulin-like growth factor IB precursor (SEQ ID NO:220) localization is believed to be Secreted.  
      The mean serum IGF I levels of controls and early-stage endometriosis patients were significantly lower than those in the late stage of endometrosis (Gurgan et al, J Reprod Med. 1999 May; 44(5):450-4). Variants of this cluster are suitable as diagnostic markers for endometriosis.  
      The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Amyotrophic lateral sclerosis; Neuropathy; Osteoporosis; Wound healing; Cancer; Diabetes; Neuropathy, diabetic. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Insulin like growth factor 1 agonist; Insulin like growth factor 2 agonist; Insulin like growth factor agonist. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Ophthalmological; Growth hormone; Vulnerary; Osteoporosis treatment; Neuroprotective; Antidiabetic; Nutritional supplement; Antiarthritic; Multiple sclerosis treatment; Neurological; Symptomatic antidiabetic.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: skeletal development; DNA replication; cell motility; signal transduction; RAS protein signal transduction; muscle development; physiological processes; positive control of cell proliferation; glycolate metabolism, which are annotation(s) related to Biological Process; insulin-like growth factor receptor ligand; hormone; growth factor, which are annotation(s) related to Molecular Function; and extracellular, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      As noted above, cluster HSIGFACI features 6 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Insulin-like growth factor IB precursor (SEQ ID NO:220). A description of each variant protein according to the present invention is now provided.  
      Variant protein HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSIGFACI_PEA — 1_T9 (SEQ ID NO:198). An alignment is given to the known protein (Insulin-like growth factor IB precursor (SEQ ID NO:220)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) and Q9NP10 (SEQ ID NO:222):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPTVK (SEQ ID NO:483) corresponding to amino acids 1-7 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), a second amino acid sequence being at least 90% homologous to MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSS SRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK corresponding to amino acids 1-111 of Q9NP10 (SEQ ID NO:222), which also corresponds to amino acids 8-118 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) corresponding to amino acids 119-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPTVK (SEQ ID NO:483) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      3. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      Comparison report between HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) and Q13429 (SEQ ID NO:224):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKYQP PSTNKNTKSQRRKGSTFEERK corresponding to amino acids 3-139 of Q13429 (SEQ ID NO:224), which also corresponds to amino acids 6-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      Comparison report between HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) and IGFB_HUMAN (SEQ ID NO:220):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKYQP PSTNKNTKSQRRKG corresponding to amino acids 22-151 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 6-135 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence STFEERK corresponding to amino acids 136-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      3. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence STFEERK in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      Comparison report between HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) and Q14620 (SEQ ID NO:221):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 90% homologous to MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNK PTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQ K corresponding to amino acids 1-118 of Q14620 (SEQ ID NO:221), which also corresponds to amino acids 1-118 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) corresponding to amino acids 119-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HSIGFACI_PEA_L P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      Comparison report between HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) and IGFA_HUMAN (SEQ ID NO:223):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK corresponding to amino acids 22-134 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 6-118 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) corresponding to amino acids 119-142 of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      3. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P5 (SEQ ID NO:225), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGSTFEERK (SEQ ID NO:484) in HSIGFACI_PEA — 1_P5 (SEQ ID NO:225).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 5                          Amino acid mutations                         SNP position(s) on amino acid   Alternative           sequence   amino acid(s)   Previously known SNP?               28   S -&gt; N   No                  
 
      Variant protein HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) is encoded by the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) is shown in bold; this coding portion starts at position 835 and ends at position 1260. Transcript also has the following SNPs as listed in Table 6 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P5 (SEQ ID NO:225) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 6                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative           sequence   nucleic acid   Previously known SNP?                                 917   G -&gt; A   No       942   G -&gt; A   Yes       1071   C -&gt; T   Yes       1324   G -&gt; A   Yes       1403   A -&gt; G   Yes       1450   A -&gt;   Yes       1558   A -&gt; T   Yes       1642   C -&gt; G   Yes       1905   T -&gt; A   Yes       2050   A -&gt;   Yes       2068   T -&gt; C   Yes       2081   A -&gt; C   Yes       2139   A -&gt; T   Yes       2221   T -&gt; A   Yes       2453   G -&gt; T   Yes       2500   T -&gt; A   Yes       2518   G -&gt; C   Yes       2834   G -&gt; A   Yes       3015   T -&gt; G   Yes       3021   C -&gt; G   Yes       3021   C -&gt; T   Yes       3050   C -&gt; A   Yes       3067   T -&gt; C   Yes       3246   T -&gt; A   Yes       3563   T -&gt; G   Yes       3662   A -&gt; G   Yes       3797   T -&gt; G   Yes       3950   T -&gt; C   Yes       4014   G -&gt; A   Yes       4284   T -&gt; G   Yes       4421   A -&gt; G   Yes       4524   C -&gt; G   No       4547   T -&gt; G   Yes       4690   C -&gt; T   Yes       5010   G -&gt; A   Yes       5018   G -&gt; A   Yes       5027   G -&gt; A   Yes       5239   C -&gt; T   Yes       5267   T -&gt; G   Yes       5273   A -&gt; G   Yes       5311   G -&gt; A   Yes       5713   T -&gt; G   Yes       5729   A -&gt; T   Yes       5735   T -&gt; A   Yes       5839   T -&gt; C   Yes       5855   G -&gt; C   Yes       6061   G -&gt; C   Yes       6505   T -&gt; G   Yes       6573   T -&gt; G   Yes       6689   T -&gt; C   Yes       6764   G -&gt; A   Yes       6808   A -&gt; T   Yes       6853   T -&gt; G   Yes       6912   G -&gt; A   Yes       6974   T -&gt; G   Yes       6982   G -&gt; T   Yes       7205   T -&gt; G   No       7396   G -&gt; A   Yes       7475   C -&gt; T   Yes       7614   T -&gt; C   Yes       7687   C -&gt; T   Yes       7736   G -&gt; C   Yes       7810   C -&gt; A   Yes       7825   T -&gt; G   Yes                  
 
      Variant protein HSIGFACI_PEA — 1_P2 (SEQ ID NO:226) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSIGFACI_PEA — 1_T12 (SEQ ID NO:200). An alignment is given to the known protein (Insulin-like growth factor IB precursor (SEQ ID NO:220)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSIGFACI_PEA — 1_P2 (SEQ ID NO:226) and IGFA_HUMAN (SEQ ID NO:223):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), and a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYFNKPTGY GSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQKEVH LKNASRGSAGNKNYRM (SEQ ID NO:487) corresponding to amino acids 22-153 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 6-137 of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P2 (SEQ ID NO:226).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSIGFACI_PEA — 1_P2 (SEQ ID NO:226) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P2 (SEQ ID NO:226) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Amino acid mutations                         SNP position(s) on amino acid   Alternative           sequence   amino acid(s)   Previously known SNP?               28   S -&gt; N   No                  
 
      Variant protein HSIGFACI_PEA — 1_P2 (SEQ ID NO:226) is encoded by the following transcript(s): HSIGFACI_PEA — 1_T12 (SEQ ID NO:200), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSIGFACI_PEA — 1_T12 (SEQ ID NO:200) is shown in bold; this coding portion starts at position 835 and ends at position 1245. The transcript also has the following SNPs as listed in Table 8 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P2 (SEQ ID NO:226) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 8                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative           sequence   nucleic acid   Previously known SNP?                                 917   G -&gt; A   No       942   G -&gt; A   Yes       1071   C -&gt; T   Yes       1275   G -&gt; A   Yes       1354   A -&gt; G   Yes       1401   A -&gt;   Yes                  
 
      Variant protein HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSIGFACI_PEA — 1_T15 (SEQ ID NO:201). An alignment is given to the known protein (Insulin-like growth factor IB precursor (SEQ ID NO:220)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227) and IGFA_HUMAN (SEQ ID NO:223):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELV DALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKS ARSVRAQRHTDMPKTQK corresponding to amino acids 1-134 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 1-134 of HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence YQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGK KGK (SEQ ID NO:486) corresponding to amino acids 135-195 of HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence YQPPSTNKNTKSQRRKGWPKTHPGGEQKEGTEASLQIRGKKKEQRREIGSRNAECRGK KGK (SEQ ID NO:486) in HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 9                          Amino acid mutations                         SNP position(s) on amino acid   Alternative           sequence   amino acid(s)   Previously known SNP?                                 2   G -&gt; E   Yes       44   S -&gt; N   No       187   A -&gt; D   Yes                  
 
      Variant protein HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227) is encoded by the following transcript(s): HSIGFACI_PEA — 1_T15 (SEQ ID NO:201), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSIGFACI_PEA — 1_T15 (SEQ ID NO:201) is shown in bold; this coding portion starts at position 266 and ends at position 850. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P6 (SEQ ID NO: 227) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative           sequence   nucleic acid   Previously known SNP?                                 254   A -&gt; T   Yes       270   G -&gt; A   Yes       396   G -&gt; A   No       421   G -&gt; A   Yes       550   C -&gt; T   Yes       825   C -&gt; A   Yes       1210   T -&gt; C   Yes       1351   C -&gt; T   No                  
 
      Variant protein HSIGFACI_PEA — 1_P1 (SEQ ID NO:228) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSIGFACI_PEA — 1_T16 (SEQ ID NO:202). An alignment is given to the known protein (Insulin-like growth factor IB precursor (SEQ ID NO:220)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSIGFACI_PEA — 1_P1 (SEQ ID NO:228) and IGFB_HUMAN (SEQ ID NO:220):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELV DALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKS ARSVRAQRHTDMPKTQK corresponding to amino acids 1-134 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 1-134 of HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence EVHLKNASRGSAGNKNYRM (SEQ ID NO:487) corresponding to amino acids 135-153 of HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P1 (SEQ ID NO:228), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence EVHLKNASRGSAGNKNYRM (SEQ ID NO:487) in HSIGFACI_PEA — 1_P1 (SEQ ID NO:228).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSIGFACI_PEA — 1_P1 (SEQ ID NO:228) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 11, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P1 (SEQ ID NO:228) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 11                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 2   G -&gt; E   Yes       44   S -&gt; N   No                  
 
      Variant protein HSIGFACI_PEA — 1_P1 (SEQ ID NO:228) is encoded by the following transcript(s): HSIGFACI_PEA — 1_T16 (SEQ ID NO:202), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSIGFACI_PEA — 1_T16 (SEQ ID NO:202) is shown in bold; this coding portion starts at position 266 and ends at position 724. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P1 (SEQ ID NO:228) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 12                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?               254   A -&gt; T   Yes       270   G -&gt; A   Yes       396   G -&gt; A   No       421   G -&gt; A   Yes       550   C -&gt; T   Yes       754   G -&gt; A   Yes       833   A -&gt; G   Yes       880   A -&gt;   Yes                  
 
      Variant protein HSIGFACI_PEA — 1_P7 (SEQ ID NO:229) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). An alignment is given to the known protein (Insulin-like growth factor IB precursor (SEQ ID NO:220)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSIGFACI_PEA — 1_P7 (SEQ ID NO:229) and IGFB_HUMAN (SEQ ID NO:220):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELV DALQFVCGDRGFYF corresponding to amino acids 1-73 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 1-73 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 74-108 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P7 (SEQ ID NO:229).  
      Comparison report between HSIGFACI_PEA — 1_P7 (SEQ ID NO:229) and IGFA_HUMAN (SEQ ID NO:223):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a first amino acid sequence being at least 90% homologous to MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELV DALQFVCGDRGFYF corresponding to amino acids 1-73 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 1-73 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 74-108 of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P7 (SEQ ID NO:229), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P7 (SEQ ID NO:229).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSIGFACI_PEA — 1_P7 (SEQ ID NO:229) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P7 (SEQ ID NO:229) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 13                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                2   G -&gt; E   Yes       44   S -&gt; N   No                  
 
      Variant protein HSIGFACI_PEA — 1_P7 (SEQ ID NO:229) is encoded by the following transcript(s): HSIGFACI_PEA — 1_T10 (SEQ ID NO:199), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSIGFACI_PEA — 1_T10 (SEQ ID NO:199) is shown in bold; this coding portion starts at position 266 and ends at position 589. The transcript also has the following SNPs as listed in Table 14 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P7 (SEQ ID NO:229) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 14                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 254   A -&gt; T   Yes       270   G -&gt; A   Yes       396   G -&gt; A   No       421   G -&gt; A   Yes       687   G -&gt; A   Yes       810   A -&gt; G   Yes       850   A -&gt; C   Yes       853   G -&gt; A   Yes       859   A -&gt; C   Yes       909   C -&gt; T   Yes       1096   C -&gt; T   Yes       1300   G -&gt; A   Yes       1379   A -&gt; G   Yes       1426   A -&gt;   Yes       1534   A -&gt; T   Yes       1618   C -&gt; G   Yes       1881   T -&gt; A   Yes       2026   A -&gt;   Yes       2044   T -&gt; C   Yes       2057   A -&gt; C   Yes       2115   A -&gt; T   Yes       2197   T -&gt; A   Yes       2429   G -&gt; T   Yes       2476   T -&gt; A   Yes       2494   G -&gt; C   Yes       2810   G -&gt; A   Yes       2991   T -&gt; G   Yes       2997   C -&gt; G   Yes       2997   C -&gt; T   Yes       3026   C -&gt; A   Yes       3043   T -&gt; C   Yes       3222   T -&gt; A   Yes       3539   T -&gt; G   Yes       3638   A -&gt; G   Yes       3773   T -&gt; G   Yes       3926   T -&gt; C   Yes       3990   G -&gt; A   Yes       4260   T -&gt; G   Yes       4397   A -&gt; G   Yes       4500   C -&gt; G   No       4523   T -&gt; G   Yes       4666   C -&gt; T   Yes       4986   G -&gt; A   Yes       4994   G -&gt; A   Yes       5003   G -&gt; A   Yes       5215   C -&gt; T   Yes       5243   T -&gt; G   Yes       5249   A -&gt; G   Yes       5287   G -&gt; A   Yes       5689   T -&gt; G   Yes       5705   A -&gt; T   Yes       5711   T -&gt; A   Yes       5815   T -&gt; C   Yes       5831   G -&gt; C   Yes       6037   G -&gt; C   Yes       6481   T -&gt; G   Yes       6549   T -&gt; G   Yes       6665   T -&gt; C   Yes       6740   G -&gt; A   Yes       6784   A -&gt; T   Yes       6829   T -&gt; G   Yes       6888   G -&gt; A   Yes       6950   T -&gt; G   Yes       6958   G -&gt; T   Yes       7181   T -&gt; G   No       7372   G -&gt; A   Yes       7451   C -&gt; T   Yes       7590   T -&gt; C   Yes       7663   C -&gt; T   Yes       7712   G -&gt; C   Yes       7786   C -&gt; A   Yes       7801   T -&gt; G   Yes                  
 
      Variant protein HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSIGFACI_PEA — 1_T17 (SEQ ID NO:203). An alignment is given to the known protein (Insulin-like growth factor IB precursor (SEQ ID NO:220)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) and Q9NP10 (SEQ ID NO:222):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPTVK (SEQ ID NO:483) corresponding to amino acids 1-7 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 1-50 of Q9NP10 (SEQ ID NO:222), which also corresponds to amino acids 8-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPTVK (SEQ ID NO:483) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      3. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      Comparison report between HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) and Q13429 (SEQ ID NO:224):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 3-54 of Q13429 (SEQ ID NO:224), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      3. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      Comparison report between HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) and Q14620 (SEQ ID NO:221):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 90% homologous to MITPTVKMHTMSSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 1-57 of Q14620 (SEQ ID NO:221), which also corresponds to amino acids 1-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      Comparison report between HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) and IGFB_HUMAN (SEQ ID NO:220):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 22-73 of IGFB_HUMAN (SEQ ID NO:220), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      3. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      Comparison report between HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) and IGFA_HUMAN (SEQ ID NO:223):  
      1. An isolated chimeric polypeptide encoding for HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a first amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence MITPT (SEQ ID NO:485) corresponding to amino acids 1-5 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), a second amino acid sequence being at least 90% homologous to VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF corresponding to amino acids 22-73 of IGFA_HUMAN (SEQ ID NO:223), which also corresponds to amino acids 6-57 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), and a third amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) corresponding to amino acids 58-92 of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a head of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence MITPT (SEQ ID NO:485) of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      3. An isolated polypeptide encoding for a tail of HSIGFACI_PEA — 1_P8 (SEQ ID NO:230), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SRKILLKLRSSVARCSGSLLKFQQFERPRQENCLS (SEQ ID NO:488) in HSIGFACI_PEA — 1_P8 (SEQ ID NO:230).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 15                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?               28   S -&gt; N   No                  
 
      Variant protein HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) is encoded by the following transcript(s): HSIGFACI_PEA — 1_T17 (SEQ ID NO:203), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSIGFACI_PEA — 1_T17 (SEQ ID NO:203) is shown in bold; this coding portion starts at position 835 and ends at position 1110. The transcript also has the following SNPs as listed in Table 16 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSIGFACI_PEA — 1_P8 (SEQ ID NO:230) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 16                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 917   G -&gt; A   No       942   G -&gt; A   Yes       1208   G -&gt; A   Yes       1331   A -&gt; G   Yes       1371   A -&gt; C   Yes       1374   G -&gt; A   Yes       1380   A -&gt; C   Yes       1430   C -&gt; T   Yes       1617   C -&gt; T   Yes       1892   C -&gt; A   Yes       2277   T -&gt; C   Yes       2418   C -&gt; T   No                  
 
      As noted above, cluster HSIGFACI features 16 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HSIGFACI_PEA — 1_node — 0 (SEQ ID NO:204) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T10 (SEQ ID NO:199), HSIGFACI_PEA — 1_T15 (SEQ ID NO:201) and HSIGFACI_PEA — 1_T16 (SEQ ID NO:202). Table 17 below describes the starting and ending position of this segment on each transcript.  
               TABLE 17                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HSIGFACI_PEA_1_T10 (SEQ ID   1   328       NO: 199)       HSIGFACI_PEA_1_T15 (SEQ ID   1   328       NO: 201)       HSIGFACI_PEA_1_T16 (SEQ ID   1   328       NO: 202)                  
 
      Segment cluster HSIGFACI_PEA — 1_node — 2 (SEQ ID NO:205) according to the present invention is supported by 14 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198), HSIGFACI_PEA — 1_T12 (SEQ ID NO:200) and HSIGFACI_PEA — 1_T17 (SEQ ID NO:203). Table 18 below describes the starting and ending position of this segment on each transcript.  
               TABLE 18                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HSIGFACI_PEA_1_T9 (SEQ ID   1   849       NO: 198)       HSIGFACI_PEA_1_T12 (SEQ ID   1   849       NO: 200)       HSIGFACI_PEA_1_T17 (SEQ ID   1   849       NO: 203)                  
 
      Segment cluster HSIGFACI_PEA — 1_node — 6 (SEQ ID NO:206) according to the present invention is supported by 62 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198), HSIGFACI_PEA — 1_T10 (SEQ ID NO:199), HSIGFACI_PEA — 1_T12 (SEQ ID NO:200), HSIGFACI_PEA — 1_T15 (SEQ ID NO:201), HSIGFACI_PEA — 1_T16 (SEQ ID NO:202) and HSIGFACI_PEA — 1_T17 (SEQ ID NO:203). Table 19 below describes the starting and ending position of this segment on each transcript.  
               TABLE 19                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HSIGFACI_PEA_1_T9 (SEQ ID   850   1006       NO: 198)       HSIGFACI_PEA_1_T10 (SEQ ID   329   485       NO: 199)       HSIGFACI_PEA_1_T12 (SEQ ID   850   1006       NO: 200)       HSIGFACI_PEA_1_T15 (SEQ ID   329   485       NO: 201)       HSIGFACI_PEA_1_T16 (SEQ ID   329   485       NO: 202)       HSIGFACI_PEA_1_T17 (SEQ ID   850   1006       NO: 203)                  
 
      Segment cluster HSIGFACI_PEA — 1_node — 9 (SEQ ID NO:207) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T10 (SEQ ID NO:199) and HSIGFACI_PEA — 1_T17 (SEQ ID NO:203). Table 20 below describes the starting and ending position of this segment on each transcript.  
               TABLE 20                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HSIGFACI_PEA_1_T10 (SEQ ID   486   1031       NO: 199)       HSIGFACI_PEA_1_T17 (SEQ ID   1007   1552       NO: 203)                  
 
      Segment cluster HSIGFACI_PEA — 1_node — 11 (SEQ ID NO:208) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198), HSIGFACI_PEA — 1_T10 (SEQ ID NO:199), HSIGFACI_PEA — 1_T12 (SEQ ID NO:200), HSIGFACI_PEA — 1_T15 (SEQ ID NO:201), HSIGFACI_PEA — 1_T16 (SEQ ID NO:202) and HSIGFACI_PEA — 1_T17 (SEQ ID NO:203). Table 21 below describes the starting and ending position of this segment on each transcript.  
               TABLE 21                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HSIGFACI_PEA_1_T9 (SEQ ID   1007   1188           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   1032   1213           NO: 199)           HSIGFACI_PEA_1_T12 (SEQ ID   1007   1188           NO: 200)           HSIGFACI_PEA_1_T15 (SEQ ID   486   667           NO: 201)           HSIGFACI_PEA_1_T16 (SEQ ID   486   667           NO: 202)           HSIGFACI_PEA_1_T17 (SEQ ID   1553   1734           NO: 203)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 14 (SEQ ID NO:209) according to the present invention is supported by 22 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T15 (SEQ ID NO:201) and HSIGFACI_PEA — 1_T17 (SEQ ID NO:203). Table 22 below describes the starting and ending position of this segment on each transcript.  
               TABLE 22                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HSIGFACI_PEA_1_T15 (SEQ ID   717   1681           NO: 201)           HSIGFACI_PEA_1_T17 (SEQ ID   1784   2748           NO: 203)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 19 (SEQ ID NO:210) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198), HSIGFACI_PEA — 1_TIO (SEQ ID NO:199), HSIGFACI_PEA — 1_T12 (SEQ ID NO:200) and HSIGFACI_PEA — 1_T16 (SEQ ID NO:202). Table 23 below describes the starting and ending position of this segment on each transcript.  
               TABLE 23                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HSIGFACI_PEA_1_T9 (SEQ ID   1238   5030           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   1214   5006           NO: 199)           HSIGFACI_PEA_1_T12 (SEQ ID   1189   1406           NO: 200)           HSIGFACI_PEA_1_T16 (SEQ ID   668   885           NO: 202)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 20 (SEQ ID NO:211) according to the present invention is supported by 10 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 24 below describes the starting and ending position of this segment on each transcript.  
               TABLE 24                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HSIGFACI_PEA_1_T9 (SEQ ID   5031   5198           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   5007   5174           NO: 199)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 21 (SEQ ID NO:212) according to the present invention is supported by 57 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 25 below describes the starting and ending position of this segment on each transcript.  
               TABLE 25                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HSIGFACI_PEA_1_T9 (SEQ ID   5199   7012           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   5175   6988           NO: 199)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 24 (SEQ ID NO:213) according to the present invention is supported by 57 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 26 below describes the starting and ending position of this segment on each transcript.  
               TABLE 26                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HSIGFACI_PEA_1_T9 (SEQ ID   7071   7396           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   7047   7372           NO: 199)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 25 (SEQ ID NO:214) according to the present invention is supported by 54 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 27 below describes the starting and ending position of this segment on each transcript.  
               TABLE 27                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HSIGFACI_PEA_1_T9 (SEQ ID   7397   7557           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   7373   7533           NO: 199)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 26 (SEQ ID NO:215) according to the present invention is supported by 51 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 28 below describes the starting and ending position of this segment on each transcript.  
               TABLE 28                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HSIGFACI_PEA_1_T9 (SEQ ID   7558   7783           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   7534   7759           NO: 199)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 27 (SEQ ID NO:216) according to the present invention is supported by 37 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 29 below describes the starting and ending position of this segment on each transcript.  
               TABLE 29                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                       HSIGFACI_PEA_1_T9 (SEQ ID   7784   7935           NO: 198)           HSIGFACI_PEA_1_T10 (SEQ ID   7760   7911           NO: 199)                      
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HSIGFACI_PEA — 1_node — 13 (SEQ ID NO:217) according to the present invention is supported by 17 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198), HSIGFACI_PEA — 1_T15 (SEQ ID NO:201) and HSIGFACI_PEA — 1_T17 (SEQ ID NO:203). Table 30 below describes the starting and ending position of this segment on each transcript.  
               TABLE 30                          Segment location on transcripts                                     Segment   Segment               starting   ending           Transcript name   position   position                                             HSIGFACI_PEA_1_T9 (SEQ ID   1189   1237           NO: 198)           HSIGFACI_PEA_1_T15 (SEQ ID   668   716           NO: 201)           HSIGFACI_PEA_1_T17 (SEQ ID   1735   1783           NO: 203)                      
 
      Segment cluster HSIGFACI_PEA — 1_node — 22 (SEQ ID NO:218) according to the present invention is supported by 23 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 31 below describes the starting and ending position of this segment on each transcript.  
               TABLE 31                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSIGFACI_PEA_1_T9 (SEQ ID   7013   7045       NO: 198)       HSIGFACI_PEA_1_T10 (SEQ ID   6989   7021       NO: 199)                  
 
      Segment cluster HSIGFACI_PEA — 1_node — 23 (SEQ ID NO:219) according to the present invention can be found in the following transcript(s): HSIGFACI_PEA — 1_T9 (SEQ ID NO:198) and HSIGFACI_PEA — 1_T10 (SEQ ID NO:199). Table 32 below describes the starting and ending position of this segment on each transcript.  
               TABLE 32                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSIGFACI_PEA_1_T9 (SEQ ID   7046   7070       NO: 198)       HSIGFACI_PEA_1_T10 (SEQ ID   7022   7046       NO: 199)                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: Q9NP10 (SEQ ID NO:222)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P5 (SEQ ID NO:225) ×       Q9NP10 (SEQ ID NO:222)   . .               Alignment segment 1/1:                                 Quality:   1107.00   Escore:   0           Matching length:   111   Total length:   111       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               8   MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF   57           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF   50                            .         .         .         .         .       58   NKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRA   107           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   NKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSVRA   100                            .       108   QRHTDMPKTQK   118           |||||||||||       101   QRHTDMPKTQK   111                             Sequence name: Q13429 (SEQ ID NO:224)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P5 (SEQ ID NO:225) ×       Q13429 (SEQ ID NO:224)   . .               Alignment segment 1/1:                                 Quality:   1369.00   Escore:   0           Matching length:   137   Total length:   137       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               6   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   55           ||||||||||||||||||||||||||||||||||||||||||||||||||       3   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   52                            .         .         .         .         .       56   YFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   105           ||||||||||||||||||||||||||||||||||||||||||||||||||       53   YFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   102                            .         .         .       106   RAQRHTDMPKTQKYQPPSTNKNTKSQRRKGSTFEERK   142           |||||||||||||||||||||||||||||||||||||       103   RAQRHTDMPKTQKYQPPSTNKNTKSQRRKGSTFEERK   139                             Sequence name: IGFB_HUMAN (SEQ ID NO:220)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P5 (SEQ ID NO:225) ×       IGFB_HUMAN (SEQ ID NO:220)   . .               Alignment segment 1/1:                                 Quality:   1300.00   Escore:   0           Matching length:   130   Total length:   130       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               6   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   55           ||||||||||||||||||||||||||||||||||||||||||||||||||       22   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   71                            .         .         .         .         .       56   YFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   105           ||||||||||||||||||||||||||||||||||||||||||||||||||       72   YFNFPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   121                            .         .         .       106   RAQRHTDMPKTQKYQPPSTNKNTKSQRRKG   135           |||||||||||||||||||||||||||||       122   RAQRHTDMPKTQKYQPPSTNKNTKSQRRKG   151                             Sequence name: Q14620 (SEQ ID NO:221)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P5 (SEQ ID NO:225) ×       Q14620 (SEQ ID NO:221)   . .               Alignment segment 1/1:                                 Quality:   1175.00   Escore:   0           Matching length:   118   Total length:   118       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVC   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVC   50                            .         .         .         .         .       51   GDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAK   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   GDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAK   100                            .       101   SARSVRAQRHTDMPKTQK   118           ||||||||||||||||||       101   SARSVRAQRHTDMPKTQK   118                             Sequence name: IGFA_HUMAN (SEQ ID NO:223)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P5 (SEQ ID NO:225) ×       IGFA_HUMAN (SEQ ID NO:223)   . .               Alignment segment 1/1:                                 Quality:   1125.00   Escore:   0           Matching length:   113   Total length:   113       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               6   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   55           ||||||||||||||||||||||||||||||||||||||||||||||||||       22   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   71                            .         .         .         .         .       56   YFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   105           ||||||||||||||||||||||||||||||||||||||||||||||||||       72   YFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   121                            .       106   RAQRHTDMPKTQK   118           |||||||||||||       122   RAQRHTDMPKTQK   134                             Sequence name: IGFA_HUMAN (SEQ ID NO:223)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P2 (SEQ ID NO:226) ×       IGFA_HUMAN (SEQ ID NO:223)   . .               Alignment segment 1/1:                                 Quality:   1313.00   Escore:   0           Matching length:   132   Total length:   132       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               6   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF 55           ||||||||||||||||||||||||||||||||||||||||||||||||||       22   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   71                            .         .         .         .         .       56   YFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   105           ||||||||||||||||||||||||||||||||||||||||||||||||||       72   YFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSARSV   121                            .         .         .       106   RAQRHTDMPKTQKEVHLKNASRGSAGNKNYRM   137           ||||||||||||||||||||||||||||||||       122   RAQRHTDMPKTQKEVHLKNASRGSAGNKNYRM   153                             Sequence name: IGFA_HUMAN (SEQ ID NO:223)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_26 (SEQ ID NO: 227) ×       IGFA_HUMAN (SEQ ID NO:223)   . .               Alignment segment 1/1:                                 Quality:   1343.00   Escore:   0           Matching length:   134   Total length:   134       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50                            .         .         .         .         .       51   ETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSC   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   ETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSC   100                            .         .         .       101   DLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK   134           ||||||||||||||||||||||||||||||||||       101   DLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK   134                             Sequence name: IGFB_HUMAN (SEQ ID NO:220)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P1 (SEQ ID NO:228) ×       IGFB HUMAN (SEQ ID NO:220)   . .               Alignment segment 1/1:                                 Quality:   1343.00   Escore:   0           Matching length:   134   Total length:   134       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50                            .         .         .         .         .       51   ETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSC   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   ETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSC   100                            .         .         .       101   DLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK   134           ||||||||||||||||||||||||||||||||||       101   DLRRLEMYCAPLKPAKSARSVRAQRHTDMPKTQK   134                             Sequence name: IGFB_HUMAN (SEQ ID NO:220)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P7 (SEQ ID NO:229) ×       IGFB HUMAN (SEQ ID NO:220)   . .               Alignment segment 1/1:                                 Quality:   729.00   Escore:   0           Matching length:   75   Total length:   75       Matching Percent   100.00   Matching Percent   97.33       Similarity:       Identity:       Total Percent   100.00   Total Percent   97.33       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50                            .         .       51   ETLCGAELVDALQFVCGDRGFYFSR   75           |||||||||||||||||||||||::       51   ETLCGAELVDALQFVCGDRGFYFNK   75                             Sequence name: IGFA_HUMAN (SEQ ID NO:223)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P7 (SEQ ID NO:229) ×       IGFA HUMAN (SEQ ID NO:223)   . .               Alignment segment 1/1:                                 Quality:   729.00   Escore:   0           Matching length:   75   Total length:   75       Matching Percent   100.00   Matching Percent   97.33       Similarity:       Identity:       Total Percent   100.00   Total Percent   97.33       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MGKISSLPTQLFKCCFCDFLKVKMHTMSSSHLFYLALCLLTFTSSATAGP   50                            .         .       51   ETLCGAELVDALQFVCGDRGFYFSR   75           |||||||||||||||||||||||||       51   ETLCGAELVDALQFVCGDRGFYFNK   75                             Sequence name: Q9NP10 (SEQ ID NO:222)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P8 (SEQ ID NO:230) ×       Q9NP10 (SEQ ID NO:222)               Alignment segment 1/1:                                 Quality:   493.00   Escore:   0           Matching length:   52   Total length:   52       Matching Percent   100.00   Matching Percent   96.15       Similarity:       Identity:       Total Percent   100.00   Total Percent   96.15       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               8   MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF   57           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGFYF   50               58   YFSR   59           ||::       51   YFNK   52                             Sequence name: Q13429 (SEQ ID NQ:224)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P8 (SEQ ID NO:230) ×       Q13429 (SEQ ID NO:224)   . .               Alignment segment 1/1:                                 Quality:   511.00   Escore:   0           Matching length:   54   Total length:   54       Matching Percent   100.00   Matching Percent   96.30       Similarity:       Identity:       Total Percent   100.00   Total Percent   96.30       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               6   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   55           ||||||||||||||||||||||||||||||||||||||||||||||||||       3   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   52               56   YFSR   59           ||::       53   YFNK   56                             Sequence name: Q14620 (SEQ ID NO:221)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P8 (SEQ ID NO:230) ×       Q14620 (SEQ ID NO:221)   . .               Alignment segment 1/1:                                 Quality:   561.00   Escore:   0           Matching length:   59   Total length:   59       Matching Percent   100.00   Matching Percent   96.61       Similarity:       Identity:       Total Percent   100.00   Total Percent   96.61       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVC   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MITPTVKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVC   50               51   GDRGFYFSR   59           |||||||::       51   GDRGFYFNK   59                             Sequence name: IGFB_HUMAN (SEQ ID NO:220)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P8 (SEQ ID NO:230) ×       IGFB_HUMAN (SEQ ID NO:220)   . .               Alignment segment 1/1:                                 Quality:   511.00   Escore:   0           Matching length:   54   Total length:   54       Matching Percent   100.00   Matching Percent   96.30       Similarity:       Identity:       Total Percent   100.00   Total Percent   96.30       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               6   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   55           ||||||||||||||||||||||||||||||||||||||||||||||||||       22   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   71               56   YFSR   59           ||::       72   YFNK   75                             Sequence name: IGFA_HUMAN (SEQ ID NO:223)                   Sequence documentation:       Alignment of: HSIGFACI_PEA_1_P8 (SEQ ID NO:230) ×       IGFA HUMAN (SEQ ID NO:223)   . .               Alignment segment 1/1:                                 Quality:   511.00   Escore:   0           Matching length:   54   Total length:   54       Matching Percent   100.00   Matching Percent   96.30       Similarity:       Identity:       Total Percent   100.00   Total Percent   96.30       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               6   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   55           ||||||||||||||||||||||||||||||||||||||||||||||||||       22   VKMHTMSSSHLFYLALCLLTFTSSATAGPETLCGAELVDALQFVCGDRGF   71               56   YFSR   59           ||::       72   YFNK   75          
 
     Description for Cluster HSSTROMR  
      Cluster HSSTROMR features 1 transcript(s) and 11 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       HSSTROMR_PEA_1_T3   231                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 HSSTROMR_PEA_1_node_0 
                 232 
               
               
                   
                 HSSTROMR_PEA_1_node_5 
                 233 
               
               
                   
                 HSSTROMR_PEA_1_node_7 
                 234 
               
               
                   
                 HSSTROMR_PEA_1_node_9 
                 235 
               
               
                   
                 HSSTROMR_PEA_1_node_13 
                 236 
               
               
                   
                 HSSTROMR_PEA_1_node_16 
                 237 
               
               
                   
                 HSSTROMR_PEA_1_node_18 
                 238 
               
               
                   
                 HSSTROMR_PEA_1_node_20 
                 239 
               
               
                   
                 HSSTROMR_PEA_1_node_28 
                 240 
               
               
                   
                 HSSTROMR_PEA_1_node_14 
                 241 
               
               
                   
                 HSSTROMR_PEA_1_node_22 
                 242 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                   
                 Sequence 
                   
               
               
                 Protein Name 
                 ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HSSTROMR_PEA_1_P4 
                 244 
                 HSSTROMR_PEA_1_T3 
               
               
                   
                   
                 (SEQ ID NO: 231) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Stromelysin-1 precursor (SEQ ID NO:243) (SwissProt accession identifier MM03_HUMAN; known also according to the synonyms EC 3.4.24.17; Matrix metalloproteinase-3; MMP-3; Transin-1; SL-1), referred to herein as the previously known protein.  
      Protein Stromelysin-1 precursor (SEQ ID NO:243) is known or believed to have the following function(s): can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase. The sequence for protein Stromelysin-1 precursor is given at the end of the application, as “Stromelysin-1 precursor amino acid sequence” (SEQ ID NO:243). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on           amino acid sequence   Comment                             45   K -&gt; E. /FTId = VAR_013090.       420   P -&gt; L                  
 
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: proteolysis and peptidolysis, which are annotation(s) related to Biological Process; stromelysin 1; calcium binding; zinc binding; hydrolase, which are annotation(s) related to Molecular Function; and extracellular matrix; extracellular space, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      This protein was found to be upregulated in endometriosis (Yang et al, Best Pract Res Clin Obstet Gynaecol. 2004 April; 18(2):305-18). Variants of this cluster are suitable for use as diagnostic markers for endometriosis.  
      As noted above, cluster HSSTROMR features 1 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Stromelysin-1 precursor (SEQ ID NO:243). A description of each variant protein according to the present invention is now provided.  
      Variant protein HSSTROMR_PEA — 1_P4 (SEQ ID NO:244) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). An alignment is given to the known protein (Stromelysin-1 precursor (SEQ ID NO:243)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HSSTROMR_PEA — 1_P4 (SEQ ID NO:244) and MM03_HUMAN (SEQ ID NO:243):  
      1. An isolated chimeric polypeptide encoding for HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), comprising a first amino acid sequence being at least 90% homologous to MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLV corresponding to amino acids 1-34 of MM03_HUMAN (SEQ ID NO:243), which also corresponds to amino acids 1-34 of HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), and a second amino acid sequence being at least 90% homologous to QKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVNYTPDLP KDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNVLAHA YAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHS LTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVSTLR GEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQFWAIR GNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEPGFP KQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC corresponding to amino acids 68-477 of MM03_HUMAN (SEQ ID NO:243), which also corresponds to amino acids 35-444 of HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise VQ, having a structure as follows: a sequence starting from any of amino acid numbers 34−x to 34; and ending at any of amino acid numbers 35+((n−2)−x), in which x varies from 0 to n−2.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HSSTROMR_PEA — 1_P4 (SEQ ID NO:244) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 5, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROMR_PEA — 1_P4 (SEQ ID NO:244) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 5                          Amino acid mutations                         SNP position(s) on   Alternative   Previously       amino acid sequence   amino acid(s)   known SNP?                                 29   T -&gt; N   No       38   L -&gt; P   No       38   L -&gt;   No       48   S -&gt; F   No       56   K -&gt;   No       56   K -&gt; N   No       80   H -&gt; P   Yes       147   V -&gt;   No       254   P -&gt; A   No       366   K -&gt;   No       413   F -&gt; L   No       413   F -&gt; V   No       427   P -&gt;   No                  
 
      The glycosylation sites of variant protein HSSTROMR_PEA — 1_P4 (SEQ ID NO:244), as compared to the known protein Stromelysin-1 precursor (SEQ ID NO:243), are described in Table 6 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 6                          Glycosylation site(s)                         Position(s) on known   Present in variant   Position in variant       amino acid sequence   protein?   protein?               120   yes   87                  
 
      Variant protein HSSTROMR_PEA — 1_P4 (SEQ ID NO:244) is encoded by the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HSSTROMR_PEA — 1_T3 (SEQ ID NO:231) is shown in bold; this coding portion starts at position 70 and ends at position 1401. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HSSTROMR_PEA — 1_P4 (SEQ ID NO:244) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative   Previously known       sequence   nucleic acid   SNP?                                 49   A -&gt; G   No       155   C -&gt; A   No       182   T -&gt;   No       182   T -&gt; C   No       212   C -&gt; T   No       237   G -&gt;   No       237   G -&gt; C   No       258   C -&gt; T   Yes       276   C -&gt; G   No       308   A -&gt; C   Yes       509   T -&gt;   No       762   A -&gt; G   Yes       829   C -&gt; G   No       1056   C -&gt; T   Yes       1165   A -&gt;   No       1306   T -&gt; C   No       1306   T -&gt; G   No       1350   A -&gt;   No       1425   A -&gt;   No       1437   T -&gt;   No       1518   C -&gt; T   Yes       1538   C -&gt; T   Yes       1557   G -&gt; A   Yes                  
 
      As noted above, cluster HSSTROMR features 11 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HSSTROMR_PEA — 1_node — 0 (SEQ ID NO:232) according to the present invention is supported by 39 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 8 below describes the starting and ending position of this segment on each transcript.  
               TABLE 8                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   1   174       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 5 (SEQ ID NO:233) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 9 below describes the starting and ending position of this segment on each transcript.  
               TABLE 9                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   175   320       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 7 (SEQ ID NO:234) according to the present invention is supported by 41 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 10 below describes the starting and ending position of this segment on each transcript.  
               TABLE 10                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   321   469       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 9 (SEQ ID NO:235) according to the present invention is supported by 40 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 11 below describes the starting and ending position of this segment on each transcript.  
               TABLE 11                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   470   595       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 13 (SEQ ID NO:236) according to the present invention is supported by 46 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 12 below describes the starting and ending position of this segment on each transcript.  
               TABLE 12                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   596   730       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 16 (SEQ ID NO:237) according to the present invention is supported by 43 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 13 below describes the starting and ending position of this segment on each transcript.  
               TABLE 13                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   761   905       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 18 (SEQ ID NO:238) according to the present invention is supported by 45 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 14 below describes the starting and ending position of this segment on each transcript.  
               TABLE 14                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   906   1039       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 20 (SEQ ID NO:239) according to the present invention is supported by 57 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 15 below describes the starting and ending position of this segment on each transcript.  
               TABLE 15                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   1040   1199       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 28 (SEQ ID NO:240) according to the present invention is supported by 66 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 16 below describes the starting and ending position of this segment on each transcript.  
               TABLE 16                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   1304   1738       NO: 231)                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HSSTROMR_PEA — 1_node — 14 (SEQ ID NO:241) according to the present invention is supported by 42 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 17 below describes the starting and ending position of this segment on each transcript.  
               TABLE 17                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   731   760       NO: 231)                  
 
      Segment cluster HSSTROMR_PEA — 1_node — 22 (SEQ ID NO:242) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HSSTROMR_PEA — 1_T3 (SEQ ID NO:231). Table 18 below describes the starting and ending position of this segment on each transcript.  
               TABLE 18                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HSSTROMR_PEA_1_T3 (SEQ ID   1200   1303       NO: 231)                  
 
      Variant protein alignment to the previously known protein: Sequence name: MM03_HUMAN (SEQ ID NO:243)  
                          Sequence name: MN03_HUMAN (SEQ ID NO:243)                   Sequence documentation:       Alignment of: HSSTROMR_PEA_1_P4 (SEQ ID NO:244) ×       MN03_HUMAN (SEQ ID NO:243)   . .               Alignment segment 1/1:                                 Quality:   4302.00   Escore:   0           Matching length:   444   Total length:   477       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   93.08   Total Percent   93.08       Similarity:       Identity:       Gaps:   1                             Alignment:                                              .         .         .         .         .               1   MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLV................   34           ||||||||||||||||||||||||||||||||||       1   MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQ   50                            .         .         .         .         .       35   .................QKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHF   67                            |||||||||||||||||||||||||||||||||       51   FVRRKDSGPVVKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHF   100                            .         .         .         .         .       68   RTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFS   117           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   RTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKALKVWEEVTPLTFS   150                            .         .         .         .         .       118   RLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDD   167           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   RLYEGEADIMISFAVREHGDFYPFDGPGNVLAHAYAPGPGINGDAHFDDD   200                            .         .         .         .         .       168   EQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFR   217           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   EQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLYHSLTDLTRFR   250                            .         .         .         .         .       218   LSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVS   267           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   LSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVS   300                            .         .         .         .         .       268   TLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKD   317           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   TLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKD   350                            .         .         .         .         .       318   LVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKT   367           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   LVFIFKGNQFWAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKT   400                            .         .         .         .         .       368   YFFVEDKYWRFDEKRNSMEPGFPKQIAEDFFGIDSKIDAVFEEFGFFYFF   417           ||||||||||||||||||||||||||||||||||||||||||||||||||       401   YFFVEDKYWRFDEKRNSMEPGFPKQIAEDFPGIDSKIDAVFEEFGFFYFF   450                            .         .       418   TGSSQLEFDPNAKKVTHTLKSNSWLNC   444           |||||||||||||||||||||||||||       451   TGSSQLEFDPNAKKVTHTLKSNSWLNC   477          
 
     Description for Cluster HUM4COLA  
      Cluster HUM4COLA features 3 transcript(s) and 27 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       HUM4COLA_PEA_1_T1   245           HUM4COLA_PEA_1_T5   246           HUM4COLA_PEA_1_T6   247                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 HUM4COLA_PEA_1_node_0 
                 248 
               
               
                   
                 HUM4COLA_PEA_1_node_2 
                 249 
               
               
                   
                 HUM4COLA_PEA_1_node_4 
                 250 
               
               
                   
                 HUM4COLA_PEA_1_node_7 
                 251 
               
               
                   
                 HUM4COLA_PEA_1_node_11 
                 252 
               
               
                   
                 HUM4COLA_PEA_1_node_19 
                 253 
               
               
                   
                 HUM4COLA_PEA_1_node_40 
                 254 
               
               
                   
                 HUM4COLA_PEA_1_node_41 
                 255 
               
               
                   
                 HUM4COLA_PEA_1_node_8 
                 256 
               
               
                   
                 HUM4COLA_PEA_1_node_9 
                 257 
               
               
                   
                 HUM4COLA_PEA_1_node_10 
                 258 
               
               
                   
                 HUM4COLA_PEA_1_node_12 
                 259 
               
               
                   
                 HUM4COLA_PEA_1_node_13 
                 260 
               
               
                   
                 HUM4COLA_PEA_1_node_16 
                 261 
               
               
                   
                 HUM4COLA_PEA_1_node_17 
                 262 
               
               
                   
                 HUM4COLA_PEA_1_node_22 
                 263 
               
               
                   
                 HUM4COLA_PEA_1_node_23 
                 264 
               
               
                   
                 HUM4COLA_PEA_1_node_24 
                 265 
               
               
                   
                 HUM4COLA_PEA_1_node_25 
                 266 
               
               
                   
                 HUM4COLA_PEA_1_node_26 
                 267 
               
               
                   
                 HUM4COLA_PEA_1_node_27 
                 268 
               
               
                   
                 HUM4COLA_PEA_1_node_29 
                 269 
               
               
                   
                 HUM4COLA_PEA_1_node_30 
                 270 
               
               
                   
                 HUM4COLA_PEA_1_node_32 
                 271 
               
               
                   
                 HUM4COLA_PEA_1_node_33 
                 272 
               
               
                   
                 HUM4COLA_PEA_1_node_36 
                 273 
               
               
                   
                 HUM4COLA_PEA_1_node_37 
                 274 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                   
                 Sequence ID 
                   
               
               
                 Protein Name 
                 No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HUM4COLA_PEA_1_P7 
                 276 
                 HUM4COLA_PEA_1_T6 
               
               
                   
                   
                 (SEQ ID NO: 247) 
               
               
                 HUM4COLA_PEA_1_P14 
                 277 
                 HUM4COLA_PEA_1_T1 
               
               
                   
                   
                 (SEQ ID NO: 245) 
               
               
                 HUM4COLA_PEA_1_P15 
                 278 
                 HUM4COLA_PEA_1_T5 
               
               
                   
                   
                 (SEQ ID NO: 246) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein 92 kDa type IV collagenase precursor (SEQ ID NO:275) (SwissProt accession identifier MM09_HUMAN; known also according to the synonyms EC 3.4.24.35; 92 kDa gelatinase; Matrix metalloproteinase-9; MMP-9; Gelatinase B; GELB), referred to herein as the previously known protein.  
      Protein 92 kDa type IV collagenase precursor (SEQ ID NO:275) is known or believed to have the following function(s): could play a role in bone osteoclastic resorption. The sequence for protein 92 kDa type IV collagenase precursor is given at the end of the application, as “92 kDa type IV collagenase precursor amino acid sequence” (SEQ ID NO:275). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s)           on amino acid           sequence   Comment                             20   A -&gt; V (in dbSNP: 1805088). /FTId = VAR_013780.       82   E -&gt; K (in dbSNP: 1805089). /FTId = VAR_013781.       279   R -&gt; Q (common polymorphism; dbSNP: 17576).           /FTId = VAR_013782.       668   R -&gt; Q (in dbSNP: 17577). /FTId = VAR_014742.       574   P -&gt; R                  
 
      The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Peyronie&#39;s disease; Burns; Glaucoma; Wound healing; Ulcer; Dupuytren&#39;s disease. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: Collagenase stimulant; Metalloproteinase-9 inhibitor; Microbial collagenase inhibitor; T cell stimulant. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Urological; Anticancer; Vulnerary; Musculoskeletal; Antiglaucoma; Neurological; Anti-inflammatory; Diagnostic; Monoclonal antibody, murine.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: proteolysis and peptidolysis, which are annotation(s) related to Biological Process; gelatinase B; collagenase; zinc binding; hydrolase, which are annotation(s) related to Molecular Function; and extracellular matrix; extracellular space, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      For the known protein, mRNA expression in endometriosis was higher than in normal endometrium (Ueda et al, Gynecol Endocrinol. 2002 October; 16(5):391-402). Variants of this cluster are suitable as diagnostic markers for endometriosis.  
      As noted above, cluster HUM4COLA features 3 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein 92 kDa type IV collagenase precursor (SEQ ID NO:275). A description of each variant protein according to the present invention is now provided.  
      Variant protein HUM4COLA_PEA — 1_P7 (SEQ ID NO:276) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). An alignment is given to the known protein (92 kDa type IV collagenase precursor (SEQ ID NO:275)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUM4COLA_PEA — 1_P7 (SEQ ID NO:276) and MM09_HUMAN (SEQ ID NO:275):  
      1. An isolated chimeric polypeptide encoding for HUM4COLA_PEA — 1_P7 (SEQ ID NO:276), comprising a first amino acid sequence being at least 90% homologous to MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVA EMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKW HHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEH GDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHF PFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFP FIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVF PFTFLGKE corresponding to amino acids 1-357 of MM09_HUMAN (SEQ ID NO:275), which also corresponds to amino acids 1-357 of HUM4COLA_PEA — 1_P7 (SEQ ID NO:276), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SSP (SEQ ID NO:481) corresponding to amino acids 358-360 of HUM4COLA_PEA — 1_P7 (SEQ ID NO:276), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUM4COLA PEA — 1_P7 (SEQ ID NO:276), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence SSP (SEQ ID NO:481) in HUM4COLA_PEA — 1_P7 (SEQ ID NO:276).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUM4COLA_PEA — 1_P7 (SEQ ID NO:276) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUM4COLA_PEA — 1_P7 (SEQ ID NO:276) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Amino acid mutations                         SNP position(s) on amino acid   Alternative amino   Previously known       sequence   acid(s)   SNP?                                 6   P -&gt;   No       20   A -&gt;   No       20   A -&gt; V   Yes       65   K -&gt; E   No       82   E -&gt; G   No       82   E -&gt; K   Yes       113   D -&gt;   No       127   N -&gt; K   Yes       160   Y -&gt; *   Yes       165   D -&gt; N   Yes       170   F -&gt;   No       174   E -&gt;   No       190   H -&gt; R   No       205   D -&gt; G   No       222   F -&gt; L   No       229   A -&gt;   No       237   E -&gt;   No       255   W -&gt; R   No       279   R -&gt; Q   Yes       296   G -&gt;   No       306   G -&gt;   No       313   W -&gt;   No                  
 
      The glycosylation sites of variant protein HUM4COLA_PEA — 1_P7 (SEQ ID NO:276), as compared to the known protein 92 kDa type IV collagenase precursor (SEQ ID NO:275), are described in Table 8 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 8                          Glycosylation site(s)                         Position(s) on known amino   Present in variant   Position in variant       acid sequence   protein?   protein?                                 38   yes   38       127   yes   127       120   yes   120                  
 
      Variant protein HUM4COLA_PEA — 1_P7 (SEQ ID NO:276) is encoded by the following transcript(s): HUM4COLA_PEA — 1_T6 (SEQ ID NO:247), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUM4COLA_PEA — 1_T6 (SEQ ID NO:247) is shown in bold; this coding portion starts at position 33 and ends at position 1112. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUM4COLA_PEA — 1_P7 (SEQ ID NO:276) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 9                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative nucleic   Previously known       sequence   acid   SNP?                                 48   C -&gt;   No       91   C -&gt;   No       91   C -&gt; T   Yes       225   A -&gt; G   No       276   G -&gt; A   Yes       277   A -&gt; G   No       371   C -&gt;   No       413   C -&gt; G   Yes       503   T -&gt; C   No       512   C -&gt; G   Yes       525   G -&gt; A   Yes       540   T -&gt;   No       554   G -&gt;   No       601   A -&gt; G   No       646   A -&gt; G   No       698   T -&gt; G   No       713   -&gt; A   No       713   -&gt; T   No       719   C -&gt;   No       743   G -&gt;   No       795   T -&gt; C   No       868   G -&gt; A   Yes       918   G -&gt;   No       948   G -&gt;   No       970   G -&gt;   No       1112   C -&gt; T   Yes       1118   C -&gt; T   Yes       1409   G -&gt;   No       1493   C -&gt; G   Yes       1527   C -&gt; A   No       1566   G -&gt; A   No       1593   A -&gt; C   Yes       1608   G -&gt; A   Yes       1634   G -&gt; A   Yes       1716   C -&gt; A   No       1717   G -&gt; A   No       1775   G -&gt; A   Yes       1794   C -&gt; T   Yes       1854   G -&gt; A   Yes       1899   C -&gt; T   Yes       1914   G -&gt;   No       1935   A -&gt; C   Yes       1952   G -&gt; A   Yes       1992   C -&gt; T   Yes       2042   T -&gt; C   Yes       2086   T -&gt;   No       2086   T -&gt; C   No       2087   T -&gt; A   No       2087   T -&gt; C   No                  
 
      Variant protein HUM4COLA_PEA — 1_P14 (SEQ ID NO:277) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUM4COLA_PEA — 1_T1 (SEQ ID NO:245). An alignment is given to the known protein (92 kDa type IV collagenase precursor (SEQ ID NO:275)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUM4COLA_PEA — 1_P14 (SEQ ID NO:277) and MM09_HUMAN (SEQ ID NO:275):  
      1. An isolated chimeric polypeptide encoding for HUM4COLA_PEA — 1_P14 (SEQ ID NO:277), comprising a first amino acid sequence being at least 90% homologous to MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVA EMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKW HHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEH GDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHF PFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSE corresponding to amino acids 1-274 of MM09_HUMAN (SEQ ID NO:275), which also corresponds to amino acids 1-274 of HUM4COLA_PEA — 1_P14 (SEQ ID NO:277), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence SE corresponding to amino acids 275-276 of HUM4COLA_PEA — 1_P14 (SEQ ID NO:277), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUM4COLA_PEA — 1_P14 (SEQ ID NO:277) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUM4COLA_PEA — 1_P14 (SEQ ID NO:277) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Amino acid mutations                         SNP position(s) on amino acid   Alternative amino   Previously known       sequence   acid(s)   SNP?                                 6   P -&gt;   No       20   A -&gt;   No       20   A -&gt; V   Yes       65   K -&gt; E   No       82   E -&gt; G   No       82   E -&gt; K   Yes       113   D -&gt;   No       127   N -&gt; K   Yes       160   Y -&gt; *   Yes       165   D -&gt; N   Yes       170   F -&gt;   No       174   E -&gt;   No       190   H -&gt; R   No       205   D -&gt; G   No       222   F -&gt; L   No       229   A -&gt;   No       237   E -&gt;   No       255   W -&gt; R   No                  
 
      The glycosylation sites of variant protein HUM4COLA_PEA — 1_P14 (SEQ ID NO:277), as compared to the known protein 92 kDa type IV collagenase precursor (SEQ ID NO:275), are described in Table 11 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 11                          Glycosylation site(s)                         Position(s) on known amino   Present in variant   Position in variant       acid sequence   protein?   protein?                                 38   yes   38       127   yes   127       120   yes   120                  
 
      Variant protein HUM4COLA_PEA — 1_P14 (SEQ ID NO:277) is encoded by the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUM4COLA_PEA — 1_T1 (SEQ ID NO:245) is shown in bold; this coding portion starts at position 33 and ends at position 860. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUM4COLA_PEA — 1_P14 (SEQ ID NO:277) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 12                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative nucleic   Previously known       sequence   acid   SNP?                                 48   C -&gt;   No       91   C -&gt;   No       91   C -&gt; T   Yes       225   A -&gt; G   No       276   G -&gt; A   Yes       277   A -&gt; G   No       371   C -&gt;   No       413   C -&gt; G   Yes       503   T -&gt; C   No       512   C -&gt; G   Yes       525   G -&gt; A   Yes       540   T -&gt;   No       554   G -&gt;   No       601   A -&gt; G   No       646   A -&gt; G   No       698   T -&gt; G   No       713   -&gt; A   No       713   -&gt; T   No       719   C -&gt;   No       743   G -&gt;   No       795   T -&gt; C   No       951   -&gt; A   No       1125   G -&gt; A   Yes       1175   G -&gt;   No       1205   G -&gt;   No       1227   G -&gt;   No       1539   C -&gt;   No       1629   C -&gt; T   Yes       1635   C -&gt; T   Yes       1926   G -&gt;   No       2010   C -&gt; G   Yes       2044   C -&gt; A   No       2083   G -&gt; A   No       2110   A -&gt; C   Yes       2125   G -&gt; A   Yes       2151   G -&gt; A   Yes       2233   C -&gt; A   No       2234   G -&gt; A   No       2292   G -&gt; A   Yes       2311   C -&gt; T   Yes       2371   G -&gt; A   Yes       2416   C -&gt; T   Yes       2431   G -&gt;   No       2452   A -&gt; C   Yes       2469   G -&gt; A   Yes       2509   C -&gt; T   Yes       2559   T -&gt; C   Yes       2603   T -&gt;   No       2603   T -&gt; C   No       2604   T -&gt; A   No       2604   T -&gt; C   No                  
 
      Variant protein HUM4COLA_PEA — 1_P15 (SEQ ID NO:278) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUM4COLA_PEA — 1_T5 (SEQ ID NO:246). An alignment is given to the known protein (92 kDa type IV collagenase precursor (SEQ ID NO:275)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUM4COLA_PEA — 1_P15 (SEQ ID NO:278) and MM09_HUMAN:  
      1. An isolated chimeric polypeptide encoding for HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), comprising a first amino acid sequence being at least 90% homologous to MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVA EMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKW HHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEH GDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGV corresponding to amino acids 1-216 of MM09_HUMAN (SEQ ID NO:275), which also corresponds to amino acids 1-216 of HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GEILSPPGP (SEQ ID NO:482) corresponding to amino acids 217-225 of HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GEILSPPGP (SEQ ID NO:482) in HUM4COLA_PEA — 1_P15 (SEQ ID NO:278).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUM4COLA_PEA — 1_P15 (SEQ ID NO:278) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 13, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUM4COLA_PEA — 1_P15 (SEQ ID NO:278) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 13                          Amino acid mutations                         SNP position(s) on   Alternative amino   Previously       amino acid sequence   acid(s)   known SNP?                                 6   P -&gt;   No       20   A -&gt;   No       20   A -&gt; V   Yes       65   K -&gt; E   No       82   E -&gt; G   No       82   E -&gt; K   Yes       113   D -&gt;   No       127   N -&gt; K   Yes       160   Y -&gt; *   Yes       165   D -&gt; N   Yes       170   F -&gt;   No       174   E -&gt;   No       190   H -&gt; R   No       205   D -&gt; G   No       218   E -&gt; *   Yes                  
 
      The glycosylation sites of variant protein HUM4COLA_PEA — 1_P15 (SEQ ID NO:278), as compared to the known protein 92 kDa type IV collagenase precursor (SEQ ID NO:275), are described in Table 14 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 14                          Glycosylation site(s)                         Position(s) on known   Present in   Position in       amino acid sequence   variant protein?   variant protein?                                 38   yes   38       127   yes   127       120   yes   120                  
 
      Variant protein HUM4COLA_PEA — 1_P15 (SEQ ID NO:278) is encoded by the following transcript(s): HUM4COLA_PEA — 1_T5 (SEQ ID NO:246), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) is shown in bold; this coding portion starts at position 33 and ends at position 707. The transcript also has the following SNPs as listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUM4COLA_PEA — 1_P15 (SEQ ID NO:278) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 15                          Nucleic acid SNPs                         SNP position on   Alternative   Previously       nucleotide sequence   nucleic acid   known SNP?                                 48   C -&gt;   No       91   C -&gt;   No       91   C -&gt; T   Yes       225   A -&gt; G   No       276   G -&gt; A   Yes       277   A -&gt; G   No       371   C -&gt;   No       413   C -&gt; G   Yes       503   T -&gt; C   No       512   C -&gt; G   Yes       525   G -&gt; A   Yes       540   T -&gt;   No       554   G -&gt;   No       601   A -&gt; G   No       646   A -&gt; G   No       684   G -&gt; T   Yes       790   T -&gt; G   No       805   -&gt; A   No       805   -&gt; T   No       811   C -&gt;   No       835   G -&gt;   No       887   T -&gt; C   No       960   G -&gt; A   Yes       1010   G -&gt;   No       1040   G -&gt;   No       1062   G -&gt;   No       1374   C -&gt;   No       1464   C -&gt; T   Yes       1470   C -&gt; T   Yes       1761   G -&gt;   No       1845   C -&gt; G   Yes       1879   C -&gt; A   No       1918   G -&gt; A   No       1945   A -&gt; C   Yes       1960   G -&gt; A   Yes       1986   G -&gt; A   Yes       2068   C -&gt; A   No       2069   G -&gt; A   No       2127   G -&gt; A   Yes       2146   C -&gt; T   Yes       2206   G -&gt; A   Yes       2251   C -&gt; T   Yes       2266   G -&gt;   No       2287   A -&gt; C   Yes       2304   G -&gt; A   Yes       2344   C -&gt; T   Yes       2394   T -&gt; C   Yes       2438   T -&gt;   No       2438   T -&gt; C   No       2439   T -&gt; A   No       2439   T -&gt; C   No                  
 
      As noted above, cluster HUM4COLA features 27 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HUM4COLA_PEA — 1_node — 0 (SEQ ID NO:248) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 16 below describes the starting and ending position of this segment on each transcript.  
               TABLE 16                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1   170       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1   170       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1   170       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 0 (SEQ ID NO:249) according to the present invention is supported by 60 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 17 below describes the starting and ending position of this segment on each transcript.  
               TABLE 17                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   171   403       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   171   403       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   171   403       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 4 (SEQ ID NO:250) according to the present invention is supported by 51 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA-PEA — 1_T6 (SEQ ID NO:247). Table 18 below describes the starting and ending position of this segment on each transcript.  
               TABLE 18                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   404   552       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   404   552       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   404   552       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 7 (SEQ ID NO:251) according to the present invention is supported by 64 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 19 below describes the starting and ending position of this segment on each transcript.  
               TABLE 19                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   553   681       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   553   681       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   553   681       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 1 (SEQ ID NO:252) according to the present invention is supported by 2 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245). Table 20 below describes the starting and ending position of this segment on each transcript.  
               TABLE 20                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   856   1112       NO: 245)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 19 (SEQ ID NO:253) according to the present invention is supported by 81 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245) and HUM4COLA_PEA — 1_T5 (SEQ ID NO:246). Table 21 below describes the starting and ending position of this segment on each transcript.  
               TABLE 21                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1464   1619       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1299   1454       NO: 246)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 40 (SEQ ID NO:254) according to the present invention is supported by 129 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 22 below describes the starting and ending position of this segment on each transcript.  
               TABLE 22                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   2295   2453       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   2130   2288       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1778   1936       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 41 (SEQ ID NO:255) according to the present invention is supported by 112 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 23 below describes the starting and ending position of this segment on each transcript.  
               TABLE 23                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   2454   2616       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   2289   2451       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1937   2099       NO: 247)                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HUM4COLA_PEA — 1_node — 8 (SEQ ID NO:256) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T5 (SEQ ID NO:246). Table 24 below describes the starting and ending position of this segment on each transcript.  
               TABLE 24                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T5 (SEQ ID   682   773       NO: 246)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 9 (SEQ ID NO:257) according to the present invention is supported by 59 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 25 below describes the starting and ending position of this segment on each transcript.  
               TABLE 25                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   682   736       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   774   828       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   682   736       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 10 (SEQ ID NO:258) according to the present invention is supported by 63 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 26 below describes the starting and ending position of this segment on each transcript.  
               TABLE 26                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   737   855       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   829   947       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   737   855       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 12 (SEQ ID NO:259) according to the present invention is supported by 60 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 27 below describes the starting and ending position of this segment on each transcript.  
               TABLE 27                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position                                 HUM4COLA_PEA_1_T1 (SEQ ID   1113   1167       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   948   1002       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   856   910       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 13 (SEQ ID NO:260) according to the present invention is supported by 67 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 28 below describes the starting and ending position of this segment on each transcript.  
               TABLE 28                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position                                 HUM4COLA_PEA_1_T1 (SEQ ID   1168   1286       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1003   1121       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   911   1029       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 16 (SEQ ID NO:261) according to the present invention is supported by 73 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 29 below describes the starting and ending position of this segment on each transcript.  
               TABLE 29                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1287   1359       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1122   1194       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1030   1102       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 17 (SEQ ID NO:262) according to the present invention is supported by 79 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245) and HUM4COLA_PEA — 1_T5 (SEQ ID NO:246). Table 30 below describes the starting and ending position of this segment on each transcript.  
               TABLE 30                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1360   1463       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1195   1298       NO: 246)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 22 (SEQ ID NO:263) according to the present invention is supported by 66 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 31 below describes the starting and ending position of this segment on each transcript.  
               TABLE 31                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1620   1663       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1455   1498       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1103   1146       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node-23 (SEQ ID NO:264) according to the present invention can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA-PEA — 1_T6 (SEQ ID NO:247). Table 32 below describes the starting and ending position of this segment on each transcript.  
               TABLE 32                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1664   1682       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1499   1517       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1147   1165       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 24 (SEQ ID NO:265) according to the present invention is supported by 52 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 33 below describes the starting and ending position of this segment on each transcript.  
               TABLE 33                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1683   1780       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1518   1615       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1166   1263       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 25 (SEQ ID NO:266) according to the present invention is supported by 46 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 34 below describes the starting and ending position of this segment on each transcript.  
               TABLE 34                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1781   1833       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1616   1668       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1264   1316       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 26 (SEQ ID NO:267) according to the present invention is supported by 55 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 35 below describes the starting and ending position of this segment on each transcript.  
               TABLE 35                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1834   1893       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1669   1728       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1317   1376       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 27 (SEQ ID NO:268) according to the present invention can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 36 below describes the starting and ending position of this segment on each transcript.  
               TABLE 36                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1894   1899       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1729   1734       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1377   1382       NO: 247)                  
 
      Segment cluster HUM4COLA-PEA — 1_node — 29 (SEQ ID NO:269) according to the present invention is supported by 86 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA-PEA — 1_T1 (SEQ ID NO:245), HUM4COLA PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 37 below describes the starting and ending position of this segment on each transcript.  
               TABLE 37                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   1900   2008       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1735   1843       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1383   1491       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 30 (SEQ ID NO:270) according to the present invention is supported by 83 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 38 below describes the starting and ending position of this segment on each transcript.  
               TABLE 38                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   2009   2039       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1844   1874       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1492   1522       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 32 (SEQ ID NO:271) according to the present invention is supported by 103 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 39 below describes the starting and ending position of this segment on each transcript.  
               TABLE 39                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   2040   2158       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1875   1993       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1523   1641       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 33 (SEQ ID NO:272) according to the present invention is supported by 101 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 40 below describes the starting and ending position of this segment on each transcript.  
               TABLE 40                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   2159   2190       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   1994   2025       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1642   1673       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 36 (SEQ ID NO:273) according to the present invention is supported by 108 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 41 below describes the starting and ending position of this segment on each transcript.  
               TABLE 41                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   2191   2242       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   2026   2077       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1674   1725       NO: 247)                  
 
      Segment cluster HUM4COLA_PEA — 1_node — 37 (SEQ ID NO:274) according to the present invention is supported by 118 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUM4COLA_PEA — 1_T1 (SEQ ID NO:245), HUM4COLA_PEA — 1_T5 (SEQ ID NO:246) and HUM4COLA_PEA — 1_T6 (SEQ ID NO:247). Table 42 below describes the starting and ending position of this segment on each transcript.  
               TABLE 42                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUM4COLA_PEA_1_T1 (SEQ ID   2243   2294       NO: 245)       HUM4COLA_PEA_1_T5 (SEQ ID   2078   2129       NO: 246)       HUM4COLA_PEA_1_T6 (SEQ ID   1726   1777       NO: 247)                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: MM09_HUMAN (SEQ ID NO:275)                   Sequence documentation:       Alignment of: HUM4COLA_PEA_1_P7 (SEQ ID NO:276) ×       MM09_HUMAN (SEQ ID NO:275)   . .               Alignment segment 1/1:                                 Quality:   3559.00   Escore:   0           Matching length:   359   Total length:   359       Matching Percent   99.72   Matching Percent   99.72       Similarity:       Identity:       Total Percent   99.72   Total Percent   99.72       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLY   50                            .         .         .         .         .       51   RYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   RYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKANRTPRCG   100                            .         .         .         .         .       101   VPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSA   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   VPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSA   150                            .         .         .         .         .       151   VTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQG   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   VTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQG   200                            .         .         .         .         .       201   DAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRS   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   DAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRS   250                            .         .         .         .         .       251   DGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFPFIFQGQSYS   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   DGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFPFIFQGQSYS   300                            .         .         .         .         .       301   ACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFP   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   ACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFP   350               351   FTFLGKESS   359           |||||||||       351   FTFLGKEYS   359                             Sequence name: MM09_HUMAN (SEQ ID NO:275)                   Sequence documentation:       Alignment of: HUM4COLA_PEA_1_P14 (SEQ ID NO:277) ×       MM09_HUMAN (SEQ ID NO:275)   . .               Alignment segment 1/1:                                 Quality:   2715.00   Escore:   0           Matching length:   274   Total length:   274       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLY   50                            .         .         .         .         .       51   RYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKANRTPRCG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   RYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKANRTPRCG   100                            .         .         .         .         .       101   VPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSA   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   VPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSA   150                            .         .         .         .         .       151   VTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQG   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   VTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQG   200                            .         .         .         .         .       201   DAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRS   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   DAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRS   250                            .         .       251   DGLPWCSTTANYDTDDRFGFCPSE   274           ||||||||||||||||||||||||       251   DGLPWCSTTANYDTDDRFGFCPSE   274                             Sequence name: MM09_HUMAN (SEQ ID NO:275)                   Sequence documentation:       Alignment of: HUM4COLA_PEA_1_P15 (SEQ ID NO:278) ×       MM09_HUMAN (SEQ ID NO:275)   . .               Alignment segment 1/1:                                 Quality:   2124.00   Escore:   0           Matching length:   216   Total length:   216       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLY   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLY   50                            .         .         .         .         .       51   RYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCG   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   RYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCG   100                            .         .         .         .         .       101   VPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSA   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   VPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSA   150                            .         .         .         .         .       151   VTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQG   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   VTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQG   200                            .       201   DAHFDDDELWSLGKGV   216           ||||||||||||||||       201   DAHFDDDELWSLGKGV   216          
 
     Description for Cluster HUMICAMA1A  
      Cluster HUMICAMA1A features 6 transcript(s) and 22 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       HUMICAMA1A_PEA_1_T2   279           HUMICAMA1A_PEA_1_T4   280           HUMICAMA1A_PEA_1_T5   281           HUMICAMA1A_PEA_1_T8   282           HUMICAMA1A_PEA_1_T12   283           HUMICAMA1A_PEA_1_T16   284                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 HUMICAMA1A_PEA_1_node_0 
                 285 
               
               
                   
                 HUMICAMA1A_PEA_1_node_3 
                 286 
               
               
                   
                 HUMICAMA1A_PEA_1_node_12 
                 287 
               
               
                   
                 HUMICAMA1A_PEA_1_node_13 
                 288 
               
               
                   
                 HUMICAMA1A_PEA_1_node_14 
                 289 
               
               
                   
                 HUMICAMA1A_PEA_1_node_20 
                 290 
               
               
                   
                 HUMICAMA1A_PEA_1_node_21 
                 291 
               
               
                   
                 HUMICAMA1A_PEA_1_node_24 
                 292 
               
               
                   
                 HUMICAMA1A_PEA_1_node_25 
                 293 
               
               
                   
                 HUMICAMA1A_PEA_1_node_27 
                 294 
               
               
                   
                 HUMICAMA1A_PEA_1_node_29 
                 295 
               
               
                   
                 HUMICAMA1A_PEA_1_node_2 
                 296 
               
               
                   
                 HUMICAMA1A_PEA_1_node_4 
                 297 
               
               
                   
                 HUMICAMA1A_PEA_1_node_15 
                 298 
               
               
                   
                 HUMICAMA1A_PEA_1_node_16 
                 299 
               
               
                   
                 HUMICAMA1A_PEA_1_node_17 
                 300 
               
               
                   
                 HUMICAMA1A_PEA_1_node_18 
                 301 
               
               
                   
                 HUMICAMA1A_PEA_1_node_19 
                 302 
               
               
                   
                 HUMICAMA1A_PEA_1_node_22 
                 303 
               
               
                   
                 HUMICAMA1A_PEA_1_node_23 
                 304 
               
               
                   
                 HUMICAMA1A_PEA_1_node_26 
                 305 
               
               
                   
                 HUMICAMA1A_PEA_1_node_28 
                 306 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                 Protein Name 
                 Sequence ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HUMICAMA1A_PEA_1_P2 
                 309 
                 HUMICAMA1A_PEA_1_T2 (SEQ 
               
               
                   
                   
                 ID NO: 279) 
               
               
                 HUMICAMA1A_PEA_1_P5 
                 310 
                 HUMICAMA1A_PEA_1_T5 
               
               
                   
                   
                 (SEQ ID NO: 281); 
               
               
                   
                   
                 HUMICAMA1A_PEA_1_T12 
               
               
                   
                   
                 (SEQ ID NO: 283); 
               
               
                   
                   
                 HUMICAMA1A_PEA_1_T16 
               
               
                   
                   
                 (SEQ ID NO: 284) 
               
               
                 HUMICAMA1A_PEA_1_P8 
                 311 
                 HUMICAMA1A_PEA_1_T8 
               
               
                   
                   
                 (SEQ ID NO: 282) 
               
               
                 HUMICAMA1A_PEA_1_P15 
                 312 
                 HUMICAMA1A_PEA_1_T4 
               
               
                   
                   
                 (SEQ ID NO: 280) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Intercellular adhesion molecule-1 precursor (SEQ ID NO:307) (SwissProt accession identifier ICA1_HUMAN; known also according to the synonyms ICAM-1; Major group rhinovirus receptor; CD54 antigen), referred to herein as the previously known protein.  
      Protein Intercellular adhesion molecule-1 precursor (SEQ ID NO:307) is known or believed to have the following function(s): ICAM proteins are ligands for the leukocyte adhesion LFA-1 protein (Integrin alpha-L/beta-2). The sequence for protein Intercellular adhesion molecule-1 precursor is given at the end of the application, as “Intercellular adhesion molecule-1 precursor amino acid sequence” (SEQ ID NO:307). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations or Known Protein                     SNP position(s)           on amino acid           sequence   Comment                56   K -&gt; M (in Kilifi; dbSNP: 5491). /FTId = VAR_010204.       155   K -&gt; N (in dbSNP: 5492). /FTId = VAR_014651.       241   G -&gt; R (in dbSNP: 1799969). /FTId = VAR_014186.       315   V -&gt; M (in dbSNP: 5495). /FTId = VAR_014652.       352   P -&gt; L (in dbSNP: 1801714). /FTId = VAR_014653.       397   R -&gt; Q (in dbSNP: 5497). /FTId = VAR_014654.       469   E -&gt; K (in dbSNP: 5498). /FTId = VAR_014187.       478   R -&gt; W. /FTId = VAR_016267.       9-10   AL -&gt; PV                  
 
      Protein Intercellular adhesion molecule-1 precursor (SEQ ID NO:307) localization is believed to be Type I membrane protein.  
      A lower serum concentration of soluble ICAM-1 is seen in women with stage III and IV endometriosis (Barrier et al, J Soc Gynecol Investig. 2002 March-April; 9(2):98-101). Variants of this cluster are suitable as diagnostic markers for endometriosis.  
      The previously known protein also has the following indication(s) and/or potential therapeutic use(s): Infection, rhinovirus. It has been investigated for clinical/therapeutic use in humans, for example as a target for an antibody or small molecule, and/or as a direct therapeutic; available information related to these investigations is as follows. Potential pharmaceutically related or therapeutically related activity or activities of the previously known protein are as follows: ICAM 1 antagonist; Immunostimulant; Protein synthesis antagonist. A therapeutic role for a protein represented by the cluster has been predicted. The cluster was assigned this field because there was information in the drug database or the public databases (e.g., described herein above) that this protein, or part thereof, is used or can be used for a potential therapeutic indication: Anti-inflammatory; Immunological; antibody; Antiallergic, non-asthma; Otological; Antiviral; GI inflammatory/bowel disorders; Cardiovascular; Antipruritic/inflammation, allergic; Anti-inflammatory, topical; Antiarthritic, immunological; Antisense therapy; Anti-infective; Anticancer; Prophylactic vaccine.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: cell-cell adhesion, which are annotation(s) related to Biological Process; transmembrane receptor; protein binding, which are annotation(s) related to Molecular Function; and integral plasma membrane protein, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      As noted above, cluster HUMICAMA1A features 6 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Intercellular adhesion molecule-1 precursor (SEQ ID NO:307). A description of each variant protein according to the present invention is now provided.  
      Variant protein HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279). An alignment is given to the known protein (Intercellular adhesion molecule-1 precursor (SEQ ID NO:307)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309) and ICA1_HUMAN (SEQ ID NO:307):  
      1. An isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIE TPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELA PLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRR DHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVV CSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILG NQSQETLQTVTIYS corresponding to amino acids 1-309 of ICA1_HUMAN (SEQ ID NO:307), which also corresponds to amino acids 1-309 of HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence KKGQGRSGASWGCDLNPGRGSLCAYSRLSGAQRDSDEARGLRRDRGDSEV (SEQ ID NO:479) corresponding to amino acids 310-359 of HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence KKGQGRSGASWGCDLNPGRGSLCAYSRLSGAQRDSDEARGLRRDRGDSEV (SEQ ID NO:479) in HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 7, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                56   K -&gt; M   Yes       155   K -&gt; N   Yes       238   S -&gt;   No       241   G -&gt; R   Yes       272   A -&gt; G   No       272   A -&gt;   No       285   T -&gt; A   No       320   W -&gt; *   Yes       342   R -&gt; H   Yes                  
 
      The glycosylation sites of variant protein HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309), as compared to the known protein Intercellular adhesion molecule-1 precursor (SEQ ID NO:307, are described in Table 8 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 8                          Glycosylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?               385   no           296   yes   296       202   yes   202       145   yes   145       130   yes   130       406   no       183   yes   183       267   yes   267                  
 
      Variant protein HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309) is encoded by the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279) is shown in bold; this coding portion starts at position 1332 and ends at position 2408. The transcript also has the following SNPs as listed in Table 9 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P2 (SEQ ID NO:309) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 9                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 1   G -&gt; C   No       169   G -&gt; A   Yes       490   A -&gt;   Yes       1288   C -&gt; T   Yes       1291   T -&gt; G   No       1323   A -&gt; C   Yes       1498   A -&gt; T   Yes       1796   G -&gt; C   Yes       2033   C -&gt; A   Yes       2045   C -&gt;   No       2052   G -&gt; A   Yes       2054   G -&gt; T   Yes       2146   C -&gt;   No       2146   C -&gt; G   No       2168   C -&gt; T   Yes       2177   C -&gt; T   Yes       2184   A -&gt; G   No       2198   G -&gt; A   No       2291   G -&gt; A   Yes       2356   G -&gt; A   Yes       2414   C -&gt;   No       2414   C -&gt; G   No       2468   C -&gt; T   Yes       2508   C -&gt; T   Yes       2534   C -&gt;   No       2534   C -&gt; A   No       2544   G -&gt;   No       2598   C -&gt;   No       2818   A -&gt; G   No       2975   C -&gt;   No       3064   G -&gt; T   No       3119   C -&gt;   No       3137   G -&gt;   No       3446   C -&gt;   No       3732   T -&gt;   No       3732   T -&gt; C   No       3859   T -&gt; A   No       3866   C -&gt; T   No       3982   -&gt; T   No       4082   -&gt; G   No       4082   -&gt; T   No       4180   G -&gt; A   No       4312   T -&gt; G   No                  
 
      Variant protein HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMICAMA1A_PEA_T5 (SEQ ID NO:281). An alignment is given to the known protein (Intercellular adhesion molecule-1 precursor (SEQ ID NO:307)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310) and ICA1_HUMAN (SEQ ID NO:307):  
      1. An isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIE TPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELA PLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRR DHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVV CSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILG NQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRA QLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVL corresponding to amino acids 1-393 of ICA1_HUMAN (SEQ ID NO:307), which also corresponds to amino acids 1-393 of HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence CEWGCWSMAPIPQGPISLKVP (SEQ ID NO:480) corresponding to amino acids 394-414 of HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence CEWGCWSMAPIPQGPISLKVP (SEQ ID NO:480) in HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310).  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 10, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Amino acid mutations                         SNP position(s) on amino acid       Previously       sequence   Alternative amino acid(s)   known SNP?                                 56   K -&gt; M   Yes       155   K -&gt; N   Yes       238   S -&gt;   No       241   G -&gt; R   Yes       272   A -&gt;   No       272   A -&gt; G   No       285   T -&gt; A   No       315   V -&gt; M   Yes       334   A -&gt; G   No       334   A -&gt;   No       352   P -&gt; L   Yes       374   T -&gt;   No       374   T -&gt; N   No       377   V -&gt;   No                  
 
      The glycosylation sites of variant protein HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310), as compared to the known protein Intercellular adhesion molecule-1 precursor (SEQ ID NO:307), are described in Table 11 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 11                          Glycosylation site(s)                         Position(s) on known amino       Position in       acid sequence   Present in variant protein?   variant protein?               385   yes   385       296   yes   296       202   yes   202       145   yes   145       130   yes   130       406   no       183   yes   183       267   yes   267                  
 
      Variant protein HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310) is encoded by the following transcript(s): HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281) is shown in bold; this coding portion starts at position 1332 and ends at position 2573. The transcript also has the following SNPs as listed in Table 12 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P5 (SEQ ID NO:310) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 12                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 1   G -&gt; C   No       169   G -&gt; A   Yes       490   A -&gt;   Yes       1288   C -&gt; T   Yes       1291   T -&gt; G   No       1323   A -&gt; C   Yes       1498   A -&gt; T   Yes       1796   G -&gt; C   Yes       2033   C -&gt; A   Yes       2045   C -&gt;   No       2052   G -&gt; A   Yes       2054   G -&gt; T   Yes       2146   C -&gt;   No       2146   C -&gt; G   No       2168   C -&gt; T   Yes       2177   C -&gt; T   Yes       2184   A -&gt; G   No       2198   G -&gt; A   No       2274   G -&gt; A   Yes       2332   C -&gt;   No       2332   C -&gt; G   No       2386   C -&gt; T   Yes       2426   C -&gt; T   Yes       2452   C -&gt;   No       2452   C -&gt; A   No       2462   G -&gt;   No       2641   C -&gt;   No       2861   A -&gt; G   No       3018   C -&gt;   No       3107   G -&gt; T   No       3162   C -&gt;   No       3180   G -&gt;   No       3489   C -&gt;   No       3775   T -&gt;   No       3775   T -&gt; C   No       3902   T -&gt; A   No       3909   C -&gt; T   No       4025   -&gt; T   No       4125   -&gt; G   No       4125   -&gt; T   No       4223   G -&gt; A   No       4355   T -&gt; G   No                  
 
      Variant protein HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282). An alignment is given to the known protein (Intercellular adhesion molecule-1 precursor (SEQ ID NO:307)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311) and ICA1_HUMAN-V1 (SEQ ID NO:308):  
      1. An isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPG corresponding to amino acids 1-23 of ICA1_HUMAN_V1 (SEQ ID NO:308), which also corresponds to amino acids 1-23 of HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311), and a second amino acid sequence being at least 90% homologous to TPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEV TTTVLVRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLE VDTQGTVVCSLDGLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQ RLTCAVILGNQSQETLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVP AQPLGPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPG NWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQ GEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTP MKPNTQATPP corresponding to amino acids 112-532 of ICA1_HUMAN_V1 (SEQ ID NO:308), which also corresponds to amino acids 24-444 of HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise GT, having a structure as follows: a sequence starting from any of amino acid numbers 23−x to 23; and ending at any of amino acid numbers 24+((n−2)−x), in which x varies from 0 to n−2.  
      It should be noted that the known protein sequence (ICA1_HUMAN (SEQ ID NO:307)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for ICA1_HUMAN_V1 (SEQ ID NO:308). These changes were previously known to occur and are listed in the table below.  
               TABLE 13                          Changes to ICA1_HUMAN_V1 (SEQ ID NO: 308)                     SNP position(s) on           amino acid sequence   Type of change               470   variant                  
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: membrane. The protein localization is believed to be membrane because although both signal-peptide prediction programs agree that this protein has a signal peptide, both trans-membrane region prediction programs predict that this protein has a trans-membrane region downstream of this signal peptide.  
      Variant protein HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 14, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 14                          Amino acid mutations                         SNP position(s) on               amino acid sequence   Alternative amino acid(s)   Previously known SNP?                                 67   K -&gt; N   Yes       150   S -&gt;   No       153   G -&gt; R   Yes       184   A -&gt;   No       184   A -&gt; G   No       197   T -&gt; A   No       227   V -&gt; M   Yes       246   A -&gt; G   No       246   A -&gt;   No       264   P -&gt; L   Yes       286   T -&gt;   No       286   T -&gt; N   No       289   V -&gt;   No       307   G -&gt;   No       381   K -&gt; E   No       433   T -&gt;   No                  
 
      Variant protein HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311) is encoded by the following transcript(s): HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282) is shown in bold; this coding portion starts at position 1332 and ends at position 2663. The transcript also has the following SNPs as listed in Table 15 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P8 (SEQ ID NO:311) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 15                          Nucleic acid SNPs                         SNP position on               nucleotide sequence   Alternative nucleic acid   Previously known SNP?                                 1   G -&gt; C   No       169   G -&gt; A   Yes       490   A -&gt;   Yes       1288   C -&gt; T   Yes       1291   T -&gt; G   No       1323   A -&gt; C   Yes       1532   G -&gt; C   Yes       1769   C -&gt; A   Yes       1781   C -&gt;   No       1788   G -&gt; A   Yes       1790   G -&gt; T   Yes       1882   C -&gt;   No       1882   C -&gt; G   No       1904   C -&gt; T   Yes       1913   C -&gt; T   Yes       1920   A -&gt; G   No       1934   G -&gt; A   No       2010   G -&gt; A   Yes       2068   C -&gt;   No       2068   C -&gt; G   No       2122   C -&gt; T   Yes       2162   C -&gt; T   Yes       2188   C -&gt;   No       2188   C -&gt; A   No       2198   G -&gt;   No       2252   C -&gt;   No       2472   A -&gt; G   No       2629   C -&gt;   No       2718   G -&gt; T   No       2773   C -&gt;   No       2791   G -&gt;   No       3100   C -&gt;   No       3386   T -&gt;   No       3386   T -&gt; C   No       3513   T -&gt; A   No       3520   C -&gt; T   No       3636   -&gt; T   No       3736   -&gt; G   No       3736   -&gt; T   No       3834   G -&gt; A   No       3966   T -&gt; G   No                  
 
      Variant protein HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280). An alignment is given to the known protein (Intercellular adhesion molecule-1 precursor (SEQ ID NO:307)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312) and ICA1_HUMAN (SEQ ID NO:307):  
      1. An isolated chimeric polypeptide encoding for HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312), comprising a first amino acid sequence being at least 90% homologous to MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGIE TPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELA PLPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRR DHHGANFSCRTELDLRPQGLELFENTSAPYQLQTF corresponding to amino acids 1-212 of ICA1_HUMAN (SEQ ID NO:307), which also corresponds to amino acids 1-212 of HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GED corresponding to amino acids 213-215 of HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 16, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 16                          Amino acid mutations                         SNP position(s) on               amino acid sequence   Alternative amino acid(s)   Previously known SNP?                                 56   K -&gt; M   Yes       155   K -&gt; N   Yes                  
 
      The glycosylation sites of variant protein HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312), as compared to the known protein Intercellular adhesion molecule-1 precursor (SEQ ID NO:307), are described in Table 17 (given according to their position(s) on the amino acid sequence in the first column; the second column indicates whether the glycosylation site is present in the variant protein; and the last column indicates whether the position is different on the variant protein).  
               TABLE 17                          Glycosylation site(s)                         Position(s) on known   Present           amino acid sequence   in variant protein?   Position in variant protein?               385   no           296   no       202   yes   202       145   yes   145       130   yes   130       406   no       183   yes   183       267   no                  
 
      Variant protein HUMICAMA1A_PEA — 1_P15 (SEQ ID NO: 312) is encoded by the following transcript(s): HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280) is shown in bold; this coding portion starts at position 1332 and ends at position 1976. The transcript also has the following SNPs as listed in Table 18 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMICAMA1A_PEA — 1_P15 (SEQ ID NO:312) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 18                          Nucleic acid SNPs                         SNP position on               nucleotide sequence   Alternative nucleic acid   Previously known SNP?                                 1   G -&gt; C   No       169   G -&gt; A   Yes       490   A -&gt;   Yes       1288   C -&gt; T   Yes       1291   T -&gt; G   No       1323   A -&gt; C   Yes       1498   A -&gt; T   Yes       1796   G -&gt; C   Yes       2023   C -&gt; T   Yes       2094   A -&gt; G   No       2132   T -&gt; C   No       2279   C -&gt; A   Yes       2291   C -&gt;   No       2298   G -&gt; A   Yes       2300   G -&gt; T   Yes       2392   C -&gt;   No       2392   C -&gt; G   No       2414   C -&gt; T   Yes       2423   C -&gt; T   Yes       2430   A -&gt; G   No       2444   G -&gt; A   No       2520   G -&gt; A   Yes       2578   C -&gt;   No       2578   C -&gt; G   No       2632   C -&gt; T   Yes       2672   C -&gt; T   Yes       2698   C -&gt;   No       2698   C -&gt; A   No       2708   G -&gt;   No       2762   C -&gt;   No       2982   A -&gt; G   No       3139   C -&gt;   No       3228   G -&gt; T   No       3283   C -&gt;   No       3301   G -&gt;   No       3610   C -&gt;   No       3896   T -&gt;   No       3896   T -&gt; C   No       4023   T -&gt; A   No       4030   C -&gt; T   No       4146   -&gt; T   No       4246   -&gt; G   No       4246   -&gt; T   No       4344   G -&gt; A   No       4476   T -&gt; G   No                  
 
      As noted above, cluster HUMICAMA1A features 22 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HUMICAMA1A_PEA_node — 0 (SEQ ID NO:285) according to the present invention is supported by 50 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA-1-T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 19 below describes the starting and ending position of this segment on each transcript.  
               TABLE 19                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   1   1398       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   1   1398       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   1   1398       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   1   1398       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   1   1398       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   1   1398       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 3 (SEQ ID NO:286) according to the present invention is supported by 66 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 20 below describes the starting and ending position of this segment on each transcript.  
               TABLE 20                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMICAMA1A_PEA_1_T2 (SEQ ID   1464   1620       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   1464   1620       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   1464   1620       NO: 281)       HUMICAMA1A_PEA_1_T12 (SEQ   1464   1620       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   1464   1620       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 12 (SEQ ID NO:287) according to the present invention is supported by 87 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 21 below describes the starting and ending position of this segment on each transcript.  
               TABLE 21                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMICAMA1A_PEA_1_T2 (SEQ ID   1663   1968       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   1663   1968       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   1663   1968       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   1399   1704       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   1663   1968       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   1663   1968       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA_node — 13 (SEQ ID NO:288) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280). Table 22 below describes the starting and ending position of this segment on each transcript.  
               TABLE 22                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMICAMA1A_PEA_1_T4 (SEQ ID   1969   2214       NO: 280)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 14 (SEQ ID NO:289) according to the present invention is supported by 88 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 23 below describes the starting and ending position of this segment on each transcript.  
               TABLE 23                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   1969   2256       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   2215   2502       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   1969   2256       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   1705   1992       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   1969   2256       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   1969   2256       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 20 (SEQ ID NO:290) according to the present invention is supported by 7 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 24 below describes the starting and ending position of this segment on each transcript.  
               TABLE 24                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T5 (SEQ ID   2512   2636       NO: 281)       HUMICAMA1A_PEA_1_T12 (SEQ   2512   2636       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2512   2636       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 21 (SEQ ID NO:291) according to the present invention is supported by 91 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA-1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 25 below describes the starting and ending position of this segment on each transcript.  
               TABLE 25                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2594   2820       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   2758   2984       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   2637   2863       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2248   2474       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   2637   2863       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2637   2863       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 24 (SEQ ID NO:292) according to the present invention is supported by 109 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA_T16 (SEQ ID NO:284). Table 26 below describes the starting and ending position of this segment on each transcript.  
               TABLE 26                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2840   2986       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   3004   3150       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   2883   3029       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2494   2640       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   2969   3115       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2969   3115       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 25 (SEQ ID NO:293) according to the present invention is supported by 108 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282) and HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283). Table 27 below describes the starting and ending position of this segment on each transcript.  
               TABLE 27                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2987   3118       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   3151   3282       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   3030   3161       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2641   2772       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   3116   3247       ID NO: 283)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 27 (SEQ ID NO:294) according to the present invention is supported by 225 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282) and HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283). Table 28 below describes the starting and ending position of this segment on each transcript.  
               TABLE 28                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   3138   4204       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   3302   4368       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   3181   4247       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2792   3858       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   3267   4333       ID NO: 283)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 29 (SEQ ID NO:295) according to the present invention is supported by 53 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282) and HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283). Table 29 below describes the starting and ending position of this segment on each transcript.  
               TABLE 29                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   4209   4341       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   4373   4505       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   4252   4384       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   3863   3995       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   4338   4470       ID NO: 283)                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HUMICAMA1A_PEA — 1_node — 2 (SEQ ID NO:296) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 30 below describes the starting and ending position of this segment on each transcript.  
               TABLE 30                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   1399   1463       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   1399   1463       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   1399   1463       NO: 281)       HUMICAMA1A_PEA_1_T12 (SEQ   1399   1463       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   1399   1463       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 4 (SEQ ID NO:297) according to the present invention is supported by 62 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 31 below describes the starting and ending position of this segment on each transcript.  
               TABLE 31                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   1621   1662       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   1621   1662       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   1621   1662       NO: 281)       HUMICAMA1A_PEA_1_T12 (SEQ   1621   1662       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   1621   1662       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 15 (SEQ ID NO:298) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279). Table 32 below describes the starting and ending position of this segment on each transcript.  
               TABLE 32                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2257   2338       NO: 279)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 16 (SEQ ID NO:299) according to the present invention is supported by 58 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 33 below describes the starting and ending position of this segment on each transcript.  
               TABLE 33                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2339   2457       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   2503   2621       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   2257   2375       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   1993   2111       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   2257   2375       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2257   2375       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 17 (SEQ ID NO:300) according to the present invention can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 34 below describes the starting and ending position of this segment on each transcript.  
               TABLE 34                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2458   2478       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   2622   2642       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   2376   2396       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2112   2132       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   2376   2396       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2376   2396       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 18 (SEQ ID NO:301) according to the present invention is supported by 57 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 35 below describes the starting and ending position of this segment on each transcript.  
               TABLE 35                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2479   2568       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   2643   2732       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   2397   2486       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2133   2222       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   2397   2486       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2397   2486       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 19 (SEQ ID NO:302) according to the present invention can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 36 below describes the starting and ending position of this segment on each transcript.  
               TABLE 36                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2569   2593       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   2733   2757       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   2487   2511       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2223   2247       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   2487   2511       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2487   2511       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA_node — 22 (SEQ ID NO:303) according to the present invention can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282), HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 37 below describes the starting and ending position of this segment on each transcript.  
               TABLE 37                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   2821   2839       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   2985   3003       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   2864   2882       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2475   2493       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   2864   2882       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2864   2882       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 23 (SEQ ID NO:304) according to the present invention is supported by 5 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283) and HUMICAMA1A_PEA — 1_T16 (SEQ ID NO:284). Table 38 below describes the starting and ending position of this segment on each transcript.  
               TABLE 38                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T12 (SEQ   2883   2968       ID NO: 283)       HUMICAMA1A_PEA_1_T16 (SEQ   2883   2968       ID NO: 284)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 26 (SEQ ID NO:305) according to the present invention can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA — 1_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282) and HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283). Table 39 below describes the starting and ending position of this segment on each transcript.  
               TABLE 39                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   3119   3137       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   3283   3301       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   3162   3180       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   2773   2791       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   3248   3266       ID NO: 283)                  
 
      Segment cluster HUMICAMA1A_PEA — 1_node — 28 (SEQ ID NO:306) according to the present invention can be found in the following transcript(s): HUMICAMA1A_PEA — 1_T2 (SEQ ID NO:279), HUMICAMA1A_PEA_T4 (SEQ ID NO:280), HUMICAMA1A_PEA — 1_T5 (SEQ ID NO:281), HUMICAMA1A_PEA — 1_T8 (SEQ ID NO:282) and HUMICAMA1A_PEA — 1_T12 (SEQ ID NO:283). Table 40 below describes the starting and ending position of this segment on each transcript.  
               TABLE 40                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMICAMA1A_PEA_1_T2 (SEQ ID   4205   4208       NO: 279)       HUMICAMA1A_PEA_1_T4 (SEQ ID   4369   4372       NO: 280)       HUMICAMA1A_PEA_1_T5 (SEQ ID   4248   4251       NO: 281)       HUMICAMA1A_PEA_1_T8 (SEQ ID   3859   3862       NO: 282)       HUMICAMA1A_PEA_1_T12 (SEQ   4334   4337       ID NO: 283)                  
 
      Variant protein alignment to the previously known protein:  
                          Sequence name: ICA1_HUMAN (SEQ ID NO:307)                   Sequence documentation:       Alignment of: HUMICAMA1A_PEA_1_P2 (SEQ ID NO:309) ×       ICA1_HUMAN (SEQ ID NO:307)   . .               Alignment segment 1/1:                                 Quality:   2994.00   Escore:   0           Matching length:   309   Total length:   309       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCST   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSvLVTCST   50                            .         .         .         .         .       51   SCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQ   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   SCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPNCYSNCPDGQ   100                            .         .         .         .         .       101   STAKTFLTVYWTPERVELAPLPSWQPVGRNLTLRCQVEGGAPRANLTVVL   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   STAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVL   150                            .         .         .         .         .       151   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   200                            .         .         .         .         .       201   ENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQV   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   ENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQV   250                            .         .         .         .         .       251   HLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   HLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE   300               301   TLQTVTIYS   309           |||||||||       301   TLQTVTIYS   309                             Sequence name: ICA1_HUMAN (SEQ ID NO:307)                   Sequence documentation:       Alignment of: HUMICAMA1A_PEA_1_P5 (SEQ ID NO:310) ×       ICA1_HUMAN (SEQ ID NO:307)   . .               Alignment segment 1/1:                                 Quality:   3802.00   Escore:   0           Matching length:   393   Total length:   393       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCST   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCST   50                            .         .         .         .         .       51   SCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQ   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   SCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQ   100                            .         .         .         .         .       101   STAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVL   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   STAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVL   150                            .         .         .         .         .       151   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   200                            .         .         .         .         .       201   ENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQV   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   ENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQV   250                            .         .         .         .         .       251   HLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   HLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE   300                            .         .         .         .         .       301   TLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPL   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   TLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPL   350                            .         .         .         .       351   GPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVL   393           |||||||||||||||||||||||||||||||||||||||||||       351   GPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVL   393                             Sequence name: ICA1_HUMAN_V1 (SEQ ID NO:308)                   Sequence documentation:       Alignment of: HUMICAMA1A_PEA_1_P8 (SEQ ID NO:311) ×       ICA1_HUMAN_V1 (SEQ ID NO:308)   . .               Alignment segment 1/1:                                 Quality:   4214.00   Escore:   0           Matching length:   444   Total length:   532       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   83.46   Total Percent   83.46       Similarity:       Identity:       Gaps:   1                             Alignment:                                              .         .         .         .         .               1   MAPSSPRPALPALLVLLGALFPG...........................   23           ||||||||||||||||||||||       1   MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCST   50                            .         .         .         .         .       23   ..................................................   23               51   SCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQ   100                            .         .         .         .         .       24   ...........TPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVL   62                      |||||||||||||||||||||||||||||||||||||||       101   STAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVL   150                            .         .         .         .         .       63   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   112           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   200                            .         .         .         .         .       113   ENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQV   162           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   ENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLDGLFPVSEAQV   250                            .         .         .         .         .       163   HLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE   212           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   HLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE   300                            .         .         .         .         .       213   TLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPL   262           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   TLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPL   350                            .         .         .         .         .       263   GPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDE   312           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   GPRAQLLLKATPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDE   400                            .         .         .         .         .       313   RDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRD   362           ||||||||||||||||||||||||||||||||||||||||||||||||||       401   RDCPGNWTWPENSQQTPMCQAWGNPLPELKCLKDGTFPLPIGESVTVTRD   450                            .         .         .         .         .       363   LEGTYLCRARSTQGEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLST   412           ||||||||||||||||||||||||||||||||||||||||||||||||||       451   LEGTYLCRARSTQGEVTRKVTVNVLSPRYEIVIITVVAAAVIMGTAGLST   500                            .         .         .       413   YLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP   444           ||||||||||||||||||||||||||||||||       501   YLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP   532                             Sequence name: ICA1_HUMAN (SEQ ID NO:307)                   Sequence documentation:       Alignment of: HUMICAMA1A_PEA_1_P15 (SEQ ID NO:312) ×       ICA1_HUMAN (SEQ ID NO:307)   . .               Alignment segment 1/1:                                 Quality:   2076.00   Escore:   0           Matching length:   212   Total length:   212       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCST   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCST   50                            .         .         .         .         .       51   SCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQ   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   SCDQPKLLGIETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQ   100                            .         .         .         .         .       101   STAKTFLTVYWTPERVELAPLPSWQPVGKNLTLRCQVEGGAPRANLTVVL   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   STAKTFLTVYWTPERVELAPLPSWQFVGKNLTLRCQVEGGAPRANLTVVL   150                            .         .         .         .         .       151   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   LRGEKELKREPAVGEPAEVTTTVLVRRDHHGANFSCRTELDLRPQGLELF   200                            .       201   ENTSAPYQLQTF   212           ||||||||||||       201   ENTSAPYQLQTF   212          
 
     Description for Cluster HUMLYSYL  
      Cluster HUMLYSYL features 10 transcript(s) and 44 segment(s) of interest, the names for which are given in Tables 1 and 2, respectively, the sequences themselves are given at the end of the application. The selected protein variants are given in table 3.  
               TABLE 1                          Transcripts of interest                             Transcript Name   Sequence ID No.                       HUMLYSYL_PEA_1_T2   313           HUMLYSYL_PEA_1_T4   314           HUMLYSYL_PEA_1_T5   315           HUMLYSYL_PEA_1_T6   316           HUMLYSYL_PEA_1_T8   317           HUMLYSYL_PEA_1_T9   318           HUMLYSYL_PEA_1_T19   319           HUMLYSYL_PEA_1_T20   320           HUMLYSYL_PEA_1_T22   321           HUMLYSYL_PEA_1_T24   322                      
 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                   
               
               
                 Segments of interest 
               
            
           
           
               
               
               
            
               
                   
                 Segment Name 
                 Sequence ID No. 
               
               
                   
                   
               
               
                   
                 HUMLYSYL_PEA_1_node_6 
                 323 
               
               
                   
                 HUMLYSYL_PEA_1_node_14 
                 324 
               
               
                   
                 HUMLYSYL_PEA_1_node_19 
                 325 
               
               
                   
                 HUMLYSYL_PEA_1_node_38 
                 326 
               
               
                   
                 HUMLYSYL_PEA_1_node_55 
                 327 
               
               
                   
                 HUMLYSYL_PEA_1_node_59 
                 328 
               
               
                   
                 HUMLYSYL_PEA_1_node_61 
                 329 
               
               
                   
                 HUMLYSYL_PEA_1_node_62 
                 330 
               
               
                   
                 HUMLYSYL_PEA_1_node_65 
                 331 
               
               
                   
                 HUMLYSYL_PEA_1_node_71 
                 332 
               
               
                   
                 HUMLYSYL_PEA_1_node_72 
                 333 
               
               
                   
                 HUMLYSYL_PEA_1_node_3 
                 334 
               
               
                   
                 HUMLYSYL_PEA_1_node_4 
                 335 
               
               
                   
                 HUMLYSYL_PEA_1_node_8 
                 336 
               
               
                   
                 HUMLYSYL_PEA_1_node_10 
                 337 
               
               
                   
                 HUMLYSYL_PEA_1_node_11 
                 338 
               
               
                   
                 HUMLYSYL_PEA_1_node_12 
                 339 
               
               
                   
                 HUMLYSYL_PEA_1_node_16 
                 340 
               
               
                   
                 HUMLYSYL_PEA_1_node_20 
                 341 
               
               
                   
                 HUMLYSYL_PEA_1_node_23 
                 342 
               
               
                   
                 HUMLYSYL_PEA_1_node_25 
                 343 
               
               
                   
                 HUMLYSYL_PEA_1_node_28 
                 344 
               
               
                   
                 HUMLYSYL_PEA_1_node_30 
                 345 
               
               
                   
                 HUMLYSYL_PEA_1_node_31 
                 346 
               
               
                   
                 HUMLYSYL_PEA_1_node_33 
                 347 
               
               
                   
                 HUMLYSYL_PEA_1_node_34 
                 348 
               
               
                   
                 HUMLYSYL_PEA_1_node_36 
                 349 
               
               
                   
                 HUMLYSYL_PEA_1_node_40 
                 350 
               
               
                   
                 HUMLYSYL_PEA_1_node_41 
                 351 
               
               
                   
                 HUMLYSYL_PEA_1_node_42 
                 352 
               
               
                   
                 HUMLYSYL_PEA_1_node_44 
                 353 
               
               
                   
                 HUMLYSYL_PEA_1_node_45 
                 354 
               
               
                   
                 HUMLYSYL_PEA_1_node_46 
                 355 
               
               
                   
                 HUMLYSYL_PEA_1_node_48 
                 356 
               
               
                   
                 HUMLYSYL_PEA_1_node_49 
                 357 
               
               
                   
                 HUMLYSYL_PEA_1_node_52 
                 358 
               
               
                   
                 HUMLYSYL_PEA_1_node_53 
                 359 
               
               
                   
                 HUMLYSYL_PEA_1_node_56 
                 360 
               
               
                   
                 HUMLYSYL_PEA_1_node_63 
                 361 
               
               
                   
                 HUMLYSYL_PEA_1_node_64 
                 362 
               
               
                   
                 HUMLYSYL_PEA_1_node_66 
                 363 
               
               
                   
                 HUMLYSYL_PEA_1_node_67 
                 364 
               
               
                   
                 HUMLYSYL_PEA_1_node_68 
                 365 
               
               
                   
                 HUMLYSYL_PEA_1_node_70 
                 366 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                   
               
               
                 Proteins of interest 
               
            
           
           
               
               
               
            
               
                   
                 Sequence 
                   
               
               
                 Protein Name 
                 ID No. 
                 Corresponding Transcript(s) 
               
               
                   
               
               
                 HUMLYSYL_PEA_1_P2 
                 369 
                 HUMLYSYL_PEA_1_T2 
               
               
                   
                   
                 (SEQ ID NO: 313) 
               
               
                 HUMLYSYL_PEA_1_P4 
                 370 
                 HUMLYSYL_PEA_1_T4 
               
               
                   
                   
                 (SEQ ID NO: 314) 
               
               
                 HUMLYSYL_PEA_1_P5 
                 371 
                 HUMLYSYL_PEA_1_T5 
               
               
                   
                   
                 (SEQ ID NO: 315) 
               
               
                 HUMLYSYL_PEA_1_P6 
                 372 
                 HUMLYSYL_PEA_1_T6 
               
               
                   
                   
                 (SEQ ID NO: 316) 
               
               
                 HUMLYSYL_PEA_1_P7 
                 373 
                 HUMLYSYL_PEA_1_T9 
               
               
                   
                   
                 (SEQ ID NO: 318) 
               
               
                 HUMLYSYL_PEA_1_P13 
                 374 
                 HUMLYSYL_PEA_1_T19 
               
               
                   
                   
                 (SEQ ID NO: 319) 
               
               
                 HUMLYSYL_PEA_1_P14 
                 375 
                 HUMLYSYL_PEA_1_T20 
               
               
                   
                   
                 (SEQ ID NO: 320) 
               
               
                 HUMLYSYL_PEA_1_P16 
                 376 
                 HUMLYSYL_PEA_1_T22 
               
               
                   
                   
                 (SEQ ID NO: 321) 
               
               
                 HUMLYSYL_PEA_1_P18 
                 377 
                 HUMLYSYL_PEA_1_T24 
               
               
                   
                   
                 (SEQ ID NO: 322) 
               
               
                 HUMLYSYL_PEA_1_P24 
                 378 
                 HUMLYSYL_PEA_1_T8 
               
               
                   
                   
                 (SEQ ID NO: 317) 
               
               
                   
               
            
           
         
       
     
      These sequences are variants of the known protein Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367) (SwissProt accession identifier PLO1_HUMAN; known also according to the synonyms EC 1.14.11.4; Lysyl hydroxylase 1; LH1), referred to herein as the previously known protein.  
      Protein Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367) is known or believed to have the following function(s): forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen crosslinks. The sequence for protein Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor is given at the end of the application, as “Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor amino acid sequence” (SEQ ID NO:367). Known polymorphisms for this sequence are as shown in Table 4.  
               TABLE 4                          Amino acid mutations for Known Protein                     SNP position(s) on           amino acid sequence   Comment                99   T -&gt; A. /FTId = VAR_014220.       367-371   Missing (in EDS-VI). /FTId = VAR_009269.       532   Missing (in EDS-VI). /FTId = VAR_006354.       612   W -&gt; C (in EDS-VI). /FTId = VAR_006355.       678   G -&gt; R (in EDS-VI). /FTId = VAR_006356.       120   A -&gt; S                  
 
      Protein Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor localization is believed to be Membrane bound in cisternae of rough endoplasmic reticulum.  
      The known protein was shown to be related to endometriosis (Yang et al, Best Pract Res Clin Obstet Gynaecol. 2004 April; 18(2):305-18). Variants of this cluster are suitable as diagnostic markers for endometriosis.  
      The following GO Annotation(s) apply to the previously known protein. The following annotation(s) were found: protein modification; epidermal differentiation, which are annotation(s) related to Biological Process; electron transporter; procollagen-lysine 5-dioxygenase; oxidoreductase; oxidoreductase, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen, which are annotation(s) related to Molecular Function; and endoplasmic reticulum; membrane, which are annotation(s) related to Cellular Component.  
      The GO assignment relies on information from one or more of the SwissProt/TremBl Protein knowledgebase, available from &lt;http://www.expasy.ch/sprot/&gt;; or Locuslink, available from &lt;http://www.ncbi.nlm.nih.gov/projects/LocusLink/&gt;.  
      As noted above, cluster HUMLYSYL features 10 transcript(s), which were listed in Table 1 above. These transcript(s) encode for protein(s) which are variant(s) of protein Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367). A description of each variant protein according to the present invention is now provided.  
      Variant protein HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369) and PLO1_HUMAN-V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQ corresponding to amino acids 1-490 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-490 of HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSQERAAQDALWMGQAGRMCSCS (SEQ ID NO:474) corresponding to amino acids 491-513 of HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSQERAAQDALWMGQAGRMCSCS (SEQ ID NO:474) in HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369).  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 5                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                     SNP position(s) on           amino acid sequence   Type of change               100   variant                  
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 6, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 6                          Amino acid mutations                         SNP position(s) on amino acid   Alternative   Previously       sequence   amino acid(s)   known SNP?                                 67   E -&gt; D   Yes       98   F -&gt;   No       99   A -&gt; T   Yes       120   A -&gt; S   Yes       178   S -&gt;   No       179   D -&gt; N   No       204   C -&gt;   No       232   A -&gt; G   No       232   A -&gt;   No       310   R -&gt; W   Yes       381   V -&gt; M   Yes       386   A -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313) is shown in bold; this coding portion starts at position 104 and ends at position 1642. The transcript also has the following SNPs as listed in Table 7 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P2 (SEQ ID NO:369) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 7                          Nucleic acid SNPs                         SNP position               on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       304   G -&gt; C   Yes       370   A -&gt; G   Yes       397   C -&gt;   No       397   C -&gt; T   Yes       398   G -&gt; A   Yes       461   G -&gt; T   Yes       636   G -&gt;   No       638   G -&gt; A   No       715   C -&gt;   No       798   C -&gt;   No       798   C -&gt; G   No       1031   C -&gt; T   Yes       1244   G -&gt; A   Yes       1260   C -&gt;   No       1309   C -&gt; T   Yes       1489   G -&gt; C   No       1788   A -&gt; C   Yes       2057   G -&gt;   No       2088   C -&gt; T   Yes       2094   G -&gt; C   Yes       2118   G -&gt; T   Yes       2280   T -&gt; C   Yes       2289   C -&gt; G   Yes       2300   G -&gt;   No       2306   C -&gt;   No       2404   G -&gt;   No       2411   C -&gt; G   Yes       2417   C -&gt;   No       2541   C -&gt;   No       2541   C -&gt; T   No       2561   C -&gt;   No       2598   G -&gt; A   No       2637   C -&gt;   No       2637   C -&gt; G   No       2651   C -&gt; T   No       2724   G -&gt; A   No       2724   G -&gt; C   No       2764   G -&gt;   No       2771   C -&gt; T   Yes       2780   G -&gt; C   Yes       2873   C -&gt;   No       2887   G -&gt; C   Yes       2939   C -&gt; T   Yes       2954   G -&gt; T   Yes       3010   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPE corresponding to amino acids 1-25 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-25 of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence APCCQEGLRAGGSGSLHLGRDFTVLAGARGSPSPSVSSIPRFWIPGS (SEQ ID NO:504) corresponding to amino acids 26-72 of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), and a third amino acid sequence being at least 90% homologous to DNLLVLTVATKETEGFRRFKRSAQFFNYKIQALGLGEDWNVEKGTSAGGGQKVRLLK KALEKHADKEDLVILFADSYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETK YPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITLD HRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYLGNYIPR FWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQRLLRLHYPQKHMR LFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARNMGADLCRQDRSCT YYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWGALSADGYYARSED YVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQS SDLFHHSKLDPDMAFCANIRQQDV FMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHMNQIGFE REWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSLMPHHDASTFTINIAL NRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEGLPTTRGTRYIAVSFVD P corresponding to amino acids 26-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 73-774 of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for APCCQEGLRAGGSGSLHLGRDFTVLAGARGSPSPSVSSIPRFWIPGS (SEQ ID NO:504), corresponding to HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370).  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 8                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                     SNP position(s) on           amino acid sequence   Type of change               100   variant                  
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 9, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 9                          Amino acid mutations                         SNP position(s)               on amino acid   Alternative   Previously       sequence   amino acid(s)   known SNP?                                 114   E -&gt; D   Yes       145   F -&gt;   No       146   A -&gt; T   Yes       167   A -&gt; S   Yes       225   S -&gt;   No       226   D -&gt; N   No       251   C -&gt;   No       279   A -&gt;   No       279   A -&gt; G   No       357   R -&gt; W   Yes       428   V -&gt; M   Yes       433   A -&gt;   No       681   R -&gt;   No       693   K -&gt; N   Yes       701   M -&gt; I   Yes       762   R -&gt;   No       764   T -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314) is shown in bold; this coding portion starts at position 104 and ends at position 2425. The transcript also has the following SNPs as listed in Table 10 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P4 (SEQ ID NO:370) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 10                          Nucleic acid SNPs                         SNP position               on nucleotide   Alternative   Previously       sequence   nucleic acid   known SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       358   C -&gt; A   Yes       445   G -&gt; C   Yes       511   A -&gt; G   Yes       538   C -&gt;   No       538   C -&gt; T   Yes       539   G -&gt; A   Yes       602   G -&gt; T   Yes       777   G -&gt;   No       779   G -&gt; A   No       856   C -&gt;   No       939   C -&gt;   No       939   C -&gt; G   No       1172   C -&gt; T   Yes       1385   G -&gt; A   Yes       1401   C -&gt;   No       1450   C -&gt; T   Yes       1630   G -&gt; C   No       1876   A -&gt; C   Yes       2145   G -&gt;   No       2176   C -&gt; T   Yes       2182   G -&gt; C   Yes       2206   G -&gt; T   Yes       2368   T -&gt; C   Yes       2377   C -&gt; G   Yes       2388   G -&gt;   No       2394   C -&gt;   No       2492   G -&gt;   No       2499   C -&gt; G   Yes       2505   C -&gt;   No       2629   C -&gt;   No       2629   C -&gt; T   No       2649   C -&gt;   No       2686   G -&gt; A   No       2725   C -&gt;   No       2725   C -&gt; G   No       2739   C -&gt; T   No       2812   G -&gt; A   No       2812   G -&gt; C   No       2852   G -&gt;   No       2859   C -&gt; T   Yes       2868   G -&gt; C   Yes       2961   C -&gt;   No       2975   G -&gt; C   Yes       3027   C -&gt; T   Yes       3042   G -&gt; T   Yes       3098   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIG corresponding to amino acids 1-281 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-281 of HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371), and a second amino acid sequence being at least 90% homologous to RLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARN MGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWG ALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQSSDLFHHSKLDP DMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIH QNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGY ENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPS LMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEG LPTTRGTRYIAVSFVDP corresponding to amino acids 307-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 282-702 of HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated chimeric polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise GR, having a structure as follows: a sequence starting from any of amino acid numbers 281-x to 281; and ending at any of amino acid numbers 282+((n−2)−x), in which x varies from 0 to n−2.  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 11                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                     SNP position(s) on           amino acid sequence   Type of change               100   variant                  
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 12, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 12                          Amino acid mutations                         SNP position(s)               on amino acid   Alternative   Previously       sequence   amino acid(s)   known SNP?                                 67   E -&gt; D   Yes       98   F -&gt;   No       99   A -&gt; T   Yes       120   A -&gt; S   Yes       178   S -&gt;   No       179   D -&gt; N   No       204   C -&gt;   No       232   A -&gt; G   No       232   A -&gt;   No       285   R -&gt; W   Yes       356   V -&gt; M   Yes       361   A -&gt;   No       609   R -&gt;   No       621   K -&gt; N   Yes       629   M -&gt; I   Yes       690   R -&gt;   No       692   T -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA_T5 (SEQ ID NO:315) is shown in bold; this coding portion starts at position 104 and ends at position 2209. The transcript also has the following SNPs as listed in Table 13 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P5 (SEQ ID NO:371) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 13                          Nucleic acid SNPs                         SNP position on   Alternative   Previously known       nucleotide sequence   nucleic acid   SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       304   G -&gt; C   Yes       370   A -&gt; G   Yes       397   C -&gt;   No       397   C -&gt; T   Yes       398   G -&gt; A   Yes       461   G -&gt; T   Yes       636   G -&gt;   No       638   G -&gt; A   No       715   C -&gt;   No       798   C -&gt;   No       798   C -&gt; G   No       956   C -&gt; T   Yes       1169   G -&gt; A   Yes       1185   C -&gt;   No       1234   C -&gt; T   Yes       1414   G -&gt; C   No       1660   A -&gt; C   Yes       1929   G -&gt;   No       1960   C -&gt; T   Yes       1966   G -&gt; C   Yes       1990   G -&gt; T   Yes       2152   T -&gt; C   Yes       2161   C -&gt; G   Yes       2172   G -&gt;   No       2178   C -&gt;   No       2276   G -&gt;   No       2283   C -&gt; G   Yes       2289   C -&gt;   No       2413   C -&gt;   No       2413   C -&gt; T   No       2433   C -&gt;   No       2470   G -&gt; A   No       2509   C -&gt;   No       2509   C -&gt; G   No       2523   C -&gt; T   No       2596   G -&gt; A   No       2596   G -&gt; C   No       2636   G -&gt;   No       2643   C -&gt; T   Yes       2652   G -&gt; C   Yes       2745   C -&gt;   No       2759   G -&gt; C   Yes       2811   C -&gt; T   Yes       2826   G -&gt; T   Yes       2882   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKI corresponding to amino acids 1-55 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-55 of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence QPVLRGVSL (SEQ ID NO:505) corresponding to amino acids 56-64 of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), and a third amino acid sequence being at least 90% homologous to QALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRE LLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEW EGQDSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARN LAYDTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVL VGVFIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVK LVGPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIA PLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALR GELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLW EVFSNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQW SLGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFD LAFVVRYKPDEQPSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGW TLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP corresponding to amino acids 56-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 65-736 of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), wherein said first amino acid sequence, second amino acid sequence and third amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for QPVLRGVSL (SEQ ID NO:505), corresponding to HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372).  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 14                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                             SNP position(s) on               amino acid sequence   Type of change                       100   variant                      
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 15, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 15                          Amino acid mutations                         SNP position(s) on   Alternative   Previously known       amino acid sequence   amino acid(s)   SNP?                                 76   E -&gt; D   Yes       107   F -&gt;   No       108   A -&gt; T   Yes       129   A -&gt; S   Yes       187   S -&gt;   No       188   D -&gt; N   No       213   C -&gt;   No       241   A -&gt;   No       241   A -&gt; G   No       319   R -&gt; W   Yes       390   V -&gt; M   Yes       395   A -&gt;   No       643   R -&gt;   No       655   K -&gt; N   Yes       663   M -&gt; I   Yes       724   R -&gt;   No       726   T -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316) is shown in bold; this coding portion starts at position 104 and ends at position 2311. The transcript also has the following SNPs as listed in Table 16 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P6 (SEQ ID NO:372) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 16                          Nucleic acid SNPs                         SNP position on   Alternative   Previously known       nucleotide sequence   nucleic acid   SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       331   G -&gt; C   Yes       397   A -&gt; G   Yes       424   C -&gt;   No       424   C -&gt; T   Yes       425   G -&gt; A   Yes       488   G -&gt; T   Yes       663   G -&gt;   No       665   G -&gt; A   No       742   C -&gt;   No       825   C -&gt;   No       825   C -&gt; G   No       1058   C -&gt; T   Yes       1271   G -&gt; A   Yes       1287   C -&gt;   No       1336   C -&gt; T   Yes       1516   G -&gt; C   No       1762   A -&gt; C   Yes       2031   G -&gt;   No       2062   C -&gt; T   Yes       2068   G -&gt; C   Yes       2092   G -&gt; T   Yes       2254   T -&gt; C   Yes       2263   C -&gt; G   Yes       2274   G -&gt;   No       2280   C -&gt;   No       2378   G -&gt;   No       2385   C -&gt; G   Yes       2391   C -&gt;   No       2515   C -&gt;   No       2515   C -&gt; T   No       2535   C -&gt;   No       2572   G -&gt; A   No       2611   C -&gt;   No       2611   C -&gt; G   No       2625   C -&gt; T   No       2698   G -&gt; A   No       2698   G -&gt; C   No       2738   G -&gt;   No       2745   C -&gt; T   Yes       2754   G -&gt; C   Yes       2847   C -&gt;   No       2861   G -&gt; C   Yes       2913   C -&gt; T   Yes       2928   G -&gt; T   Yes       2984   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGAL corresponding to amino acids 1-214 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-214 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSPWGQGHLPGACYELTASVLTSELSVMPSFPA (SEQ ID NO:506) corresponding to amino acids 215-247 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), a third amino acid sequence being at least 90% homologous to VV corresponding to amino acids 217-218 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 248-249 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), and a fourth amino acid sequence being at least 90% homologous to LQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQR LLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARN MGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFWG ALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQSSDLFHHSKLDP DMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIH QNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGY ENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPS LMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEG LPTTRGTRYIAVSFVDP corresponding to amino acids 248-727 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 250-729 of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), wherein said first amino acid sequence, second amino acid sequence, third amino acid sequence and fourth amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising an amino acid sequence being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence encoding for VSPWGQGHLPGACYELTASVLTSELSVMPSFPA (SEQ ID NO:506), corresponding to HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373).  
      3. A bridge portion of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise LV, having a structure as follows (numbering according to HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373)): a sequence starting from any of amino acid numbers 214−x to 214; and ending at any of amino acid numbers 215+((n−2)−x), in which x varies from 0 to n−2.  
      4. An isolated chimeric polypeptide encoding for an edge portion of HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373), comprising a polypeptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise VL, having a structure as follows: a sequence starting from any of amino acid numbers 249−x to 249; and ending at any of amino acid numbers 250+((n−2)−x), in which x varies from 0 to n−2.  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 17                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                             SNP position(s) on               amino acid sequence   Type of change                       100   variant                      
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 18, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 18                          Amino acid mutations                         SNP position(s) on   Alternative   Previously known       amino acid sequence   amino acid(s)   SNP?                                 67   E -&gt; D   Yes       98   F -&gt;   No       99   A -&gt; T   Yes       120   A -&gt; S   Yes       178   S -&gt;   No       179   D -&gt; N   No       204   C -&gt;   No       312   R -&gt; W   Yes       383   V -&gt; M   Yes       388   A -&gt;   No       636   R -&gt;   No       648   K -&gt; N   Yes       656   M -&gt; I   Yes       717   R -&gt;   No       719   T -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318) is shown in bold; this coding portion starts at position 104 and ends at position 2290. The transcript also has the following SNPs as listed in Table 19 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P7 (SEQ ID NO:373) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 19                          Nucleic acid SNPs                         SNP position on   Alternative   Previously known       nucleotide sequence   nucleic acid   SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       304   G -&gt; C   Yes       370   A -&gt; G   Yes       397   C -&gt;   No       397   C -&gt; T   Yes       398   G -&gt; A   Yes       461   G -&gt; T   Yes       636   G -&gt;   No       638   G -&gt; A   No       715   C -&gt;   No       1037   C -&gt; T   Yes       1250   G -&gt; A   Yes       1266   C -&gt;   No       1315   C -&gt; T   Yes       1495   G -&gt; C   No       1741   A -&gt; C   Yes       2010   G -&gt;   No       2041   C -&gt; T   Yes       2047   G -&gt; C   Yes       2071   G -&gt; T   Yes       2233   T -&gt; C   Yes       2242   C -&gt; G   Yes       2253   G -&gt;   No       2259   C -&gt;   No       2357   G -&gt;   No       2364   C -&gt; G   Yes       2370   C -&gt;   No       2494   C -&gt;   No       2494   C -&gt; T   No       2514   C -&gt;   No       2551   G -&gt; A   No       2590   C -&gt;   No       2590   C -&gt; G   No       2604   C -&gt; T   No       2677   G -&gt; A   No       2677   G -&gt; C   No       2717   G -&gt;   No       2724   C -&gt; T   Yes       2733   G -&gt; C   Yes       2826   C -&gt;   No       2840   G -&gt; C   Yes       2892   C -&gt; T   Yes       2907   G -&gt; T   Yes       2963   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL PEA — 1_T19 (SEQ ID NO:319). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVF SNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLG NNK corresponding to amino acids 1-585 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-585 of HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence GCPESGTSASMAGHESKP (SEQ ID NO:475) corresponding to amino acids 586-603 of HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P13 (SEQ ID NO:3741, comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence GCPESGTSASMAGHESKP (SEQ ID NO:475) in HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374).  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 20                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                             SNP position(s) on               amino acid sequence   Type of change                       100   variant                      
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 21, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 21                          Amino acid mutations                         SNP position(s) on   Alternative   Previously known       amino acid sequence   amino acid(s)   SNP?                                 67   E -&gt; D   Yes       98   F -&gt;   No       99   A -&gt; T   Yes       120   A -&gt; S   Yes       178   S -&gt;   No       179   D -&gt; N   No       204   C -&gt;   No       232   A -&gt; G   No       232   A -&gt;   No       310   R -&gt; W   Yes       381   V -&gt; M   Yes       386   A -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319) is shown in bold; this coding portion starts at position 104 and ends at position 1912. The transcript also has the following SNPs as listed in Table 22 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P13 (SEQ ID NO:374) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 22                          Nucleic acid SNPs                         SNP position on   Alternative   Previously known       nucleotide sequence   nucleic acid   SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       304   G -&gt; C   Yes       370   A -&gt; G   Yes       397   C -&gt;   No       397   C -&gt; T   Yes       398   G -&gt; A   Yes       461   G -&gt; T   Yes       636   G -&gt;   No       638   G -&gt; A   No       715   C -&gt;   No       798   C -&gt;   No       798   C -&gt; G   No       1031   C -&gt; T   Yes       1244   G -&gt; A   Yes       1260   C -&gt;   No       1309   C -&gt; T   Yes       1489   G -&gt; C   No       1735   A -&gt; C   Yes       1917   C -&gt;   No       1931   G -&gt; C   Yes       1983   C -&gt; T   Yes       1998   G -&gt; T   Yes       2054   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVF SNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLG NNK corresponding to amino acids 1-585 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-585 of HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence TATPENLLGDRRGICAQLDLLLACGEGSDRSTHHTGSPCPGCL (SEQ ID NO:476) corresponding to amino acids 586-628 of HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence TATPENLLGDRRGICAQLDLLLACGEGSDRSTHHTGSPCPGCL (SEQ ID NO:476) in HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375).  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 23                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                             SNP position(s) on               amino acid sequence   Type of change                       100   variant                      
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 24, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 24                          Amino acid mutations                         SNP position(s) on amino acid   Alternative amino   Previously known       sequence   acid(s)   SNP?                                 67   E -&gt; D   Yes       98   F -&gt;   No       99   A -&gt; T   Yes       120   A -&gt; S   Yes       178   S -&gt;   No       179   D -&gt; N   No       204   C -&gt;   No       232   A -&gt; G   No       232   A -&gt;   No       310   R -&gt; W   Yes       381   V -&gt; M   Yes       386   A -&gt;   No       605   L -&gt; F   Yes       610   G -&gt; W   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) is shown in bold; this coding portion starts at position 104 and ends at position 1987. The transcript also has the following SNPs as listed in Table 25 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P14 (SEQ ID NO:375) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 25                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative nucleic   Previously known       sequence   acid   SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       304   G -&gt; C   Yes       370   A -&gt; G   Yes       397   C -&gt;   No       397   C -&gt; T   Yes       398   G -&gt; A   Yes       461   G -&gt; T   Yes       636   G -&gt;   No       638   G -&gt; A   No       715   C -&gt;   No       798   C -&gt;   No       798   C -&gt; G   No       1031   C -&gt; T   Yes       1244   G -&gt; A   Yes       1260   C -&gt;   No       1309   C -&gt; T   Yes       1489   G -&gt; C   No       1735   A -&gt; C   Yes       1864   G -&gt; C   Yes       1916   C -&gt; T   Yes       1931   G -&gt; T   Yes       1987   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), comprising a first amino acid sequence being at least 90% homologous to MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAY DTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGV FIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVG PEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLM TRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGEL QSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVF SNPEDWKEKYIHQNYTKALAGKLVET corresponding to amino acids 1-550 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-550 of HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VRAMDTLLDQPCLLQGAGHRRETACPGEWGTAGWEL (SEQ ID NO:477) corresponding to amino acids 551-586 of HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VRAMDTLLDQPCLLQGAGHRRETACPGEWGTAGWEL (SEQ ID NO:477) in HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376).  
      It should be noted that the known protein sequence (PLO1_HUMAN) Has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 26                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                             SNP position(s) on               amino acid sequence   Type of change                       100   variant                      
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 27, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 27                          Amino acid mutations                         SNP position(s) on amino acid   Alternative amino   Previously known       sequence   acid(s)   SNP?                                 67   E -&gt; D   Yes       98   F -&gt;   No       99   A -&gt; T   Yes       120   A -&gt; S   Yes       178   S -&gt;   No       179   D -&gt; N   No       204   C -&gt;   No       232   A -&gt; G   No       232   A -&gt;   No       310   R -&gt; W   Yes       381   V -&gt; M   Yes       386   A -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321) is shown in bold; this coding portion starts at position 104 and ends at position 88889. The transcript also has the following SNPs as listed in Table 28 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P16 (SEQ ID NO:376) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 28                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative nucleic   Previously known       sequence   acid   SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       304   G -&gt; C   Yes       370   A -&gt; G   Yes       397   C -&gt;   No       397   C -&gt; T   Yes       398   G -&gt; A   Yes       461   G -&gt; T   Yes       636   G -&gt;   No       638   G -&gt; A   No       715   C -&gt;   No       798   C -&gt;   No       798   C -&gt; G   No       1031   C -&gt; T   Yes       1244   G -&gt; A   Yes       1260   C -&gt;   No       1309   C -&gt; T   Yes       1489   G -&gt; C   No       1735   A -&gt; C   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P18 (SEQ ID NO:377) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P18 (SEQ ID NO:377) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 29, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P18 (SEQ ID NO:377) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 29                          Amino acid mutations                         SNP position(s) on amino acid   Alternative amino   Previously known       sequence   acid(s)   SNP?                                 74   L -&gt;   No       77   R -&gt; G   Yes       79   P -&gt;   No       120   S -&gt;   No       120   S -&gt; F   No       127   P -&gt;   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P18 (SEQ ID NO:377) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322) is shown in bold; this coding portion starts at position 104 and ends at position 514. The transcript also has the following SNPs as listed in Table 30 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P18 (SEQ ID NO:377) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 30                          Nucleic acid SNPs                         SNP position on nucleotide   Alternative nucleic   Previously known       sequence   acid   SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       325   G -&gt;   No       332   C -&gt; G   Yes       338   C -&gt;   No       462   C -&gt;   No       462   C -&gt; T   No       482   C -&gt;   No       519   G -&gt; A   No       558   C -&gt;   No       558   C -&gt; G   No       572   C -&gt; T   No       645   G -&gt; A   No       645   G -&gt; C   No       685   G -&gt;   No       692   C -&gt; T   Yes       701   G -&gt; C   Yes       794   C -&gt;   No       808   G -&gt; C   Yes       860   C -&gt; T   Yes       875   G -&gt; T   Yes       931   C -&gt; A   Yes                  
 
      Variant protein HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378) according to the present invention has an amino acid sequence as given at the end of the application; it is encoded by transcript(s) HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317). An alignment is given to the known protein (Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor (SEQ ID NO:367)) at the end of the application. One or more alignments to one or more previously published protein sequences are given at the end of the application. A brief description of the relationship of the variant protein according to the present invention to each such aligned protein is as follows:  
      Comparison report between HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378) and PLO1_HUMAN_V1 (SEQ ID NO:368):  
      1. An isolated chimeric polypeptide encoding for HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), comprising a first amino acid sequence being at least 90% homologous to MRPLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQFFNYKIQAL GLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYDVLFASGPRELLK KFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQ DSDSDQLFYTKIFLDPEKR corresponding to amino acids 1-193 of PLO1_HUMAN_V1 (SEQ ID NO:368), which also corresponds to amino acids 1-193 of HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), and a second amino acid sequence being at least 70%, optionally at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% homologous to a polypeptide having the sequence VSRLHS (SEQ ID NO:478) corresponding to amino acids 194-199 of HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order.  
      2. An isolated polypeptide encoding for a tail of HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378), comprising a polypeptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to the sequence VSRLHS (SEQ ID NO:478) in HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378).  
      It should be noted that the known protein sequence (PLO1_HUMAN (SEQ ID NO:367)) has one or more changes than the sequence given at the end of the application and named as being the amino acid sequence for PLO1_HUMAN_V1 (SEQ ID NO:368). These changes were previously known to occur and are listed in the table below.  
               TABLE 31                          Changes to PLO1_HUMAN_V1 (SEQ ID NO: 368)                             SNP position(s) on               amino acid sequence   Type of change                       100   variant                      
 
      The location of the variant protein was determined according to results from a number of different software programs and analyses, including analyses from SignalP and other specialized programs. The variant protein is believed to be located as follows with regard to the cell: secreted. The protein localization is believed to be secreted because both signal-peptide prediction programs predict that this protein has a signal peptide, and neither trans-membrane region prediction program predicts that this protein has a trans-membrane region.  
      Variant protein HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378) also has the following non-silent SNPs (Single Nucleotide Polymorphisms) as listed in Table 32, (given according to their position(s) on the amino acid sequence, with the alternative amino acid(s) listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 32                          Amino acid mutations                         SNP position(s) on amino acid   Alternative amino   Previously known       sequence   acid(s)   SNP?                                 67   E -&gt; D   Yes       98   F -&gt;   No       99   A -&gt; T   Yes       120   A -&gt; S   Yes       178   S -&gt;   No       179   D -&gt; N   No                  
 
      Variant protein HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378) is encoded by the following transcript(s): HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), for which the sequence(s) is/are given at the end of the application. The coding portion of transcript HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317) is shown in bold; this coding portion starts at position 104 and ends at position 700. The transcript also has the following SNPs as listed in Table 33 (given according to their position on the nucleotide sequence, with the alternative nucleic acid listed; the last column indicates whether the SNP is known or not; the presence of known SNPs in variant protein HUMLYSYL_PEA — 1_P24 (SEQ ID NO:378) Sequence provides support for the deduced sequence of this variant protein according to the present invention).  
               TABLE 33                          Nucleic acid SNPs                         SNP position on nucleotide       Previously       sequence   Alternative nucleic acid   known SNP?                                 37   C -&gt;   No       71   C -&gt;   No       102   C -&gt;   No       217   C -&gt; A   Yes       304   G -&gt; C   Yes       370   A -&gt; G   Yes       397   C -&gt;   No       397   C -&gt; T   Yes       398   G -&gt; A   Yes       461   G -&gt; T   Yes       636   G -&gt;   No       638   G -&gt; A   No       820   G -&gt; A   Yes       839   G -&gt; A   Yes       971   C -&gt;   No       1054   C -&gt;   No       1054   C -&gt; G   No       1287   C -&gt; T   Yes       1500   G -&gt; A   Yes       1516   C -&gt;   No       1565   C -&gt; T   Yes       1745   G -&gt; C   No       1991   A -&gt; C   Yes       2260   G -&gt;   No       2291   C -&gt; T   Yes       2297   G -&gt; C   Yes       2321   G -&gt; T   Yes       2483   T -&gt; C   Yes       2492   C -&gt; G   Yes       2503   G -&gt;   No       2509   C -&gt;   No       2607   G -&gt;   No       2614   C -&gt; G   Yes       2620   C -&gt;   No       2744   C -&gt;   No       2744   C -&gt; T   No       2764   C -&gt;   No       2801   G -&gt; A   No       2840   C -&gt;   No       2840   C -&gt; G   No       2854   C -&gt; T   No       2927   G -&gt; A   No       2927   G -&gt; C   No       2967   G -&gt;   No       2974   C -&gt; T   Yes       2983   G -&gt; C   Yes       3076   C -&gt;   No       3090   G -&gt; C   Yes       3142   C -&gt; T   Yes       3157   G -&gt; T   Yes       3213   C -&gt; A   Yes                  
 
      As noted above, cluster HUMLYSYL features 44 segment(s), which were listed in Table 2 above and for which the sequence(s) are given at the end of the application. These segment(s) are portions of nucleic acid sequence(s) which are described herein separately because they are of particular interest. A description of each segment according to the present invention is now provided.  
      Segment cluster HUMLYSYL_PEA — 1_node — 6 (SEQ ID NO:323) according to the present invention is supported by 3 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314). Table 34 below describes the starting and ending position of this segment on each transcript.  
               TABLE 34                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMLYSYL_PEA_1_T4 (SEQ ID   180   320       NO: 314)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 14 (SEQ ID NO:324) according to the present invention is supported by 122 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 35 below describes the starting and ending position of this segment on each transcript.  
               TABLE 35                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   406   569       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   547   710       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   406   569       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   433   596       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   406   569       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   406   569       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   406   569       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   406   569       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   406   569       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 19 (SEQ ID NO:325) according to the present invention is supported by 4 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317). Table 36 below describes the starting and ending position of this segment on each transcript.  
               TABLE 36                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMLYSYL_PEA_1_T8 (SEQ ID   683   938       NO: 317)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 38 (SEQ ID NO:326) according to the present invention is supported by 94 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 37 below describes the starting and ending position of this segment on each transcript.  
               TABLE 37                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   1306   1431       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1447   1572       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1231   1356       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1333   1458       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1562   1687       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1312   1437       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1306   1431       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1306   1431       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1306   1431       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 55 (SEQ ID NO:327) according to the present invention is supported by 149 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317) and HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318). Table 38 below describes the starting and ending position of this segment on each transcript.  
               TABLE 38                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1912   2040       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2000   2128       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1784   1912       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1886   2014       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2115   2243       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1865   1993       NO: 318)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 59 (SEQ ID NO:328) according to the present invention is supported by 161 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317) and HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318). Table 39 below describes the starting and ending position of this segment on each transcript.  
               TABLE 39                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   2059   2184       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2147   2272       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1931   2056       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2033   2158       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2262   2387       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2012   2137       NO: 318)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 61 (SEQ ID NO:329) according to the present invention is supported by 196 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA_T8 (SEQ ID NO:317) and HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318). Table 40 below describes the starting and ending position of this segment on each transcript.  
               TABLE 40                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   2185   2350       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2273   2438       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2057   2222       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2159   2324       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2388   2553       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2138   2303       NO: 318)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 62 (SEQ ID NO:330) according to the present invention is supported by 275 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — _T9 (SEQ ID NO:318) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 41 below describes the starting and ending position of this segment on each transcript.  
               TABLE 41                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2351   2622       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2439   2710       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2223   2494       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2325   2596       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2554   2825       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2304   2575       NO: 318)       HUMLYSYL_PEA_1_T24 (SEQ ID   272   543       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 65 (SEQ ID NO:331) according to the present invention is supported by 233 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 42 below describes the starting and ending position of this segment on each transcript.  
               TABLE 42                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2675   2814       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2763   2902       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2547   2686       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2649   2788       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2878   3017       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2628   2767       NO: 318)       HUMLYSYL_PEA_1_T24 (SEQ ID   596   735       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 71 (SEQ ID NO:332) according to the present invention is supported by 187 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 43 below describes the starting and ending position of this segment on each transcript.  
               TABLE 43                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2895   3027       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2983   3115       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2767   2899       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2869   3001       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   3098   3230       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2848   2980       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1939   2071       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1872   2004       NO: 320)       HUMLYSYL_PEA_1_T24 (SEQ ID   816   948       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 72 (SEQ ID NO:333) according to the present invention is supported by 143 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 44 below describes the starting and ending position of this segment on each transcript.  
               TABLE 44                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   3028   3069       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   3116   3157       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2900   2941       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   3002   3043       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   3231   3272       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2981   3022       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   2072   2113       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   2005   2046       NO: 320)       HUMLYSYL_PEA_1_T24 (SEQ ID   949   990       NO: 322)                  
 
      According to an optional embodiment of the present invention, short segments related to the above cluster are also provided. These segments are up to about 120 bp in length, and so are included in a separate description.  
      Segment cluster HUMLYSYL_PEA — 1_node — 3 (SEQ ID NO:334) according to the present invention is supported by 68 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL-PEA-1_T19 (SEQ ID NO:319), HUMLYSYL PEA — 1_T20 (SEQ ID NO:320), HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 45 below describes the starting and ending position of this segment on each transcript.  
               TABLE 45                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1   76       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1   76       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1   76       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1   76       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1   76       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1   76       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1   76       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1   76       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1   76       NO: 321)       HUMLYSYL_PEA_1_T24 (SEQ ID   1   76       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 4 (SEQ ID NO:335) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320), HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 46 below describes the starting and ending position of this segment on each transcript.  
               TABLE 46                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   77   179       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   77   179       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   77   179       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   77   179       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   77   179       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   77   179       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   77   179       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   77   179       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   77   179       NO: 321)       HUMLYSYL_PEA_1_T24 (SEQ ID   77   179       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 8 (SEQ ID NO:336) according to the present invention is supported by 108 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320), HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 47 below describes the starting and ending position of this segment on each transcript.  
               TABLE 47                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   180   271       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   321   412       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   180   271       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   180   271       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   180   271       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   180   271       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   180   271       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   180   271       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   180   271       NO: 321)       HUMLYSYL_PEA_1_T24 (SEQ ID   180   271       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 10 (SEQ ID NO:337) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316). Table 48 below describes the starting and ending position of this segment on each transcript.  
               TABLE 48                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMLYSYL_PEA_1_T6 (SEQ ID   272   298       NO: 316)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 11 (SEQ ID NO:338) according to the present invention is supported by 120 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 49 below describes the starting and ending position of this segment on each transcript.  
               TABLE 49                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   272   355       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   413   496       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   272   355       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   299   382       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   272   355       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   272   355       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   272   355       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   272   355       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   272   355       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 12 (SEQ ID NO:339) according to the present invention is supported by 111 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA_T2 (SEQ ID NO:313), HUMLYSYL PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 50 below describes the starting and ending position of this segment on each transcript.  
               TABLE 50                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   356   405       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   497   546       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   356   405       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   383   432       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   356   405       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   356   405       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   356   405       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   356   405       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   356   405       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 16 (SEQ ID NO:340) according to the present invention is supported by 127 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 51 below describes the starting and ending position of this segment on each transcript.  
               TABLE 51                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   570   682       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   711   823       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   570   682       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   597   709       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   570   682       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   570   682       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   570   682       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   570   682       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   570   682       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 20 (SEQ ID NO:341) according to the present invention is supported by 107 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 52 below describes the starting and ending position of this segment on each transcript.  
               TABLE 52                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   683   746       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   824   887       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   683   746       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   710   773       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   939   1002       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   683   746       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   683   746       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   683   746       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   683   746       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 23 (SEQ ID NO:342) according to the present invention is supported by 111 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 53 below describes the starting and ending position of this segment on each transcript.  
               TABLE 53                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   747   844       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   888   985       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   747   844       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   774   871       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1003   1100       NO: 317)       HUMLYSYL_PEA_1_T19 (SEQ ID   747   844       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   747   844       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   747   844       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 25 (SEQ ID NO:343) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318). Table 54 below describes the starting and ending position of this segment on each transcript.  
               TABLE 54                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T9 (SEQ ID   747   850       NO: 318)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 28 (SEQ ID NO:344) according to the present invention is supported by 105 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 55 below describes the starting and ending position of this segment on each transcript.  
               TABLE 55                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   845   946       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   986   1087       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   845   946       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   872   973       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1101   1202       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   851   952       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   845   946       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   845   946       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   845   946       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 30 (SEQ ID NO:345) according to the present invention is supported by 86 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 56 below describes the starting and ending position of this segment on each transcript.  
               TABLE 56                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   947   1021       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1088   1162       NO: 314)       HUMLYSYL_PEA_1_T6 (SEQ ID   974   1048       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1203   1277       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   953   1027       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   947   1021       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   947   1021       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   947   1021       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 31 (SEQ ID NO:346) according to the present invention is supported by 79 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 57 below describes the starting and ending position of this segment on each transcript.  
               TABLE 57                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   1022   1078       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1163   1219       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   947   1003       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1049   1105       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1278   1334       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1028   1084       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1022   1078       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1022   1078       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1022   1078       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 33 (SEQ ID NO:347) according to the present invention is supported by 81 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 58 below describes the starting and ending position of this segment on each transcript.  
               TABLE 58                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1079   1162       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1220   1303       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1004   1087       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1106   1189       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1335   1418       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1085   1168       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1079   1162       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1079   1162       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1079   1162       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 34 (SEQ ID NO:348) according to the present invention is supported by 74 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 59 below describes the starting and ending position of this segment on each transcript.  
               TABLE 59                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1163   1200       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1304   1341       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1088   1125       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1190   1227       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1419   1456       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1169   1206       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1163   1200       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1163   1200       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1163   1200       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 36 (SEQ ID NO:349) according to the present invention is supported by 90 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 60 below describes the starting and ending position of this segment on each transcript.  
               TABLE 60                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1201   1305       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1342   1446       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1126   1230       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1228   1332       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1457   1561       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1207   1311       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1201   1305       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1201   1305       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1201   1305       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 40 (SEQ ID NO:350) according to the present invention is supported by 96 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 61 below describes the starting and ending position of this segment on each transcript.  
               TABLE 61                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1432   1468       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1573   1609       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1357   1393       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1459   1495       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1688   1724       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1438   1474       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1432   1468       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1432   1468       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1432   1468       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 41 (SEQ ID NO:351) according to the present invention is supported by 109 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 62 below describes the starting and ending position of this segment on each transcript.  
               TABLE 62                          Segment location on transcripts                             Segment               starting   Segment       Transcript name   position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1469   1573       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1610   1714       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1394   1498       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1496   1600       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1725   1829       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1475   1579       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1469   1573       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1469   1573       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1469   1573       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1 node — 42 (SEQ ID NO:352) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313). Table 63 below describes the starting and ending position of this segment on each transcript.  
               TABLE 63                          Segment location on transcripts                             Segment   Segment       Transcript name   starting position   ending position               HUMLYSYL_PEA_1_T2 (SEQ ID   1574   1626       NO: 313)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 44 (SEQ ID NO:353) according to the present invention can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 64 below describes the starting and ending position of this segment on each transcript.  
               TABLE 64                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   1627   1646       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1715   1734       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1499   1518       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1601   1620       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1830   1849       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1580   1599       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1574   1593       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1574   1593       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1574   1593       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 45 (SEQ ID NO:354) according to the present invention is supported by 99 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 65 below describes the starting and ending position of this segment on each transcript.  
               TABLE 65                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   1647   1685       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1735   1773       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1519   1557       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1621   1659       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1850   1888       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1600   1638       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1594   1632       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1594   1632       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1594   1632       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 46 (SEQ ID NO:355) according to the present invention is supported by 106 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA —1 _T22 (SEQ ID NO:321). Table 66 below describes the starting and ending position of this segment on each transcript.  
               TABLE 66                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   1686   1740       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1774   1828       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1558   1612       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1660   1714       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1889   1943       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1639   1693       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1633   1687       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1633   1687       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1633   1687       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 48 (SEQ ID NO:356) according to the present invention is supported by 116 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 67 below describes the starting and ending position of this segment on each transcript.  
               TABLE 67                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   1741   1806       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1829   1894       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1613   1678       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1715   1780       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   1944   2009       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1694   1759       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1688   1753       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1688   1753       NO: 320)       HUMLYSYL_PEA_1_T22 (SEQ ID   1688   1753       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 49 (SEQ ID NO:357) according to the present invention is supported by 1 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T22 (SEQ ID NO:321). Table 68 below describes the starting and ending position of this segment on each transcript.  
               TABLE 68                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T22 (SEQ ID   1754   1862       NO: 321)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 52 (SEQ ID NO:358) according to the present invention is supported by 114 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319) and HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320). Table 69 below describes the starting and ending position of this segment on each transcript.  
               TABLE 69                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   1807   1835       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1895   1923       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1679   1707       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1781   1809       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2010   2038       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1760   1788       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1754   1782       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1754   1782       NO: 320)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 53 (SEQ ID NO:359) according to the present invention is supported by 126 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319) and HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320). Table 70 below describes the starting and ending position of this segment on each transcript.  
               TABLE 70                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   1836   1911       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   1924   1999       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1708   1783       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   1810   1885       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2039   2114       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1789   1864       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1783   1858       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1783   1858       NO: 320)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 56 (SEQ ID NO:360) according to the present invention can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317) and HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318). Table 71 below describes the starting and ending position of this segment on each transcript.  
               TABLE 71                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position               HUMLYSYL_PEA_1_T2 (SEQ ID   2041   2058       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2129   2146       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   1913   1930       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2015   2032       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2244   2261       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   1994   2011       NO: 318)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 63 (SEQ ID NO:361) according to the present invention can be found in the following transcript(s): HUMLYSYL PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 72 below describes the starting and ending position of this segment on each transcript.  
               TABLE 72                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2623   2644       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2711   2732       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2495   2516       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2597   2618       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2826   2847       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2576   2597       NO: 318)       HUMLYSYL_PEA_1_T24 (SEQ ID   544   565       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 64 (SEQ ID NO:362) according to the present invention is supported by 208 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 73 below describes the starting and ending position of this segment on each transcript.  
               TABLE 73                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2645   2674       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2733   2762       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2517   2546       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2619   2648       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   2848   2877       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2598   2627       NO: 318)       HUMLYSYL_PEA_1_T24 (SEQ ID   566   595       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 66 (SEQ ID NO:363) according to the present invention can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL PEA — 1_T19 (SEQ ID NO:319) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 74 below describes the starting and ending position of this segment on each transcript.  
               TABLE 74                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2815   2821       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2903   2909       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2687   2693       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2789   2795       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   3018   3024       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2768   2774       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1859   1865       NO: 319)       HUMLYSYL_PEA_1_T24 (SEQ ID   736   742       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 67 (SEQ ID NO:364) according to the present invention is supported by 198 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 75 below describes the starting and ending position of this segment on each transcript.  
               TABLE 75                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2822   2854       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2910   2942       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2694   2726       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2796   2828       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   3025   3057       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2775   2807       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1866   1898       NO: 319)       HUMLYSYL_PEA_1_T24 (SEQ ID   743   775       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 68 (SEQ ID NO:365) according to the present invention is supported by 187 libraries. The number of libraries was determined as previously described. This segment can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319) and HUMLYSYL PEA — 1_T24 (SEQ ID NO:322). Table 76 below describes the starting and ending position of this segment on each transcript.  
               TABLE 76                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2855   2881       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2943   2969       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2727   2753       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2829   2855       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   3058   3084       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2808   2834       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1899   1925       NO: 319)       HUMLYSYL_PEA_1_T24 (SEQ ID   776   802       NO: 322)                  
 
      Segment cluster HUMLYSYL_PEA — 1_node — 70 (SEQ ID NO:366) according to the present invention can be found in the following transcript(s): HUMLYSYL_PEA — 1_T2 (SEQ ID NO:313), HUMLYSYL_PEA — 1_T4 (SEQ ID NO:314), HUMLYSYL_PEA — 1_T5 (SEQ ID NO:315), HUMLYSYL_PEA — 1_T6 (SEQ ID NO:316), HUMLYSYL_PEA — 1_T8 (SEQ ID NO:317), HUMLYSYL_PEA — 1_T9 (SEQ ID NO:318), HUMLYSYL_PEA — 1_T19 (SEQ ID NO:319), HUMLYSYL_PEA — 1_T20 (SEQ ID NO:320) and HUMLYSYL_PEA — 1_T24 (SEQ ID NO:322). Table 77 below describes the starting and ending position of this segment on each transcript.  
               TABLE 77                          Segment location on transcripts                                 Segment           Segment   ending       Transcript name   starting position   position                                 HUMLYSYL_PEA_1_T2 (SEQ ID   2882   2894       NO: 313)       HUMLYSYL_PEA_1_T4 (SEQ ID   2970   2982       NO: 314)       HUMLYSYL_PEA_1_T5 (SEQ ID   2754   2766       NO: 315)       HUMLYSYL_PEA_1_T6 (SEQ ID   2856   2868       NO: 316)       HUMLYSYL_PEA_1_T8 (SEQ ID   3085   3097       NO: 317)       HUMLYSYL_PEA_1_T9 (SEQ ID   2835   2847       NO: 318)       HUMLYSYL_PEA_1_T19 (SEQ ID   1926   1938       NO: 319)       HUMLYSYL_PEA_1_T20 (SEQ ID   1859   1871       NO: 320)       HUMLYSYL_PEA_1_T24 (SEQ ID   803   815       NO: 322)                  
 
      Variant protein alignment to the previously known protein:  
      Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)  
                          Sequence documentation:           Alignment of: HUMLYSYL_PEA_1_P2 (SEQ ID NO:369) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   4794.00   Escore:   0           Matching length:   490   Total length:   490       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100                            .         .         .         .         .       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150                            .         .         .         .         .       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200                            .         .         .         .         .       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250                            .         .         .         .         .       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300                            .         .         .         .         .       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350                            .         .         .         .         .       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400                            .         .         .         .         .       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450           ||||||||||||||||||||||||||||||||||||||||||||||||||       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450                            .         .         .         .       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQ   490           ||||||||||||||||||||||||||||||||||||||||       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQ   490                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1_P4 (SEQ ID NO:370) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   7109.00   Escore:   0           Matching length:   727   Total length:   774       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   93.93   Total Percent   93.93       Similarity:       Identity:       Gaps:   1                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEAPCCQEGLRAGGSGSLHLGRDFTVL   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPE.........................   25                            .         .         .         .         .       51   AGARGSPSPSVSSIPRFWIPGSDNLLVLTVATKETEGFRRFKRSAQFFNY   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       26   ......................DNLLVLTVATKETEGFRRFKRSAQFFNY   53                            .         .         .         .         .       101   KIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYD   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       54   KIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFADSYD   103                            .         .         .         .         .       151   VLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLG   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       104   VLFASGFRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKRFLG   153                            .         .         .         .         .       201   SGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITLDHR   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       154   SGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITLDHR   203                            .         .         .         .         .       251   CRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYL   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       204   CRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYL   253                            .         .         .         .         .       301   GNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSL   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       254   GNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSL   303                            .         .         .         .         .       351   FFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPE   400           ||||||||||||||||||||||||||||||||||||||||||||||||||       304   FFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPE   353                            .         .         .         .         .       401   VRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNV   450           ||||||||||||||||||||||||||||||||||||||||||||||||||       354   VRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNV   403                            .         .         .         .         .       451   IAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISN   500           ||||||||||||||||||||||||||||||||||||||||||||||||||       404   IAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPYISN   453                            .         .         .         .         .       501   IYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLG   550           ||||||||||||||||||||||||||||||||||||||||||||||||||       454   IYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLG   503                            .         .         .         .         .       551   HLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVETPCP   600           ||||||||||||||||||||||||||||||||||||||||||||||||||       504   HLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVETPCP   553                            .         .         .         .         .       601   DVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHM   650           ||||||||||||||||||||||||||||||||||||||||||||||||||       554   DVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHM   603                            .         .         .         .         .       651   NQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSL   700       ||||||||||||||||||||||||||||||||||||||||||||||||||       604   NQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSL   653                            .         .         .         .         .       701   MPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGR   750           ||||||||||||||||||||||||||||||||||||||||||||||||||       654   MPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGR   703                            .         .       751   LTHYHEGLPTTRGTRYIAVSFVDP   774           ||||||||||||||||||||||||       704   LTHYHEGLPTTRGTRYIAVSFVDP   727                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1_P5 (SEQ ID NO:371) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   6869.00   Escore:   0           Matching length:   702   Total length:   727       Matching Percent Similarity:   100.00   Matching Percent Identity:   100.00       Total Percent Similarity:   96.56   Total Percent Identity:   96.56       Gaps:   1                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100                            .         .         .         .         .       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150                            .         .         .         .         .       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200                            .         .         .         .         .       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGFTKLQL   250                            .         .         .         .         .       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIG...................   281           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300                            .         .         .         .         .       282   ......RLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   325           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350                            .         .         .         .         .       326   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   375           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400                            .         .         .         .         .       376   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   425           ||||||||||||||||||||||||||||||||||||||||||||||||||       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450                            .         .         .         .         .       426   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRH   475           ||||||||||||||||||||||||||||||||||||||||||||||||||       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRH   500                            .         .         .         .         .       476   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   525           ||||||||||||||||||||||||||||||||||||||||||||||||||       501   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   550                            .         .         .         .         .       526   PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTID   575           ||||||||||||||||||||||||||||||||||||||||||||||||||       551   PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQGGYENVPTID   600                            .         .         .         .         .       576   IHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQ   625           ||||||||||||||||||||||||||||||||||||||||||||||||||       601   IHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQ   650                            .         .         .         .         .       626   PSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMH   675           ||||||||||||||||||||||||||||||||||||||||||||||||||       651   PSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRAPRKGWTLMH   700                            .         .       676   PGRLTHYHEGLPTTRGTRYIAVSFVDP   702           |||||||||||||||||||||||||||       701   PGRLTHYHEGLPTTRGTRYIAVSFVDP   727                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1_P6 (SEQ ID NO:372) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   7109.00   Escore:   0           Matching length:   727   Total length:   736       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   98.78   Total Percent   98.78       Similarity:       Identity:       Gaps:   1                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQPVLRGVSLQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADK   100           |||||         ||||||||||||||||||||||||||||||||||||       51   FNYKI.........QALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADK   91                            .         .         .         .         .       101   EDLVILFADSYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETK   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       92   EDLVILFADSYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETK   141                            .         .         .         .         .       151   YPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPE   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       142   YPVVSDGKRFLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPE   191                            .         .         .         .         .       201   KREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLFVLIH   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       192   KREQINITLDHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIH   241                            .         .         .         .         .       251   GNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVG   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       242   GNGPTKLQLNYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVG   291                            .         .         .         .         .       301   VFIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHG   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       292   VFIEQPTPFVSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHG   341                            .         .         .         .         .       351   SEYQSVKLVGPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPN   400           ||||||||||||||||||||||||||||||||||||||||||||||||||       342   SEYQSVKLVGPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPN   391                            .         .         .         .         .       401   SLRLLIQQNKNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGR   450           ||||||||||||||||||||||||||||||||||||||||||||||||||       392   SLRLLIQQNKNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGR   441                            .         .         .         .         .       451   RVGVWNVPYISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQD   500           ||||||||||||||||||||||||||||||||||||||||||||||||||       442   RVGVWNVPYISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQD   491                            .         .         .         .         .       501   VFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTK   550           ||||||||||||||||||||||||||||||||||||||||||||||||||       492   VFMFLTNRHTLGHLLSLDSYRTTHLHNDLWEVFSNFEDWKEKYIHQNYTK   541                            .         .         .         .         .       551   ALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQG   600           ||||||||||||||||||||||||||||||||||||||||||||||||||       542   ALAGKLVETPCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNKDNRIQG   591                            .         .         .         .         .       601   GYENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAF   650           ||||||||||||||||||||||||||||||||||||||||||||||||||       592   GYENVPTIDIHMNQIGFEREWHKFLLEYIAPMTEKLYPGYYTRAQFDLAF   641                            .         .         .         .         .       651   VVRYKPDEQPSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRA   700           ||||||||||||||||||||||||||||||||||||||||||||||||||       642   VVRYKPDEQPSLMPHHDASTFTINIALNRVGVDYEGGGCRFLRYNCSIRA   691                            .         .         .       701   PRKGWTLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP   736           ||||||||||||||||||||||||||||||||||||       692   PRKGWTLMHPGRLTHYHEGLPTTRGTRYIAVSFVDP   727                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1_P7 (SEQ ID NO:373) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   6697.00   Escore:   0           Matching length:   698   Total length:   758       Matching Percent   99.71   Matching Percent   99.71       Similarity:       Identity:       Total Percent   91.82   Total Percent   91.82       Similarity:       Identity:       Gaps:   2                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100                            .         .         .         .         .       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150                            .         .         .         .         .       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200                            .         .         .         .         .       201   DHRCRIFQNLDGALVSPWGQGHLPGACYELTASVLTSELSVMPSFPAVV.   249           ||||||||||||||                                  ||       201   DHRCRIFQNLDGAL...............................DEVVL   219                            .         .         .         .         .       250   ............................LQLNYLGNYIPRFWTFETGCTV   271           ||||||||||||||||||||||||||||||||||||||||||||||||||       220   KFEMGHVRARNLAYDTLPVLIHGNGPTKLQLNYLGNYIPRFWTFETGCTV   269                            .         .         .         .         .       272   CDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQRLLRLHYPQKHMR   321           ||||||||||||||||||||||||||||||||||||||||||||||||||       270   CDEGLRSLKGIGDEALPTVLVGVFIEQPTPFVSLFFQRLLRLHYFQKHMR   319                            .         .         .         .         .       322   LFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARNMGADLC   371           ||||||||||||||||||||||||||||||||||||||||||||||||||       320   LFIHNHEQHHKAQVEEFLAQHGSEYQSVKLVGPEVRMANADARNMGADLC   369                            .         .         .         .         .       372   RQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFW   421           ||||||||||||||||||||||||||||||||||||||||||||||||||       370   RQDRSCTYYFSVDADVALTEPNSLRLLIQQNKNVIAPLMTRHGRLWSNFW   419                            .         .         .         .         .       422   GALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQSS   471           ||||||||||||||||||||||||||||||||||||||||||||||||||       420   GALSADGYYARSEDYVDIVQGRRVGVWNVPYISNIYLIKGSALRGELQSS   469                            .         .         .         .         .       472   DLFHHSKLDPDMAFCANIRQQDVFNFLTNRHTLGHLLSLDSYRTTHLHND   521           ||||||||||||||||||||||||||||||||||||||||||||||||||       470   DLFHHSKLDPDMAFCANIRQQDVFMFLTNRHTLGHLLSLDSYRTTHLHND   519                            .         .         .         .         .       522   LWEVFSNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDEL   571           ||||||||||||||||||||||||||||||||||||||||||||||||||       520   LWEVFSNPEDWKEKYIHQNYTKALAGKLVETPCPDVYWFPIFTEVACDEL   569                            .         .         .         .         .       572   VEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFLLEY   621           ||||||||||||||||||||||||||||||||||||||||||||||||||       570   VEEMEHFGQWSLGNNKDNRIQGGYENVPTIDIHMNQIGFEREWHKFLLEY   619                            .         .         .         .         .       622   IAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSLMPHHDASTFTINIALN   671           ||||||||||||||||||||||||||||||||||||||||||||||||||       620   IAPMTEKLYPGYYTRAQFDLAFVVRYKPDEQPSLMPHHDASTFTINIALN   669                            .         .         .         .         .       672   RVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEGLPTTRGTRY   721           ||||||||||||||||||||||||||||||||||||||||||||||||||       670   RVGVDYEGGGCRFLRYNCSIRAPRKGWTLMHPGRLTHYHEGLPTTRGTRY   719               722   IAVSFVDP   729           ||||||||       720   IAVSFVDP   727                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1 P13 (SEQ ID NO:374) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   5773.00   Escore:   0           Matching length:   585   Total length:   585       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100                            .         .         .         .         .       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150                            .         .         .         .         .       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200                            .         .         .         .         .       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTELQL   250                            .         .         .         .         .       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300                            .         .         .         .         .       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350                            .         .         .         .         .       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400                            .         .         .         .         .       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450           ||||||||||||||||||||||||||||||||||||||||||||||||||       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450                            .         .         .         .         .       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRH   500           ||||||||||||||||||||||||||||||||||||||||||||||||||       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRH   500                            .         .         .         .         .       501   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   550           ||||||||||||||||||||||||||||||||||||||||||||||||||       501   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   550                            .         .         .       551   PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNK   585           |||||||||||||||||||||||||||||||||||       551   PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNK   585                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1_P14 (SEQ ID NO:375) ×       PLO1_HUMAN_V1 (SEQ ID NO: 368)   . .               Alignment segment 1/1:                             +TL,Quality:   5773.00   Escore:   0       Matching length:   585   Total length:   585       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100                            .         .         .         .         .       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150                            .         .         .         .         .       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200                            .         .         .         .         .       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250                            .         .         .         .         .       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300                            .         .         .         .         .       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350                            .         .         .         .         .       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400                            .         .         .         .         .       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450           ||||||||||||||||||||||||||||||||||||||||||||||||||       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450                            .         .         .         .         .       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRH   500           ||||||||||||||||||||||||||||||||||||||||||||||||||       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFNFLTNRH   500                            .         .         .         .         .       501   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   550           ||||||||||||||||||||||||||||||||||||||||||||||||||       501   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   550                            .         .         .       551   PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNK   585           |||||||||||||||||||||||||||||||||||       551   PCPDVYWFPIFTEVACDELVEEMEHFGQWSLGNNK   585                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1_P16 (SEQ ID NO:376) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   5400.00   Escore:   0           Matching length:   550   Total length:   550       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100                            .         .         .         .         .       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYFVVSDGKR   150                            .         .         .         .         .       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200           ||||||||||||||||||||||||||||||||||||||||||||||||||       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKREQINITL   200                            .         .         .         .         .       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250           ||||||||||||||||||||||||||||||||||||||||||||||||||       201   DHRCRIFQNLDGALDEVVLKFEMGHVRARNLAYDTLPVLIHGNGPTKLQL   250                            .         .         .         .         .       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300           ||||||||||||||||||||||||||||||||||||||||||||||||||       251   NYLGNYIPRFWTFETGCTVCDEGLRSLKGIGDEALPTVLVGVFIEQPTPF   300                            .         .         .         .         .       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350           ||||||||||||||||||||||||||||||||||||||||||||||||||       301   VSLFFQRLLRLHYPQKHMRLFIHNHEQHHKAQVEEFLAQHGSEYQSVKLV   350                            .         .         .         .         .       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400           ||||||||||||||||||||||||||||||||||||||||||||||||||       351   GPEVRMANADARNMGADLCRQDRSCTYYFSVDADVALTEPNSLRLLIQQN   400                            .         .         .         .         .       401   KNVIAPLMTRXGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450           ||||||||||||||||||||||||||||||||||||||||||||||||||       401   KNVIAPLMTRHGRLWSNFWGALSADGYYARSEDYVDIVQGRRVGVWNVPY   450                            .         .         .         .         .       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRH   500           ||||||||||||||||||||||||||||||||||||||||||||||||||       451   ISNIYLIKGSALRGELQSSDLFHHSKLDPDMAFCANIRQQDVFMFLTNRH   500                            .         .         .         .         .       501   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   550           ||||||||||||||||||||||||||||||||||||||||||||||||||       501   TLGHLLSLDSYRTTHLHNDLWEVFSNPEDWKEKYIHQNYTKALAGKLVET   550                             Sequence name: PLO1_HUMAN_V1 (SEQ ID NO:368)                   Sequence documentation:       Alignment of: HUMLYSYL_PEA_1_P24 (SEQ ID NO:378) ×       PLO1_HUMAN_V1 (SEQ ID NO:368)   . .               Alignment segment 1/1:                                 Quality:   1850.00   Escore:   0           Matching length:   193   Total length:   193       Matching Percent   100.00   Matching Percent   100.00       Similarity:       Identity:       Total Percent   100.00   Total Percent   100.00       Similarity:       Identity:       Gaps:   0                             Alignment:                                              .         .         .         .         .               1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50           ||||||||||||||||||||||||||||||||||||||||||||||||||       1   MRPLLLLALLGWLLLAEAKGDAKPEDNLLVLTVATKETEGFRRFKRSAQF   50                            .         .         .         .         .       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100           ||||||||||||||||||||||||||||||||||||||||||||||||||       51   FNYKIQALGLGEDWNVEKGTSAGGGQKVRLLKKALEKHADKEDLVILFAD   100                            .         .         .         .         .       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150           ||||||||||||||||||||||||||||||||||||||||||||||||||       101   SYDVLFASGPRELLKKFRQARSQVVFSAEELIYPDRRLETKYPVVSDGKR   150                            .         .         .         .       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKR   193           |||||||||||||||||||||||||||||||||||||||||||       151   FLGSGGFIGYAPNLSKLVAEWEGQDSDSDQLFYTKIFLDPEKR   193          
 
     Additional Examples of Endometrial Markers  
      The present invention also encompasses additional examples of markers that are suitable for use with endometriosis. These markers relate to the chordin-like-2 (CHL2) family of variants that was discovered by the present applicants. These variants are disclosed in PCT Application No. WO 01/34796 and in PCT Application No. IL2004/000735, both of which are hereby incorporated by reference as if fully set forth herein. Preferably, these markers are serum markers but optionally they are immunohistochemistry markers. They are useful for diagnosis with any suitable biological, including but not limited to the examples listed previously.  
      As previously published by the present applicants (Oren et al, Gene. 2004 Apr. 28; 331:17-31), these variants bind Activin A specifically (and not BMP-2, 4, 6 as other members of the chordin family). By the literature, Activin A is associated with endometriosis. For example, there is evidence for local production and secretion of Activin A in ovarian endometriotic cysts (Reis et al, Fertil Steril. 2001 February; 75(2):367-73; Florio et al, Steroids. 2003 November; 68(10-13):801-7). All of these references are hereby incorporated by reference as if fully set forth herein. A brief description of these sequences is provided below.  
      Chordin is an abundant glycoprotein, and is a secreted protein of 955 amino acids (aa) with a molecular mass of 120 Kda. It is a key developmental protein that dorsalizes early vertebrate embryonic tissues by binding to ventralizing TGF-beta-like bone morphogenic proteins (BMP) and sequestering them in latent complexes. BMPs participate in a broad spectrum of cellular inducing events involving all three germ layers during metazoan development. Chordin binds to ventral BMP-2 and BMP-4 signals in the extracellular space, blocking the interaction of BMPs with their receptors. Chordin mimics the action of the Spemann organizer and can induce the formation of neural tissue from ectoderm and dorsalization of the ventral mesoderm to form muscle.  
      During early embryogenesis of vertebrates and invertebrates, antagonism between BMPs and several unrelated proteins is a general mechanism by which the dorso-ventral axis is established. One of these extracellular antagonists is Chordin, which binds with high affinity to certain BMPs, preventing their interaction with their cognate cell surface receptors. Chordin plays a role in dorso-ventral axis formation and induction, as well as in maintenance and differentiation of neural tissues in early vertebrate embryogenesis. The inhibitory activity of Chordin on BMPs is mediated by binding through specific domains named Cysteine-Rich (CR) repeats.  
      The conservation of each specific CR repeat between Chordin orthologs in different species is higher than that of different CRs within a particular ortholog. The individual CR repeats in Chordin vary in their binding affinity to BMPs, but they function cooperatively in the full-length protein.  
      Several alternatively spliced transcripts have been reported for the human Chordin gene. These variants were found to be differentially expressed in various tissues, and code for C-truncated isoforms of the Chordin protein that vary in their content of CR repeats and in their biological activity as BMP antagonists.  
      A New Chordin-like protein (CHL) was recently reported. CHL also binds and inhibits BMP activity. During embryogenesis and organogenesis, Chordin and CHL display distinct spatiotemporal expression patterns. Several splicing variants of mouse and human CHL have been reported which differ primarily in the length and sequence of their C-termini.  
      CHL has been shown to be secreted and to bind BMPs and other TGFb superfamily members. Expression patterns as well as functional studies in mouse, chicken and xenopus, indicate that it may function as a modulator of BMP signaling during embryonic development.  
      Recently, another chordin-like protein, which is structurally most homologous to CHL/neuralin/ventroptin, was identified (Development, 2004 January; 131(1):229-40. Epub 2003 Dec. 03.). When injected into  Xenopus  embryos, RNA of this protein induced a secondary dorso-ventral axis. Recombinant protein interacted directly with BMPs in a competitive manner to prevent binding to the type I BMP receptor ectodomain, and inhibited BMP-dependent induction of alkaline phosphatase in C2Cl2 cells. Thus, this protein behaves as a secreted BMP-binding inhibitor. In situ hybridization revealed that expression of this protein is restricted to chondrocytes of various developing joint cartilage surfaces and connective tissues in reproductive organs. Adult mesenchymal progenitor cells expressed this protein, and its levels decreased during chondrogenic differentiation. Addition of this protein to a chondrogenic culture system reduced cartilage matrix deposition. Consistently, protein transcripts were weakly detected in normal adult joint cartilage. However, its expression was upregulated in middle zone chondrocytes in osteoarthritic joint cartilage (where hypertrophic markers are induced). This protein depressed chondrocyte mineralization when added during the hypertrophic differentiation of cultured hyaline cartilage particles. Thus, this protein may play negative roles in the (re)generation and maturation of articular chondrocytes in the hyaline cartilage of both developing and degenerated joints.  
      A novel member of the Chordin-like protein family was identified and characterized by the present applicant in human and in mouse (PCT Application No. WO 01/34796, hereby incorporated by reference as if fully set forth herein). This novel protein, named CLH, shows high similarity to the recently reported CHL protein, also named Neuralin-1 or Ventroptin. For the sake of clarity, CLH will be referred to here as CHL2, since it is most closely related to the CHL sequence reported by Nakayama et al.  
      The high level of homology between CHL2 and CHL is reflected not only in the protein sequence, for example with regard to the number and location of the CR repeats (two adjacent repeats at the N′-terminus, and a third one further downstream), and the absence of other recognizable protein domains, but also in the gene structure, number and size of exons and the spacing of the CR repeats within the exons. Further characterization of CHL2 revealed ubiquitous expression in a variety of tissues and complex alternative splicing, resulting in differentially expressed CHL2 isoforms that differ in their C-termini, the presence of a signal peptide, and the content of their CR repeats.  
      It has been postulated that Chordin may be expressed by cells of the osteoblast lineage to limit BMP actions in osteoblasts. This may suggest an important function for Chordin as a BMP binding protein since excessive BMP-4 has been implicated in pathogenesis of Fibrodysplasia Ossificans Progressiva (FOP). FOP is a rare genetic disease in which muscles, tendons, ligaments and other connective tissues may ossify into bone. BMPs can cause induction of noggin and Chordin mRNA and protein levels in skeletal cells by transcriptional mechanisms, and these, in turn, prevent the effect of BMPs in osteoblasts in a negative-feedback mechanism. The induction of these proteins by BMPs appears to be a mechanism to limit the BMP effect in bones. Existing therapies which are being investigated for their effectiveness in preventing heterotopic bone formation include inhibitors of BMPs.  
      The Chordin-like protein 2 (CHL2) variants according to the present invention are useful for diagnosis of endometriosis, as markers. These markers may optionally comprise an isolated nucleic acid molecule comprising the sequence of any one of SEQ ID NO: 379 to SEQ ID NO: 383, fragments of said sequences having at least 20 nucleic acids, or a molecule comprising a sequence having at least 80%, preferably 90%, and most preferably 95% or 98% identity to any one of SEQ ID NO:379 to SEQ ID NO: 383, as well as sequences complementary thereto and/or capable of hybridizing therewith, preferably under moderate to stringent conditions (described above). Optionally and more preferably, a nucleic acid molecule comprising or consisting of a non-coding sequence which is complementary to that of any one of SEQ ID NO: 379 to SEQ ID NO: 383, or complementary to a sequence having at least 80%, preferably 90%, most preferably 95% or 98% identity to said sequences or a fragment of said sequences. The complementary sequence may be a DNA sequence which hybridizes to any one of the sequences of SEQ ID NO: 379 to SEQ ID NO: 383, or hybridizes to a portion of these sequences which includes the “unique” sequences or bridges, and which has a length sufficient to inhibit the transcription of any one of the sequences of SEQ ID NO:379 to SEQ ID NO:383. The complementary sequence may be a DNA sequence which can be transcribed into an mRNA being an antisense of the mRNA transcribed from any one of SEQ ID NO: 379 to SEQ ID NO: 383 amend or into an mRNA which is an antisense to a fragment of the mRNA transcribed from any one of SEQ ID NO: 379 to SEQ ID NO: 383 which has a length sufficient to hybridize with the mRNA transcribed from any one of SEQ ID NO: 379 to SEQ ID NO: 383, so as to inhibit its translation. The complementary sequence may also be the mRNA or the fragment of the mRNA itself.  
      These markers may optionally comprise a protein or polypeptide comprising or consisting of an amino acid sequence encoded by any of the above nucleic acid sequences, termed herein “CHL2 product”, for example, an amino acid sequence having the sequence in any one of SEQ ID NO: 389 to 393, fragments of the above amino acid sequences having a length of at least 10 amino acids, as well as homologues of the amino acid sequences of any one of SEQ ID NO: 389 to 393 in which one or more of the amino acid residues has been substituted (by conservative or non-conservative substitution) added, deleted, or chemically modified.  
      Markers according to the present invention may also optionally comprise nucleic acid molecule comprising or consisting of a sequence which encodes the above amino acid sequences (including the fragments and analogs of the amino acid sequences). Due to the degenerative nature of the genetic code, a plurality of alternative nucleic acid sequences, beyond SEQ ID NO: 379 to SEQ ID NO: 383, can code for the amino acid sequence of the invention. Those alternative nucleic acid sequences which code for the same amino acid sequences encoded by the sequences of SEQ ID NO:379 to SEQ ID NO: 383 are also an aspect of the of the present invention.  
      The first variant (SEQ ID NO: 379, termed “Var I” in the figures) lacks exon 9b ( FIG. 3 ), creating a unique sequence (bridge) between exons 9 and 10.  
      The second variant (SEQ ID NO: 380, termed “Var III” in the figures) is identical to SEQ ID NO: 379 except that it skips exon 8, and ends with exon 9, creating a unique sequence (bridge) between exons 7 and 9.  
      The third variant (SEQ ID NO: 381, termed “Var VII” in the figures) Starts from exon 2a, skips exon 3 and exon 9b, as described in  FIG. 3 , creating a unique sequence (bridge) between exon 2 and 4 and another unique sequence (bridge) between 9(a) and 10.  
      The fourth variant (SEQ ID NO: 382, termed “Var VIII” in the figures) Starts at exon 2a, skips exon 5 and terminates at exon 9, without exons 9b, 10 and 11, creating a unique sequence (bridge) between exons 4 and 6.  
      The fifth variant (SEQ ID NO: 383, termed “Var IX” in the figures) is identical to SEQ ID NO: 382, but without exon 3, creating a unique sequence (bridge) between exons 2 and 4, and another unique sequence (bridge) between exons 4 and 6.  
      It should be noted that the amino acid sequences of the above variants (for which nucleic acid sequences are shown in SEQ ID Nos: 379-383) are preferably described as “consisting essentially of” the numbered sequences; for example, the fifth variant preferably is of a nucleic acid sequence having a sequence consisting essentially of the sequence shown in SEQ ID NO:383.  
      SEQ IDs NO: 389-393 are the amino acid sequences encoded by SEQ IDs NO: 379-383, respectively.  
      “Primers and Amplicons According to the Present Invention” 
      SEQ ID NOs: 399-426 are Primers Used for PCR Amplifications:  
     
         
         
           
              a. hCHL2:  
              SEQ ID NO: 399 is referred to in the description below as p1.  
              SEQ ID NO: 400 is referred to in the description below as p2.  
              SEQ ID NO: 401 is referred to in the description below as p3.  
              SEQ ID NO: 402 is referred to in the description below as p4.  
              SEQ ID NO: 403 is referred to in the description below as p5.  
              SEQ ID NO: 404 is referred to in the description below as p6.  
              SEQ ID NO: 405 is referred to in the description below as p7.  
              SEQ ID NO: 406 is referred to in the description below as p8.  
              SEQ ID NO: 407 is referred to in the description below as p9.  
              b. mCHL2:  
              SEQ ID NO: 408 is referred to in the description below as p1.  
              SEQ ID NO: 409 is referred to in the description below as p2.  
              SEQ ID NO: 410 is referred to in the description below as p3.  
              SEQ ID NO: 411 is referred to in the description below as p4.  
              SEQ ID NO: 412 is referred to in the description below as p5.  
              SEQ ID NO: 413 is referred to in the description below as p6.  
              c. Human Osteocalcin: SEQ ID NOs: 414 and 415.  
              d. Mouse Osteocalcin: SEQ ID NOs: 416 and 417.  
              e. Mouse Myogenin: SEQ ID NOs: 418 and 419.  
              f. ATP synthase 6: SEQ ID NOs: 420 and 421.  
              g. 26SPSP: SEQ ID NOs: 422 and 423.  
              h. Mouse GAPDH: SEQ ID NOs: 424 and 425.  
              SEQ ID NO 426: mouse CHL2 nucleotide sequence  
              SEQ ID NO 427: mouse CHL2 protein sequence  
              SEQ ID NO 428: HPRT1-Forward primer  
              SEQ ID NO 429: HPRT1-Reverse primer  
              SEQ ID NO 430: HPRT1 amplicon  
              SEQ ID NO 431: PBGD-Forward primer  
              SEQ ID NO 432: PBGD-Reverse primer  
              SEQ ID NO 433: PBGD amplicon  
              SEQ ID NO 434: SDHA-Forward primer  
              SEQ ID NO 435: SDHA-Reverse primer  
              SEQ ID NO 436: SDHA amplicon  
              SEQ ID NO 437: G6PD-Forward primer  
              SEQ ID NO 438: G6PD-Reverse primer  
              SEQ ID NO 439: G6PD amplicon  
              SEQ ID NO 440: Exon 2a-Forward primer  
              SEQ ID NO 441: Exon 2a-Reverse primer  
              SEQ ID NO 442: amplicon exon 2a  
              SEQ ID NO 443: Ubiquitin-Forward primer  
              SEQ ID NO 444: Ubiquitin-Reverse primer  
              SEQ ID NO 445: Ubiquitin Amplicon  
              SEQ ID NO 446: Exon 4a Forward primer  
              SEQ ID NO 447: Exon 4a-Reverse primer  
              SEQ ID NO 448: Exon 4a-amplicon  
              SEQ ID NO 449: RPL-19-Forward primer  
              SEQ ID NO 450: RPL-19-Reverse primer  
              SEQ ID NO 451: RPL-19 amplicon  
           
         
       
    
      “CLH2 (Chordin Like Homolog) Sequences”:  
      All of the sequences described in this section refer to Group II CLH2 sequences.  
      SEQ ID NO: 384 (described in the figures as “Var II”) Has an accession number of AX140199. Var II contains an additional exon between exons 9 and 10, referred as “9b” in  FIG. 3 , creating a unique amino acid sequence.  
      SEQ ID NO: 394 is the amino acid sequence encoded by SEQ ID NO: 384.  
      SEQ ID NO: 385 (described in the figures as “Var IV”) Has an accession number of AX140202. Var IV starts from a unique exon 2a, as is demonstrated in  FIG. 3 , and contains an additional exon between exons 9 and 10, referred as “9b” in  FIG. 3 , creating a unique amino acid sequence. SEQ ID NO: 395 is the amino acid sequence encoded by SEQ ID NO: 385.  
      SEQ ID NO: 386 (described in the figures as “Var V”) Has an accession number of AX140203. Var V is identical to Var IV, while it skips exon 8, creating a unique sequence (bridge) between exons 7 and 9. SEQ ID NO: 396 is the amino acid sequence encoded by SEQ ID NO: 386.  
      SEQ ID NO: 387 (described in the figures as “Var VI”) Has an accession number of AX140204. Var VI starts from a unique exon 2a, as is demonstrated in  FIG. 3 , it skips exon 8, creating a unique sequence (bridge) between exons 7 and 9, and it does not contain exon 9b, creating a unique sequence (bridge) between exons 9 and 10.  
      SEQ ID NO: 397 is the amino acid sequence encoded by SEQ ID NO: 387.  
      SEQ ID NO: 388 (described in the figures as “Var X”) Has an accession number of AX140201. Var X starts from a unique exon 4a, as is demonstrated in  FIG. 3 . SEQ ID NO: 398 is the amino acid sequence encoded by SEQ ID NO: 388.  
      SEQ ID NOS 452-462 are amino acid sequences corresponding to the nucleic acid sequences shown in SEQ ID NOS 452-462, and so form Group II CLH nucleotide fragments. SEQ ID NOS 463-473 form amino acid sequences corresponding to Group II CLH polypeptides.  
      SEQ ID NO 474: mouse CHL2, corresponding to genbank accession number: AAH19399.  
      Thus, Group I sequences include amino acid sequences having at least about 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homology to any of SEQ ID NOs 389-393; and nucleic acid sequences having at least about 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homology to any of SEQ ID NOs 379-383.  
      Group II sequences include amino acid sequences having at least about 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homology to any of SEQ ID NOs 394-398 or 463-473; and nucleic acid sequences having at least about 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homology to any of SEQ ID NOs 384-388 or 452-462.  
      In addition, it should be noted that Group I sequences also have unique bridges. These bridges were noted above for the nucleotide sequences in terms of the exons. They are described below in terms of the amino acid sequences, although it should be noted that optionally a nucleotide sequence could be constructed according to any of the amino acid sequences below and used for any purpose ascribed to a nucleotide sequence as described herein. All the alignments were done against Var II, such that the bridges are described with regard to the amino acid sequence of Var II (SEQ ID NO: 394). The bridge is marked on a portion of the actual sequence below by //, which indicates that a portion of the sequence for that SEQ ID NO (relative to the sequence of Var II) is not present.  
                          (SEQ ID NO 389)                                 Variant I bridge:               RFALEHEASDLVEIYL WKLVK // GIFHLTQIKKV           RKQDFQKEAQHFRLLA          
 
      This bridge is present between amino acid positions 373 (lys) and 374 (gly), and preferably comprises a peptide having a sequence taken from either side of these positions. For example, the peptide could optionally comprise a bridge portion of SEQ ID NO: 389, comprising a peptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KG, having a structure as follows (numbering according to SEQ ID NO:389): a sequence starting from any of amino acid number 373−x to 373; and ending at any of amino acid numbers 374+((n−2)−x), in which x varies from 0 to n−2.  
      For example, for peptides of 10 amino acids (such that n=10), the starting position could be as “early” in the sequence as amino acid number 365 if x=n−2=8 (ie 365=373-8), such that the peptide would end at amino acid number 374 (374+(8−8=0)). On the other hand, the peptide could start at amino acid number 373 if x=0 (ie 373=373-0), and could end at amino acid 382 (374+(8−0=8)).  
      The bridge portion above may comprise a peptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to at least one sequence described above.  
      Similarly, the bridge portion may optionally be relatively short, such as from about 4 to about 9 amino acids in length. For four amino acids, the first bridge portion would comprise the following peptides: VKGI, KGIF, or LVKG. All peptides feature KG as a portion thereof. Peptides of from about five to about nine amino acids could optionally be similarly constructed.  
                          (SEQ ID NO 390)                         Variant III bridge:           PRHFRPKGAGSTFFVKIVLKEKHKK//EDKADPGHSEISSTRCPKAPGRV       LVHTSVSPSPDNLRRFALEHEA          
 
      This bridge is present between amino acid positions 250 (lys) and 251 (glu), and preferably comprises a peptide having a sequence taken from either side of these positions. For example, the peptide could optionally comprise a bridge portion of SEQ ID NO: 390, comprising a peptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise KE, having a structure as follows (numbering according to SEQ ID NO:390): a sequence starting from any of amino acid number 250−x to 250; and ending at any of amino acid numbers 251+((n−2)−x), in which x varies from 0 to n−2.  
      The bridge portion above may comprise a peptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to at least one sequence described above.  
      Similarly, the bridge portion may optionally be relatively short, such as from about 4 to about 9 amino acids in length. For four amino acids, the first bridge portion would comprise the following peptides: KKED, HKKE, or KEDK. All peptides feature KE as a portion thereof. Peptides of from about five to about nine amino acids could optionally be similarly constructed.  
                          (SEQ ID NO 391)                                 Variant VII bridge:               PDMIFCLFHGKRYSPGESWIIPYLEPQGLMYCLRCTCSE //           NLTLPLDSGPHQSPASTTGPCLFHGKRYSPGESWH          
 
      This bridge is present between amino acid positions 45 (glu) and 46 (asn), and preferably comprises a peptide having a sequence taken from either side of these positions. For example, the peptide could optionally comprise a bridge portion of SEQ ID NO: 391, comprising a peptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EN, having a structure as follows (numbering according to SEQ ID NO:391): a sequence starting from any of amino acid number 45-x to 45; and ending at any of amino acid numbers 46+((n−2)−x), in which x varies from 0 to n-2; wherein if the peptide is 50 amino acids in length, the starting position cannot be any smaller than 1.  
      The bridge portion above may comprise a peptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to at least one sequence described above.  
      Similarly, the bridge portion may optionally be relatively short, such as from about 4 to about 9 amino acids in length. For four amino acids, the first bridge portion would comprise the following peptides: SENL, ENLT, or CSEN. All peptides feature EN as a portion thereof. Peptides of from about five to about nine amino acids could optionally be similarly constructed.  
      This variant also has a new N-terminal sequence, which may optionally be constructed as part of a bridge as described above: MALVGLPG.  
                          (SEQ ID NO 392)                         Variant VIII bridge:           TPSGLRAPPKSCQHNGTMYQHGEIFSAHELFPSRLPNQCVLCSCT //       MRQVSNRMKRTVCSRSMG          
 
      This bridge is present between amino acid positions 124 (thr) and 125 (met), and preferably comprises a peptide having a sequence taken from either side of these positions. For example, the peptide could optionally comprise a bridge portion of SEQ ID NO: 392, comprising a peptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise TM, having a structure as follows (numbering according to SEQ ID NO:392): a sequence starting from any of amino acid number 124−x to 124 and ending at any of amino acid numbers 125+((n−2)−x), in which x varies from 0 to n−2, wherein the ending position is not greater than 142.  
      The bridge portion above may comprise a peptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to at least one sequence described above.  
      Similarly, the bridge portion may optionally be relatively short, such as from about 4 to about 9 amino acids in length. For four amino acids, the first bridge portion would comprise the following peptides: CTMR, SCTM, or TMRQ. All peptides feature TM as a portion thereof. Peptides of from about five to about nine amino acids could optionally be similarly constructed.  
      This variant also has a new N-terminal sequence, which may optionally be constructed as part of a bridge as described above:  
                          MALVGLPG                                 (SEQ ID NO 393)                         Variant IX bridge:           PDMFCLFHGKRYSPGESWHPYLEPQGLMYCLRCTCSE // NLTLPLDSG       PHQSPASTTGPCLFHGKRYSPGESWHPYLEPQGLMYCLRCTCS          
 
      This bridge is present between amino acid positions 45 (glu) and 46 (asn), and preferably comprises a peptide having a sequence taken from either side of these positions. For example, the peptide could optionally comprise a bridge portion of SEQ ID NO: 393, comprising a peptide having a length “n”, wherein n is at least about 10 amino acids in length, optionally at least about 20 amino acids in length, preferably at least about 30 amino acids in length, more preferably at least about 40 amino acids in length and most preferably at least about 50 amino acids in length, wherein at least two amino acids comprise EN, having a structure as follows (numbering according to SEQ ID NO:393): a sequence starting from any of amino acid number 45-x to 45; and ending at any of amino acid numbers 46+((n−2)−x), in which x varies from 0 to n−2; wherein if the peptide is 50 amino acids in length, the starting position cannot be any smaller than 1.  
      The bridge portion above may comprise a peptide being at least 70%, optionally at least about 80%, preferably at least about 85%, more preferably at least about 90% and most preferably at least about 95% homologous to at least one sequence described above.  
      Similarly, the bridge portion may optionally be relatively short, such as from about 4 to about 9 amino acids in length. For four amino acids, the first bridge portion would comprise the following peptides: SENL, ENLT, or CSEN. All peptides feature EN as a portion thereof. Peptides of from about five to about nine amino acids could optionally be similarly constructed.  
      This variant also has a new N-terminal sequence, which may optionally be constructed as part of a bridge as described above: 
          MALVGLPG        

      “Unique sequence”—as a result of alternative splicing, a non terminal exon is skipped (see for example variant 1 (exon 9b skipped), 2 (exons 9b and 3 are skipped), etc. Skipping of a non-terminal exon creates a unique sequence not present in the parent CHL2 which is the result of a ligation of the two exons flanking the “skipped” exon. This unique sequence results from the unique skipping pattern of the specific variant distinguishing the variant CHL2 of the invention from the parent chordin, or other known variants of chordin. Another possible unique sequence is intron-included sequences marked as exon 2a (variants IV, V, VI, VII, VIII) or exon 4a (variant X). Specific positions of the unique sequences are specified herein.  
      In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, described hereinbelow.  
       FIG. 1  shows a comparison of the human and mouse CHL2 variant I and CHL proteins. Amino acid sequence alignment of the orthologous and paralogous proteins indicates high conservation between these two vertebrate genes. The position of the signal peptide (SP) and the three CR repeats (CR1-CR3) is indicated. Sequences were aligned using the ClustalW program. Identical and similar residues are indicated by dark and light shading, respectively. Dashes indicate gaps introduced to align sequences. Protein sequences taken for the analysis were: hCHL2 (SEQ ID NO:11), mCHL2 (SEQ ID NO:96), hCHL (amino acid sequence corresponding to nucleotide sequence given in Genbank accession number AX175130), and mCHL (genebank accession number BC066832).  
       FIG. 2  shows a schematic representation of the human and mouse CHL2 and CHL genes (sequence identification numbers as for  FIG. 1 ). Shown is the intron-exon genomic organization of the genes. Exons are depicted as boxes, and their size is given in bp. Introns, not drawn to scale, are drawn as thin lines. Coding and untranslated sequences are shown in gray and white, respectively. Sequences encoding for the signal peptide and the CR repeats are indicated on top. Note that CR1 and CR2 are each encoded by two exons, while CR3 is encoded by a single exon.  
       FIG. 3  shows alternative splicing of the hCHL2 gene. The exon-intron organization and the primers employed in the RT-PCR analysis are indicated on the top diagram, which shows the entire gene. The various splice variants identified are shown. UTRs are depicted in white, and the ORFs of the splice variants encoding different isoforms are indicated in gray or varying patterns. The size of the protein isoforms is given in amino acids, and the existence of a signal peptide (SP) and the CR repeats is indicated for each isoform.  
      Primers p1 (SEQ ID NO:399)+p4 (SEQ ID NO: 402) were used to detect variants I, II, III; primers p1 (SEQ ID NO:399)+p8 (SEQ ID NO: 406) were used to detect variants I, II; primers p2 (SEQ ID NO: 400)+p4 (SEQ ID NO: 402) were used to detect variants IV, V, VI, VII, VIII, IX; primers p3 (SEQ ID NO: 401)+p4 (SEQ ID NO: 402) were used to detect variant X; primers p2 (SEQ ID NO: 400)+p7 (SEQ ID NO: 405) were used to detect variants IV, VIII; primers p5 (SEQ ID NO: 403)+p7 (SEQ ID NO: 405) were used to detect variants containing exon 8; primers p1 (SEQ ID NO:399)+p6 (SEQ ID NO: 404) were used to detect variant III) in adult human tissues (results not shown).  
      The following describes the exons that characterize variants according to the present invention and primers that may optionally used to amplify each exon: exon 1 (p1 (SEQ ID NO:399)+p4 (SEQ ID NO: 402)) characterizes variants I, II and III; exon 2a (p2 (SEQ ID NO: 400)+p4 (SEQ ID NO: 402)) characterizes variants IV, V, VI, VII, VIII, IX; exon 4a (p3 (SEQ ID NO: 401)+p7 (SEQ ID NO: 405)) characterizes variant X; exon 8 (p5 (SEQ ID NO: 403)+p7 (SEQ ID NO: 405)) characterizes variants I, II, IV, VII, VIII, IX, X) Splice variants.  
      Relative expression of hCHL2 transcripts containing the amplicon of the unique exon 2a, SEQ ID NO: 442 (e.g., variant no. IV, V, VI, VII, VIII, IX), in normal and cancerous breast tissues was determined by real time PCR using primers for SEQ ID NO: 442 (SEQ ID NO: 440, 441). Expression was normalized to the averaged expression of four housekeeping genes PBGD (GenBank Accession No. BC019323; amplicon—SEQ ID NO: 433, primers SEQ ID Nos: 431, 432), HPRT1 (GenBank Accession No. NM — 000194; amplicon—SEQ ID NO: 430, primers SEQ ID Nos: 428, 429), G-6_PD (GenBank Accession No. NM — 000402; amplicon—SEQ ID NO: 439, primers SEQ ID Nos: 437, 438) and SDHA (GenBank Accession No. NM — 004168; amplicon—SEQ ID NO: 436, primers SEQ ID Nos: 434, 435); results not shown. However, the primers were able to successfully amplify the desired amplicon.  
      Relative expression of hCHL2 transcripts containing the amplicon of the unique exon 4a, SEQ ID NO: 448, (e.g., variant no. X) in normal, benign and cancerous prostate tissues was determined by real time PCR using primers for SEQ ID NO: 448 (SEQ ID NO: 446, 447). Expression was normalized to the averaged expression of four housekeeping genes; results not shown. However, the primers were able to successfully amplify the desired amplicon.  
      It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.  
      Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.